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ABSTRACT	  
Preterm	  birth	  is	  a	  worldwide	  health	  concern	  accounting	  for	  11.1%	  of	  all	  births.	  It	  is	  linked	  to	  adverse	  
outcomes	   including	   cerebral	   palsy	   and	   chronic	   lung	  disease.	  Parturition	   is	   associated	  with	  marked	  
inflammation	  in	  the	  gestational	  tissues	  with	  the	  myometrium	  being	  the	  key	  effector,	  responsible	  for	  
coordinated	   contractions	   that	   lead	   to	   delivery	   of	   the	   fetus.	   Despite	   multiple	   theories,	   the	  
mechanism	  underlying	  the	  onset	  of	  human	  labour	  remains	  unclear.	  As	  there	  is	  currently	  no	  effective	  
method	   in	   stopping	   labour	   once	   the	   process	   has	   begun,	   research	   is	   focused	   on	   prevention.	  
Currently,	  the	  only	  drug	  agent	  with	  proven	  efficacy	  is	  progesterone	  (P4),	  which	  has	  been	  shown	  to	  
reduce	  the	  incidence	  of	  preterm	  labour	  (PTL)	  by	  up	  to	  40%.	  P4	  is	  known	  to	  have	  anti-­‐inflammatory	  
action,	  however	  its	  mode	  of	  action	  in	  the	  context	  of	  reducing	  the	  rate	  of	  PTL	  remains	  unclear.	  The	  
overall	   aim	   of	   this	   project	   was	   to	   further	   understand	   the	   mechanism	   of	   P4	   action	   in	   order	   to	  
facilitate	  the	  development	  of	  superior	  drugs	  to	  combat	  PTL.	  	  
Using	   a	   pregnant	  murine	  model,	  my	   studies	   have	   shown	   that	   vehicle	   control	   labour	   is	   associated	  
with	  inflammation.	  Further,	  P4	  supplementation	  was	  sufficient	  to	  delay	  labour	  by	  at	  least	  two	  days	  
in	  association	  with	  a	  delay	  in	  inflammation	  and	  a	  loss	  of	  the	  rise	  in	  contraction-­‐associated	  proteins	  
including	  connexin-­‐43.	  	  	  
A	  second	  pregnant	  murine	  model	  was	  used	  to	  block	  P4	  action	  with	  the	  mixed	  progesterone	  receptor	  
(PR)	  and	  glucocorticoid	   receptor	  antagonist	  mifepristone	   (RU486),	  with	  animals	  delivering	  preterm	  
at	   17.4	   ±	   0.35	   hours	   post	   administration.	   A	   pre-­‐delivery	   (9	   hours	   post	   RU486)	   significant	   up-­‐
regulation	  of	   the	  contraction-­‐associated	  proteins	  connexin-­‐43	  and	  oxytocin	  receptor	  was	  observed	  
in	   association	  with	   a	   peak	   in	   p65	   and	   p38	   phosphorylation.	   Inflammatory	   cytokines,	   such	   as	   IL-­‐6,	  
peaked	  at	  the	  time	  of	  labour	  at	  the	  RNA	  level	  and	  demonstrated	  a	  bimodal	  peak	  at	  the	  protein	  level	  
(9	  hours	  and	  labour).	  	  
Much	  of	  the	   in	  vitro	  work	  on	  myometrial	  function	  is	  hampered	  by	  a	  lack	  of	  physiological	  relevance	  
due	  low	  PR	  levels	  and	  the	  requirement	  for	  treatment	  with	  high	  P4	  doses.	  In	  order	  to	  address	  this,	  I	  
have	   developed	   and	   validated	   via	   microarray	   a	   myometrial	   explant	   model	   to	   study	   P4	   function.	  
Subsequently,	   I	  have	  shown	  that,	   in	  this	  model,	  P4	  signals	  via	  PR	  and	  that	  this	   is	  associated	  with	  a	  
reduction	   in	   p65	   and	   c-­‐Jun	  phosphorylation	   in	   an	   IL-­‐1β-­‐driven	  model	   of	   inflammation.	   I	   have	   also	  
shown	   that	   in	   explants	   obtained	   from	   labouring	   patients,	   P4	   does	   not	   lose	   the	   ability	   to	   repress	  
inflammation.	  	  
Finally,	   several	   authors	   have	   proposed	   a	   variety	   of	   mechanisms	   to	   account	   of	   the	   functional	  
withdrawal	  of	  P4	  in	  human	  parturition.	  In	  order	  to	  investigate	  some	  of	  these	  further,	  I	  have	  used	  the	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group’s	  myometrial	  tissue	  bank.	  I	  have	  shown	  that	  myometrial	  P4	  levels	  do	  not	  change	  with	  labour	  
onset	   and	   confirmed	   other	   groups’	   reports	   that	   term	   labour	   is	   associated	   with	   a	   shift	   to	   PR-­‐A	  
dominance.	   I	   went	   on	   to	   show	   that,	   compared	   with	   idiopathic	   preterm	   labour,	   preterm	   labour	  
secondary	   to	   chorioamnionitis	   is	   associated	   with	   a	   significant	   reduction	   in	   nuclear	   receptor	  
corepressor	   (NCoR)	   and	   steroid	   receptor	   coactivator	   1	   (SRC1),	   as	   well	   as	   a	   significant	   increase	   in	  
heat-­‐shock	  protein	  90	  (HSP90)	  and	  FK506-­‐binding	  protein	  51	  (FKBP51).	  Additionally,	  I	  demonstrated	  
that	  preterm	  labour	  in	  twins	  is	  associated	  with	  a	  significant	  up-­‐regulation	  of	  NCoR.	  
In	  summary,	  the	  findings	  of	  this	  thesis	  broaden	  our	  understanding	  of	  P4	  function	  and	  will	  help	  drive	  
the	  field	  of	  parturition	  and	  PTL	  forward.	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ABBREVIATIONS	  
ANOVA	  	   analysis	  of	  variance	  
AP-­‐1	  	   	   activator	  protein-­‐1	  
BSA	   bovine	  serum	  albumin	  
cAMP	   cyclic	  adenosine	  monophosphate	  
CAPs	   	   contraction	  associated	  proteins	  
CCL2	   C-­‐C	  Motif	  Chemokine	  Ligand	  2	  
CCL5	   C-­‐C	  Motif	  Chemokine	  Ligand	  5	  
cDNA	   	   complementary	  DNA	  
CXCL1	   Chemokine	  (C-­‐X-­‐C	  motif)	  ligand	  1	  
CXCL2	   Chemokine	  (C-­‐X-­‐C	  motif)	  ligand	  2	  	  
COX	   	   cyclo-­‐oxygenase	  
CRH	   corticotropin-­‐releasing	  hormone	  
DEG	   differentially	  expressed	  gene	  
Dex	   	   dexamethasone	  
DMEM	   	   Dulbecco’s	  modified	  eagle	  medium	  
DMSO	   	   dimethyl	  sulfoxide	  
DNA	   	   deoxyribonucleic	  acid	  
dNTP	   	   deoxyribonucleoside	  triphosphate	  
DTT	   dithiothreitol	  
ERK	   	   extracellular-­‐signal-­‐regulated	  kinases	  
FCS	   fetal	  calf	  serum	  
FKBP	   	   FK506-­‐binding	  protein	  
GAPDH	  	   glyceraldehyde-­‐3-­‐phosphate	  dehydrogenase	  
GCSF	   granulocyte-­‐colony	  stimulating	  factor	  
GR	   	   glucocorticoid	  receptor	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HSP	   	   heat	  shock	  protein	  
IFN-­‐γ	   interferon-­‐gamma	  
IκBα	   nuclear	  factor-­‐kappa	  B	  inhibitor	  α	  
IL-­‐1α	   interleukin-­‐1	  alpha	  
IL-­‐1β	   	   interleukin-­‐1	  beta	  
IL-­‐10	   interleukin-­‐10	  
IL-­‐6	   interleukin-­‐6	  
IL-­‐8	   interleukin-­‐8	  
LPS	   lipopolysaccharide	  
LSCS	   	   lower	  segment	  Caesarean	  section	  
MAPK	   mitogen	  activated	  protein	  kinase	  
MPA	   medroxyprogesterone	  acetate	  
MMP1	   matrix	  metalloproteinase	  1	  
NF-­‐κB	   	  	   nuclear	  factor-­‐kappa	  B	  
OTR	   oxytocin	  receptor	  
P4	   	   progesterone	  
PBS	   	   phosphate	  buffered	  saline	  
PCA	   principal	  component	  analysis	  
PGRMC	   progesterone	  receptor	  membrane	  component	  
PMSF	   phenylmethanesulfonylfluoride	  
PR	   	   progesterone	  receptor	  
PTL	   preterm	  labour	  
PVDF	   polyvinylidene	  difluoride	  
qPCR	   	   quantitative	  real-­‐time	  polymerase	  chain	  reaction	  
RNA	   	   ribonucleic	  acid	  
SDS	   	   sodium	  dodecyl	  sulphate	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siRNA	   	   small	  interfering	  RNA	  
TBS-­‐T	   	   tris	  buffered	  saline-­‐tween	  20	  
TNF-­‐α	   tumour	  necrosis	  factor	  alpha	  
TLR	   Toll-­‐like	  receptor	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
24	  
	  
ALTERNATIVE	  NAMES	  
Gene	  Name	   Protein	  Name	  
ESR1	   ERα	  
GJA1	   Connexin-­‐43	  
NR3C1	   GR	  
OXTR	   OTR	  
PGR	   PR	  
PTGS2	   COX-­‐2	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1.	  INTRODUCTION	  
	  
1.1.	  Pregnancy	  and	  Parturition	  
A	   viable	   pregnancy	   is	   the	   result	   of	   fertilisation	   of	   an	   ovum	   by	   a	   spermatozoon	   and	   successful	  
implantation	   of	   the	   developing	   blastocyct	   into	   a	   receptive	   endometrium.	   The	  median	   duration	   of	  
human	  pregnancy	  is	  268	  days	  (38	  weeks	  +	  2	  days)	  from	  ovulation	  (1),	  with	  gestations	  from	  37	  to	  42	  
weeks	  considered	  to	  be	  term	  (2).	  	  
Parturition,	  or	   labour,	   is	  defined	  as	   the	  process	  whereby	  the	   fetus	  and	  placenta	  are	  expelled	   from	  
the	  uterus.	  It	  is	  a	  clinical	  diagnosis	  identified	  by	  the	  onset	  of	  regular,	  painful	  uterine	  contractions	  in	  
association	  with	  cervical	  dilatation.	  In	  humans,	  clinicians	  divide	  labour	  into	  three	  stages	  (Fig.	  1.1.):	  
First	  stage:	  labour	  onset	  to	  full	  cervival	  dilatation;	  this	  is	  further	  sub-­‐divided	  into	  two	  distinct	  phases:	  
• Early/Latent	  phase:	  characterised	  by	  cervical	  effacement,	  commencement	  of	  dilatation	  and	  
increasing	  frequency	  and	  intensity	  of	  uterine	  contractions.	  
• Established/Active	   phase:	   characterised	   by	   rapid	   cervical	   dilatation	   and	   regular,	   strong	  
uterine	  contractions.	  
Second	  stage:	  from	  full	  cervical	  dilatation	  to	  delivery	  of	  the	  fetus.	  
Third	  stage:	  from	  delivery	  of	  the	  fetus	  to	  delivery	  of	  the	  placenta.	  
	  
Figure	  1.1.	  The	  stages	  of	  parturition.	  Adapted	  from	  Williams	  Obstetrics	  (3).	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1.1.1.	  The	  myometrium	  	  
The	  uterus	  is	  composed	  of	  the	  cervix,	  body	  and	  fundus	  and	  is	  comprised	  of	  four	  layers	  (Fig.	  1.2.)	  (4).	  
The	  outer	  layer	  is	  termed	  the	  serosa	  or	  perimetrium,	  below	  which	  is	  a	  subserous	  layer	  consisting	  of	  
connective	   tissue.	   Below	   that	   is	   the	  myometrium,	  which	   is	   the	  muscular	   layer	   of	   the	   uterus.	   The	  
innermost	  layer	  is	  termed	  the	  endometrium	  and	  lines	  the	  cavity	  of	  the	  uterus.	  	  
	  
Figure	  1.2.	  Anatomy	  of	  the	  female	  reproductive	  tract.	  Adapted	  from	  The	  Big	  Picture:	  Gross	  Anatomy	  (5).	  
The	  myometrium	   is	   principally	   composed	   of	   smooth	  muscle	   cells	   as	  well	   as	   supporting	   structures	  
such	   as	   connective	   tissue,	   blood	   vessels,	   nerves	   and	   lymphatics.	   Smooth	   muscle	   is	   non-­‐striated	  
muscle	  under	  the	  control	  of	  the	  autonomic	  nervous	  system.	  	  
During	   pregnancy,	   the	   uterus	   greatly	   increases	   in	   size	   in	   order	   to	   accommodate	   the	   developing	  
fetus,	   with	   the	   myometrium	   being	   the	   main	   component	   responsible	   for	   this	   process	   (6).	   This	   is	  
achieved	   by	   hyperplasia,	   an	   increase	   in	   the	   absolute	   number	   of	   myometrial	   cells,	   as	   well	   as	  
hypertrophy,	   an	   increase	   in	  myometrial	   cell	   size	   from	   50-­‐90µm	   to	   500-­‐800µm	   (7).	   Both	   of	   these	  
processes	   appear	   to	   be	   dependent	   on	   oestrogen	   and	   progesterone	   (6,	   7).	   Furthermore,	   the	  
connective	  tissue	  expands	  with	  advancing	  gestation.	  Importantly,	  the	  myometrium	  is	  a	  key	  effector	  
organ	  of	  the	  female	  reproductive	  system	  as	  it	  is	  responsible	  for	  the	  rhythmic	  contractions	  that	  bring	  
about	  delivery	  of	  the	  fetus	  and	  placenta.	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1.1.2.	  Molecular	  mechanisms	  of	  labour	  onset	  
The	   precise	   mechanism	   of	   labour	   onset	   remains	   poorly	   understood	   with	   evidence	   indicating	  
significant	   inter-­‐species	   variation.	   Indeed,	   upon	   comparing	   humans	   to	   chimpanzees,	   one	   of	   the	  
closest	  non-­‐human	  primates	  with	  whom	  humans	  share	  approximately	  95%	  of	  DNA	  sequences,	   the	  
greatest	  differences	  arise	  in	  reproduction	  and	  host	  defence	  (8).	  	  From	  a	  biochemical	  and	  endocrine	  
perspective,	  pregnancy	  and	  parturition	  can	  be	  divided	  into	  4	  phases	  (Fig.	  1.3.)	  (9).	  
Phase	  1:	  corresponds	  to	  pregnancy	  itself,	  during	  which	  the	  myometrium	  is	  maintained	  in	  a	  state	  of	  
quiescence	  by	   the	  action	  of	   various	  molecules	   including	  progesterone	   (P4),	   corticotropin-­‐releasing	  
hormone	   (CRH),	   prostacyclin,	   relaxin,	   nitric	   oxide,	   parathyroid	   hormone-­‐related	   peptide,	   human	  
placental	   lactogen,	   calcitonin	   gene-­‐related	   peptide,	   adrenomedullin	   and	   vasoactive	   intestinal	  
peptide.	  
Phase	  2:	   uterine	   activation,	   under	   the	   increasing	   influence	  of	  oestrogens,	   occurs	   thus	  priming	   the	  
uterus	  for	  labour.	  	  
During	   this	   stage,	   there	   is	   a	  marked	   invasion	   of	   the	  myometrium,	   cervix	   and	   fetal	  membranes	   by	  
circulating	   leukocytes,	   specifically	   neutrophils	   and	   macrophages	   (10).	   These	   cells,	   along	   with	   the	  
myometrium	   and	   cervix	   themselves,	   release	   various	   pro-­‐inflammatory	   mediators	   (11),	   with	   the	  
resulting	   inflammation	   being	   associated	  with	   increased	   expression	   of	   a	   group	  of	   proteins,	   termed	  
contraction-­‐associated	   proteins	   (CAPs)	   (12).	   These	   include	   (i)	   cyclooxygenase-­‐2	   (COX-­‐2),	   the	   key	  
enzyme	   in	  prostaglandin	  synthesis,	  which	  contributes	  to	  the	  uterine	  pro-­‐contractile	  phenotype,	   (ii)	  
oxytocin	   receptor	   (OTR),	   which	   binds	   the	   pro-­‐contractile	   hormone	   oxytocin	   and	   (iii)	   connexin-­‐43,	  
which	   forms	   intra-­‐myometrial	   gap	   junctions	   hence	   facilitating	   intrapartum	   synchrony.	   Pro-­‐
inflammatory	  cytokines	  also	  drive	  the	  expression	  of	  matrix	  metalloproteinases	  (MMPs)	  in	  the	  cervix	  
hence	   facilitating	  collagen	  breakdown,	  which	   is	   responsible	   for	  cervical	  dilatation	   (13).	   In	  addition,	  
inflammation	   is	  associated	  with	   increased	   intracellular	   calcium	  within	  myocytes,	  which	   is	  essential	  
for	  the	  operation	  of	  the	  actin-­‐myosin	  contractile	  apparatus	  (14).	  Together,	  these	  mechanisms,	  lead	  
to	  cervical	  dilatation	  and	  regular	  uterine	  contractions.	  
Phase	   3:	   the	   primed	  uterus	   responds	   to	   stimuli	   such	   as	   oxytocin	   by	   contracting	   and	   expelling	   the	  
contents	  of	  the	  uterus.	  As	  with	  other	  smooth	  muscle	  tissues,	  myometrial	  contractions	  are	  brought	  
about	   by	   ATP-­‐dependent	   binding	   of	   myosin	   to	   actin;	   this	   interaction	   is	   itself	   dependent	   on	   the	  
phosphorylation	  of	  myosin	   light	  chain	  by	  myosin	   light	  chain	  kinase	  –	  a	  calcium-­‐dependent	  enzyme	  
(15).	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Phase	  4:	  this	  stage	  is	  also	  termed	  involution	  whereby	  the	  uterus	  returns	  to	  its	  pre-­‐pregnancy	  state	  
under	  the	  influence	  of	  oxytocin.	  	  
	  
Figure	  1.3.	  Phases	  of	  uterine	  activity	  in	  pregnancy.	  Adapted	  from	  Williams	  Obstetrics	  (3).	  
It	  is	  evident	  that	  the	  maintenance	  of	  pregnancy	  and	  the	  onset	  of	  parturition	  involve	  the	  integration	  
of	  multiple	  biochemical	  and	  mechanical	  signals.	  CRH,	  which	   is	  produced	  by	  the	  placenta,	   increases	  
with	  advancing	  gestation	  and	  peaks	  at	  the	  time	  of	  labour	  both	  preterm	  (16,	  17)	  and	  at	  term	  (18).	  For	  
this	   reason,	   it	   has	   been	   suggested	   that	   it	   regulates	   labour	   onset	   and	   hence	   has	   been	   termed	   the	  
‘placental	  clock’.	  The	  myometrium	  has	  several	  CRH	  receptor	  isoforms	  (19)	  and	  it	  has	  been	  proposed	  
that	  during	  pregnancy	  CRH	  acts	   to	  promote	  uterine	  quiescence.	  At	   the	   time	  of	   labour	  onset,	   CRH	  
signals	   via	  different	   receptor	   subtypes	   to	  promote	  a	   contractile	  phenotype	   (20).	  Additionally,	   as	   it	  
crosses	   into	   the	   fetus,	   CRH	   stimulates	   adrenocorticotrophic	   hormone	   which	   stimulates	   adrenal	  
production	   of	   cortisol	   and	   dehydroepiandrostenedione	   sulphate.	   The	   former	   aids	   in	   fetal	   lung	  
maturity	  and	  stimulates	  placental	  CRH	  production	  (21)	  and	  the	  latter	  acts	  as	  a	  substrate	  for	  placental	  
oestrogen	  synthesis	  (22).	  
	  
1.1.3.	  Preterm	  labour	  
Preterm	  labour	   is	  defined	  as	  delivery	  prior	  to	  37	  weeks	  of	  gestation	  (23).	  Babies	  born	  prematurely	  
are	  further	  sub-­‐categorised	  into	  extremely	  preterm	  (<28	  weeks),	  very	  preterm	  (28	  to	  <32	  weeks)	  and	  
moderate	  to	  late	  preterm	  (32	  to	  <37	  weeks).	  Moderate	  to	  late	  prematurity	  accounts	  for	  84.3%	  of	  all	  
preterm	   births,	   with	   the	   corresponding	   numbers	   for	   extremely	   preterm	   and	   very	   preterm	   births	  
being	  5.2%	  and	  10.4%	  respectively	   (23).	  Morbidity	  and	  mortality	   rates	   increase	  with	  the	  degree	  of	  
prematurity	  (23-­‐25).	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1.1.3.1.	  Epidemiology	  of	  preterm	  birth	  
In	   the	   year	   2000,	   all	   member	   states	   of	   the	   United	   Nations	   established	   eight	   Millennium	  
Development	  Goals	  (MDG)	  to	  be	  achieved	  by	  2015	  (26).	  MDG	  4	  aimed	  to	  decrease	  child	  mortality;	  
specifically	  it	  set	  the	  target	  of	  reducing	  mortality	  of	  children	  under	  5	  years	  old	  by	  two	  thirds	  between	  
1990	  and	  2015	   (26).	  Despite	  an	   increase	   in	   the	  number	  of	  births	  over	   this	   time	  period,	   significant	  
progress	  has	  been	  made	  in	  reducing	  child	  mortality	  (27).	  However,	  most	  of	  the	  contribution	  to	  this	  
reduction	  was	  made	  by	  the	  1	  to	  59	  month	  age	  group.	  As	  a	  result,	  the	  contribution	  to	  the	  rate	  made	  
by	   the	   neonatal	   population	   and	   specifically	   preterm	   birth	   has	   increased	   (28)	   and	   concerningly,	   it	  
became	  clear	  that	  the	  MDG	  4	  target	  would	  not	  be	  achieved	  (27).	   In	   late	  2015,	   the	  UN	  Sustainable	  
Development	   Goals	   (SDG)	  were	   adopted	   by	   all	   country	  members	   to	   be	   achieved	   by	   2030.	   SDG	   3	  
includes	  the	  aim	  to	  ‘end	  preventable	  deaths	  of	  newborns	  and	  children	  under	  5	  years	  of	  age,	  with	  all	  
countries	   aiming	   to	   reduce	   neonatal	   mortality	   to	   at	   least	   as	   low	   as	   12	   per	   1,000	   live	   births	   and	  
under-­‐5	  mortality	  to	  at	  least	  as	  low	  as	  25	  per	  1,000	  live	  births’	  (29).	  
On	   an	   annual	   basis,	   15	  million	   babies	   are	   born	   prematurely	  worldwide	   (23).	  Most	   of	   the	   disease	  
burden	  lies	  in	  South	  Asia	  and	  Sub-­‐Saharan	  Africa	  (Fig.	  1.4.),	  but	  even	  in	  higher-­‐income	  countries	  such	  
as	  England	  and	  Wales	  the	  rate	  is	  not	  improving	  (30).	  	  
Figure	  1.4.	  Worldwide	  estimated	  preterm	  birth	  rates	  for	  the	  year	  2010.	  Adapted	  from	  Blencowe	  et	  al.	  (31).	  
Preterm	  birth	   is	   the	   leading	   cause	  of	  death	   in	   the	  neonatal	   period	  accounting	   for	  nearly	  1	  million	  
deaths	  in	  2013	  worldwide	  (Table	  1.1.)	  (28).	  Furthermore,	  preterm	  babies	  are	  at	  an	  increased	  risk	  of	  
dying	  due	  to	  other	  causes	  including	  neonatal	  infections.	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Neonates	   Number	  of	  deaths	  (UR;	  millions)	  
Preterm	  birth	  complications	   0·∙965	  (0·∙615–1·∙537)	  
Intrapartum-­‐related	  complications	   0·∙662	  (0·∙421–1·∙054)	  
Sepsis	   0·∙421	  (0·∙269–0·∙688)	  
Congenital	  abnormalities	   0·∙276	  (0·∙175–0·∙438)	  
Other	  disorders	   0·∙232	  (0·∙145–0·∙373)	  
Neonatal	  pneumonia	   0·∙136	  (0·∙084–0·∙219)	  
Tetanus	   0·∙049	  (0·∙032–0·∙079)	  
Neonatal	  diarrhoea	   0·∙020	  (0·∙012–0·∙033)	  
Table	  1.1.	  Estimated	  numbers	  of	  neonatal	  deaths	  in	  2013.	  UR:	  uncertainty	  range.	  Adapted	  from	  Liu	  et	  al.	  (28).	  
For	   surviving	  neonates,	   the	  burden	  of	  preterm	  birth	   continues	   into	   childhood	  and	  adulthood	  with	  
impaired	  neurological	  development	  associated	  with	  learning	  difficulties,	  blindness	  and	  deafness	  (32,	  
33).	   In	   addition,	   an	   association	   with	   increased	   risk	   of	   other	   diseases	   such	   as	   diabetes	   and	  
cardiovascular	  disease	  has	  been	   reported	   (34).	   Studies	   into	   the	  economic	   impact	  of	  preterm	  birth	  
vary	  greatly	  based	  on	  variables	  such	  as	  the	  study	  population,	  but	  a	  recent	  review	  using	  mean	  costs	  
from	  four	  American	  studies	  identified	  the	  cost	  of	  an	  extremely	  premature	  baby	  to	  be	  in	  the	  region	  of	  
US$	   100,000	   for	   the	   first	   year	   of	   life	   (35).	   An	   older	   study	   carried	   out	   in	   England	   and	  Wales	   (36),	  
reported	  an	  annual	   cost	  of	  £2.496	  billion	   to	   the	  National	  Health	  Service.	  Predictably,	  both	   studies	  
reported	  an	  inverse	  relationship	  between	  gestational	  age	  and	  cost	  burden.	  	  
1.1.3.2.	  Causes	  of	  preterm	  birth	  
Preterm	   birth	   does	   not	   represent	   a	   single	   disease	   entity	   but	   rather	   a	   syndrome	   with	   multiple	  
underlying	   aetiologies	   (23).	   It	   can	   broadly	   be	   divided	   into	   iatrogenic,	   which	   accounts	   for	   30%	   of	  
cases,	   or	   spontaneous,	  which	   accounts	   for	   the	   remaining	   70%	  of	   cases	   (Table	   1.2.)	   (23,	   37).	  On	   a	  
worldwide	  basis,	  infection	  is	  the	  single	  most	  important	  cause	  of	  preterm	  birth	  (37).	  
Spontaneous	   Iatrogenic	  
Infection	   Hypertension	  
Premature	  rupture	  of	  membranes	   Diabetes	  
Idiopathic	  contractions	   Intrauterine	  growth	  restriction	  
Multiple	  pregnancy	   	  
Cervical	  dysfunction	   	  
Antepartum	  haemorrhage	   	  
Stress	   	  
Malnutrition	   	  
Table	  1.2.	  Causes	  of	  preterm	  birth.	  Adapted	  from	  Steer	  (37).	  
1.1.3.3.	  Preterm	  labour	  management	  
Tocolytic	  drugs,	  including	  	  oxytocin	  receptor	  antagonists,	  calcium	  channel	  blockers,	  β2-­‐adrenoceptor	  
agonists,	  nitric	  oxide	  donors	  and	  magnesium	  sulphate,	  for	  the	  management	  of	  preterm	  labour	  have	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failed	   to	   prevent	   delivery	   (38-­‐41).	   This	  was	   to	   be	   expected	   given	   that	   these	   agents	   target	   uterine	  
contractions	  and	  not	  the	  underlying	  cause	  of	  preterm	  labour.	  Nevertheless,	  these	  drugs	  continue	  to	  
be	  used	  but	  not	  with	  the	  aim	  of	  abolishing	  preterm	  labour	  but	  rather	  delaying	  parturition	  by	  24-­‐48	  
hours,	   allowing	   administration	   of	   corticosteroids	   to	   the	   mother	   to	   aid	   fetal	   lung	   maturity	   (42).	  
Indeed,	  it	  is	  now	  accepted	  that	  in	  certain	  circumstances,	  notably	  in	  the	  setting	  of	  chorioamnionitis,	  
delay	  in	  delivery	  is	  likely	  to	  be	  more	  detrimental	  than	  beneficial	  to	  the	  fetus	  (43).	  	  
Thus,	  much	  of	  the	  focus	  of	  research	   in	  the	  field	  has	  moved	  towards	  prevention	  of	  preterm	  labour.	  
The	   two	  major	   identified	  modifiable	   risk	   factors	   for	   prematurity	   are	   previous	   preterm	   labour	   (44)	  
and	  a	  short	  cervix	  (45).	  Antibiotic	  prophylaxis	  (46)	  and	  bed	  rest	  (47),	  either	  at	  home	  or	   in	  hospital,	  
have	  now	  been	  accepted	  as	  ineffective	  prevention	  modalities.	  Further,	  cervical	  pessary	  (48)	  for	  the	  
prevention	  of	  preterm	  labour	  has	  also	  been	  shown	  to	  be	  ineffective.	   Indeed	  the	  only	  two	  effective	  
interventions	  are	  cervical	  cerclage	  (49)	  and	  progesterone	  supplementation	  in	  singleton	  pregnancies.	  
The	   efficacy	   of	   progesterone	   in	   singleton	   pregnancies	   was	   demonstrated	   using	   both	   natural	  
progesterone	  administered	  vaginally	   (50-­‐52)	  and	  the	  synthetic	  progestin	  17α-­‐hydroxyprogesterone	  
caproate	   administered	   intramuscularly	   (53).	   No	   difference	   in	   preterm	   labour	   rates	  were	   reported	  
between	  the	  two	  progestin	  preparations	  and	  routes	  of	  administration	  (54).	  No	  maternal,	  neonatal	  or	  
long-­‐term	   childhood	   sequelae	   have	   been	   identified	   with	   P4	   supplementation	   (55),	   whereas	   17α-­‐
hydroxyprogesterone	   caproate	  has	  been	   linked	  with	   increased	   rates	  of	  maternal	   impaired	  glucose	  
tolerance	  and	  gestational	  diabetes	  mellitus	  (56).	  	  
More	  recently,	   the	  OPPTIMUM	  trial	  has	  cast	  some	  doubt	  on	   the	  efficacy	  of	  progesterone,	  with	  no	  
reduction	   in	   the	   preterm	   labour	   rate	   identified	   with	   vaginal	   progesterone	   supplementation	   (55),	  
lending	   support	   to	   an	   older	   and	   relatively	   smaller	   study	   (57).	   Additionally,	   progestin	  
supplementation	  was	  found	  to	  be	  ineffective	  in	  preterm	  labour	  prevention	  in	  twin	  and	  higher	  order	  
gestations	   (58)	  as	  well	  as	   in	   the	  context	  of	   threatened	  preterm	   labour	   (58).	  Despite	   the	   increasing	  
controversy	  surrounding	  progesterone	  action,	   its	  pro-­‐quiescent	  actions	   (discussed	  below)	  highlight	  
the	   importance	   of	   determining	   the	   mode	   of	   action	   of	   this	   hormone	   with	   the	   ultimate	   aim	   of	  
developing	  novel	  therapeutic	  agents	  to	  combat	  preterm	  labour.	  	  
	  
1.2.	  Progesterone	  	  
Progesterone	  is	  a	  steroid	  hormone	  that	  was	  independently	  discovered	  by	  two	  different	  groups	  in	  the	  
1930s	  (59,	  60).	  Like	  all	  steroid	  hormones,	  it	  is	  derived	  from	  cholesterol	  (Fig.	  1.5.).	  In	  early	  pregnancy	  
in	  humans,	  it	  is	  synthesised	  by	  the	  corpus	  luteum,	  which	  is	  maintained	  by	  the	  production	  of	  human	  
chorionic	   gonadotrophin	   by	   the	   placenta.	   By	   week	   7-­‐10	   of	   pregnancy,	   the	   placenta	   takes	   over	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progesterone	  synthesis	  until	  the	  end	  of	  pregnancy.	  Placental	  progesterone	  production	  peaks	  in	  the	  
third	  trimester	  at	  more	  than	  250mg	  per	  day	  (61).	  	  
	  
Figure	  1.5.	  Progesterone	  biosynthesis	  pathway.	  Adapted	  from	  Neunzig	  and	  Bernhardt	  (62).	  
1.2.1.	  Physiology	  and	  pathology	  of	  progesterone	  
Apart	   from	   its	   crucial	   role	   in	   endometrial	   decidualisation	   and	   the	   maintenance	   of	   pregnancy	  
(discussed	  below),	  progesterone	  has	  a	  physiological	  role	  in	  various	  other	  tissues	  (63).	  Progesterone	  
is	  known	  to	  affect	  sexually	  responsive	  behaviour	  through	  its	  effects	  in	  the	  central	  nervous	  system.	  In	  
humans,	   it	   appears	   to	   reduce	   sexual	   desire	   and	   its	   metabolites	   exert	   neuroprotective	   effects	   on	  
traumatic	  and	  ischaemic	  brain	  injuries,	  as	  well	  as	  slow	  down	  the	  progression	  of	  Alzheimer’s	  disease	  
(64).	   In	  the	  breast,	  progesterone	  plays	  a	  role	   in	   lobular-­‐alveolar	  development,	  which	   is	  essential	   in	  
preparing	   for	   lactation	   (63).	   Further,	   it	   has	  been	  proposed	   that	  progesterone	  plays	   a	   role	   in	  bone	  
turnover	  by	  antagonising	  glucocorticoid-­‐mediated	  bone	  loss	  (63).	  	  	  
Progesterone	  and	  the	  progesterone	  receptor	  have	  been	  linked	  with	  various	  diseases.	  The	  impact	  on	  
mood	   and	   fatigue	   seen	   in	   premenstrual	   syndrome	   is	   believed	   to	   be	   linked	   to	   low	   levels	   of	  
progesterone	   (64).	   Further,	   progesterone	   receptor	   negative	   breast	   cancers	   are	   associated	   with	   a	  
poorer	  prognosis	  (65).	  Conversely,	  high	  progesterone	  levels	  are	  believed	  to	  drive	  leiomyoma	  growth,	  
which	  can	  precipitate	  menorrhagia,	  fertility	  problems,	  pelvic	  pain	  and	  indeed	  is	  the	  leading	  cause	  of	  
hysterectomy	   in	   females	   of	   reproductive	   age	   (66).	   Progesterone	   and	   its	   receptor	   have	   also	   been	  
linked	  to	  cervical	  cancer	  with	  evidence	  suggesting	  that	  they	  facilitate	  human	  papilloma	  virus	  (HPV)	  
DNA	  integration	  into	  the	  host	  genome	  (66).	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1.2.2.	  Progesterone	  receptor	  
Progesterone	  does	  not	  signal	  through	  a	  single	  receptor	  but	  rather	  multiple	  different	  entities.	  Indeed,	  
the	  progesterone	  receptor	  (PR)	  can	  broadly	  be	  divided	  into	  the	  nuclear	  progesterone	  receptor	  and	  
the	  membrane	  progesterone	  receptor.	  
1.2.2.1.	  Nuclear	  progesterone	  receptor	  	  
The	   nuclear	   progesterone	   receptor	   belongs	   to	   the	   nuclear	   receptor	   superfamily	   (67,	   68)	   and	   is	  
composed	  of	  three	  distinct	  domains	  (Fig.	  1.6.)	  (68-­‐70):	  	  
1. Ligand-­‐	  or	  hormone-­‐binding	  domain:	  this	   is	   located	  at	  the	  carboxyl	  terminus	  of	  the	  protein	  
and	   even	   though	   it	   is	   well-­‐conserved	   between	   different	   nuclear	   receptors,	   it	   allows	   for	  
specific	  hormone	  recognition.	  
2. DNA-­‐binding	   domain:	   located	   in	   the	   centre	   of	   the	   protein	   and	   contains	   two	   zinc-­‐finger	  
motifs.	  The	  portion	  of	  the	  protein	  between	  the	  ligand-­‐binding	  domain	  and	  the	  DNA-­‐binding	  
domain	  is	  termed	  the	  hinge.	  	  
3. N-­‐terminal	  or	  variable	  domain:	  this	  is	  located	  at	  the	  amino	  terminus	  of	  the	  protein	  and	  binds	  
co-­‐regulatory	  proteins	  and	  other	  transcription	  factors.	  
Additionally,	   nuclear	  progesterone	   receptor	   contains	   at	   least	   two	   transcription	  activation	  domains	  
which	  bind	  co-­‐regulatory	  proteins:	  AF-­‐1	   is	   located	   in	   the	  N-­‐terminal	  domain	  and	  AF-­‐2	   is	   located	   in	  
the	  ligand-­‐binding	  domain	  (71).	  	  
	  
Figure	   1.6.	   Nuclear	   progesterone	   receptor	   isoforms.	  NTD:	   N-­‐terminal	   domain;	   DBD:	   DNA-­‐binding	   domain;	  
LBD:	  ligand-­‐binding	  domain;	  AF-­‐1,	  2	  and	  3:	  activation	  domain	  1,	  2	  and	  3.	  Adapted	  from	  Patel	  et	  al.	  (66).	  
	  
The	  nuclear	  progesterone	  receptor	  is	  encoded	  by	  the	  PGR	  gene	  on	  chromosome	  11	  (11q22-­‐q23)	  and	  
is	  expressed	  as	   two	  major	   isoforms	  and	  controlled	  by	   two	  promoters	   (66,	  72,	  73).	  PR-­‐B	   is	   the	   full-­‐
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length	  isoform	  (116kDa)	  whereas	  PR-­‐A	  (94kDa)	  is	  a	  truncated	  version	  lacking	  164	  amino	  acids	  from	  
the	   N-­‐terminal	   domain	   (71,	   73)	   (Fig.	   1.6.).	   As	   a	   consequence,	   PR-­‐A	   lacks	   a	   third	   transcription	  
activation	   domain	   (AF-­‐3),	   which	   is	   present	   on	   PR-­‐B	   (74)	  making	   the	   latter	   the	  main	   transcription	  
activator	  of	  progesterone-­‐driven	  genes	  and	  the	  former	  a	  transcriptional	  repressor	  (75,	  76).	  Several	  
other	  shorter	  PR	  isoforms	  have	  been	  identified,	  such	  as	  PR-­‐C,	  although	  their	  role	  in	  pathophysiology	  
remains	   uncertain	   (77,	   78)	   (Fig.	   1.6.).	   Additionally,	   nuclear	   progesterone	   receptors	   can	   undergo	   a	  
multitude	  of	  post-­‐translational	  modifications	   including	  phosphorylation,	   acetylation,	  ubiquitination	  
and	   SUMOylation	   which	   consequently	   impact	   on	   receptor	   intracellular	   localisation,	   protein	  
interactions	  and	  transcriptional	  activity	  (79).	  
1.2.2.2.	  Membrane	  progesterone	  receptor	  
The	  ability	  of	  progesterone	  to	  bind	  to	  membrane	  receptors	  was	  first	   identified	  more	  than	  30	  years	  
ago	  (80,	  81),	  with	  membrane	  progesterone	  receptors	  (mPRs)	  being	  discovered	  more	  recently	  in	  fish	  
and	   humans	   (82,	   83).	   At	   least	   three	   membrane	   progesterone	   receptors	   have	   been	   identified	   in	  
humans	  to	  date:	  mPRα,	  β	  and	  γ,	  which	  are	  related	  to	  G-­‐protein-­‐coupled	  receptors,	  each	  made	  up	  of	  
seven	   trans-­‐membrane	   domains	   with	   the	   N-­‐terminus	   facing	   the	   extracellular	   space	   (82,	   83).	  
However	  some	  controversy	  exists	  with	  some	  researchers	  suggesting	   that	   the	  N-­‐terminus	   faces	   the	  
cytosolic	  side	  (84).	  
Progesterone	  receptor	  membrane	  component	  1	  and	  2	  (PGRMC1	  and	  PGRMC2)	  represent	  a	  separate	  
family	  of	  membrane	  progesterone	  receptors	  (85,	  86).	  Unlike	  mPRα,	  β	  and	  γ,	  PGRMCs	  are	  comprised	  
of	  a	  single	  transmembrane	  domain	  (87).	  It	  has	  been	  proposed	  that	  PGRMC1	  acts	  in	  conjunction	  with	  
serpine	   1	   mRNA	   binding	   protein	   I	   (SERBP1)	   to	   activate	   protein	   kinase	   G	   and	   lower	   intracellular	  
calcium	  levels	  (88,	  89).	  By	  comparison,	  very	  little	  is	  known	  about	  PGRMC2.	  	  
	  
1.2.3.	  Progesterone	  receptor	  co-­‐regulators,	  chaperones	  and	  co-­‐chaperones	  
Nuclear	  progesterone	  receptors	  have	  been	  shown	  not	  to	  act	  in	  isolation	  but	  rather,	  their	  function	  is	  
modulated	   by	   a	   variety	   of	   proteins	   broadly	   classified	   as	   co-­‐regulators,	   chaperones	   and	   co-­‐
chaperones	   (90).	   This	   provides	   an	   additional	   layer	   of	   regulation	   of	   progesterone	   signalling	   which	  
may	  be	  cell	  type-­‐	  as	  well	  as	  target	  gene-­‐specific	  (90).	  
The	   nuclear	   progesterone	   receptor	   is	   maintained	   in	   the	   cytoplasm	   in	   a	   multi-­‐protein	   structure	  
including	   heat	   shock	   protein-­‐70	   (HSP70)	   and	   HSP90;	   this	   ensures	   the	   receptor’s	   correct	   folding,	  
stability	   and	   ability	   to	   bind	   progesterone	   (91-­‐94).	   Additionally,	   HSP40,	   Hop	   and	   p23	   are	   vital	   for	  
assembly	   of	   the	   progesterone	   receptor	   complex	   in	   the	   cytoplasm,	   which	   can	   efficiently	   bind	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progesterone	  (95,	  96).	  Co-­‐chaperone	  proteins	  interact	  with	  chaperone	  proteins;	  in	  the	  case	  of	  HSP90	  
these	  are	   comprised	  of	  FK506-­‐binding	  protein	  1	   (FKBP51),	   FKBP52,	  CyP40	  and	  PP5	   (94).	   These	   co-­‐
chaperones	  compete	  for	  binding	  to	  HSP90	  and	  thus	  contribute	  to	  protein	  folding	  as	  well	  as	  receptor	  
sensitivity	   to	   hormone	   (94,	   97).	   High	   FKBP51	   levels	   in	   New	  World	   monkeys	   as	   compared	   to	   Old	  
World	  monkeys	   have	   been	   linked	   to	   glucocorticoid	   resistance	   (98)	   leading	   to	   the	   hypothesis	   that	  
FKBP51	   serves	   as	   an	   important	   regulator	   of	   tissue	   hormone	   sensitivity	   (99).	   Further,	   Fkbp52	  
knockout	   mice	   were	   found	   to	   be	   infertile	   despite	   normal	   progesterone	   receptor	   expression	   and	  
progesterone	  levels,	  highlighting	  the	  crucial	  role	  of	  this	  co-­‐chaperone	  in	  reproduction	  (100).	  
Once	   progesterone	   binds	   to	   the	   ligand-­‐binding	   domain	   of	   the	   progesterone	   receptor,	   a	  
conformational	  change	  occurs	  with	  dissociation	  of	   the	  receptor	   from	  the	  chaperone/co-­‐chaperone	  
complex,	  receptor	  dimerisation	  and	  subsequent	  nuclear	  translocation	  where	  the	  receptor	   interacts	  
with	  multiple	  other	  proteins	  as	  well	  as	  chromatin.	  	  
The	  term	  co-­‐regulator	  refers	  to	  a	   family	  of	  non-­‐DNA-­‐binding	  proteins	  comprising	  co-­‐activators	  and	  
co-­‐repressors.	  Liganded	  progesterone	  receptors	  bind	  to	  progesterone	  response	  elements	  where	  co-­‐
activators	   serve	   to	   mediate	   their	   signal	   for	   transcription	   by	   a	   variety	   of	   activities	   including	  
phosphorylation,	   acetylation,	  methylation	   and	   ubiquitination	   (101).	   Classically,	   the	   P4-­‐PR	   complex	  
interacts	   with	   p160	   co-­‐activators,	   comprised	   of	   steroid	   receptor	   co-­‐activator	   1	   (SRC1),	   SRC2	   and	  
SRC3	  (102,	  103),	  as	  well	  as	  histone	  acetyltransferases	  such	  as	  p300/CREB-­‐binding	  protein	  (101,	  104)	  
and	  DNA	  helicases	   (105).	   The	  end-­‐result	   of	   this	   protein	   complex	   is	   chromatin	   alteration	   such	   that	  
transcription	  is	  facilitated	  and	  allowed	  to	  proceed	  (106).	  	  
The	  relative	  importance	  of	  p160	  co-­‐activators	  in	  reproduction	  has	  been	  identified	  in	  animal	  studies.	  
Src1-­‐deficient	  mice	  demonstrated	  decreased	  uterine	   growth	  and	  mammary	   gland	  development	   as	  
well	  as,	   interestingly,	  raised	  SRC2	  levels	  suggesting	  a	  degree	  of	  compensation	  (107).	  Mice	   in	  which	  
Src2	  was	   conditionally	  knocked	  down	   in	   cells	  expressing	  progesterone	   receptor	  were	   shown	   to	  be	  
infertile	   (108)	   whereas	   work	   carried	   out	   on	   Src3-­‐null	   mice	   demonstrated	   reduced	   fertility	   and	  
impaired	   mammary	   gland	   development	   (109).	   Further	   and	   paradoxically,	   parturition	   was	  
significantly	  delayed	  in	  mice	  deficient	  in	  both	  SRC1	  and	  SRC2	  with	  the	  authors	  postulating	  that	  this	  
effect	  was	  due	  to	   the	   impact	  of	   these	  co-­‐activators	  on	  surfactant	  protein-­‐A	  and	  platelet	  activating	  
factor	   production	   (110).	   Taken	   together	   these	   studies	   demonstrate	   that	   p160	   co-­‐activators	   play	   a	  
crucial	  role	  in	  reproductive	  function	  and	  demonstrate	  a	  degree	  of	  overlap	  in	  their	  function.	  
In	   contrast,	   nuclear	   receptor	   co-­‐repressor	   (NCoR)	   and	   silencing	   mediator	   for	   retinoid	   or	   thyroid	  
hormone	   (SMRT)	   are	   related	   proteins	   of	   approximately	   270kDa,	   which	  make	   up	   the	   principal	   co-­‐
repressors	   (111).	   They	   act	   to	   suppress	   progesterone	   receptor	   action	   by	   creating	   a	   histone	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environment	   which	   is	   not	   favourable	   for	   transcription	   via	   recruitment	   of	   histone	   deacetylase	  
enzymes	  (101).	  Their	  role	  in	  progesterone	  receptor	  physiology	  is	  however	  contested	  (106)	  although,	  
interestingly,	   in	  vitro	  experiments	  have	  demonstrated	   that	  PR-­‐A	   interacts	  with	  co-­‐repressors	  more	  
readily	  that	  PR-­‐B	  and	  conversely	  PR-­‐B	  interacts	  with	  co-­‐activators	  whereas	  PR-­‐A	  does	  not	  (112).	  
It	   is	   interesting	   to	  note	   that	   co-­‐regulator	  molecules	  do	  not	  universally	  affect	   transcription	  as	   their	  
name	  would	   suggest	  with	   reports	   in	   the	   literature	   of	   co-­‐activators	   acting	   to	   repress	   transcription	  
(113-­‐115)	  and	  conversely,	  co-­‐repressors	  acting	  to	  enhance	  transcription	  (116).	  
	  
1.2.4.	  Progesterone	  action	  
As	   suggested	   by	   its	   name,	   progesterone	   is	   a	   progestational	   hormone	   that	   maintains	   pregnancy.	  
Along	  with	  oestrogen,	  it	  promotes	  hyperplasia	  and	  hypertrophy	  of	  myometrial	  cells	  hence	  allowing	  
the	  growing	  fetus	  to	  be	  accommodated	  within	  the	  uterus	  (66).	  At	  least	  in	  the	  field	  of	  parturition,	  the	  
most	   important	  and	  widely	  accepted	  action	  of	  progesterone	   is	  as	  a	  physiological	  brake	  on	  uterine	  
contractility	  and	  inflammation	  (117).	  Evidence	  in	  support	  of	  this	  hypothesis	  was	  put	  forward	  in	  the	  
1970s	   by	   Csapo,	   who	   demonstrated	   that	   removal	   of	   the	   source	   of	   progesterone	   production	   by	  
luteectomy	   in	   early	   pregnancy	   was	   sufficient	   to	   induce	   uterine	   contractions	   and	   pregnancy	   loss	  
(118).	   As	   discussed,	   progesterone	   binds	   to	   progesterone	   receptors	   and	   subsequently	   modulates	  
cellular	  function	  through	  genomic	  and	  non-­‐genomic	  actions.	  In	  addition,	  more	  recently,	  it	  has	  been	  
proposed	   that	   some	   of	   the	   actions	   of	   progesterone	  may	   also	   be	   mediated	   by	   the	   glucocorticoid	  
receptor	  (119,	  120).	  
1.2.4.1.	  Genomic	  progesterone	  action	  
The	  term	  genomic	  refers	  to	  an	  alteration	  in	  gene	  expression	  and	  this	  is	  postulated	  to	  be	  the	  principal	  
pathway	  of	  progesterone	  signalling	  in	  pregnancy	  and	  parturition	  (66).	  Upon	  progesterone	  binding	  in	  
the	  cytoplasm,	   the	  progesterone	   receptor	   forms	  a	  dimer	  and	   translocates	   to	   the	  nucleus	  where	   it	  
binds	   to	   progesterone	   response	   elements,	   which	   are	   DNA	   sequences	   usually	   upstream	   of	   the	  
transcription	   start	   site	   (Fig.	   1.7)	   (90,	   121,	   122).	   Several	   other	   proteins,	   such	   as	   co-­‐regulators	   are	  
recruited	  in	  order	  to	  facilitate	  transcription.	  	  
The	  importance	  of	  genomic	  progesterone	  action	  in	  reproduction	  is	  highlighted	  by	  the	  administration	  
of	   the	  antiprogestin	  mifepristone	   (RU486),	  which	   is	   sufficient	   to	   induce	  parturition	   (123-­‐125).	  This	  
drug,	   which	   has	   mixed	   agonist	   and	   antagonist	   actions,	   has	   been	   shown	   to	   act	   on	   nuclear	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progesterone	   receptors	   by	   promoting	   receptor	   dimerisation	   followed	   by	   progesterone	   response	  
element	  binding	  (126,	  127).	  
In	  addition,	  nuclear	  progesterone	  receptors	  have	  been	  implicated	  in	  indirect	  genomic	  progesterone	  
signalling	   by	   interacting	   with	   other	   transcription	   factors.	   For	   example,	   PR-­‐B	   has	   been	   shown	   to	  
interact	  with	  the	  Src-­‐homology	  3	  (SH3)	  domain	  of	  Src	  tyrosine	  kinases	  and	  subsequently	  activating	  
mitogen-­‐activated	  protein	  kinase	  (MAPK)	  signalling	  (128).	  Interestingly,	  PR-­‐A	  lacks	  this	  function	  (129)	  
(Fig.	  1.7).	   	  Another	  example	  of	   indirect	  signalling	  has	  been	  observed	   in	  cancer	  cell	   lines	  where	  the	  
P4-­‐PR	  complex	  has	  been	  shown	  to	  alter	  transcription	  by	  interacting	  with	  the	  Sp1	  transcription	  factor	  
(130-­‐132).	  
	  
Figure	  1.7.	  Genomic	  and	  non-­‐genomic	  progesterone	  signalling.	  CR:	  coregulator;	  PRE:	  progesterone	  response	  
element;	  TF:	  transcription	  factor.	  Adapted	  from	  Mesiano	  et	  al.	  (133).	  
Multiple	   in	   vitro	   studies	   have	   shown	   that	   PR-­‐B	   broadly	   mediates	   the	   effects	   of	   progesterone	   by	  
enhancing	  gene	  transcription	   in	  association	  with	  co-­‐activator	  proteins	   (112,	  134).	  Conversely,	  PR-­‐A	  
has	  been	  shown	  to	  act	  in	  association	  with	  co-­‐repressors	  to	  suppress	  transcription	  (75,	  76,	  112,	  135).	  
However,	  more	  recent	  research	  has	  challenged	  this	  rather	  simplistic	  view	  by	  demonstrating	  that	  PR-­‐
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A	  has	  minimal	  repressive	  activity	  and	  is	  transcriptionally	  active	  in	  its	  own	  right	  (136-­‐139).	  	  It	  is	  now	  
accepted	  that	  the	  balance	  of	  actions	  of	  the	  two	  receptor	  isoforms,	  which	  varies	  by	  tissue	  and	  disease	  
state,	  determines	  	  the	  observed	  phenotype	  (133).	  	  
The	  net	  result	  of	  genomic	  progesterone	  action	  in	  pregnancy	  is	  maintenance	  of	  uterine	  quiescence	  by	  
the	  suppression	  of	  inflammation	  and	  contractility.	  This	  is	  achieved,	  at	  least	  in	  part,	  by	  the	  reduction	  
of	   expression	   of	   (i)	   contraction-­‐associated	   proteins	   such	   as	   cyclooxygenase-­‐2	   (COX-­‐2)	   (120,	   140,	  
141),	  oxytocin	  receptor	  (OTR),	  prostaglandin	  F2α	  receptor	  (FP)	  and	  functional	  connexin-­‐43	  (142-­‐144)	  
(ii)	   pro-­‐inflammatory	   transcription	   factors	   including	   nuclear	   factor-­‐κB	   (NF-­‐κB)	   (140)	   and	   activator	  
protein-­‐1	  (AP-­‐1)	  (145)	  and	  (iii)	  pro-­‐inflammatory	  chemokines	  and	  cytokines	  (141).	  	  It	  may	  be	  that	  the	  
indirect	   action	   of	   nuclear	   progesterone	   receptor	   also	   contributes	   to	   the	   pregnancy	   phenotype,	   as	  
evidenced	   by	   progesterone	   action	   on	   oestrogen-­‐induced	   genes	   (146,	   147),	   which	   supports	   the	  
hypothesis	   of	   an	   inverse	   relationship	   with	   respect	   to	   uterine	   activation	   between	   these	   two	  
hormones.	   Further,	   nuclear	   progesterone	   receptor	   enhances	   the	   actions	   of	   the	   pro-­‐quiescent	  
cAMP/protein	  kinase	  A	  (PKA)	  pathway	  by	  stimulating	  PKA-­‐mediated	  inactivation	  of	  phospholipase	  C	  
hence	  maintaining	  low	  intracellular	  calcium	  levels	  (148).	  	  	  
It	   is	   also	   increasingly	   recognised	   that	   progesterone,	   like	   oestrogen,	   affects	   circadian	   rhythm	   gene	  
expression	   in	   the	   reproductive	   organs	   including	   the	   uterus	   through	   genomic	   actions	   (149-­‐152).	  
Indeed,	   it	   is	  now	  accepted	  that	  organs	  other	   than	  the	  suprachiasmatic	  nucleus	   in	   the	  brain,	  which	  
traditionally	   regulates	   circadian	   rhythm,	   express	   circadian	   rhythm	  genes	   (152)	   and	   the	   concept	   of	  
clocks	  in	  reproductive	  biology	  is	  not	  new	  (153).	  	  The	  evolutionary	  advantage	  of	  animals	  being	  able	  to	  
time	   pregnancy	   and	   parturition	   is	   clear	   in	   terms	   of	   offspring	   survival	   (154).	   It	   is	   also	   evident	   that	  
parturition	   in	  animals	  and	  humans,	  both	  at	   term	  and	  preterm,	   tends	  to	  occur	  at	  predictable	   times	  
with	  rats	   labouring	   in	  the	  day	  (155)	  and	  humans	  at	  night	  (156-­‐158).	  Further,	  shift	  workers	  have	  an	  
increased	  rate	  of	  adverse	  pregnancy	  outcomes,	  including	  preterm	  birth	  (159).	  
Multiple	  clock	  genes	  have	  been	  identified	  to	  date	  and	  their	  expression	  is	  inter-­‐regulated	  in	  a	  circuit	  
of	   three	   interlocking	   feedback	   loops	   (Fig.	   1.8.)	   (160).	   In	  mammals,	   at	   the	   centre	  of	   this	   circuit	   are	  
Clock,	   or	   alternatively	   Npas2,	   and	   Bmal1,	   which	   dimerise	   and	   bind	   to	   their	   promoter	   regions.	  
Amongst	  other	  genes,	  they	  upregulate	  the	  expression	  of	  Per	  and	  Cry	  which	  act	  as	  repressors	  of	  Clock	  
and	   Bmal1.	   Nuclear	   receptors,	   including	   the	   Rev-­‐Erb	   and	   retinoid-­‐related	   orphan	   receptor	   (ROR)	  
families,	   are	   also	   implicated	   in	   circadian	   rhythm	   regulation.	   Members	   of	   the	   Rev-­‐Erb	   family,	  
including	  Nr1d2,	   repress	   Bmal1	   whereas	   ROR	  members,	   including	   Rorc,	   enhance	   Bmal1.	   Further,	  
Ppargc1a	   modulates	   ROR	   expression.	   A	   third	   feedback	   loop	   exists	   containing	   the	   transcriptional	  
activators	   D-­‐box-­‐binding	   protein	   (DBP),	   thyrotroph	   embryonic	   factor	   (TEF)	   and	   hepatic	   leukaemia	  
factor	  (HLF)	  as	  well	  as	  the	  transcriptional	  repressor	  E4	  promoter-­‐binding	  protein	  4	  (E4BP4).	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Dysfunction	   of	   circadian	   rhythm	  genes	   in	   reproductive	   organs,	   as	   seen	   for	   example	   in	   conditional	  
myometrial	  Bmal1	  knock-­‐out	  mice	  which	   is	  associated	  with	  a	  failure	  of	  parturition	  at	  the	  expected	  
time	  window,	  highlights	   the	   importance	  of	   these	  genes	   (161).	   The	  expression	  of	  myometrial	   clock	  
genes	  including	  Clock,	  Npas2,	  Cry1,	  Per1,	  Nr1d2,	  Rorc	  and	  Ppargc1	  has	  been	  shown	  to	  be	  modulated	  
by	  progesterone	  (152).	  	  
Circadian	   rhythm	  has	   been	   proposed	   to	   play	   an	   important	   role	   in	   parturition	   and	   preterm	   labour	  
through	   its	  modulation	  of	   inflammation	   via	   a	   variety	  of	   signalling	  pathways	   including	   cAMP	   (160),	  
nuclear	   factor-­‐κB	   (NF-­‐κB)	   (162)	   and	   activator	   protein-­‐1	   (AP-­‐1)	   (163).	   The	   exact	   mechanisms	  
underlying	  modulation	   of	   gene	   expression	   by	   circadian	   genes	   remains	   poorly	   characterised	   (160).	  
Indeed	  a	  degree	  of	  possible	  contradiction	  exists	  in	  the	  literature;	  for	  example	  Clock	  has	  been	  shown	  
to	  be	  progesterone-­‐driven	  (152)	  but	  also	  enhances	  pro-­‐inflammatory	  gene	  expression	  by	  virtue	  of	  its	  
interaction	  with	  NF-­‐κB	  (162).	  
	  
Figure	  1.8.	  Mammalian	  circadian	  clock.	  Adapted	  from	  Zhang	  et	  al.	  (160).	  
1.2.4.2.	  Non-­‐genomic	  progesterone	  action	  
The	  scientific	  community	  has	  known	  since	  the	  1940s	  that	  progesterone	  is	  capable	  of	  having	  a	  rapid	  
onset	  of	   action	   (164).	   This	  observation	  has	  been	  observed	   in	   a	   variety	  of	  other	  biological	   systems	  
(165,	   166)	   and	   cannot	   be	   explained	   by	   genomic	   progesterone	   signalling	   as	   this	   can	   take	   hours	   in	  
order	  to	  lead	  to	  a	  change	  in	  the	  phenotype.	  Indeed	  substantial	  research	  has	  now	  been	  undertaken	  
into	  elucidating	  the	  non-­‐genomic	  actions	  of	  progesterone,	  which	  do	  not	  rely	  on	  DNA	  transcription	  or	  
RNA	  translation	  to	  form	  new	  proteins.	  	  
As	   discussed	   earlier,	   several	   receptors	   have	   been	   shown	   to	   be	   involved	   in	   non-­‐genomic	  
progesterone	  signalling	  and	  these	  do	  not	  solely	  include	  membrane	  progesterone	  receptors	  but	  also	  
nuclear	  progesterone	  receptor	  variants,	  which	  are	  predicted	  to	  localise	  solely	  to	  the	  cytoplasm,	  and	  
allosteric	   regulation	   of	   non-­‐progesterone	   receptors	   such	   as	   OTR	   and	   GABAA	   receptor	   (167).	  
Progesterone	   has	   been	   shown	   in	   vitro	   to	   be	   capable	   of	   binding	   to	  OTR	   and	   inhibiting	   its	   function	  
(168),	  although	  these	  findings	  have	  since	  been	  contested	  (169).	  Further,	  progesterone	  metabolites	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such	   as	   allopregnanolone	   have	   also	   been	   shown	   to	   be	   capable	   of	   directly	   binding	   to	   unrelated	  
receptors	  including	  GABAA	  and	  subsequently	  modulating	  function	  (170).	  	  
Through	  non-­‐genomic	   actions,	   it	   has	   been	  proposed	   that	   progesterone	   is	   capable	   of	   reducing	   the	  
intracellular	   calcium	   concentration	   (171,	   172),	   which	   is	   vital	   for	   myometrial	   cell	   contractility.	  
Administration	  of	  high-­‐doses	  of	  progesterone	  was	  shown	  to	  rapidly	  reduce	  contractility	   in	  humans	  
(173)	  and	  in	  vitro	  (174).	  It	  has	  also	  been	  proposed	  that	  progesterone	  can	  increase	  intracellular	  cAMP	  
levels	  (175,	  176),	  which	  acts	  to	  enhance	  progesterone	  action	  and	  promote	  uterine	  quiescence	  (177,	  
178).	  	  
	  
1.2.5.	  Progesterone	  withdrawal	  
One	   of	   the	   main	   challenges	   of	   human	   parturition	   is	   that	   progesterone	   levels	   continue	   to	   rise	  
throughout	   gestation	   and	   do	   not	   drop	   with	   labour	   onset	   (179-­‐181)	   (Fig.	   1.8.).	   However,	   as	  
mentioned	   above,	   the	   nuclear	   progesterone	   receptor	   antagonist	   mifepristone	   remains	   able	   to	  
induce	  parturition	  at	  any	  gestation	  (123-­‐125)	  suggesting	  that	  (i)	  even	  though	  systemic	  progesterone	  
levels	  may	  not	  alter,	  progesterone	   function	   is	   lost	  at	   labour	  onset	  and	   (ii)	  even	  though	  membrane	  
progesterone	  receptors	  may	  play	  a	  role	   in	  progesterone	  signalling,	  nuclear	  progesterone	  receptors	  
are	  crucial	  in	  uterine	  quiescence.	  This	  has	  led	  to	  the	  concept	  of	  functional	  progesterone	  withdrawal	  
(182,	   183)	   and	   many	   research	   groups	   have	   aimed	   to	   identify	   the	   mechanisms	   underlying	   this	  
phenomenon.	  	  	  
	  
Figure	  1.9.	  Serum	  progesterone	  levels	  in	  mammalian	  pregnancy.	  Adapted	  from	  Mitchell	  et	  al.	  (184).	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1.2.5.1.	  Progesterone	  withdrawal	  in	  animals	  
The	  phenomenon	  of	  a	  systemic	  drop	  in	  progesterone	  levels	   in	  animals	  such	  as	  rodents	  (185)	  raises	  
questions	  as	  to	  the	  translatability	  of	  such	  research	  into	  humans	  although	  arguably,	  in	  vivo	  research	  is	  
superior	   to	   in	  vitro.	  Early	   research	  demonstrated	  that	  progesterone	  receptor	  knock-­‐out	  mice	  were	  
infertile	  (186).	  This	  was	  followed	  by	  research	  in	  which	  specific	  progesterone	  receptor	  isoforms	  were	  
knocked-­‐out	  demonstrating	  that	  mice	  lacking	  PR-­‐A	  were	  also	  infertile	  (187)	  and	  that	  PR-­‐B	  knock-­‐out	  
mice	   exhibited	   mammary	   gland	   abnormalities	   but	   maintained	   the	   ability	   to	   sustain	   a	   pregnancy	  
(188).	   These	   findings	  highlight	   that	   the	   two	   isoforms	  may	  mediate	  different	  progesterone	  actions.	  
Perhaps	  more	  importantly,	  PR-­‐B	  is	  not	  essential	  in	  murine	  pregnancy	  despite	  having	  been	  shown	  in	  
vitro	  to	  mediate	  P4	  action.	  
Many	   mammals,	   including	   mice,	   depend	   on	   the	   corpus	   luteum	   for	   progesterone	   production	   and	  
upon	  luteolysis,	  a	  systemic	  decline	  in	  progesterone	  levels	  occurs	  with	  labour	  ensuing	  as	  well	  an	  up-­‐
regulation	   in	   all	   progesterone	   receptor	   isoforms	   (189).	   It	   is	   interesting	   to	   note	   that,	   at	   least	   in	  
rodents,	  progesterone	  levels	  remain	  above	  the	  dissociation	  constant	  (Kd)	  for	  progesterone	  receptor	  
binding	  despite	  the	  systemic	  decline	  in	  levels	  (190).	  Indeed,	  mice	  lacking	  Trp53	  in	  uterine	  tissue	  have	  
raised	   preterm	   labour	   rates	   in	   the	   absence	   of	   a	   decline	   in	   systemic	   progesterone	   levels	   due	   to	  
elevated	  COX-­‐2	  levels	  (191).	  
In	   mice,	   it	   has	   been	   proposed	   that	   the	   signal	   for	   luteolysis	   is	   provided	   by	   rising	   levels	   of	  
prostaglandin	   F2α	   (192).	   Some	   investigators	   have	   also	   suggested	   that	   the	   fetal	   lung-­‐derived	  
surfactant	  protein-­‐A	  is	  responsible	  for	  labour	  initiation	  in	  mice	  (193).	  In	  contrast,	  the	  mechanism	  of	  
the	   systemic	   decline	   in	   progesterone	   levels	   in	   sheep	   is	   different:	   an	   increase	   in	   fetal	   cortisol	  
stimulates	  conversion	  of	  progesterone	  into	  oestrogen	  by	  17α-­‐hydroxylase	  (194).	  	  
1.2.5.2.	  Genomic	  mechanisms	  of	  functional	  progesterone	  withdrawal	  
A	   multitude	   of	   mechanisms	   have	   been	   put	   forward	   to	   account	   for	   functional	   progesterone	  
withdrawal	  and	   these	  will	  be	  discussed	  below.	   It	   is	  plausible	   that	   these	  mechanisms	  do	  not	  act	   in	  
isolation	  but	  rather	  in	  conjunction	  and	  indeed	  evidence	  to	  this	  effect	  has	  recently	  been	  put	  forward	  
by	  Nadeem	  and	  colleagues	  (195).	  	  
An	   increase	   in	   the	   PR-­‐A:PR-­‐B	   ratio	   at	   the	   time	   of	   labour	   onset	   is	   one	   of	   the	   principal	   proposed	  
mechanisms	  underlying	  functional	  progesterone	  withdrawal.	  PR-­‐A	  dominance	  has	  been	  observed	  in	  
humans	  by	  several	  groups	  (134,	  196,	  197)	  with	  similar	  findings	  observed	  in	  the	  rhesus	  monkey	  (198).	  
Some	  authors	  have	  taken	  this	  observation	  further	  by	  carrying	  out	  cell	  line	  work	  demonstrating	  that	  
the	  potential	  mechanism	  underlying	   the	  PR-­‐A:PR-­‐B	   increase	   could	  be	   an	   increase	   in	  prostaglandin	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F2α	  levels	  (199).	  However,	  direct	  evidence	  that	  a	  switch	  in	  the	  PR-­‐A:PR-­‐B	  ratio	  underlies	  functional	  
progesterone	  withdrawal	  is	  still	  lacking.	  	  	  
A	   change	   in	   the	   expression	   of	   nuclear	   progesterone	   receptor	   co-­‐regulator	   levels	   has	   also	   been	  
forward	   as	   a	   possible	   mechanism	   for	   functional	   progesterone	   withdrawal.	   Indeed	   a	   decreased	  
interaction	   between	   progesterone	   receptor	   and	  DNA	   has	   been	   observed	  with	   labour	   onset	   (200).	  
Following	  this,	  several	  investigators	  have	  shown	  a	  decline	  in	  co-­‐activator	  levels	  in	  various	  gestational	  
tissues	   with	   the	   onset	   of	   labour	   (201,	   202).	   Some	   co-­‐activators	   possess	   histone	   acetyltransferase	  
activity	  hence	  allowing	  assembly	  of	  the	  transcriptional	  apparatus	  at	  gene	  promoter	  sites	  (201).	  Thus,	  
a	   loss	  of	  co-­‐activator	  function	  could	  result	   in	  suppression	  of	  transcription	  and	  loss	  of	  progesterone	  
function.	  	  
Even	   though	   systemic	   progesterone	   levels	   do	   not	   decline	   prior	   to	   human	   parturition,	   it	   has	   been	  
proposed	   that	   altered	   local	  metabolism	   brings	   about	   a	   tissue-­‐level	   decline.	  Mice	   lacking	   enzymes	  
crucial	   in	   progesterone	   catabolism	   including	   5α-­‐reductase	   (203,	   204)	   or	   20α-­‐hydroxysteroid	  
dehydrogenase	  (205,	  206)	  fail	  to	  go	  into	  labour	  at	  term	  despite	  a	  systemic	  progesterone	  drop.	  Early	  
studies	  in	  humans	  supported	  the	  hypothesis	  of	  altered	  local	  P4	  metabolism,	  leading	  to	  accumulation	  
of	   inactive	   P4	   metabolites,	   playing	   a	   role	   in	   human	   labour	   (207-­‐209).	   A	   down-­‐regulation	   in	   the	  
progesterone-­‐synthesising	  enzyme	  17β-­‐hydroxysteroid	  dehydrogenase	   type	  2	  was	   identified	   in	   the	  
cervix	  of	  pregnant	  women	  in	  labour	  (210)	  as	  well	  as	  a	  myometrial	  up-­‐regulation	  of	  the	  progesterone-­‐
metabolising	  20α-­‐hydroxysteroid	  dehydrogenase	   (195)	  providing	   further	  support	   to	   the	  hypothesis	  
that	  this	  mechanism	  may	  occur	  in	  human	  parturition.	  	  
Antagonism	  of	  progesterone	  receptor	  action	  by	  pro-­‐inflammatory	  transcription	  factors	  including	  NF-­‐
κB	   has	   been	   put	   forward	   as	   a	  mechanism	   of	   functional	   progesterone	  withdrawal	   in	   its	   own	   right	  
rather	   than	  simply	  being	  the	  end	  result	  of	  other	  processes	  underlying	   loss	  of	  progesterone	  action.	  
This	  is	  on	  the	  basis	  of	  the	  mutual	  repression	  that	  has	  been	  identified	  between	  the	  two	  transcription	  
factors	   in	  various	   in	  vitro	  models	  (120,	  140,	  189,	  211,	  212).	   Indeed,	   increased	  NF-­‐κB	  activation	  has	  
been	  observed	  with	  labour	  onset	  (189).	  It	  is	  postulated	  NF-­‐κB	  dominance	  at	  labour	  onset	  occurs	  as	  a	  
result	   of	   increasing	   inflammation	   and	   a	   decline	   in	   progesterone	   receptor	   function	   by	   other	  
mechanisms	  described	  above	   (12),	  however	  questions	  remain	  as	  to	  which	  event(s)	  actually	   initiate	  
the	  process	  of	  parturition.	  	  
It	   has	   been	   postulated	   that	  microRNAs,	  which	   are	   short	   RNA	   sequences	  with	   a	   regulatory	   role	   in	  
multiple	  biological	  processes,	  may	  also	  account	  for	  functional	  progesterone	  withdrawal	  (213).	  miR-­‐
200	  members,	  which	  have	  been	  shown	  to	  increase	  at	  term,	  act	  to	  reduce	  the	  expression	  of	  ZEB1	  and	  
ZEB2	   transcription	   factors	   and	   further,	   overexpression	   of	   these	   transcription	   factors	   in	   vitro	   is	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associated	   with	   inhibition	   of	   the	   expression	   of	   contraction-­‐associated	   proteins	   (214).	   It	   has	   been	  
suggested	   that	   the	   mechanism	   underlying	   the	   increase	   in	   miR-­‐200	   members,	   which	   are	  
progesterone-­‐driven,	  at	  term	  is	  via	  induction	  of	  20α-­‐hydroxysteroid	  dehydrogenase	  and	  hence	  local	  
progesterone	   metabolism	   (213).	   Additionally,	   miR-­‐199	   members,	   which	   have	   been	   shown	   to	   be	  
downregulated	  at	  term	  (213),	  are	  capable	  of	  inhibiting	  NF-­‐κB	  activation	  (215,	  216)	  hence	  providing	  a	  
potential	  second	  mechanism	  underlying	  functional	  progesterone	  withdrawal.	  	  
1.2.5.3.	  Non-­‐genomic	  mechanisms	  of	  functional	  P4	  withdrawal	  
Of	   the	   nuclear	   progesterone	   receptor	   variants,	   PR-­‐C	   expression	   was	   shown	   to	   increase	   with	   the	  
onset	  of	  human	  parturition	  (189).	  Further,	  the	  same	  group	  showed	  in	  the	  hTERT-­‐HM	  myometrial	  cell	  
line	  that	  PR-­‐C	  inhibits	  PR-­‐B	  action	  hence	  concluding	  this	  could	  represent	  a	  mechanism	  for	  functional	  
P4	  withdrawal	  (189).	  However,	  other	  investigators	  have	  since	  concluded	  that	  PR-­‐C	  is	  not	  a	  naturally	  
occurring	  isoform	  (217).	  Indeed,	  Madsen	  et	  al.	  have	  shown	  that	  the	  putative	  PR-­‐C	  band	  identified	  on	  
immunobloting	  is	  in	  fact	  predominantly	  comprised	  of	  the	  cytoskeletal	  proteins	  vimentin	  and	  desmin	  
(218).	  
Membrane	   progesterone	   receptors	   have	   also	   been	   implicated	   in	   progesterone	   signalling	   in	  
pregnancy	   and	   parturition	   (219-­‐221).	  Most	   notably,	   Karteris	   et	   al.	   implicated	  mPRα	   and	  mPRβ	   in	  
functional	  progesterone	  withdrawal	  by	  demonstrating	  that	  these	  receptors	   inhibit	  adenylyl	  cyclase	  
and	  activate	  myosin	   light	   chain	  by	  phosphorylation,	   hence	   leading	   to	   a	   loss	   of	   uterine	  quiescence	  
(222)	   (Fig.	   1.7.).	   However	   these	   findings	   have	   been	   contested	   after	   membrane	   progesterone	  
receptors	  were	  shown	  not	  to	  localise	  to	  the	  plasma	  membrane	  or	  to	  be	  activated	  by	  progesterone	  
(223).	  
Both	   PGRMC1	   and	   PGRMC2	   mRNA	   levels	   are	   increased	   in	   the	   endometrium	   of	   pregnant	   cows,	  
although	   the	   significance	   of	   this	   observation	   remains	   unclear	   (224).	   A	   decline	   in	  myometrial	   RNA	  
levels	   of	   both	   receptors	   was	   identified	   with	   the	   onset	   of	   human	   parturition	   both	   at	   term	   and	  
preterm	   suggesting	   a	   potential	   role	   in	   progesterone	   withdrawal	   (225,	   226).	   However,	   conclusive	  
evidence	  that	  PGRMCs	  bind	  progesterone	  is	  still	  lacking	  (87,	  227).	  
In	   summary,	   several	  non-­‐genomic	  progesterone	  signalling	  pathways	  have	  been	  proposed,	   some	  of	  
which	   have	   been	   implicated	   in	   functional	   progesterone	   withdrawal.	   However,	   many	   conflicting	  
reports	   exist	   in	   the	   literature	   regarding	   non-­‐genomic	   progesterone	   action	   and	   more	   research	   is	  
required.	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1.2.5.4.	  Other	  mechanisms	  of	  labour	  onset	  
More	   recently,	   Phillippe	   has	   put	   forward	   a	   hypothesis	   to	   account	   for	   labour	   onset	   that	   is	  
independent	  of	  progesterone	  action	  (228).	  Specifically,	  he	  postulated	  that	  cell-­‐free	  fetal	  DNA	  which	  
is	  shed	  from	  the	  placenta	  in	  the	  maternal	  circulation	  is	  responsible	  for	  labour	  onset	  at	  all	  gestations	  
(228).	  This	  is	  based	  on	  the	  observation	  that	  cell	  free	  DNA	  (i)	  peaks	  at	  the	  end	  of	  pregnancy	  and	  drops	  
dramatically	  in	  the	  postpartum	  period	  (229,	  230)	  and	  (ii)	  activates	  TLR9	  which	  drives	  NF-­‐κB	  incuding	  
the	  labour-­‐associated	  inflammatory	  myometrial	  phenotype	  (231).	  
	  
1.3.	  Inflammation	  
Inflammation	  was	  first	  recognised	  by	  Hippocrates	  in	  Ancient	  Greece	  as	  being	  a	  key	  aspect	  of	  healing	  
after	  injury	  and	  characterised	  by	  oedema	  (232).	  It	  was	  further	  defined	  in	  Ancient	  Rome	  as	  featuring	  
tumor	  (oedema),	  rubor	  (redness),	  calor	  (heat)	  and	  dolor	  (pain).	  It	  is	  now	  understood	  that	  upon	  tissue	  
injury,	  cytokines	  and	  chemokines	  are	  released	  which	  serve	  to	  recruit	  innate	  immune	  cells,	  comprised	  
of	  neutrophils	  and	  macrophages	  (233).	  Neutrophils	  are	  usually	  the	  first	  inflammatory	  cells	  to	  arrive	  
at	   the	   site	  of	   injury	   followed	  by	  monocytes,	  which	  once	  outside	   the	   vasculature	  differentiate	   into	  
macrophages	  (233).	  Inflammation	  is	  implicated	  in	  multiple	  aspects	  of	  pathology	  but	  also	  physiology.	  
Indeed,	  it	  is	  a	  recurrent	  event	  in	  reproduction	  and	  is	  a	  feature	  of	  ovulation	  (234),	  implantation	  (235,	  
236)	  and	  parturition,	  both	  preterm	  and	  at	  term	  (10,	  237).	  
Cytokines	   represent	   a	   family	   of	   proteins	   that	   serve	   to	  modulate	   inflammation.	   They	   are	   classified	  
according	  to	  their	  function	  into	  (i)	  pro-­‐inflammatory	  cytokines	  including	  IL-­‐1α,	  IL-­‐1β,	  IL-­‐6,	  IL-­‐8,	  TNF-­‐α	  
and	   IFNγ,	   (ii)	   anti-­‐inflammatory	   cytokines	   including	   IL-­‐10,	   and	   (iii)	   adaptive	   immunity	   cytokines	  
including	  GM-­‐CSF	  (238).	  	  
As	  implied	  by	  their	  name,	  chemokines	  are	  group	  of	  chemotactic	  proteins.	  They	  are	  subdivided	  into	  
four	  groups	  based	  on	  the	  positioning	  of	  the	  N-­‐terminal	  cysteine	  residues:	  (i)	  CC	  family	  including	  CCL2	  
and	  CCL5,	  (ii)	  C	  family	  including	  XCL1,	  (iii)	  CXC	  family	  including	  CXCL1	  and	  CXCL2	  and	  (iv)	  CX3C	  family	  
including	  CX3CL1	  (238).	  
At	  the	  centre	  of	  most	  known	  inflammatory	  processes,	  are	  key	  transcription	  factors	  including	  NF-­‐κB,	  
AP-­‐1	   and	   CAAT/enhancer	   binding	   protein	   (C/EBP).	   NF-­‐κB	  was	   first	   recognised	   in	   B	   cells	   (239)	   and	  
represents	   a	   family	   of	   transcription	   factors	   that	   play	   a	   crucial	   role	   in	   inflammation	   (240).	   	   In	   the	  
absence	  of	  an	   inflammatory	  stimulus,	  the	  most	  abundant	  NF-­‐κB	  subtypes	  p65	  and	  p50	  exist	   in	  the	  
cytoplasm	  as	  heterodimers	  bound	   to	   their	   inhibitor	   IκBα	   (240).	  Upon	  activation,	  NF-­‐κB	  dissociates	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from	  IκBα	  and	  translocates	  to	  the	  nucleus	  where,	  after	  p65	  phosphorylation	  (241,	  242),	  it	  modulates	  
the	  transcription	  of	  various	  pro-­‐inflammatory	  mediators	  (240).	  
AP-­‐1	  represents	  another	  family	  of	  transcription	  factors,	  which	  also	  enhance	  pro-­‐inflammatory	  gene	  
expression.	   AP-­‐1,	   typically	   composed	   of	   c-­‐Fos	   and	   c-­‐Jun	   heterodimers,	   is	   activated	   by	  
phosphorylation	   (243).	   Signal	   transduction	   from	   the	   cell	   membrane	   reaches	   AP-­‐1	   via	   the	   MAPK	  
signalling	   cascade,	   comprised	   of	   extracellular	   signal-­‐related	   kinases	   (ERK)	   1/2,	   p38	   and	   Jun	   N-­‐
terminal	  kinase	  (JNK),	  which	  are	  themselves	  activated	  by	  phosphorylation	  (243).	  MAPK	  phosphatase-­‐
1	   (MKP-­‐1)	   acts	   to	   regulate	   this	   cascade	   by	  MAPK	   dephosphorylation	   and	   has	   been	   shown	   to	   be	  
inducible	   by	   progesterone	   (145,	   244).	   Similarly	   to	  NF-­‐κB,	   once	   activated,	   AP-­‐1	   translocates	   to	   the	  
nucleus	  where	  it	  binds	  to	  its	  response	  elements	  hence	  modulating	  transcription.	  	  
C/EBP	   is	  a	   third	   family	  of	   transcription	   factors	  of	  which	   the	  C/EBPβ	  member	  has	  been	  reported	  to	  
play	   a	   role	   in	   the	   inflammatory	   response	   (245).	   It	   exists	   as	   two	   isoforms:	   liver-­‐activating	   protein	  
(LAP),	   the	   full-­‐length	   version,	   and	   liver-­‐inhibiting	   protein	   (LIP),	   the	   truncated	   version	   (246).	   The	  
relative	  expression	  of	  these	  isoforms	  determines	  the	  net	  action	  of	  the	  transcription	  factor	  on	  gene	  
expression	  (247).	  	  
	  
1.3.1.	  Inflammation	  in	  term	  labour	  
Physiological	  labour	  at	  term	  is	  associated	  with	  inflammation	  in	  the	  myometrium	  as	  well	  as	  the	  cervix	  
and	   fetal	  membranes.	   (248).	   This	   is	   evidenced	  by	  mast	   cell	   activation	   (249,	  250),	   an	   influx	  of	  pro-­‐
inflammatory	  cells,	  comprised	  of	  neutrophils	  and	  macrophages,	   from	  the	  circulation	  and	   increased	  
levels	  of	  pro-­‐inflammatory	  cytokines	  and	  chemokines,	  including	  IL-­‐1β,	  IL-­‐6,	  IL-­‐8	  and	  TNF-­‐α	  (10,	  251).	  
These	   cytokines	   originate	   from	   the	   myometrium	   and	   fetal	   membranes	   as	   well	   as	   the	   invading	  
leukocytes	   themselves	   (11,	   252).	   Indeed,	   the	   main	   functions	   of	   neutrophils	   (253,	   254)	   and	  
macrophages	   (255,	   256)	   are	   to	   release	  pro-­‐inflammatory	   cytokines	   and	  matrix	  metalloproteinases	  
(MMPs).	   Apart	   from	   their	   chemo-­‐attractant	   properties,	   these	   substances	   stimulate	   prostaglandin	  
(257,	  258),	  MMP	  synthesis	  (259)	  as	  well	  as	  elevated	  oxytocin	  receptor	  expression	  (260).	  	  
Myometrial	   gene	   expression	   profiling	   demonstrates	   that	   inflammatory	   pathways	   are	   enhanced	   in	  
association	  with	   parturition	   at	   term	   (6,	   261-­‐264).	   These	  data	   have	  been	   further	   supported	  by	   the	  
first	   high	   throughput	   RNA	   sequencing	   to	   compare	   myometrium	   prior	   and	   after	   labour	   onset,	  
demonstrating	  similar	  results	  to	  the	  microarray	  studies	  (265).	  	  	  
As	   with	   any	   other	   inflammatory	   phenotype,	   labour	   is	   associated	   with	   up-­‐regulation	   of	   the	   pro-­‐
inflammatory	   transcription	   factors	   NF-­‐κB	   (189,	   193,	   212,	   266-­‐268)	   and	   AP-­‐1	   (269-­‐271).	   NF-­‐κB	   up-­‐
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regulation	  sets	  up	  a	  positive	  feedback	  loop	  where	  it	  activates	  and	  is	  activated	  by	  pro-­‐inflammatory	  
cytokines	  (240,	  272-­‐274).	  
As	  a	  result	  of	  activation	  of	  these	  transcription	  factors,	  it	  is	  postulated	  that	  there	  is	  an	  up-­‐regulation	  
in	   contraction-­‐associated	   protein	   expression	   (275),	   including	   COX-­‐2	   (212,	   268,	   274),	   connexin-­‐43	  
(276),	  OTR	  (277),	  MMPs	  (268,	  278)	  and	  prostaglandin	  F2α	  receptor	  (279)	  (Fig.	  1.10.).	  C/EBP	  has	  not	  
been	  widely	   implicated	   in	   parturition	   although	   it	  may	  play	   a	   role	   in	   stretch-­‐induced	  expression	  of	  
OTR	  (280).	  
It	   is	   interesting	   to	  note	   that	  parturition	   is	  also	  associated	  with	  up-­‐regulation	   in	  expression	  of	  anti-­‐
inflammatory	  mediators	  including	  IL-­‐10	  (281)	  and	  the	  receptors	  for	  the	  anti-­‐inflammatory	  mediator	  
lipoxin	  (282)	  (Fig.	  1.10.).	  It	  is	  plausible	  that	  this	  allows	  for	  regulation	  of	  the	  degree	  of	  inflammation.	  	  
	  
	  
Figure	   1.10.	   Pro-­‐inflammatory	   and	   anti-­‐inflammatory	   pathways	   in	   parturition.	   MMP:	   matrix	  
metalloproteinase.	  Adapted	  from	  Jabbour	  et	  al.	  (248).	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1.3.2.	  Infection	  and	  inflammation	  in	  preterm	  labour	  
Even	  though	  microarray	  analysis	  has	  demonstrated	  similarities	  between	  gene	  expression	  patterns	  in	  
term	   and	   preterm	   labour	   (269),	   it	   remains	   to	   be	   proven	   that	   they	   are	   indeed	   the	   same	   process.	  
Nevertheless,	   inflammation	   is	   a	   feature	   of	   both.	   Indeed,	   infection,	   which	   is	   characterised	   by	  
inflammation	   arising	   due	   to	   pathogenic	   stimulation	   of	   Toll-­‐like	   and	   other	   pattern	   recognition	  
receptors	   with	   subsequent	   host	   immune	   system	   activation,	   is	   the	   only	   causally	   linked	   aetiology	  
underlying	  preterm	  labour	  (237).	  Myometrial	  invasion	  by	  neutrophils	  and	  macrophages	  is	  seen	  with	  
ensuing	   cervical	   dilatation	   and	   uterine	   contractions	   leading	   to	   fetal	   delivery	   (283).	   Macrophage-­‐
depleted	  mice	  fail	  to	  go	  into	  preterm	  labour	  following	  a	  bacterial	  lipopolysaccharide	  stimulus	  (284)	  
as	  do	  mice	  treated	  with	  a	  broad	  spectrum	  chemokine	  inhibitor	  (285),	  highlighting	  the	  crucial	  role	  of	  
inflammation	  in	  infection-­‐mediated	  preterm	  labour.	  
	  
1.3.3.	  Stretch	  and	  inflammation	  in	  preterm	  labour	  
Excessive	   uterine	   stretch,	   as	   in	   multiple	   pregnancy	   and	   polyhydramnios	   (286),	   is	   known	   to	   be	  
associated	   with	   preterm	   birth.	   In	   a	   healthy	   singleton	   pregnancy,	   uterine	   growth	   with	   advancing	  
gestation	  is	  associated	  with	  a	  constant	  intra-­‐amniotic	  pressure	  (287);	  this	  effect	  is	  thought	  to	  be	  due	  
to	   the	   action	   of	   pro-­‐quiescent	   mediators	   including	   progesterone	   and	   cAMP	   (288).	   The	   effect	   of	  
stretch	  is	  enhanced	  towards	  the	  end	  of	  pregnancy	  as	  the	  uterus	  ceases	  to	  grow	  further,	  resulting	  in	  
increased	  an	  intra-­‐amnionic	  pressure.	  
One	   theory	   put	   forward	   to	   account	   for	   the	   increased	   rate	   of	   preterm	   labour	   in	   the	   context	   of	  
multiple	   pregnancy	   relates	   to	   a	   larger	   placental	   volume	   and	   hence	   increased	   levels	   of	   potentially	  
pro-­‐contractile	  signals	  such	  as	  CRH	  (289,	  290).	  However,	  this	  is	  unlikely	  to	  account	  for	  all	  incidences	  
of	  stretch-­‐related	  cases	  of	  preterm	  labour	  given	  that	  there	  is	  no	  increased	  placental	  mass	  associated	  
with	   polyhydramnios.	   Indeed,	   even	   in	  multiple	   pregnancy,	   no	   difference	  was	   found	   in	   CRH	   levels	  
between	  those	  twin	  gestations	  associated	  with	  preterm	  birth	  and	  those	  associated	  with	  term	  birth	  
(289).	  
Multiple	  in	  vitro	  experiments	  have	  shown	  that	  the	  application	  of	  mechanical	  stretch	  on	  myometrial	  
or	  amnion	  cells	   leads	  to	   increased	   levels	  of	  pro-­‐inflammatory	  mediators,	  such	  as	   IL-­‐6	  and	  IL-­‐8,	  and	  
contraction-­‐associated	  proteins,	  including	  COX-­‐2	  and	  OTR,	  in	  an	  NF-­‐κB-­‐	  and	  AP-­‐1-­‐dependent	  manner	  
(280,	   291-­‐295).	   Further	  progesterone	  was	  unable	   to	   repress	  pro-­‐inflammatory	   transcription	   factor	  
activation	   in	   the	   context	   of	   stretch,	   possibly	   accounting	   for	   the	   reason	   why	   it	   is	   ineffective	   in	  
multiple	  pregnancy	  (292).	  The	   in	  vitro	  effect	  of	  stretch	  has	  also	  been	  reproduced	   in	  animal	  studies	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where	  increased	  expression	  of	  contraction-­‐associated	  proteins	  was	  shown	  in	  the	  gravid	  uterine	  horn	  
as	  compared	  to	  the	  non-­‐gravid	  horn	  (296,	  297).	  Further,	  uterine	  overdistension	  in	  pigtail	  macaques	  
led	  to	  preterm	  labour	  in	  the	  context	  of	  raised	  levels	  of	  multiple	  pro-­‐inflammatory	  substances,	  with	  a	  
similar	   picture	   seen	   in	  women	  with	  polyhydramnios	  or	   a	   twin	  pregnancy	   (298).	  Nevertheless,	   it	   is	  
important	  to	  note	  that	  Ou	  et	  al.	  demonstrated	  that	  artificial	  stretch	  on	  its	  own	  was	  not	  sufficient	  to	  
raise	  OTR	  levels,	  suggesting	  that	  endocrine	  signals	  also	  play	  a	  crucial	  role	  (296).	  In	  summary,	  there	  is	  
evidence	   that	   excessive	   uterine	   stretch	   is	   associated	   with	   an	   inflammatory	   phenotype,	   which	  
contributes	  to	  the	  timing	  of	  labour	  onset.	  	  
	  
1.3.4.	  Contraction-­‐associated	  proteins	  
This	   term	  encompasses	  all	  proteins	   that	   facilitate	   the	   labour	  process.	  They	  can	  broadly	  be	  divided	  
into	   proteins	   that	   (i)	   enhance	  myocyte	   contractility	   such	   as	   OTR	   and	   prostaglandin	   receptors,	   (ii)	  
increase	   intercellular	   connectivity	   and	   (iiI)	   increase	   excitability	   of	   myometrial	   cells	   such	   as	   the	  
potassium	  channel	  (21).	  
1.3.4.1.	  Prostaglandins	  
The	   levels	   of	   stimulatory	   prostaglandins	   increase	   prior	   to	   spontaneous	   parturition	   (299-­‐302).	  
Further,	   they	   can	   induce	   progesterone	   withdrawal	   in	   animals	   (192)	   and	   their	   administration	   to	  
humans	  can	  induce	  labour	  at	  any	  gestation	  (303,	  304).	  Prostaglandins	  act	  to	  bring	  about	  labour	  via	  
two	  main	  mechanisms:	   (i)	  membrane	  rupture	  and	  cervical	  dilatation	  via	  MMP	  activation	  (305)	  and	  
(ii)	  stimulation	  of	  myometrial	  contractility	  through	  increased	  intracellular	  calcium	  (306-­‐308).	  	  
Prostaglandins	  are	  biologically	  active	  eicosanoids	  whose	  precursor,	  arachidonic	  acid,	   is	  synthesised	  
by	  the	  action	  of	  cytoplasmic	  phospholipase	  A2	  on	  cell	  membrane	  phospholipids	  (Fig.	  1.11.)	  (279).	  The	  
subsequent	   conversion	   of	   arachidonic	   acid	   to	   prostaglandin	   H2	   (PGH2)	   is	   catalysed	   by	   cyclo-­‐
oxygenase	  (COX)	  enzymes.	  COX-­‐1	  is	  constitutively	  expressed	  in	  most	  tissues	  (309).	  In	  contrast,	  COX-­‐2	  
is	  inducible	  in	  response	  to	  cytokines	  and	  growth	  factors	  (310),	  with	  its	  promoter	  containing	  binding	  
sites	   for	  pro-­‐inflammatory	   transcription	   factors	   including	  NF-­‐κB	  and	  AP-­‐1	   (311,	  312).	   	   Importantly,	  
the	  action	  of	  COX	  enzymes	  represents	  the	  rate-­‐limiting	  step	  in	  prostaglandin	  biosynthesis	  (313,	  314).	  
Further	  downstream,	  PGH2	  is	  converted	  by	  synthetase	  and	  isomerase	  enzymes	  into	  thromboxane	  A2,	  
PGI2,	   PGD2,	   PGE2	   or	   PGF2α	   depending	   on	   cell	   type	   (279).	   These	   prostaglandins	   signal	   through	  
dedicated	  receptors	   termed	  TP,	   I2,	  D2,	  EP1-­‐4	  and	  FP	  respectively	   (279).	  At	   the	   time	  of	   labour	  onset,	  
relaxatory	  receptor	  subtypes,	  such	  as	  EP2,	   levels	  decrease	   (315,	  316)	  and	  pro-­‐contractile	  subtypes,	  
including	  FP	  and	  EP3,	  levels	  increase	  (316).	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Figure	  1.11.	  Prostaglandin	  biosynthesis	  pathway.	  Adapted	  from	  Ratajczak	  and	  Muglia	  (317)	  
The	  evidence	  for	  the	  importance	  of	  COX-­‐2	  in	  parturition	  is	  substantial.	  COX-­‐2	  up-­‐regulation	  has	  been	  
observed	   in	   all	   gestational	   tissues	   prior	   to	   labour	   onset	   including	   the	   myometrium	   (318-­‐321).	  
Further,	  COX-­‐2	  inhibition	  reduces	  contractility	  in	  vitro	  (322)	  and	  delays	  parturition	  in	  animal	  models	  
(323).	  
1.3.4.2.	  Oxytocin	  	  
Oxytocin	   is	   a	   nonapeptide	   hormone	   released	   from	   the	   neurohypophysis,	   which	   signals	   via	   OTR.	  
Oxytocin	   acts	   to	   stimulate	   uterine	   contractions	   and	   indeed,	   its	   analogues	   are	   frequently	   used	   in	  
modern	   obstetrics	   for	   the	   augmentation	   of	   labour.	   Myometrial	   OTR	   levels	   have	   been	   shown	   to	  
increase	   prior	   to	   labour	   onset	   hence	   increasing	   uterine	   sensitivity	   to	   the	   action	   of	   oxytocin	   (277,	  
324).	   Nevertheless,	   questions	   do	   remain	   regarding	   the	   significance	   of	   oxytocin	   as	   both	   oxytocin	  
knockout	   (325)	   and	  Oxtr-­‐knockout	   (326)	   mice	   go	   into	   labour	   normally.	   The	  mechanism	   by	   which	  
oxytocin	   increases	   contractility	   is	   through	   an	   increase	   in	   intracellular	   calcium	   via	   Gαq	   and	  
phospholipase	  C	  (327).	  
1.3.4.3.	  Connexin-­‐43	  
Increased	  intra-­‐myometrial	  connections	  via	  the	  formation	  of	  gap	  junctions	  comprised	  of	  connexin-­‐43	  
facilitate	  synchronous	  powerful	  uterine	  contractions,	  which	  are	  crucial	   for	   successful	  delivery	   (21).	  
Several	   studies	  have	  shown	  up-­‐regulation	   in	  connexin-­‐43	   levels	  with	   labour	  onset	   (276,	  328).	   	  The	  
importance	  of	  this	  protein	  is	  further	  highlighted	  in	  mice	  with	  a	  conditional	  knock-­‐out	  of	  connexin-­‐43	  
in	  smooth	  muscle	  cells,	  in	  which	  pregnancy	  is	  prolonged	  in	  82%	  of	  cases	  (329).	  
1.3.4.4.	  Ion	  pumps	  and	  channels	  
The	  potential	  gradient	  across	  myocytes	  is	  maintained	  by	  the	  action	  of	  the	  sodium-­‐potassium	  pump	  
as	  well	   the	  potassium	  channel.	   The	  distribution	  of	   these	   channels	   is	   altered	   at	   the	   time	  of	   labour	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hence	  decreasing	  the	  potential	  difference	  across	  the	  membrane	  and	  facilitating	  depolarisation	  (330,	  
331).	  Indeed,	  potassium	  channel	  inhibition	  has	  been	  shown	  to	  increase	  contractility	  in	  both	  human	  
and	  mouse	  myometrium	   in	  vitro	  and,	  conversely,	  potassium	  channel	  activation	  was	  shown	  to	  have	  
the	  opposite	  effect	  (332).	  Further,	  it	  appears	  that	  progesterone	  has	  no	  effect	  on	  the	  activity	  of	  these	  
channels	  (333).	  
	  
1.4.	  Models	  for	  the	  study	  of	  parturition	  
Due	  to	  the	  inherent	  difficulties	  of	  human	  in	  vivo	  studies	  in	  the	  context	  of	  pregnancy	  and	  parturition,	  
much	  of	  reproductive	  biology	  research	  relies	  on	  animal	  models	  and	   in	  vitro	  culture	  systems.	  Sheep	  
and	  mouse	  models	   are	  used	  most	   frequently	   in	   the	   field.	   Sheep	  models	   are	   advantageous	   in	   that	  
their	  gestational	  length	  and	  number	  of	  offspring	  are	  similar	  to	  humans	  (334).	  However,	  the	  onset	  of	  
labour	   follows	  a	  decline	   in	  progesterone	   levels	   in	   these	  animals.	   This	   is	   also	   the	   case	  with	  murine	  
models.	  Other	  notable	  differences	  with	  mice	  are	  their	  bicornuate	  uterus	  and	   large	   litter	  size.	  Mice	  
are	  nevertheless	  a	  frequently	  used	  model	  due	  to	  the	  relative	  ease	  of	  genetic	  manipulation	  and	  short	  
gestation	   time,	   which	   facilitates	   multiple	   experiments	   and	  minimises	   associated	   costs	   (334).	   Less	  
frequently	   used	  models	   include	   guinea	   pigs,	  which	  maintain	   high	   progesterone	   levels	  with	   labour	  
onset.	  However	  technical	  considerations	  limit	  their	  use	  (334)	  and	  further,	  it	  has	  been	  suggested	  that	  
the	  functional	  withdrawal	  of	  these	  animals	  differs	  to	  the	  one	  observed	  in	  humans	  (335).	  
The	  in	  vitro	  cell	  culture	  models	  available	  in	  the	  field	  are	  comprised	  of	  immortalised	  myometrial	  cell	  
lines	  such	  as	  hTERT-­‐HM	  or	  primary	  myometrial	  cell	  culture.	  The	  hTERT-­‐HM	  cell	  line	  was	  derived	  from	  
human	   myometrial	   cells	   immortalised	   following	   transfection	   with	   human	   telomerase	   reverse	  
transcriptase	  (336).	  Cell	  lines	  offer	  distinct	  advantages	  such	  as	  ease	  of	  culture	  and	  reproducibility	  of	  
results,	   however	   importantly	   they	   represent	   a	   genetically	   altered	   model	   and	   hence	   arguably	   are	  
much	   removed	   from	   the	   in	   vivo	   status.	   Primary	  myometrial	   cell	   cultures	   are	  more	   physiologically	  
relevant	   than	   cell	   lines,	   however	   research	   is	   limited	   by	   supply,	   which	   is	   dependent	   on	   patients’	  
volunteering	  to	  partake	  in	  research,	  and	  slower	  cell	  growth.	  Increasingly,	  in	  vitro	  research	  is	  carried	  
out	  on	  myometrial	  tissue	  itself	  (332,	  337,	  338).	  Importantly	  though,	  none	  of	  the	  in	  vitro	  models	  have	  
ever	  been	  compared	  to	  each	  other	  or	  to	  the	  in	  vivo	  condition.	  
	  
1.5.	  Summary	  and	  clinical	  relevance	  
The	  ability	   to	   regulate	   the	   timing	  of	  parturition	   is	   a	   key	   challenge	   for	  obstetricians.	   	   The	   scientific	  
community’s	  understanding	  of	   the	  mechanisms	  underlying	   the	  physiological	  process	  of	  parturition	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has	   increased	   in	   the	   last	   decades.	   However,	   the	   mechanism(s)	   underlying	   labour	   onset	   remain	  
unclear.	   Preterm	   labour	   carries	   significant	   morbidity	   and	   mortality	   on	   a	   worldwide	   basis	   with	  
progesterone	  supplementation	  possibly	  being	  one	  of	  the	  only	  effective	  interventions.	  Progesterone	  
acts	  to	  maintain	  uterine	  quiescence	  and	  withdrawal	  of	  its	  action	  precipitates	  labour	  both	  in	  animals	  
and	  humans.	  Thus,	  understanding	  the	  molecular	  mechanisms	  of	  progesterone	  action	  is	  crucial	  in	  the	  
development	  of	  novel	  therapeutic	  agents	  that	  can	  help	  in	  the	  regulation	  of	  labour	  onset.	  	  
	  
1.6.	  Hypotheses	  and	  aims	  
1.6.1.	  Hypotheses	  
This	  thesis	  investigated	  the	  role	  of	  progesterone	  in	  preterm	  and	  term	  labour	  by	  testing	  the	  following	  
hypotheses:	  
(i)	  During	  pregnancy,	  progesterone	  acts	  via	  both	   the	  progesterone	  and	  glucocorticoid	   receptors	   to	  
drive	   gene	   expression,	   repress	   inflammation	   and	   contraction-­‐associated	   proteins,	   thus	   reducing	  
myometrial	  sensitivity	  to	  uterotonics.	  
(ii)	   At	   the	   onset	   of	   labour,	   progesterone	   action	   is	   repressed	   by	   a	   combination	   of	   altered	  
progesterone	   receptor	   isoform	   expression,	   altered	   local	   metabolism	   and	   altered	   chapterone,	   co-­‐
chaperone	  and	  co-­‐regulator	  expression.	  
	  
1.6.2.	  Aims	  	  
The	  aims	  of	  the	  study	  were	  as	  follows:	  
(i)	   To	   define	   the	   effects	   of	   progesterone	   supplementation	   and	  mifepristone	   treatment	   on	  murine	  
labour	   with	   respect	   to	   inflammatory	   mediators,	   contraction-­‐associated	   proteins,	   transcription	  
factors	  and	  circadian	  rhythm	  genes.	  
	  (ii)	   To	   develop	   and	   validate	   a	   human	   myometrial	   explant	   model	   for	   the	   in	   vitro	   study	   of	  
progesterone	   signalling	   and	   to	   use	   this	  model	   to	   determine	   the	   effect	   of	   labour	   on	   the	   action	   of	  
progesterone.	  
(iii)	  To	  use	  the	  group’s	  myometrial	  tissue	  bank	  to	  determine	  whether	  with	  the	  onset	  of	  preterm	  or	  
term	   labour	   any	   changes	   occur	   in	   local	   hormone	   levels,	   nuclear	   receptor	   expression	   or	   the	  
expression	  of	  chaperones,	  co-­‐chaperones	  and	  co-­‐regulators.	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2.	  MATERIALS	  AND	  METHODS	  
	  
2.1.	  MATERIALS	  
	  2.1.1.	  Chemicals,	  Reagents	  and	  Solvents	  
Absolute	  Ethanol	   Fisher	  Scientific	  
Bovine	  Serum	  Albumin	  (BSA)	   Applied	  Biosystems	  
Deoxyribonucleoside	  triphosphate	  (dNTP)	   Invitrogen	  
Dimethyl	  Sulfoxide	  (DMSO)	   Sigma-­‐Aldrich	  
Dithiothreitol	  (DTT)	   BioRad	  
DPX	  Mountant	   VWR	  International	  
Goat	  Serum	   Sigma-­‐Aldrich	  (G9023)	  
Haematoxylin	   Fisher	  Scientific	  
Histoclear	   Fisher	  Scientific	  
Hydrogen	  Peroxide	   	   Sigma	  
ImmPACT	  DAB	  Peroxidase	  Substrate	   	   Vector	  Laboratories	  
Methanol	   	   Fisher	  Scientific	  
Magnesium	  Chloride	  (MgCl2)	   	   Applied	  Biosystems	  
Non-­‐fat	  dried	  milk	  powder	   Applichem	  
PCR	  10x	  buffer	   Applied	  Biosystems	  
Oligo-­‐dT	  random	  primers	   Applied	  Biosystems	  
RNaseZap	   	   Ambion	  
Potassium	  Chloride	  (KCl)	   	   Sigma-­‐Aldrich	  
Shadon	  Eosin	  Y	  Aqueous	   	   Fisher	  Scientific	  
Sodium	  Chloride	  (NaCl)	   	   Sigma-­‐Aldrich	  
SYBR	  Green	   	   Applied	  Biosystems	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2.1.2.	  Antibodies	  
2.1.2.1.	  Primary	  Antibodies	  
Actin,	  Smooth	  Muscle	  Ab-­‐1	   Thermo	  Scientific,	  #MS-­‐113-­‐R7	  
AP-­‐1	  phospho-­‐c-­‐Fos	  (Ser32)	   	   Cell	  Signalling,	  5348	  
AP-­‐1	  phospho-­‐c-­‐Jun	  (Ser63)	   	   Santa	  Cruz	  Biotechnology,	  sc-­‐822	  
Connexin-­‐43	   	   Cell	  Signalling,	  3512	  
c-­‐Fos	   Cell	  Signalling,	  4384	  
c-­‐Jun	   	   Cell	  Signalling,	  9165S	  
COX-­‐2	   	   Santa	  Cruz	  Biothechnology,	  sc-­‐1745	  
ERK1/2	   Cell	  Signalling,	  9102	  
FKBP51	   Santa	  Cruz	  Biotechnology,	  sc-­‐11514	  
GAPDH	  	   Millipore,	  MAB	  374	  
GR	   	   Santa	  Cruz	  Biotechnology,	  sc-­‐1003	  
HSD11β1	   	   Abcam,	  ab83522	  
HSP70	   Abcam,	  ab2787	  
HSP90	   Abcam,	  ab1429	  
IκBα	   	   Santa	  Cruz	  Biotechnology,	  sc-­‐371	  
JNK	   Cell	  Signalling,	  9252	  
MKP-­‐1	   	   Santa	  Cruz	  Biotechnology,	  sc-­‐370	  
NCoR	  	   	   Cell	  Signalling,	  5948	  
OTR	   Santa	  Cruz	  Biotechnology,	  sc-­‐8102	  
p38	   	   Cell	  Signalling,	  9212	  
p65	   Santa	  Cruz	  Biotechnology,	  sc-­‐8008	  
Phospho-­‐ERK1/2	  (Thr202/Thr204)	   Cell	  Signalling,	  9101	  
Phospho-­‐HSP27	  (Ser82)	   Cell	  Signalling,	  9709	  
Tween	  20	   	   Sigma-­‐Aldrich	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Phospho-­‐JNK	  (Thr183/Tyr185)	   	   Cell	  Signalling,	  9251	  
Phospho-­‐NF-­‐κB	  p65	  (Ser536)	   Cell	  Signalling,	  3031	  
Phospho-­‐p38	  (Thr180/Thr182)	   	   Cell	  Signalling,	  9211	  
PR	   	   Leica,	  NCL-­‐PGR-­‐312	  and	  Santa	  Cruz,	  sc-­‐7208	  
SMRT	   	   Santa	  Cruz	  Biotechnology,	  sc-­‐13554	  &	  sc-­‐1610;	  Abcam,	  ab2780	  
SRC1	   	   Cell	  Signalling,	  2191	  
SRC2	   	   Bioss,	  13157R	  
SRC3	   	   Cell	  Signalling,	  2126	  
	  
2.1.2.2.	  Secondary	  Antibodies	  
Anti-­‐goat	  IgG,	  HRP-­‐linked	  antibody	   	   Dako,	  P0449	  
Anti-­‐mouse	  IgG,	  biotinylated	  antibody	   	   Vector	  Laboratories,	  BA-­‐9200	  
Anti-­‐mouse	  IgG,	  HRP-­‐linked	  antibody	   	   Cell	  Signalling,	  7076	  
Anti-­‐rabbit	  IgG,	  HRP-­‐linked	  antibody	   	   Cell	  Signalling,	  7074	  
	  
2.1.3.	  Buffers	  and	  Solutions	  
Acid	  Alcohol	   100%	  ethanol	  
1%	  hydrochloric	  acid	  
	   	  
Cell	  Lysis	  Buffer	   1mL	  10x	  cell	  lysis	  buffer	  
1	  tablet	  protease	  inhibitor	  
100µL	  phosphatase	  inhibitor	  
8900µL	  dH2O	  
	   	  
Phosphate	  Buffered	  Saline	  (PBS)	   140mM	  NaCl	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2.5mM	  KCl	  
1.5mM	  KH2PO4	  
10mM	  Na2HPO4	  
pH	  7.2	  
	   	  
Sodium	  Dodecyl	  Sulphate	  (SDS)	  
	  
25mM	  Tris-­‐base	  
250mM	  glycine	  
0.1%	  (w/v)	  SDS	  
pH	  8.3	  
	   	  
Tris	  Buffered	  Saline-­‐Tween	  20	  (TBS-­‐T)	   130mM	  NaCl	  
20mM	  Tris-­‐HCl,	  pH	  7.6	  
Adjusted	  to	  pH	  7.4	  with	  HCl	  
0.1%	  Tween	  20	  
	   	  
Western	  Blocking	  Buffer	   5%	  (w/v)	  non-­‐fat	  milk	  in	  TBS-­‐T	  
	   	  
Western	  Antibody	  Incubation	  Buffers	   5%	  (w/v)	  non-­‐fat	  milk	  in	  TBS-­‐T	  
5%	  (w/v)	  BSA	  in	  TBS-­‐T	  	  
1%	  (w/v)	  non-­‐fat	  milk	  in	  TBS-­‐T	  
	  
2.1.4.	  Cell	  and	  Explant	  Culture	  Materials	  and	  Media	  
Aphrodisc	  25mm	  syringe	  filter	   	   Life	  Sciences	  
Cell	  Strainer	  (70µM)	   	   VWR	  International	  
Collagenase	  1A	   	   Sigma-­‐Aldrich	  
Collagenase	  XI	   Sigma-­‐Aldrich	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Dulbecco’s	  Modified	  Eagle	  Medium	  (DMEM)	   	   Sigma-­‐Aldrich	  
Dulbecco’s	  Modified	  Eagle	  Medium/Nutrient	  mixture	  F-­‐12	  Ham	   	   Sigma-­‐Aldrich	  
Fetal	  Bovine	  Serum	  (FCS)	   	   Sigma-­‐Aldrich	  
Penicillin/Streptomycin	   	   Sigma-­‐Aldrich	  
Tissue	  culture	  plasticware	   	   Sigma-­‐Aldrich	  
Trypsin/EDTA	   	   Sigma-­‐Aldrich	  
	  
2.1.5.	  Enzymes	  
DNase	  I	  	   	   Life	  Technologies	  
MuLV	  Reverse	  Transcriptase	   	   Applied	  Biosystems	  
RNase	  inhibitor	  	   Applied	  Biosystems	  
	  
2.1.6.	  Treatments	  and	  Inhibitors	  
Dexamethasone	   	   Sigma-­‐Aldrich	  
Estradiol	   Sigma-­‐Aldrich	  
Forskolin	   Sigma-­‐Aldrich	  
GR	  inhibitor	  AL082D06	   	   ChemBo	  Pharma	  
Halt	  phosphatase	  inihibitor	   	   Thermo	  Scientific	  
Interleukin	  1β	  (IL-­‐1β)	   	   Sigma-­‐Aldrich	  
Mifepristone	  (RU486)	   	   Sigma-­‐Aldrich	  
Onapristone	  (ZK299)	   	   Arnothera	  Therapeutics	  
p38	  inhibitor	  ML3403	   Tocris	  
p38	  inhibitor	  SB203580	  	   Cell	  Signalling	  
PR	  inhibitor	  Ulipristal	   	   Gedeon	  Richter	  
PR	  inhibitor	  SC510089	   	   Enzo	  Life	  Sciences	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Progesterone	   	   Sigma-­‐Aldrich	  
Protease	  inhibitor	   	   Roche	  Diagnostics	  
	  
2.1.7.	  Kits	  
DC	  protein	  assay	  kit	   Biorad	  
Homogenising	  CK28-­‐R	  Precellys	  tubes	   Stretton	  Scientific	  
LDH	  Activity	  Assay	  kit	   	   Sigma-­‐Aldrich	  
QIAquick	  PCR	  purification	  kit	   	   Qiagen	  
RNeasy	  mini	  kit	  	   	   Qiagen	  
Steroid/Thyroid	  Hormone	  Bead	  Panel	   	   Millipore	  
TRIzol®	  Plus	  RNA	  Purification	  Kit	  	   	   Thermo	  Fisher	  
Vectastain	  Elite	  ABC	  Kit	  Standard	   	   Vector	  Laboratories	  
	  
2.1.8.	  SDS-­‐PAGE	  Electrophoresis	  and	  Western	  Blotting	  Materials	  
Amersham	  Hyperfilm	  ECL	   	   GE	  Healthcare	  
Clarity	  Western	  ECL	  substrate	   	   BioRad	  
Cell	  lysis	  buffer	   	   Cell	  Signalling	  
HeLa	  Nuclear	  Extract	   	   Millipore	  
Nu-­‐PAGE®	  LDS	  Sample	  Buffer	   	   Life	  Technologies	  
Precision	  Plus	  ProteinTM	  Dual	  Color	  Standards	   	   Biorad	  
SDS	  PAGE	  precast	  gels	   	   Biorad	  
	  
2.2.	  METHODS	  
2.2.1.	  In	  vitro	  Studies	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2.2.1.1.	  Tissue	  Specimens	  
The	  Brompton	  and	  Harefield	  Research	  Ethics	  Committee	  approved	  this	  study.	  Patients	  were	  invited	  
to	   participate	   if	   they	   did	   not	   have	   any	   of	   the	   following	   exclusion	   factors:	   induction	   of	   labour,	  
gestational	   diabetes	   mellitus,	   pre-­‐eclampsia	   and	   obstetric	   cholestasis.	   Following	   fully	   informed	  
written	  patient	  consent,	  biopsies	  of	  term	  or	  preterm	  human	  myometrium	  measuring	  approximately	  
0.5x0.5x0.5	  cm3	  were	  obtained	  from	  the	  upper	  margin	  of	  the	  uterine	  incision	  at	  elective	  Caesarean	  
section.	  Depending	  on	   the	  experimental	  protocol,	  biopsies	  were	  either	   immediately	  placed	   in	  pre-­‐
chilled	  (4°C)	  phosphate-­‐buffered	  saline	  (PBS)	  and	  processed	  within	  maximum	  1	  hour	  or	  immediately	  
frozen	  at	  -­‐80°C.	  
2.2.1.2	  Explant	  Culture	  
The	   myometrial	   biopsy	   was	   washed	   of	   excess	   blood	   with	   PBS	   and	   finely	   dissected	   in	   3x3x3mm3	  
portions	  (explants).	  Obvious	  areas	  of	  fibrosis	  or	  vasculature	  were	  not	  incorporated	  in	  explant	  pieces.	  
One	  piece	  was	   immediately	  snap	   frozen	   in	   liquid	  N2	  and	  then	  stored	  at	   -­‐80°C	   (t=0).	  The	  remaining	  
pieces	  were	  placed	  in	  Dulbecco’s	  Modified	  Eagle	  Medium	  (DMEM)	  supplemented	  with	  100	  mU/mL	  
penicillin	   and	   100	   μg/mL	   streptomycin.	   Treatments	   were	   added	   directly	   as	   per	   the	   experimental	  
protocol.	   Once	   the	   experimental	   protocol	   was	   over,	   the	   media	   were	   removed	   and	   tissue	  
immediately	  snap	  frozen	   in	   liquid	  N2	  and	  subsequently	  stored	  at	   -­‐80°C.	   In	  certain	  cases,	   the	  media	  
was	  separately	  stored	  at	  -­‐80°C.	  
2.2.1.3.	  Myometrial	  Strips	  
After	   a	   piece	   was	   immediately	   snap	   frozen	   in	   liquid	   N2,	   myometrial	   biopsies	   were	   dissected	   into	  
strips	  by	  cutting	  lengthways	  along	  fasciculata	  bundles	  and	  each	  attached	  to	  a	  glass	  weight	  of	  either	  
0.6-­‐0.7g	   (designated	   low	   tension)	   or	   2.2.-­‐2.4g	   (designated	   high	   tension)	   mass	   to	   maintain	   them	  
under	   isotonic	   tension	   once	   suspended	   in	   DMEM	   supplemented	   with	   pencillin-­‐streptomycin.	   The	  
choice	  of	  0.6-­‐0.7g	  and	  2.2-­‐2.4g	  mass	  was	  based	  on	  experimental	  data	  from	  a	  previous	  study	  (339).	  
Strips	  were	  immediately	  treated	  with	  ethanol	  vehicle	  control	  for	  24	  hours	  at	  which	  point	  they	  were	  
snap	  frozen	  in	  liquid	  N2.	  This	  work	  was	  conducted	  by	  Dr	  Pei	  Lai.	  	  
2.2.1.4.	  Primary	  Cell	  and	  Cell	  Line	  Culture	  
The	  myometrial	  biopsy	  was	  washed	   in	  PBS	  and	   finely	  dissected	  with	  a	  scalpel.	  The	  resulting	   tissue	  
pieces	  were	  digested	  for	  30	  minutes	  at	  37°C	  and	  an	  atmosphere	  of	  5%	  CO2:95%	  air	  in	  a	  collagenase	  
solution	   containing	   1	  mg/mL	   collagenase	   1A	   (Sigma-­‐Aldrich)	   and	   1	  mg/mL	   collagenase	   XI	   (Sigma-­‐
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Aldrich)	   in	  a	  mixed	  medium	  of	  50%	  DMEM	  and	  50%	  Dulbecco’s	  modified	  Eagle’s	  medium/Nutrient	  
mixture	  F-­‐12	  Ham	  (Sigma-­‐Aldrich).	  Tissue	  pieces	  were	  aspirated	  using	  a	  pasteur	  pipette	  and	  passed	  
through	   a	   70	   μm	   cell	   strainer	   (VWR).	  Myocytes	  were	   centrifuged	   at	   3000	   rpm	   for	   5	  minutes	   and	  
resuspended	  with	  DMEM	  containing	  10%	  fetal	  calf	  serum	  and	  100	  mU/mL	  penicillin	  and	  100	  μg/mL	  
streptomycin.	  Cells	  were	  cultured	  in	  T25	  flasks	  at	  37°C	  and	  an	  atmosphere	  of	  5%	  CO2:95%	  air.	  	  
The	  hTERT-­‐HM	  myometrial	  cell	  line	  was	  rapidly	  defrosted	  from	  -­‐80°C	  and	  diluted	  in	  DMEM/10%	  FCS	  
supplemented	  with	  penicillin/streptomycin	  as	  with	  primary	  cells.	  Cells	  were	  centrifuged	  at	  1000rpm	  
for	  5	  minutes	  in	  order	  to	  eliminate	  DMSO	  used	  for	  long-­‐term	  storage.	  The	  pellet	  was	  resuspended	  in	  
DMEM/10%	  FCS	  supplemented	  with	  penicillin/streptomycin	  and	  cells	  were	  plated	  in	  a	  suitable	  flask	  
and	  cultured	  at	  37°C	  and	  an	  atmosphere	  of	  5%	  CO2:95%	  air.	  
Once	   confluent,	   cells	   were	   washed	   with	   PBS	   and	   incubated	   in	   0.25%	   trypsin/0.02%	   EDTA	   for	   5	  
minutes	  in	  order	  to	  lift	  the	  cells	  off	  the	  culture	  flask.	  The	  trypsin	  was	  quenched	  with	  DMEM/10%	  FCS	  
and	  centrifuged	  at	  1000rpm	  for	  5	  minutes.	  The	  pellet	  was	  resuspended	  in	  DMEM/10%	  FCS	  and	  cells	  
seeded	  into	  culture	  flasks.	  Having	  reached	  confluence	  at	  passage	  3,	  primary	  myometrial	  cells	  were	  
trypsinised	  and	  seeded	  into	  6-­‐well	  culture	  plates.	  hTERT-­‐HM	  cells	  were	  not	  used	  beyond	  passage	  5	  
once	   thawed.	  Once	   confluent,	   cells	  were	   incubated	  overnight	  with	  DMEM	  containing	  1%	   charcoal	  
and	   dextran-­‐stripped	   FCS	   and	   penicillin/streptomycin	   (1%	   DCC-­‐FCS).	   Treatments	   as	   per	   the	  
experimental	  protocol	  were	  added	  the	  following	  morning.	  Once	  the	  experimental	  protocol	  was	  over,	  
the	   media	   were	   removed	   and	   plates	   placed	   directly	   at	   -­‐80°C.	   In	   certain	   cases	   supernatant	   was	  
separately	  stored	  at	  -­‐80°C.	  
	  
2.2.2.	  In	  vivo	  Studies	  
2.2.2.1.	  Animal	  procurement	  and	  colony	  maintenance	  
Animal	   studies	   were	   performed	   under	   the	   UK	   Home	   Office	   Licences	   70/6906	   (held	   by	   Dr	   Simon	  
Waddington)	   and	   70/7518	   (held	   by	  Dr	   Bronwen	  Herbert)	   and	   in	   accordance	  with	   the	  UK	   Animals	  
(Scientific	  Procedures)	  Act	  1986	  &	  Amendment	  Regulations	  2012,	  by	  Dr	  Lydia	  Edey,	  Dr	  Kaiyu	  Lei	  and	  
Dr	   Bronwen	   Herbert.	   All	   procedures	   were	   performed	   with	   approval	   from	   the	   Animal	   Welfare	   &	  
Ethical	   Review	   Boards	   of	   Imperial	   College	   and	   University	   College	   London.	   Analysis	   of	   all	   animal	  
tissues	  was	  performed	  by	  myself	  unless	  otherwise	  specified.	  	  
Non-­‐pregnant	   female	   and	   male	   (for	   breeding	   purposes	   only)	   CD1	   outbred	   mice	   (Charles	   River	  
Laboratories,	  UK)	  aged	  6-­‐8	  weeks	  were	  acclimatised	  for	  1	  week	  in	  open	  cages	  and	  fed	  standard	  chow	  
and	   water	   ad	   libitum	   under	   standard	   environmental	   conditions	   (12h:12h	   light-­‐dark	   cycle).	   Time	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mating	  was	  performed	  and	  the	  presence	  of	  a	  copulatory	  plug	  was	  designated	  as	  gestational	  day	  0	  
(E0).	  In	  our	  hands,	  CD1	  pregnant	  mice	  spontaneously	  go	  into	  labour	  towards	  the	  end	  of	  E18.	  	  	  
2.2.2.2.	  Experimental	  Protocol	  
Control	  mice	  underwent	  daily	  subcutaneous	  peanut	  oil	  vehicle	  injections	  (40μL)	  from	  gestational	  day	  
14	  (E14)	  until	  E18	  and	  a	  subcutaneous	  injection	  of	  20µL	  DMSO	  on	  E16.	  Animals	  were	  euthanised	  on	  
E16	   (n=6),	   E17	   (n=8),	   E18	   (n=6)	   and	   in	   labour	   (n=6),	  which	  was	   identified	   following	   delivery	   of	   at	  
least	  the	  first	  pup.	  
A	  second	  group	  of	  mice	  underwent	  daily	  peanut	  oil	  vehicle	   injections	   (40μL)	   from	  E14	  as	  well	  as	  a	  
subcutaneous	   injection	   of	   150µg	   of	   mifepristone	   dissolved	   in	   20µL	   DMSO	   on	   E16.	   Animals	   were	  
euthanised	  at	  4.5	  (n=8),	  9	  (n=8)	  and	  13.5	  hours	  (n=6)	  post-­‐RU486	  administration	  and	  upon	  delivery	  
of	  at	  least	  the	  first	  pup	  (labour)	  (n=7).	  
A	  third	  group	  of	  mice	  underwent	  daily	  subcutaneous	  injections	  of	  2mg	  P4	  dissolved	  in	  40µL	  peanut	  
oil	  from	  E14	  until	  E20	  at	  which	  point	  the	  mice	  had	  still	  not	  began	  laboring.	  Animals	  were	  euthanised	  
on	  E16	  (n=7),	  E17	  (n=8),	  E18	  (n=7),	  E19	  (n=9)	  and	  E20	  (n=7).	  Euthanasia	  of	  animals	  was	  performed	  at	  
the	  same	  time	  each	  day.	  
In	   a	   first	   experiment	   for	   p38	   inhibition,	   pregnant	   mice	   at	   E16	   were	   briefly	   anaesthetised	   using	  
isoflurane	  and	  then	  underwent	  either	  intraperitoneal	  injection	  of	  ML3403	  (25mg/kg	  in	  20μL	  DMSO)	  
or	  no	   injection	  (as	  this	  was	  a	  preliminary	  experiment)	  followed	  by	   immediate	  subcutaneous	  DMSO	  
vehicle	  or	  RU486	  (150μg)	  injection.	  In	  a	  second	  experiment	  for	  p38	  inhibition,	  pregnant	  mice	  at	  E16	  
were	  given	  a	  subcutaneous	  injection	  of	  morphine	  (5mg/kg)	  to	  provide	  suitable	  analgesia	  for	  a	  mini	  
laparotomy	  under	  5%	  isoflurance	  anaesthesia	  (1.5L/min	  flow	  rate).	  Mice	  were	  given	  an	  intrauterine	  
injection	   of	   either	   DMSO	   vehicle	   (25μL)	   or	   SB203580	   (11mg/kg	   in	   25μL	   DMSO)	   followed	   by	  
immediate	   subcutaneous	   DMSO	   vehicle	   (20μL)	   or	   RU486	   (150μg)	   injection	   post	   suturing.	  
Bupivacaine	  (2mg/kg)	  was	  applied	  to	  the	  muscle	  layer	  and	  skin	  of	  the	  abdomen	  during	  suturing	  for	  
further	  analgesia.	  Mice	  were	  allowed	  to	  recover	  in	  a	  heated	  recovery	  chamber,	  followed	  by	  single-­‐
housing	   and	   regular	   monitoring	   prior	   to	   euthanasia	   and	   tissue	   collection	   at	   9	   hours	   post-­‐RU486	  
administration.	  	  
2.2.2.3.	  Tissue	  Collection	  
In	  all	  groups,	  animals	  were	  briefly	  anaesthetised	  with	  isoflurane	  and	  euthanised	  by	  cardiac	  puncture	  
followed	   by	   immediate	   cervical	   dislocation.	   A	   laparotomy	   was	   swiftly	   performed	   and	   the	   uterus	  
identified.	  The	   left	  uterine	  horn	  and	   left	  placenta	  were	  mechanically	  separated	  and	  snap	  frozen	   in	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dry	   ice	  for	  subsequent	  RNA	  and	  protein	  extraction.	  The	  right	  uterine	  horn	  and	  right	  placenta	  were	  
also	  mechanically	   separated	  and	   snap	   frozen	  on	  dry	   ice	   for	   subsequent	  multiplex	  analysis.	   Tissues	  
were	  stored	  at	  -­‐80°C.	  
	  
2.2.3.	  Haematoxylin	  &	  Eosin	  Staining	  
Portions	   of	  myometrial	   biopsies	  measuring	   3x3x3mm3	  were	   fixed	   in	   neutral-­‐buffered	   formalin	   for	  
18-­‐24	  hours,	  embedded	  in	  paraffin,	  cut	  into	  5µm	  sections	  and	  mounted	  on	  poly-­‐D-­‐lysine	  slides	  (VXR,	  
Radnor,	   PA,	   USA).	   Slides	   were	   deparaffinised	   in	   in	   Histoclear	   (Fisher	   Scientific	   Ltd)	   followed	   by	  
rehydration	  in	  graded	  concentrations	  of	  ethanol.	  Slides	  were	  subsequently	  stained	  in	  haematoxylin,	  
rinsed,	   rapidly	  de-­‐stained	   in	  1%	  acid	  alcohol,	   rinsed	  and	  stained	   in	  eosin.	  Following	  dehydration	   in	  
graded	  concentrations	  of	  ethanol	  and	  clearing	  in	  Histoclear,	  slides	  were	  mounted	  with	  coverslips	  in	  
DPX.	  	  
	  
2.2.4.	  Immunohistochemistry	  
Portions	  of	  myometrial	  biopsies	  measuring	  3x3x3mm3	  were	  fixed	  in	  neutral	  buffered	  formalin	  for	  18-­‐
24	  hours,	   	  embedded	   in	  paraffin,	  cut	   into	  5µm	  sections	  and	  mounted	  on	  poly-­‐D-­‐lysine	  slides	   (VXR,	  
Radnor,	  PA,	  USA).	  Prior	  to	  immunostaining,	  slides	  were	  deparaffinised	  in	  Histoclear	  (Fisher	  Scientific	  
Ltd)	   followed	  by	   rehydration	   in	   graded	   concentrations	  of	   ethanol.	   Endogenous	  peroxidase	   activity	  
was	  blocked	  by	  immersing	  the	  slides	  in	  freshly	  prepared	  0.3%	  hydrogen	  peroxide	  in	  PBS.	  Slides	  were	  
subsequently	  washed	  and	  incubated	  in	  1.5%	  non-­‐immune	  goat	  serum	  in	  PBS	  for	  30	  minutes	  at	  room	  
temperature.	  The	  slides	  were	  incubated	  with	  alpha	  smooth	  muscle	  actin	  (1:1000,	  Thermo	  Scientific)	  
primary	  antibody	  at	  4°C	  in	  a	  humidified	  chamber,	  with	  one	  section	  incubated	  in	  PBS	  alone	  to	  serve	  
as	  a	  negative	  control.	  Following	  biotinylated	  secondary	  antibody	  incubation	  for	  30	  minutes	  at	  room	  
temperature	   (1:200,	   Vector	   Laboratories,	   Peterborough,	   UK),	   staining	   was	   visualised	   using	  
Vectastain	  Elite	  ABC	  reagent	  (Vector	  Laboratories)	  followed	  by	  development	  of	  the	  colour	  reaction	  
using	   diaminobenzidine	   (DAB).	   Slides	   were	   counterstained	   with	   haematoxylin	   followed	   by	  
dehydration	   in	   graded	   concentrations	   of	   alcohol	   and	   a	   clearing	   step	   in	   Histoclear.	  Mounting	   was	  
performed	  with	  DPX.	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2.2.5.	  RNA	  Extraction	  
Total	  RNA	  was	  extracted	  from	  cells	  grown	  in	  a	  monolayer	  using	  an	  RNeasy	  mini	  kit	  (Qiagen)	  as	  per	  
the	   manufacturer’s	   protocol.	   Animal	   tissue	   was	   placed	   in	   pre-­‐cooled	   Precellys®	   tubes	   (Stretton	  
Scientific)	  containing	  QIAzol	  lysis	  reagent	  (Qiagen).	  Tissues	  were	  immediately	  homogenised	  via	  two	  
20-­‐second	   cycles	   at	   5000rpm	   using	   a	   Precellys	   homogeniser.	   Total	   RNA	   and	   miRNA	   was	  
subsequently	   extracted	   using	   a	   miRNeasy	   mini	   kit	   (Qiagen)	   as	   per	   the	   manufacturer’s	   protocol.	  
Human	  tissue	  was	  placed	  in	  pre-­‐cooled	  Precellys®	  tubes	  containing	  buffer	  RLT	  (Qiagen).	  Tissues	  were	  
immediately	   homogenised	   via	   two	   20-­‐second	   cycles	   at	   5000rpm	   using	   a	   Precellys	   homogeniser.	  
Total	  RNA	  was	  subsequently	  extracted	  using	  an	  RNeasy	  mini	  kit	  (Qiagen)	  as	  per	  the	  manufacturer’s	  
protocol.	  	  
For	   the	  microarray	  project,	   total	  RNA	  was	  extracted	   from	  cells	  and	   tissue	  using	  a	  Trizol®	  Plus	  RNA	  
Purification	  kit	   (Thermo	  Fisher	  Scientific)	   as	  per	   the	  manufacturer’s	  protocol.	   Tissue	  was	  placed	   in	  
Precellys®	  tubes	  and	  homogenised	  via	  2	  20-­‐second	  cycles	  at	  5000rpm	  using	  a	  Precellys	  homogeniser.	  
On-­‐column	   DNase	   digestion	   was	   performed	   at	   the	   appropriate	   point	   in	   the	   protocol	   as	   per	   the	  
manufacturer’s	  instructions.	  
The	  concentration	  and	  purity	  of	  RNA	  was	  determined	  using	   the	  260/280	  ratio	  on	  a	  NanoDrop	  Nd-­‐
1000	  spectrophotometre,	  with	  an	  expected	  ratio	  of	  ~2.0.	  RNA	  was	  stored	  at	  	  -­‐80°C.	  
	  
2.2.6.	  Microarray	  
The	  concentration	  and	  purity	  of	  RNA	  used	  for	  microarray	  and	  validation	  of	  results	  was	  determined	  
by	  spectrophotometry	  and	   integrity	  was	  confirmed	  using	  an	  Agilent	  2100	  Bioanalyzer	  with	  an	  RNA	  
6000	  Nano	  Kit	  (Agilent	  Technologies).	  A	  minimum	  RIN	  score	  of	  8	  was	  used	  as	  cut	  off	  for	  inclusion	  in	  
the	   microarray	   analysis.	   Whole-­‐genome	   transcriptome	   analysis	   was	   conducted	   by	   hybridising	   six	  
biological	   samples	   of	   total	   RNA	   per	   condition	   to	   Affymetrix	   Human	   Gene	   2.1	   ST	   Arrays	   Strips	  
(Affymetrix).	   Expression	   data	   were	   analysed	   using	   Partek	   Genomics	   Suite	   6.6	   software	   (Partek	  
Incorporated).	   The	   raw	   CEL	   files	   were	   normalized	   using	   the	   RMA	   background	   correction	   with	  
quantile	   normalisation,	   log	   base	   2	   transformation	   and	   mean	   probe-­‐set	   summarisation	   with	  
adjustment	   for	   GC	   content.	   Differentially	   expressed	   genes	   (DEGs)	   were	   identified	   by	   a	   two-­‐way	  
ANOVA,	   and	   p-­‐values	   were	   adjusted	   using	   the	   FDR	   (false-­‐discovery	   rate)	   method	   to	   correct	   for	  
multiple	  comparisons.	  DEGs	  were	  considered	  significant	  if	  p-­‐value	  was	  ≤	  0.05	  at	  a	  fold	  change	  (FC)	  of	  
>2	  for	  the	  explant	  model	  analysis	  with	  FDR	  <0.05.	  The	  same	  cut-­‐offs	  were	  used	  for	  the	  mifepristone	  
study	  except	  that	  the	  lower	  FC	  of	  >1.5	  was	  chosen	  as	  no	  genes	  fulfilled	  the	  stricter	  cut-­‐off	  of	  >2.	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2.2.7.	  cDNA	  Synthesis	  
1.5µg	  of	  RNA	  was	   linearised	  by	  heating	  to	  70°C	   for	  5	  minutes.	  Subsequently,	   the	  RNA	  was	  reverse	  
transcribed	  to	  cDNA	  by	  the	  addition	  of	  4µL	  10x	  PCR	  buffer	  (Applied	  Biosystems),	  8µL	  25mM	  MgCl2	  
(Applied	  Biosystems),	   8µL	  10mM	  dNTPs	   (Invitrogen),	   1µL	  50µM	  oligo	  dT	   random	  primers	   (Applied	  
Biosystems),	  1µL	  MuLV	  reverse	  transcriptase	  (Applied	  Biosystems)	  and	  1µL	  RNase	  inhibitor	  (Applied	  
Biosystems).	   The	   total	   reaction	  volume	  was	  brought	   to	  40µL	  using	  RNase-­‐free	  water	   (Qiagen)	  and	  
incubated	  at	   42°C	   for	   1	  hour.	   The	   reaction	  was	   terminated	  by	  heating	   to	  95°C	   for	   5	  minutes.	   The	  
resulting	  cDNA	  volume	  was	  further	  diluted	  to	  a	  volume	  of	  100µL	  using	  RNase-­‐free	  water	  and	  stored	  
at	  -­‐20°C.	  
	  
2.2.8.	  Quantitative	  real-­‐time	  PCR	  
Primer	   sets	   were	   designed	   by	   inputing	   the	   sequence	   for	   the	   gene	   of	   interest	   into	   the	   Primer	   3	  
software	   (http://bioinfo.ut.ee/primer3-­‐0.4.0/)	  with	   the	   ‘Max	   Poly-­‐X’	   setting	   set	   to	   3	   (Tables	   2.1	  &	  
2.2).	   The	   product	   of	   the	   resulting	   primer	   sequences	   were	   entered	   into	   Nucleotide	   Blast	  
(https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch)	   in	   order	   to	   verify	   they	   matched	  
back	  to	  the	  gene	  of	  interest.	  	  
Quantitative	  real-­‐time	  PCR	  was	  performed	  in	  the	  presence	  of	  SYBR	  Green	  (Applied	  Biosystems)	  using	  
a	   Rotor	   Gene	   R-­‐G	   6000	   (Qiagen),	   which	   continuously	   measures	   fluorescence	   occurring	   upon	   dye	  
incorporation	   into	   double-­‐stranded	   DNA.	   The	   protocol	   utilised	   consisted	   of	   a	   pre-­‐PCR	   cycle	   of	   10	  
minutes	  at	  95°C	  followed	  by	  40	  cycles	  of	  95°C	  for	  20	  seconds,	  60°C	  for	  20	  seconds	  and	  72°C	  for	  20	  
seconds.	  A	   final	  melt	   step	  was	   included	   from	  72°C	   rising	   to	   99°C	   at	   1°C	   intervals,	  which	   serves	   to	  
determine	   the	   melting	   temperature	   of	   the	   product	   of	   the	   PCR	   reaction.	   The	   cycle	   at	   which	  
fluorescence	   reached	   a	   pre-­‐set	   threshold	   (cycle	   threshold)	   was	   used	   for	   quantitation;	   this	   was	  
represented	  at	  the	  point	  where	  the	  exponential	  increase	  in	  amplicon	  abundance	  was	  approximately	  
parallel	  in	  all	  samples.	  
For	   each	   set	   of	   primers,	   cDNA	   was	   used	   to	   run	   a	   PCR	   in	   order	   to	   obtain	   large	   quantities	   of	   the	  
product	   of	   interest.	   This	   was	   purified	   using	   a	   QIAquick	   PCR	   purification	   kit	   (Qiagen)	   as	   per	   the	  
manufacturer’s	   protocol.	   Subsequently,	   a	   ten-­‐fold	   dilution	   series	   was	   prepared	   and	   utilised	   for	  
quantitation	  and	  efficiency	  determination.	  All	  mouse	  data	  were	  expressed	  relative	  to	  the	  amount	  of	  
constitutively	  expressed	  Gapdh,	  shown	  to	  be	  the	  most	  stable	  housekeeping	  gene	  in	  myometrial	  cells	  
64	  
	  
when	   compared	   to	  Actb	   and	  Hprt	   (Lydia	   Edey	   thesis).	   All	   human	   data	  were	   expressed	   relative	   to	  
GAPDH	  and/or	  18S	  rRNA.	  
	  
Group	   Name	  
Forward	   (F)	   and	   Reverse	   (R)	   primer	  
sequence	  (5’-­‐3’)	  
Genbank/EMBL	  
Accession	  no.	  
Product	  
Size	  (bp)	  
Housekeeping	  
genes	  
GAPDH	   F:	  tgatgacatcaagaaggtggtgaag	   BC014085	   240	  
	   R:	  tccttggaggccatgtaggccat	   	   	  
18S	  rRNA	   F:	  aaacggctaccacatccaag	   X03205.1	   297	  
	   R:	  cctccaatggatcctcgtta	   	   	  
Progesterone	  
responsive	  
genes	  
FKBP51	   F:	  tccctcgaatgcaactctct	   NM_001145775	   194	  
	   R:	  gccacatctctgcagtcaaa	   	   	  
HSD11B1	   F:	  accttcgcagagcaatttgt	   NM_005525	   226	  
	   R:	  gccagagaggagacgacaac	   	   	  
Contraction-­‐
associated	  
proteins	  
PTGS2	   F:	  tgtgcaacacttgagtggct	  	   AY151286	  	   297	  	  
	   R:	  actttctgtactgcgggtgg	  	   	   	  
OXTR	  	   F:	  agaagcactcgcgcctctt	  	   NM_000916	   102	  
	   R:	  aggtgatgtcccacagcaact	  	   	   	  
GJA1	   F:	  aattcagacaaggcccacag	   NM_000165	   214	  
	   R:	  catggcttgattccctgact	   	   	  
Nuclear	  
receptors	  
PGR	   F:	  agcccacaatacagcttcgag	  	   NM_000926	   293	  	  
	   R:	  tttcgacctccaaggaccat	  	   	   	  
ESR1	   F:	  tccaactgcatttcctttcc	   NM_000125	  	   201	  
	   R:	  ttggaacatggcagcattta	   	   	  
NR3C1	   F:	  cttccagaaccatggtagcc	   NM_002425	   166	  
	   R:	  tacgaaactccacccaaagg	   	   	  
Cytokines	  
IL1A	   F:	  aatgacgccctcaatcaaag	   NM_000575.4	   226	  
	   R:	  tgggtatctcaggcatctcc	   	   	  
IL1B	  	   F:	  gctgaggaagatgctggttc	  	   NM_000576	  	   240	  	  
	   R:	  tccatatcctgtccctggag	  	   	   	  
IL6	   F:	  agtgaggaacaagccagagc	   NM_000600	   246	  
	   R:	  gaggtgcccatgctacattt	   	   	  
IL8	  	   F:	  gccttcctgattttgcagc	  	   NM_000584	  	   150	  	  
	   R:	  cgcagtgtggtccactctca	  	   	   	  
Smooth	  
muscle	  
phenotype	  
ACTA2	   F:	  ttcaatgtcccagccatgta	   NM_001141945	   222	  
	   R:	  gaaggaatagccacgctcag	   	   	  
TPM1	   F:	  ccacgctctcaacgatatga	   NM_000366	   215	  
	   R:	  cagtgtgtgcctggctctaa	   	   	  
MYLK	   F:	  ggccacgatgaaacagattt	   NM_005965	  	   172	  
	   R:	  ggcatgattgatgcacattt	   	   	  
Reproductive	  
function	  
TNFAIP3	   F:	  aagggtgtctgagcaggaga	   NM_001270507	   163	  
	   R:	  tgcttggtaggagaggagga	   	   	  
PTGER3	   F:	  cgccatgtcttcatcacatc	   NM_000957	   199	  
	   R:	  atgtgatcctggcagaaagg	   	   	  
Mifepristone	  
microarray	  
FXYD3	   F:	  cccgctatgatggaagtgtt	   NM_001136007	   200	  
	   R:	  ggactttgaggcttgttgga	   	   	  
PPIAL4A	   F:	  agggttcctgctttcacaga	   NM_001143883	   211	  
	   R:	  gtcttggcagcacagatgaa	   	   	  
Table	  2.1.	  Human	  primer	  sequences	  and	  gene	  accession	  numbers.	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Group	   Name	  
Forward	   (F)	   and	  Reverse	   (R)	  primer	  
sequence	  (5’-­‐3’)	  
Genbank/EMBL	  
Accession	  no.	  
Product	  
Size	  (bp)	  
Housekeeping	  
gene	  
Gapdh	   F:	  actccactcacggcaaattc	   NM_008084.3	   171	  
	   R:	  tctccatggtggtgaagaca	   	   	  
Contraction-­‐
associated	  
proteins	  
Cox2	   F:	  tgcagaattgaaagccctct	   NM_011198	   181	  
	   R:	  gctcggcttccagtattgag	   	   	  
Gja1	   F:	  gcgtgagggaagtacccaac	   NM_010288	   116	  
	   R:	  ctgggcacctctctttcactta	   	   	  
Otr	   F:	  cccacctcccatacttctga	   NM_001081147.1	   150	  
	   R:	  actgtagcacgtggcttcct	   	   	  
Chemokines	  
and	  cytokines	  
Il1a	   F:	  tactcgtcgggaggagacga	   NM_010554	   122	  
	   R:	  ggtgtttctggcaactccttc	   	   	  
Il1b	   F:	  caggcaggcagtatcactca	   NM_008361	   250	  
	   R:	  agctcatatgggtccgacag	   	   	  
Il6	   F:	  ccggagaggagacttcacag	   NM_031168	   166	  
	   R:	  ttctgcaagtgcatcatcgt	   	   	  
Il10	   F:	  ccagggagatcctttgatga	   NM_010548.2	   173	  
	   R:	  cattcccagaggaattgcat	   	   	  
Cxcl1	   F:	  gcctatcgccaatgagctg	   NM_008176	   171	  
	   R:	  aagggagcttcagggtcaag	   	   	  
Cxcl2	   F:	  ctgacctggaaaggaggagc	   NM_009140	   106	  
	   R:	  ggcacatcaggtacgatcca	   	   	  
Ccl2	   F:	  cccactcacctgctgctact	   NM_011333	   164	  
	   R:	  tctggacccattccttcttg	   	   	  
Ccl5	   F:	  ccctcaccatcatcctcact	   NM_013653	   185	  
	   R:	  ccttcgagtgacaaacacga	   	   	  
Ifng	   F:	  acggcacagtcattgaaagc	   NM_008337	   118	  
	   R:	  tcaccatccttttgccagttc	   	   	  
Gcsf	   F:	  aggtctcctgcaggctctat	   NM_009971.1	   119	  
	   R:	  cccctaggttttccatctgct	   	   	  
Tnfa	   F:	  tatggctcagggtccaactc	   NM_013693	   174	  
	   R:	  ctccctttgcagaactcagg	   	   	  
Circadian	  
rhythm	  
Clock	   F:	  gatggtgatggagggtgaac	   NM_001289826.1	   210	  
	   R:	  atgtgcccttggttctgtct	   	   	  
Bmal1	   F:	  tggagggactccagacattc	   BC025973.1	   185	  
	   R:	  ttgctgcctcatcgttactg	   	   	  
Npas2	   F:	  ccggctgtcagagtcctaag	   NM_008719.2	   190	  
	   R:	  gccacactccagacacgtta	   	   	  
Cry1	   F:	  ggatccaccatttagccaga	   NM_007771.3	   194	  
	   R:	  cacagggcagtagcagtgaa	   	   	  
Per1	   F:	  gctggaccaaccaataggaa	   NM_001159367.1	   210	  
	   R:	  tggacagaccacttcagcag	   	   	  
Nr1d2	   F:	  gacctgttggcatgtttgtg	   NM_011584.4	   152	  
	   R:	  ggccatctttcctaccatga	   	   	  
Rorc	   F:	  acaacagcagcaagtgatgg	   NM_001293734.1	   153	  
	   R:	  cctggatttatccctgctga	   	   	  
Ppargc1a	   F:	  tgccttcatgctgtggtaag	   NM_008904.2	   192	  
	   R:	  gttccctctctgctgctttg	   	   	  
Table	  2.2.	  Mouse	  primer	  sequences	  and	  gene	  accession	  numbers.	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2.2.9.	  Whole	  Cell	  Protein	  Extraction	  
Cell	  lysis	  buffer	  (Cell	  Signalling)	  supplemented	  with	  1	  protease	  tablet	  (Roche	  Diagnostics)	  and	  100µL	  
phosphatase	   inhibitor	   (Thermo	  Scientific)	   per	   10mL	  was	   added	  directly	  onto	  6-­‐well	   culture	  plates.	  
The	   lysate	  was	   centrifuged	   at	   13,000×g	   for	   20	  minutes	   at	   4°C	   in	   order	   to	   remove	   cell	   debris.	   The	  
supernatant	  was	  collected	  in	  a	  fresh	  Eppendorf	  tube.	  	  
Explant	  pieces	  were	  weighed	   in	  pre-­‐cooled	  Precellys®	  tubes	  and	  10µL	  cell	   lysis	  buffer,	  prepared	  as	  
above,	   added	   per	   1mg.	   Tissue	   was	   homogenised	   via	   two	   20-­‐second	   cycles	   at	   5000rpm	   using	   a	  
Precellys	   homogeniser.	   The	   lysate	  was	   centrifuged	   at	   13,000×g	   for	   20	  minutes	   at	   4°C	   in	   order	   to	  
remove	  cell	  debris.	  The	  supernatant	  was	  collected	  in	  a	  fresh	  Eppendorf	  tube.	  
	  
2.2.10.	  Protein	  Assay	  
Protein	  concentrations	  were	  determined	  via	  a	  DC	  protein	  assay	  (Biorad)	  as	  per	  the	  manufacturer’s	  
protocol	  using	  bovine	  serum	  albumin	  (BSA)	  reference	  standards.	  The	  plate	  was	  read	  at	  650nm	  using	  
an	  Optimax	  microplate	  reader	  (Molecular	  Devices).	  
	  
2.2.11.	  Western	  Blotting	  
Proteins	  were	  denatured	  by	  the	  addition	  of	  NuPAGE®	  LDS	  sample	  buffer	  and	  heated	  at	  75°C	  for	  10	  
minutes.	  Equal	  amounts	  of	  protein	  (20-­‐40µg)	  were	  electrophoresed	  through	  a	  4-­‐15%	  gradient	  mini-­‐
protean®	   TGXTM	   gel	   (Biorad).	   The	   separated	   proteins	  were	   subsequently	   transferred	   onto	   a	   PVDF	  
membrane	  using	   the	  Trans-­‐Blot	  Turbo	  transfer	  system	  (Biorad).	   	  The	  membrane	  was	  subsequently	  
incubated	   in	   blocking	  buffer	   (5%	  w/v	  non-­‐fat	  milk	   in	   TBS-­‐T)	   for	   1	   hour	   at	   room	   temperature	  with	  
gentle	   agitation.	   It	   was	   subsequently	   hybridized	   overnight	   at	   4°C	   with	   primary	   antibody.	   After	  
washing	  in	  TBS-­‐T,	  the	  membrane	  was	  incubated	  with	  secondary	  antibody	  at	  room	  temperature	  for	  2	  
hours.	  Clarity	  Western	  ECL	  substrate	  (Biorad)	  was	  used	  for	  immunodetection.	  
	  
2.2.12.	  Chemokine/Cytokine	  Assay	  
Myometrial	   tissue	  was	   lysed	   in	  Biorad	  Cell	   Lysis	  buffer	   supplemented	  with	  2mM	  PMSF	  and	  Biorad	  
QG	   solution.	   Tissue	   was	   homogenised	   via	   four	   20-­‐second	   cycles	   at	   5000rpm	   using	   a	   Precellys	  
homogeniser.	  Protein	  concentration	  was	  determined	  by	  DC	  Protein	  Assay.	  A	  mouse	  Bio-­‐Plex©	  ProTM	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cytokine	  assay,	   including	  IL-­‐1α,	  IL-­‐1β,	  IL-­‐6,	   IL-­‐10,	  CXCL1,	  CXCL2,	  CCL2,	  CCL5,	  IFN-­‐γ,	  GCSF	  and	  TNF-­‐α,	  
and,	  was	  performed	  according	  to	  the	  manufacturer’s	  instructions.	  500ug	  of	  protein	  diluted	  1:1	  with	  
Bio-­‐Plex	  sample	  diluents	  was	  assayed	  per	  well.	  Assays	  were	  read	  using	  a	  Bio-­‐Plex©	  MAGPIX©	  reader.	  
Tissue	  media	  were	   centrifuged	   at	   13,000×g	   for	   20	  minutes	   at	   4°C	   in	   order	   to	   remove	   cell	   debris.	  
Human	  Bio-­‐Plex©	  ProTM	  chemokine/cytokine	  assays	  were	  used	  to	  measure	  the	  concentrations	  of	  IL-­‐
1α,	   IL-­‐1β,	   IL-­‐6,	   IL-­‐8,	  CCL2,	  CCL5,	  CCL11,	  CCL20,	   ICAM	  and	  LIF	   in	  explant	  culture	  media.	  These	  were	  
performed	  according	  to	  the	  manufacturer’s	  instructions	  and	  were	  read	  using	  a	  Bio-­‐Plex©	  200	  reader	  
and	   Bio-­‐Plex	   Manager©	   v7.1	   software.	   Chemokine/cytokine	   concentrations	   were	   normalised	   to	  
tissue	  weight.	  	  
	  
2.2.13.	  Hormone	  Level	  Quantification	  
2μg	   of	   protein	   lysate	   was	   used	   to	   quantify	   progesterone,	   estradiol	   and	   cortisol	   levels	   as	   per	   the	  
manufacturer’s	   protocol	   (Millipore).	   Assays	   were	   read	   using	   a	   Bio-­‐Plex©	   MAGPIX©	   reader.	   The	  
signal-­‐to-­‐noise	   ratio	   was	   7.3	   and	   intra-­‐assay	   precision	   was	   calculated	   at	   18.4%	   (manufacturer’s	  
recommendation:	   <20%).	   A	   spiking	   and	   recovery	   experiment	   where	   lysates	   were	   spiked	   with	   3	  
different	   concentrations	   of	   standards	   falling	   in	   the	   linear	   portion	   of	   the	   curve	   demonstrated	  
accuracy	   of	   118.5%	   (manufacturer’s	   recommendation:	   80-­‐120%).	   Recovery	   was	   assessed	   by	  
comparison	   of	   the	   spiked	   sample	   to	   the	   sum	   of	   the	   standard	   alone	   and	   the	   equivalent	   standard	  
obtained	  from	  the	  standard	  curve.	  
	  
2.2.14.	  LDH	  Assay	  
2µL	  of	  DMEM	  bathing	  a	  single	  explant	  over	  a	  30	  hour	  period	  was	  brought	  to	  a	  total	  volume	  of	  50µL	  
using	  LDH	  assay	  buffer.	  	  A	  LDH	  assay	  (Sigma,	  MAK066)	  was	  ran	  as	  per	  the	  manufacturer’s	  protocol.	  
Positive	  controls	  for	  each	  tissue	  were	  prepared	  by	  bead	  homogenisation	  of	  snap	  frozen	  tissue	  at	  t=0	  
followed	   by	   two	   5	   minute	   cycles	   of	   sonication	   using	   a	   Bioruptor®	   (Diagenode).	   	   After	   an	   initial	  
incubation	  of	  3	  minutes,	   absorbance	  was	  measured	  at	  450nm	   followed	  by	  measurements	  every	  2	  
minutes	   until	   the	   value	   of	   the	   most	   active	   sample	   was	   greater	   than	   the	   value	   of	   the	   highest	  
standard.	  The	  LDH	  content	  of	  the	  positive	  control	  was	  normalised	  to	  100%.	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2.2.15.	  Statistical	  Analysis	  
Prior	  to	  statistical	  analysis,	  the	  distribution	  of	  the	  data	  was	  determined	  via	  Kolmogorov-­‐Smirnov	  test	  
for	  experiments	  with	  an	  n≤6	  or	  a	  Shapiro-­‐Wilk	  test	  for	  all	  experiments	  with	  an	  n≥7.	  	  
For	   the	  comparison	  of	  2	  paired	  groups,	  normally	  distributed	  data	  were	  analysed	  by	  a	  paired	  t	   test	  
and	   non-­‐normally	   distributed	   data	   were	   analysed	   using	   a	   Wilcoxon	   matched	   pair	   test.	   For	   the	  
comparison	  of	  2	  unpaired	  groups,	  normally	  distributed	  data	  were	  analysed	  by	  an	  unpaired	  t	  test	  and	  
non-­‐normally	  distributed	  data	  were	  analysed	  by	  a	  Mann-­‐Whitney	  test.	  	  
For	   the	   comparison	   of	   3	   or	   more	   paired	   groups,	   normally	   distributed	   data	   were	   analysed	   by	   a	  
repeated	   measures	   ANOVA	   followed	   by	   Bonferroni	   multiple	   comparison	   test	   and	   non-­‐normally	  
distributed	  data	  were	  analysed	  by	  a	  Friedman	  test	  followed	  by	  Dunn’s	  multiple	  comparison	  test.	  For	  
the	  comparison	  of	  3	  or	  more	  unpaired	  groups,	  normally	  distributed	  data	  were	  analysed	  by	  one-­‐way	  
ANOVA	   followed	   by	   Bonferroni	  multiple	   comparison	   test	   and	   non-­‐normally	   distributed	   data	  were	  
analysed	  by	  Kruskal-­‐Wallis	  test	  followed	  by	  Dunn’s	  multiple	  comparison	  test.	  	  
All	  data	  are	  presented	  as	  mean	  ±	  SEM	  with	  p<0.05	  considered	  to	  be	  statistically	  significant.	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CHAPTER	   3:	   THE	   EFFECTS	   OF	   PROGESTERONE	   AND	   MIFEPRISTONE	   ON	  
MURINE	  PARTURITION	  
	  
3.1	  Introduction	  
The	   timing	  of	  birth	   is	   a	   key	   challenge	   for	  obstetricians	  as	  both	  preterm	  and	  post-­‐dates	  birth	   carry	  
associated	   morbidity	   and	   mortality.	   Progesterone	   supplementation	   is	   able	   to	   reduce	   the	   risk	   of	  
spontaneous	   preterm	   labour	   in	   certain	   cases	   (50,	   53)	   although	   this	   effect	   is	   inconsistent	   and	  
increasingly	  controversial	  (55,	  57).	  Conversely,	  mifepristone	  (RU486)	  has	  been	  shown	  to	  be	  capable	  
of	   inducing	   labour	  at	  term	  (340).	   It	   is	  evident	  that	  understanding	  the	  mechanisms	  of	  progesterone	  
action	  are	  key	  to	  unravelling	   the	  pathophysiology	  behind	   labour	  onset.	  This	   information	  will	  aid	   in	  
the	   development	   of	   therapeutic	   agents	   that	   regulate	   the	   onset	   of	   labour	   hence	   allowing	  
obstetricians	  to	  prevent	  preterm	  labour	  and	  to	  induce	  labour,	  when	  indicated,	  more	  successfully	  and	  
with	  fewer	  side	  effects.	  
Most	  animals,	  including	  humans	  and	  mice,	  are	  dependent	  on	  high	  levels	  of	  progesterone	  to	  maintain	  
uterine	   quiescence	   during	   pregnancy.	   Csapo	   proved	   this	   principle	   by	   removing	   the	   source	   of	  
progesterone	   via	   luteectomy	   in	   women	   scheduled	   to	   terminate	   their	   pregnancy	   (prior	   to	   the	  
placenta	   becoming	   the	   dominant	   progesterone-­‐producing	   organ)	   and	   observing	   increased	   uterine	  
sensitivity	   to	   uterotonics	   and	   ultimately	   labour	   (118).	   The	   same	   results	   were	   obtained	   in	   non-­‐
luteectomised	   women	   receiving	   the	   progesterone	   antagonist	   drug	   mifepristone	   (123).	   Further,	  
supplementation	   of	   pregnant	   animals	   with	   progesterone	   has	   been	   shown	   to	   maintain	   uterine	  
quiescence	  and	  block	  labour	  onset	  (341,	  342).	  	  
In	  many	  animals,	   including	  mice,	  labour	  follows	  a	  drop	  in	  the	  systemic	  levels	  of	  progesterone	  (343,	  
344).	   	  This	  differs	  to	  humans	  who	  do	  not	  demonstrate	  a	  systemic	  withdrawal	  of	  progesterone	  (61,	  
345,	   346)	   yet	   remain	   sensitive	   to	   progesterone	  blockade	   (124),	   hence	   giving	   rise	   to	   the	   theory	   of	  
functional	   progesterone	  withdrawal.	  Despite	   this	   critical	   difference	  between	   species,	   the	   scientific	  
community	   remains	   reliant	   on	   animal	   models	   for	   the	   study	   of	   parturition	   due	   to	   the	   obvious	  
limitations	  of	  human	  research	  in	  pregnancy.	  An	  alternative	  to	  the	  use	  of	  mouse	  models	  would	  be	  the	  
use	   of	   guinea	   pigs	   given,	   as	   with	   humans,	   they	   do	   not	   demonstrate	   an	   absolute	   decline	   in	  
progesterone	   levels	   prior	   to	   labour.	   However,	   apart	   from	   evidence	   demonstrating	   that	   the	  
mechanisms	   underlying	   functional	   progesterone	   withdrawal	   differ	   in	   guinea	   pigs	   as	   compared	   to	  
humans	   (335),	   mouse	   models	   are	   more	   favoured	   for	   parturition	   research	   due	   to	   their	   shorter	  
gestations	  and	  ready	  availability	  of	  transgenic	  animals.	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A	   more	   recent	   and	   as	   yet	   minimally	   researched	   area	   is	   the	   effect	   of	   progesterone	   on	   circadian	  
rhythm	  gene	   expression	   in	   the	  myometrium.	  A	   recent	   ChIP-­‐seq	   study	  where	   ovariectomised	  mice	  
were	   acutely	   exposed	   to	   progesterone	   identified	   that	   progesterone	   modulates	   circadian	   rhythm	  
genes	   (152).	   Furthermore,	   circadian	   rhythm	   genes	   have	   been	   implicated	   in	   the	   modulation	   of	  
inflammation	  (162,	  163).	  Conditional	  myometrial	  Bmal1	  knock-­‐out	  mice	  are	  associated	  with	  a	  failure	  
of	   parturition	   at	   the	   expected	   time	   window	   despite	   comparable	   serum	   progesterone	   levels	   to	  
control	  animals	  (161).	  	  
In	  order	  to	  define	  the	  effects	  of	  progesterone,	  two	  studies	  were	  undertaken:	   in	  the	  first,	  pregnant	  
mice	   were	   treated	   with	   vehicle	   control	   or	   progesterone	   to	   prolong	   gestation;	   in	   the	   second,	  
pregnant	  mice	  were	  treated	  with	  vehicle	  control	  or	  mifepristone	  in	  order	  to	  induce	  preterm	  labour.	  
By	  preventing	  the	  systemic	  decline	  in	  progesterone,	  the	  aim	  was	  to	  study	  the	  effects	  on	  contraction-­‐
associated	   protein	   expression,	   inflammation	   and	   circadian	   rhythm	   genes	   as	   compared	   to	   vehicle	  
control	   labour.	   By	   studying	   the	   period	   after	   mifepristone	   administration	   in	   greater	   detail	   than	  
previously,	   the	   aim	   was	   to	   define	   the	   mode	   of	   action	   of	   mifepristone	   and	   compare	   it	   to	  
normal/vehicle	  control	  labour.	  	  
	  
3.2	  Results	  
	  
3.2.1.	  Murine	  progesterone	  levels	  in	  pregnancy	  
A	  dose	  of	  2mg	  progesterone	  has	  previously	  been	  shown	  to	  maintain	  pregnancy	  until	   term	   in	  mice	  
ovariectomised	   on	   E14	   (347).	   Based	   on	   this,	   preliminary	   experiments	   conducted	   by	   the	   group	  
demonstrated	   that	  supplementation	  of	  non-­‐ovariectomised	  pregnant	  mice	  with	  2mg	  progesterone	  
from	  E14	  prolonged	  pregnancy	   up	   to	   E20	   (Fig.	   3.1.).	   Based	  on	   these	   data,	   2mg	  progesterone	  was	  
chosen	  as	  the	  dose	  for	  supplementation	  in	  subsequent	  experiments.	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Figure	  3.1.	  2mg	  progesterone	  (P4)	  supplementation	  in	  pregnant	  mice.	  
Mice	  were	  administered	  daily	   subcutaneous	   injections	  of	  2mg	  progesterone	   in	  40μL	  peanut	  oil	   vehicle	   from	  
gestational	   day	   14	   (E14)	   until	   gestational	   day	   20	   (E20).	   Venepuncture	   via	   the	   tail	   vein	   was	   carried	   out	   for	  
biochemical	   analysis	   of	   progesterone	   on	   E13	   (prior	   commencement	   of	   supplementation),	   E16,	   E18	   and	  
E19/E20.	  n=3.	  These	  experiments	  were	  performed	  by	  Dr	  Kaiyu	  Lei	  and	  Dr	  Bronwen	  Herbert.	  	  
	  
3.2.2.	  Vehicle	  control	  and	  progesterone-­‐supplemented	  murine	  labour	  
Vehicle	   control	   animals	  went	   into	   labour	   at	   term	   as	   anticipated	   on	   E18	  with	   98.8%	   of	   pups	   born	  
alive.	  None	  of	   the	  progesterone-­‐supplemented	  animals	  went	   into	   labour	   at	   term	  and	   indeed	   they	  
were	  all	  still	  pregnant	  at	  E20,	  at	  which	  point	  they	  were	  sacrificed.	   It	  was	  noted	  that	  89.7%	  of	  pups	  
were	  dead	  by	  this	  gestation.	  At	  E19,	  2.17%	  of	  pups	  were	  dead	  at	  delivery.	  
	  
3.2.3.	  The	  effect	  of	  progesterone	  supplementation	  on	  murine	  labour	  
3.2.3.1	  Inflammation	  
At	   the	   RNA	   level,	   vehicle	   control	   labour	   was	   associated	   with	   a	   significant	   peak	   in	   the	   pro-­‐
inflammatory	  cytokines	  Il6	  and	  Tnfa	  (Fig.	  3.2.).	  Similar	  non-­‐significant	  trends	  were	  observed	  for	  Il1a,	  
IL1b,	  Cxcl1	  and	  Ccl5.	  Interestingly,	  a	  labour-­‐associated	  peak	  was	  also	  noted	  in	  the	  levels	  of	  the	  anti-­‐
inflammatory	  cytokine	  Il10.	  Advancing	  gestation	  was	  not	  associated	  with	  any	  change	  in	  RNA	  levels	  of	  
Cxcl2,	  Ccl20,	  Ifng	  or	  Gcsf.	  	  
Mice	  receiving	  progesterone	  supplementation	  demonstrated	  a	  delay	  in	  the	  significant	  up-­‐regulation	  
of	   Il6	   and	  a	  complete	   loss	  of	   the	  Tnfa	  peak	   (Fig.	  3.2.).	   	   Similar	  delays	  were	  observed	   for	   Il1a,	   Il1b,	  
Cxcl1	  and	  Ccl5.	  	  Progesterone	  did	  not	  enhance	  Il10	  mRNA	  levels;	  by	  contrast,	  there	  was	  a	  significant	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reduction	   when	   comparing	   vehicle	   labour	   with	   either	   E19	   or	   E20	   progesterone-­‐supplemented	  
animals.	  Whilst	  Ccl20,	  Ifng	  and	  Gcsf	  did	  not	  alter	  with	  progesterone-­‐supplementation,	  a	  peak	  at	  E20	  
was	  observed	  for	  Cxcl2	  which	  was	  significant	  when	  compared	  to	  E16	  progesterone-­‐treated	  animals.	  
	  
Figure	  3.2.	  Progesterone	  (P4)	  delays	  the	  peak	  in	  pro-­‐inflammatory	  cytokine	  mRNA	  levels.	  	  
Mice	  were	  administered	  daily	  subcutaneous	  40μL	  peanut	  oil	  vehicle	   injections	  from	  gestational	  day	  14	  (E14)	  
until	  gestational	  day	  18	  (E18)	  as	  well	  as	  a	  20μL	  subcutaneous	   injection	  of	  DMSO	  on	  gestational	  day	  16	  (E16)	  
(black	   columns)	   or	   2mg	   progesterone	   dissolved	   in	   40μL	   peanut	   oil	   E14	   until	   E20	   (white	   columns).	   Control	  
animals	  were	  culled	  by	  exsanguination	  then	  immediate	  cervical	  dislocation	  at	  the	  same	  time	  each	  day	  on	  E16	  
(n=6),	   E17	   (n=8),	   E18	   (n=7)	   and	   in	   labour	   (n=6).	   Progesterone-­‐supplemented	   animals	  were	   culled	   using	   the	  
same	  method	  on	  E16	  (n=7),	  E17	  (n=8),	  E18	  (n=7),	  E19	  (n=9)	  and	  E20	  (n=7).	  Total	  RNA	  was	  extracted	  via	  bead	  
homogenisation,	  cDNA	  synthesised	  and	  quantitative	  RT-­‐PCR	  was	  performed	  for	  A.Il1a,	  B.	  Il1b,	  C.	  Il6,	  D.	  Il10,	  E.	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Cxcl1,	  F.	   	  Cxcl2,	  G.	   	  Ccl2,	  H.	  Ccl5,	   I.	   Ifng,	   J.	  Gcsf	   and	  K.	  Tnfa.	   	  Normality	  was	  determined	   via	   a	   Kolmogorov-­‐
Smirnov	   test.	   An	   unpaired	   t	   test	   or	   a	   Mann-­‐Whitney	   test	   was	   performed	   between	   pairs	   matched	   for	  
gestational	   age;	   the	   labouring	   group	  was	   compared	   separately	  with	   E19	   P4	   and	   E20	  P4.	  A	   one-­‐way	  ANOVA	  
followed	  by	  Bonferroni’s	  post	  hoc	  testing	  or	  a	  Kruskal-­‐Wallis	  followed	  by	  Dunn’s	  multiple	  comparison	  test	  was	  
run	  for	  control	  animals	  and	  a	  separate	  ANOVA	  or	  Kruskal-­‐Wallis	  with	  the	  appropriate	  post	  hoc	  testing	  was	  ran	  
for	   progesterone	   treated	   animals.	   *,	   p<0.05;	   **,	   p<0.01;	   #,	   p<0.05	   versus	   Labouring;	   ##,	   p<0.01	   versus	  
Labouring;	  $,	  p<0.05	  versus	  E19	  P4;	  ^,	  p<0.05	  versus	  E20	  P4.	  	  	  
	  
At	  the	  protein	  level,	  vehicle	  control	   labour	  was	  associated	  with	  a	  significant	  increase	  in	  IL-­‐6,	  CXCL1	  
and	  CXCL2	  (Fig.	  3.3.).	  In	  contrast	  to	  the	  RNA	  level	  trend,	  IL-­‐1α	  demonstrated	  a	  significant	  decline	  at	  
labour	  with	  a	  similar	  pattern	  observed	  for	  IFN-­‐γ	  and	  TNF-­‐α.	  No	  changes	  were	  observed	  in	  the	  protein	  
levels	  of	  IL-­‐1β,	  IL-­‐10,	  CCL2,	  CCL5	  and	  GCSF.	  
Mice	  receiving	  progesterone	  supplementation	  demonstrated	  a	  significant	  delay	   in	  the	  peak	  of	   IL-­‐6,	  
CXCL1	  and	  CXCL2	  (Fig.	  3.3.).	  Progesterone	  supplementation	  was	  associated	  with	  a	  significant	  peak	  in	  
IL-­‐1α,	   IFN-­‐γ	   but	   also	   IL-­‐10	   at	   E20	   as	   compared	   to	   vehicle	   control	   labour.	   Similar	   trends	   were	  
observed	  for	  IL-­‐1β,	  CCL2	  and	  TNF-­‐α.	  No	  changes	  were	  observed	  in	  CCL5	  or	  GCSF.	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Figure	  3.3.	  Progesterone	  (P4)	  delays	  the	  peak	  in	  pro-­‐inflammatory	  cytokine	  and	  chemokine	  protein	  levels.	  
Mice	  were	  administered	  daily	  subcutaneous	  40μL	  peanut	  oil	  vehicle	   injections	  from	  gestational	  day	  14	  (E14)	  
until	  gestational	  day	  18	  (E18)	  as	  well	  as	  a	  20μL	  subcutaneous	   injection	  of	  DMSO	  on	  gestational	  day	  16	  (E16)	  
(black	   columns)	   or	   2mg	   progesterone	   dissolved	   in	   40μL	   peanut	   oil	   E14	   until	   E20	   (white	   columns).	   Control	  
animals	  were	  culled	  by	  exsanguination	  then	  immediate	  cervical	  dislocation	  at	  the	  same	  time	  each	  day	  on	  E16	  
(n=6),	   E17	   (n=8),	   E18	   (n=7)	   and	   in	   labour	   (n=6).	   Progesterone-­‐supplemented	   animals	  were	   culled	   using	   the	  
same	  method	  on	   E16	   (n=7),	   E17	   (n=8),	   E18	   (n=7),	   E19	   (n=9)	   and	   E20	   (n=7).	   Protein	  was	   extracted	   via	   bead	  
homogenisation,	   a	   protein	   assay	   was	   performed	   and	   500μg	   used	   to	   run	   a	   mouse	   Bio-­‐Plex©	   ProTM	  
chemokine/cytokine	  assay	  for	  A.	  IL-­‐1α,	  B.	  IL-­‐1β,	  C.	  IL-­‐6,	  D.	  IL-­‐10,	  E.	  CXCL1,	  F.	  CXCL2,	  G.	  CCL,	  H.	  CCL5,	  I.	  IFN-­‐γ,	  J.	  
GCSF	  and	  K.	  TNF-­‐α.	  	  Normality	  was	  determined	  via	  a	  Kolmogorov-­‐Smirnov	  test.	  An	  unpaired	  t	  test	  or	  a	  Mann-­‐
Whitney	  test	  was	  performed	  between	  pairs	  matched	  for	  gestational	  age;	  the	  labouring	  group	  was	  compared	  
separately	  with	  E19	  P4	  and	  E20	  P4.	  A	  one-­‐way	  ANOVA	  followed	  by	  Bonferroni’s	  post	  hoc	  testing	  or	  a	  Kruskal-­‐
Wallis	   followed	   by	   Dunn’s	  multiple	   comparison	   test	  was	   run	   for	   control	   animals	   and	   a	   separate	   ANOVA	   or	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Kruskal-­‐Wallis	  with	  the	  appropriate	  post	  hoc	  testing	  was	  ran	  for	  progesterone	  treated	  animals.	  *,	  p<0.05;	  **,	  
p<0.01;	  #,	  p<0.05	  versus	  Labouring;	  ##,	  p<0.01	  versus	  Labouring;	  $,	  p<0.05	  versus	  E19	  P4;	  ^,	  p<0.05	  versus	  E20	  
P4;	   &,	   p<0.05	   versus	   E18	   Controls.	   These	   experiments	   were	   performed	   in	   collaboration	   with	   Dr	   Bronwen	  
Herbert.	  
	  
3.2.3.2.	  Contraction-­‐associated	  proteins	  
Vehicle	  control	   labour	  was	  associated	  with	  a	  peak	   in	  Gja1	  both	  at	   the	  RNA	  and	  protein	   levels	   (Fig.	  
3.4.).	  Both	  Ptgs2	  and	  Oxtr	  showed	  a	  significant	  peak	  with	  labour	  at	  the	  RNA	  level,	  however	  this	  was	  
not	  reproducible	  at	  the	  protein	  level.	  	  
Progesterone	  supplementation	  led	  to	  a	  loss	  of	  the	  peak	  in	  connexin-­‐43	  both	  at	  the	  RNA	  and	  protein	  
levels	   with	   no	   trend	   of	   it	   rising	   post-­‐dates	   up	   to	   E20	   (Fig.	   3.4.).	   Similarly,	   the	   RNA	   peaks	   seen	   in	  
vehicle	   labour	   in	   Ptgs2	   and	   Oxtr	   were	   completely	   abolished	   in	   mice	   receiving	   progesterone.	   No	  
changes	  were	  seen	  at	  the	  protein	  level	  compared	  to	  control.	  	  
	  
Figure	  3.4.	  Progesterone	  (P4)	  prevents	  the	  labour-­‐associated	  peaks	  in	  contraction-­‐associated	  proteins.	  	  
Mice	  were	  administered	  daily	  subcutaneous	  40μL	  peanut	  oil	  vehicle	   injections	  from	  gestational	  day	  14	  (E14)	  
until	  gestational	  day	  18	  (E18)	  as	  well	  as	  a	  20μL	  subcutaneous	   injection	  of	  DMSO	  on	  gestational	  day	  16	  (E16)	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(black	   columns)	   or	   2mg	   progesterone	   dissolved	   in	   40μL	   peanut	   oil	   E14	   until	   E20	   (white	   columns).	   Control	  
animals	  were	  culled	  by	  exsanguination	  then	  immediate	  cervical	  dislocation	  at	  the	  same	  time	  each	  day	  on	  E16	  
(n=6),	   E17	   (n=8),	   E18	   (n=7)	   and	   in	   labour	   (n=6).	   Progesterone-­‐supplemented	   animals	  were	   culled	   using	   the	  
same	  method	  on	  E16	  (n=7),	  E17	  (n=8),	  E18	  (n=7),	  E19	  (n=9)	  and	  E20	  (n=7).	  Total	  RNA	  was	  extracted	  via	  bead	  
homogenisation,	  cDNA	  synthesised	  and	  quantitative	  RT-­‐PCR	  was	  performed	  for	  A.	  Gja1,	  B.	  Ptgs2	  and	  C.	  Oxtr.	  
Protein	   was	   extracted	   via	   bead	   homogenisation,	   quantified	   and	   western	   blotting	   was	   performed	   for,	   D.	  
connexin-­‐43,	   E.	   COX-­‐2	   and	   F.	   OTR.	   Data	   are	   expressed	   as	   mean	   +	   SEM.	   Normality	   was	   determined	   via	   a	  
Kolmogorov-­‐Smirnov	  test.	  Pairs	  of	  data	  were	  analysed	  with	  an	  unpaired	  t-­‐test	  or	  Mann	  Whitney	  test.	  Groups	  
of	   3	   or	  more	  data	  were	   analysed	  by	   an	  ANOVA	   followed	  by	  Bonferroni’s	  multiple	   comparison	  or	   a	   Kruskal-­‐
Wallis	  test	  followed	  by	  Dunn’s	  multiple	  comparison	  test.	  *,	  p<0.05;	  **,	  p<0.01;	  ***,	  p<0.001;	  #,	  p<0.05	  versus	  
labouring	  group;	  ##,	  p<0.01	  versus	  labouring	  group	  ;	  ###,	  p<0.001	  versus	  labouring	  group.	  
	  
3.2.3.3.	  Second	  messenger	  activation	  
Further	   downstream,	   a	   trend	   towards	   increased	   JNK	   activation	   was	   seen	   prior	   to	   vehicle	   control	  
labour	  onset	  with	  no	  marked	  changes	  in	  ERK1/2	  or	  p38	  activation	  (Fig.	  3.5.).	  Similarly	  no	  significant	  
changes	  were	  seen	  in	  p65	  activation	  although	  a	  trend	  towards	  increased	  c-­‐Jun	  phosphorylation	  was	  
observed.	  	  
Progesterone	  supplementation	  did	  not	  alter	  MAPK	  activation	  with	   the	  exception	  of	  decreased	  p38	  
phosphorylation	  at	  E17,	  which	  was	   lost	  by	   the	   subsequent	  gestational	  day	   (Fig.	  3.5.).	  Additionally,	  
increased	   levels	   of	   JNK	   phosphorylation	   were	   observed	   at	   E19.	   Finally,	   progesterone	  
supplementation	  was	  associated	  with	  decreased	   c-­‐Jun	  phosphorylation	  at	   E16,	  but	   this	   effect	  was	  
lost	  with	  advancing	  gestation.	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Figure	   3.5.	   Transcription	   factor	   levels	   in	   vehicle	   control	   and	   progesterone	   (P4)	   supplemented	   murine	  
pregnancy.	  
Mice	  were	  administered	  daily	  subcutaneous	  40μL	  peanut	  oil	  vehicle	   injections	  from	  gestational	  day	  14	  (E14)	  
until	  gestational	  day	  18	  (E18)	  as	  well	  as	  a	  20μL	  subcutaneous	   injection	  of	  DMSO	  on	  gestational	  day	  16	  (E16)	  
(black	   columns)	   or	   2mg	   progesterone	   dissolved	   in	   40μL	   peanut	   oil	   E14	   until	   E20	   (white	   columns).	   Control	  
animals	  were	  culled	  by	  exsanguination	  then	  immediate	  cervical	  dislocation	  at	  the	  same	  time	  each	  day	  on	  E16	  
(n=6),	   E17	   (n=8),	   E18	   (n=7)	   and	   in	   labour	   (n=6).	   Progesterone-­‐supplemented	   animals	  were	   culled	   using	   the	  
same	  method	  on	   E16	   (n=7),	   E17	   (n=8),	   E18	   (n=7),	   E19	   (n=9)	   and	   E20	   (n=7).	   Protein	  was	   extracted	   via	   bead	  
homogenisation,	  quantified	  and	  western	  blotting	  was	  performed	  for,	  A.	  p-­‐ERK1/2,	  B.	  p-­‐p38,	  C.	  p-­‐JNK	  D.	  p-­‐p65	  
and	  E.	  p-­‐c-­‐Jun.	  Data	  are	  expressed	  as	  mean	  +	  SEM.	  Normality	  was	  determined	  via	  a	  Kolmogorov-­‐Smirnov	  test.	  
Pairs	  of	  data	  were	  analysed	  with	  an	  unpaired	   t-­‐test	  or	  Mann	  Whitney	   test.	  Groups	  of	  3	  or	  more	  data	  were	  
analysed	   by	   an	   ANOVA	   followed	   by	   Bonferroni’s	   multiple	   comparison	   or	   a	   Kruskal-­‐Wallis	   test	   followed	   by	  
Dunn’s	  multiple	  comparison	  test.	  *,	  p<0.05.	  	  
	  
3.2.3.4.	  Circadian	  rhythm	  genes	  
Vehicle	  control	  labour	  was	  associated	  with	  a	  significant	  increase	  in	  Nr1d2	  and	  Ppargc1a	  RNA	  levels	  
as	  well	   as	   a	   trend	   in	   increased	  Clock	   levels	   (Fig.	   3.6.).	   No	   changes	  were	   observed	   in	   the	   levels	   of	  
Bmal1,	  Cry1,	  Npas2,	  Per1	  or	  Rorc.	  	  
Supplementation	  with	  progesterone	  was	  associated	  with	  a	  significant	  pre-­‐labour	  RNA	  peak	  in	  Clock,	  
Per1,	  Cry1,	  Nr1d2,	  Rorc	  and	  Ppargc1a	  (Fig.	  3.6.).	  No	  changes	  were	  seen	  in	  Bmal1	  or	  Npas2.	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Figure	  3.6.	  Progesterone	  (P4)	  supplementation	  is	  associated	  with	  a	  pre-­‐labour	  increase	  in	  circadian	  rhythm	  
genes.	  	  	  
Mice	  were	  administered	  daily	  subcutaneous	  40μL	  peanut	  oil	  vehicle	   injections	  from	  gestational	  day	  14	  (E14)	  
until	   gestational	  day	  18	   (E18)	  as	  well	   as	  a	  20μ	  subcutaneous	   injection	  of	  DMSO	  on	  gestational	  day	  16	   (E16)	  
(black	   columns)	   or	   2mg	   progesterone	   dissolved	   in	   40μL	   peanut	   oil	   E14	   until	   E20	   (white	   columns).	   Control	  
animals	  were	  culled	  by	  exsanguination	  then	  immediate	  cervical	  dislocation	  at	  the	  same	  time	  each	  day	  on	  E16	  
(n=6),	   E17	   (n=8),	   E18	   (n=7)	   and	   in	   labour	   (n=6).	   Progesterone-­‐supplemented	   animals	  were	   culled	   using	   the	  
same	  method	  on	  E16	  (n=7),	  E17	  (n=8),	  E18	  (n=7),	  E19	  (n=9)	  and	  E20	  (n=7).	  Total	  RNA	  was	  extracted	  via	  bead	  
homogenisation,	  cDNA	  synthesised	  and	  quantitative	  RT-­‐PCR	  was	  performed	  for	  A.Clock,	  B.	  Bmal1,	  C.	  Per1,	  D.	  
Cry1,	  E.	  Npas2	  and	  F.	  	  Nr1d2,	  G.	  Rorc	  and	  H.	  Ppargc1a.	  Normality	  was	  determined	  via	  a	  Kolmogorov-­‐Smirnov	  
test.	  An	  unpaired	  t	   test	  or	  a	  Mann-­‐Whitney	  test	  was	  performed	  between	  pairs	  matched	  for	  gestational	  age;	  
the	   labouring	   group	   was	   compared	   separately	   with	   E19	   progesterone	   and	   E19	   progesterone.	   A	   one-­‐way	  
ANOVA	  followed	  by	  Bonferroni’s	  post	  hoc	  testing	  or	  a	  Kruskal-­‐Wallis	  followed	  by	  Dunn’s	  multiple	  comparison	  
test	  was	  run	  for	  control	  animals	  and	  a	  separate	  ANOVA	  or	  Kruskal-­‐Wallis	  with	  the	  appropriate	  post	  hoc	  testing	  
was	  ran	  for	  P4	  treated	  animals.	  *,	  p<0.05;	  **,	  p<0.01;	  ***,	  p<0.0001;	  #,	  p<0.05	  versus	   labouring;	  ##,	  p<0.01	  
versus	  labouring.	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3.2.4.	  The	  effect	  of	  mifepristone	  administration	  on	  murine	  labour	  
As	   previously	   described	   (271,	   348),	   pregnant	  mice	  were	   administered	   150μg	  mifepristone	   at	   E16.	  
The	  time	  to	  delivery	  interval	  was	  significantly	  reduced	  post-­‐mifepristone	  administration	  (mean	  17.4h	  
±	  0.35h)	  compared	  to	  vehicle	  control	  (mean	  50.4h	  ±	  0.17h)	  (Fig.	  3.7.).	  Based	  on	  the	  time	  to	  delivery,	  
four	   tissue	   collection	   points	  were	   designated	   as	   follows:	   4.5	   hours,	   9	   hours	   and	   13.5	   hours	   post-­‐
mifepristone	  injection	  and	  at	  labour.	  	  
	  
Figure	  3.7.	  Time	  to	  delivery	  after	  mifepristone	  (RU486)	  administration.	  	  
Mice	  were	   injected	  daily	  with	  40μL	  subcutaneous	  peanut	  oil	  vehicle	   injections	  from	  gestational	  day	  14	  (E14)	  
until	   gestational	   day	   18	   (E18)	   and	   with	   20μL	   subcutaneous	   injection	   of	   DMSO	   on	   gestational	   day	   16	   (E16)	  
(black	  columns)	   (n=6)	  or	  with	  150μg	  of	  mifepristone	  dissolved	   in	  20μL	  DMSO	  on	  E16	   (white	  columns)	   (n=7).	  
Mean	  time	  to	  labour	  was	  recorded.	  	  
	  
3.2.4.1.	  Inflammation	  
The	  administration	  of	  mifepristone	  was	  associated	  with	  a	  significant	  peak	  in	  Il1b	  and	  Il6	  at	  the	  RNA	  
level	  at	   the	  time	  of	   labour	   (Fig.	  3.8.).	  Similar	   trends	  were	  observed	   for	  Cxcl1,	  Cxcl2,	  Ccl2	  and	  Tnfa.	  
Conversely,	   a	  decline	   in	   the	   levels	  of	  Gcsf	  were	   seen	   (trough	  at	  9	  hours	  post-­‐mifepristone)	  with	  a	  
similar	  trend	  seen	  for	  Ifng	  (trough	  at	  labour).	  No	  changes	  were	  seen	  in	  Il1a,	  Il10	  and	  Ccl5	  levels.	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Figure	  3.8.	  Pro-­‐inflammatory	  cytokine	  and	  chemokine	  mRNA	  levels	  are	  upregulated	  following	  mifepristone	  
administration.	  
Mice	  were	   injected	  daily	  with	  40μL	  subcutaneous	  peanut	  oil	  vehicle	   injections	  from	  gestational	  day	  14	  (E14)	  
until	   gestational	   day	   18	   (E18)	   and	   with	   20μL	   subcutaneous	   injection	   of	   DMSO	   on	   gestational	   day	   16	   (E16)	  
(black	   columns)	   or	   with	   150μg	   of	   mifepristone	   dissolved	   in	   20μL	   DMSO	   on	   E16	   (white	   columns).	   Control	  
animals	  were	  culled	  at	  the	  same	  time	  each	  day	  on	  E16	  (n=6)	  and	  E17	  (n=8).	  Mifepristone-­‐treated	  animals	  were	  
culled	   using	   the	   same	   method	   4.5	   hours	   (n=8),	   9	   hours	   (n=8),	   13.5	   hours	   (n=6)	   post-­‐mifepristone	  
administration	  and	  once	  in	  labour	  (n=7).	  Total	  RNA	  was	  extracted	  via	  bead	  homogenisation,	  cDNA	  synthesised	  
and	  qPCR	  was	  performed	  for	  A.Il1a,	  B.	  Il1b,	  C.	  Il6,	  D.	  Il10,	  E.	  Cxcl1,	  F.	  Cxcl2,	  G.	  Ccl20,	  H.	  Ccl5,	  I.	  Ifng,	  J.	  Gcsf	  and	  
K.	  Tnfa.	   	  Normality	  was	  determined	  via	  a	  Kolmogorov-­‐Smirnov	  test;	  normally	  distributed	  data	  were	  analysed	  
using	  an	  ANOVA	  followed	  by	  Bonferroni’s	  multiple	  comparison	  test	  post	  hoc	  testing	  for	  three	  groups	  or	  more.	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Data	   that	   were	   not	   normally	   distributed	   were	   analysed	   using	   a	   Kruskal-­‐Wallis	   followed	   by	   Dunn’s	  multiple	  
comparisons	  post	  hoc	  testing	  for	  three	  groups	  or	  more.	  **,	  p<0.01	  versus	  E16	  vehicle;***,	  p<0.001	  versus	  E16	  
vehicle.	  	  
	  
At	  the	  protein	  level,	  IL-­‐6	  and	  CXCL2	  demonstrated	  two	  significant	  peaks	  when	  compared	  to	  E16;	  the	  
first	  at	  9	  hours	  post-­‐mifepristone	  and	   the	  second	  at	   the	   time	  of	   labour	   (Fig.	  3.9.).	  Similar	  patterns	  
were	  observed	   for	   IL-­‐1β,	  CXCL1	  and	  CCL2.	  GCSF	  had	  a	   single	  non-­‐significant	  peak	  at	  9	  hours	  post-­‐
mifepristone	   administration	   whereas	   other	   cytokines	   (IL-­‐1α,	   IL-­‐10,	   CCL5,	   IFNγ	   and	   TNF-­‐α)	   had	   a	  
single	  early	  peak	  at	  4.5	  hours.	  	  
	  
Figure	  3.9.	  Pro-­‐inflammatory	  cytokine	  and	  chemokine	  protein	  levels	  are	  upregulated	  following	  mifepristone	  
administration.	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Mice	  were	   injected	  daily	  with	  40μ	   subcutaneous	  peanut	  oil	   vehicle	   injections	   from	  gestational	  day	  14	   (E14)	  
until	   gestational	   day	   18	   (E18)	   and	   with	   20μL	   subcutaneous	   injection	   of	   DMSO	   on	   gestational	   day	   16	   (E16)	  
(black	   columns)	   or	   with	   150μg	   of	   mifepristone	   dissolved	   in	   20μL	   DMSO	   on	   E16	   (white	   columns).	   Control	  
animals	  were	  culled	  at	  the	  same	  time	  each	  day	  on	  E16	  (n=6)	  and	  E17	  (n=8).	  Mifepristone-­‐treated	  animals	  were	  
culled	   using	   the	   same	   method	   4.5	   hours	   (n=8),	   9	   hours	   (n=8),	   13.5	   hours	   (n=6)	   post-­‐mifepristone	  
administration	  and	  once	  in	  labour	  (n=7).	  Protein	  was	  extracted	  via	  bead	  homogenisation,	  a	  protein	  assay	  was	  
performed	  and	  500μg	  used	  to	  run	  a	  mouse	  Bio-­‐Plex©	  ProTM	  chemokine/cytokine	  assay	  for	  A.	  IL-­‐1α,	  B.	  IL-­‐1β,	  
C.	  IL-­‐6,	  D.	  IL-­‐10,	  E.	  CXCL1,	  F.	  CXCL2,	  G.	  CCL,	  H.	  CCL5,	  I.	  IFN-­‐γ,	  J.	  GCSF	  and	  K.	  TNF-­‐α.	  	  Normality	  was	  determined	  
via	   a	   Kolmogorov-­‐Smirnov	   test;	   normally	   distributed	   data	   were	   analysed	   using	   an	   ANOVA	   followed	   by	  
Bonferroni’s	  multiple	  comparison	  test	  post	  hoc	  testing	  for	  three	  groups	  or	  more.	  Data	  that	  were	  not	  normally	  
distributed	  were	  analysed	  using	  a	  Kruskal-­‐Wallis	  followed	  by	  Dunn’s	  multiple	  comparisons	  post	  hoc	  testing	  for	  
three	  groups	  or	  more.	  *,	  p<0.05	  versus	  E16	  vehicle;	  **,	  p<0.01	  versus	  E16	  vehicle;	  ***,	  p<0.001	  versus	  E16	  
vehicle.	  These	  experiments	  were	  performed	  in	  collaboration	  with	  Dr	  Bronwen	  Herbert.	  
	  
3.2.4.2.Contraction-­‐associated	  proteins	  
The	  administration	  of	  mifepristone	  to	  E16	  mice	  led	  to	  a	  significant	  increase	  in	  connexin-­‐43	  and	  OTR	  
(Fig.	   3.10).	   The	   peak	   in	   connexin-­‐43	   was	   both	   at	   the	   RNA	   and	   protein	   levels	   and	   was	   initially	  
observed	   at	   9	   hours	   and	   persisted	   until	   labour.	   The	   peak	   in	   OTR	   was	   also	   both	   at	   the	   RNA	   and	  
protein	  levels	  and	  occurred	  at	  the	  9	  hour	  time	  point.	  By	  labour	  onset,	  levels	  did	  not	  differ	  from	  the	  
E16	  vehicle	  control	  group.	  
By	  contrast,	  mifepristone	  administration	  was	  not	  associated	  with	  any	  change	  in	  COX-­‐2	  levels	  either	  
at	  the	  RNA	  or	  protein	  levels.	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Figure	   3.10.	   Mifepristone	   administration	   is	   associated	   with	   up-­‐regulation	   of	   connexin-­‐43	   and	   oxytocin	  
receptor	  (OTR).	  	  
Mice	  were	   injected	  daily	  with	  40μL	  subcutaneous	  peanut	  oil	  vehicle	   injections	  from	  gestational	  day	  14	  (E14)	  
until	   gestational	   day	   18	   (E18)	   and	   with	   20μL	   subcutaneous	   injection	   of	   DMSO	   on	   gestational	   day	   16	   (E16)	  
(black	   columns)	   or	   with	   150μg	   of	   mifepristone	   dissolved	   in	   20μL	   DMSO	   on	   E16	   (white	   columns).	   Control	  
animals	  were	  culled	  at	  the	  same	  time	  each	  day	  on	  E16	  (n=6)	  and	  E17	  (n=8).	  Mifepristone-­‐treated	  animals	  were	  
culled	   using	   the	   same	   method	   4.5	   hours	   (n=8),	   9	   hours	   (n=8),	   13.5	   hours	   (n=6)	   post-­‐mifepristone	  
administration	  and	  once	  in	  labour	  (n=7).	  Total	  RNA	  was	  extracted	  via	  bead	  homogenisation,	  cDNA	  synthesised	  
and	   quantitative	   RT-­‐PCR	   was	   performed	   for	  A.	  Gja1,	  B.	   Ptgs2	   and	   C.	  Oxtr.	   Protein	   was	   extracted	   via	   bead	  
homogenisation,	   quantified	   and	  western	   blotting	  was	   performed	   for,	  D.	   connexin-­‐43,	  E.	  COX-­‐2	   and	   F.	  OTR.	  
Data	   are	   expressed	   as	   mean	   +	   SEM.	   Normality	   was	   determined	   via	   a	   Kolmogorov-­‐Smirnov	   test;	   normally	  
distributed	  data	  were	  analysed	  using	  an	  ANOVA	  followed	  by	  Bonferroni’s	  multiple	  comparison	   test	  post	  hoc	  
testing	  for	  three	  groups	  or	  more.	  Data	  that	  were	  not	  normally	  distributed	  were	  analysed	  using	  a	  Kruskal-­‐Wallis	  
followed	  by	  Dunn’s	  multiple	   comparisons	  post	  hoc	   testing	   for	   three	  groups	  or	  more.	  *indicates	  a	   significant	  
difference	  of	  p<0.05	  versus	  E16	  vehicle	  and	  **	  p<0.01	  versus	  E16	  vehicle.	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3.2.4.3.	  Second	  messenger	  activation	  
The	   peak	   in	   the	   contraction-­‐associated	   proteins	   was	   associated	   with	   a	   contemporaneous	   up-­‐
regulation	   in	   p38	   and	   p65	   activation	   (Fig.	   3.11).	   ERK1/2	   activation	   reached	   its	  maximal	   level	   at	   9	  
hours	  although	  this	  was	  not	  significantly	   raised	  as	  compared	  to	  E16.	   Interestingly	  by	   labour	  onset,	  
levels	  were	  significantly	  lower	  compared	  to	  the	  9	  hour	  time	  point.	  	  Similarly,	  although	  levels	  of	  p-­‐JNK	  
did	  not	  rise	  significantly	  above	  baseline,	  they	  were	  significantly	  lower	  at	  labour	  compared	  to	  4.5	  and	  
9	  hours	  post	  mifepristone.	  Further	  downstream,	  c-­‐Jun	  activation	  followed	  a	  similar	  pattern	  to	  p-­‐JNK.	  	  
	  
Figure	  3.11.	  Mifepristone	  administration	  is	  associated	  with	  activation	  of	  p38	  and	  p65.	  
Mice	  were	   injected	  daily	  with	  40μL	  subcutaneous	  peanut	  oil	  vehicle	   injections	  from	  gestational	  day	  14	  (E14)	  
until	   gestational	   day	   18	   (E18)	   and	   with	   20μL	   subcutaneous	   injection	   of	   DMSO	   on	   gestational	   day	   16	   (E16)	  
(black	   columns)	   or	   with	   150μg	   of	   mifepristone	   dissolved	   in	   20μL	   DMSO	   on	   E16	   (white	   columns).	   Control	  
animals	  were	  culled	  at	  the	  same	  time	  each	  day	  on	  E16	  (n=6)	  and	  E17	  (n=8).	  Mifepristone-­‐treated	  animals	  were	  
culled	   using	   the	   same	   method	   4.5	   hours	   (n=8),	   9	   hours	   (n=8),	   13.5	   hours	   (n=6)	   post-­‐mifepristone	  
administration	   and	   once	   in	   labour	   (n=7).	   Protein	   was	   extracted	   via	   bead	   homogenisation,	   quantified	   and	  
western	   blotting	   was	   performed	   for,	   A.	   p-­‐ERK1/2,	   B.	   p-­‐p38,	   C.	   p-­‐JNK	   D.	   p-­‐p65	   and	   E.	   p-­‐c-­‐Jun.	   Data	   are	  
expressed	   as	  mean	   +	   SEM.	   Normality	  was	   determined	   via	   a	   Kolmogorov-­‐Smirnov	   test;	   normally	   distributed	  
data	  were	  analysed	  using	  an	  ANOVA	   followed	  by	  Bonferroni’s	  multiple	   comparison	   test	  post	  hoc	   testing	   for	  
three	  groups	  or	  more.	  Data	  that	  were	  not	  normally	  distributed	  were	  analysed	  using	  a	  Kruskal-­‐Wallis	  followed	  
by	  Dunn’s	  multiple	  comparisons	  post	  hoc	  testing	  for	  three	  groups	  or	  more.	  *indicates	  a	  significant	  difference	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of	  p<0.05	  versus	  E16	  vehicle	  (unless	  otherwise	  indicated)	  and	  **	  p<0.01	  versus	  E16	  vehicle	  (unless	  otherwise	  
indicated).	  
	  
3.2.4.4	  Circadian	  rhythm	  genes	  
The	  administration	  of	  mifepristone	  led	  to	  a	  significant	  decline	  in	  Cry1	  RNA	  at	  9	  hours	  (Fig.	  3.12.).	  A	  
similar	  but	  non-­‐significant	  pattern	  was	  seen	  for	  Npas2.	  Conversely,	  significant	  up-­‐regulation	  in	  Clock,	  
Bmal1,	  Per1	  were	  observed	  at	   the	  time	  of	   labour.	  The	   levels	  of	  Rorc	   rose	  as	  early	  as	  4.5hours	  and	  
remained	  high	  until	  labour.	  A	  non-­‐significant	  up-­‐regulation	  was	  observed	  in	  the	  levels	  of	  both	  Nr1d2	  
and	  Ppargc1a.	  
	  
Figure	  3.12.	  The	  effect	  of	  mifepristone	  on	  circadian	  rhythm	  genes.	  	  
Mice	  were	   injected	  daily	  with	  40μL	  subcutaneous	  peanut	  oil	  vehicle	   injections	  from	  gestational	  day	  14	  (E14)	  
until	  gestational	  day	  18	  (E18)	  and	  with	  20μL	  ubcutaneous	  injection	  of	  DMSO	  on	  gestational	  day	  16	  (E16)	  (black	  
columns)	  or	  with	  150μg	  of	  mifepristone	  dissolved	  in	  20μL	  DMSO	  on	  E16	  (white	  columns).	  Control	  animals	  were	  
culled	  at	  the	  same	  time	  each	  day	  on	  E16	  (n=6)	  and	  E17	  (n=8).	  Mifepristone-­‐treated	  animals	  were	  culled	  using	  
the	  same	  method	  4.5	  hours	  (n=8),	  9	  hours	  (n=8),	  13.5	  hours	  (n=6)	  post-­‐mifepristone	  administration	  and	  once	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in	  labour	  (n=7).	  Total	  RNA	  was	  extracted	  via	  bead	  homogenisation,	  cDNA	  synthesised	  and	  qPCR	  was	  performed	  
for	   A.Clock,	   B.	   Bmal1,	   C.	   Per1,	   D.	   Cry1,	   E.	   Npas2,	   F.	   Nr1d2,	   G.	   Rorc	   and	   H.	   Ppargc1a.	   	   Normality	   was	  
determined	  via	  a	  Kolmogorov-­‐Smirnov	  test;	  normally	  distributed	  data	  were	  analysed	  using	  an	  ANOVA	  followed	  
by	   Bonferroni’s	   multiple	   comparison	   test	   post	   hoc	   testing	   for	   three	   groups	   or	   more.	   Data	   that	   were	   not	  
normally	  distributed	  were	  analysed	  using	  a	  Kruskal-­‐Wallis	   followed	  by	  Dunn’s	  multiple	  comparisons	  post	  hoc	  
testing	   for	   three	   groups	   or	  more.	   *,	   p<0.05	   versus	   E16	   vehicle;	   **,	   p<0.01	   versus	   E16	   vehicle;***,	   p<0.001	  
versus	  E16	  vehicle.	  	  
	  
3.2.5.	  The	  effect	  of	  p38	  inhibitors	  ML3403	  and	  SB203580	  on	  mifepristone-­‐induced	  preterm	  labour	  
Based	   on	   the	   simultaneous	   peak	   at	   9	   hours	   of	   key	   contraction-­‐associated	   proteins	   and	   p38	  
phosphorylation,	  experiments	  were	  designed	  to	  study	  the	  effect	  of	  p38	  inhibition	  on	  mouse	  labour	  
and	  more	  specifically	  contraction-­‐associated	  protein	  activation.	  	  
Based	  on	  the	  literature,	  ML3403	  was	  used	  first	  on	  the	  basis	  of	  its	  reduced	  hepatotoxicity	  (349,	  350)	  
compared	   to	   the	   archetypal	   p38	   inhibitor	   SB203580.	   A	   dose	   of	   25mg/kg	   was	   chosen	   based	   on	  
publications	  in	  rodent	  studies	  (351).	  Even	  though	  previous	  studies	  have	  shown	  ML3403	  was	  able	  to	  
reduce	  p38	  activation	  in	  vitro	  (350)	  and	  in	  vivo	  (352,	  353),	  these	  findings	  could	  not	  be	  reproduced	  in	  
pregnant	  mice	   both	   in	   terms	   of	   p38	   activation	   or	   activation	   of	   its	   downstream	   target	  HSP27	   (Fig.	  
3.13.).	  
For	   this	   reason,	   SB203580,	  which	  has	   also	   been	  previously	   shown	   to	  be	   effective	   at	   reducing	  p38	  
activation	  in	  vivo	  (354,	  355),	  was	  trialed	  at	  a	  concentration	  of	  11mg/kg	  via	  intrauterine	  injection.	  The	  
dose	  and	  route	  of	  administration	  were	  chosen	  based	  on	  unpublished	  observations	  by	  another	  group	  
in	  which	   it	  was	   shown	   to	   be	   effective.	   	   Unfortunately,	   no	   evidence	   of	   inhibition	   of	   p38	   or	  HSP27	  
phosphorylation	  was	  identified	  following	  SB203580	  treatment	  (Fig.	  3.13.).	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Figure	  3.13.	  Attempted	  inhibition	  of	  p38	  activation	  by	  ML3403	  and	  SB203580	  in	  pregnant	  mice.	  
A.	   &	   B.	  Mice	   at	   gestational	   day	   16	   (E16)	   received	   a	   20μL	   subcutaneous	   injection	   of	   DMSO	   or	   150μg	   of	  
mifepristone	  ±	  25mg/kg	  ML3403	  by	  intraperitoneal	  injection	  in	  20μL	  DMSO.	  C.	  &	  D.	  Mice	  at	  gestational	  day	  16	  
(E16)	  received	  a	  subcutaneous	  injection	  of	  DMSO	  or	  150μg	  of	  mifepristone	  dissolved	  in	  20μL	  DMSO.	  Prior	  to	  
mifepristone/vehicle	   administration,	   all	   animals	   underwent	   laparotomy	   and	   intrauterine	   administration	   of	  
DMSO	  vehicle	  or	  11	  mg/kg	  SB203580.	  All	  animals	  were	  by	  culled	  by	  exsanguination	  then	   immediate	  cervical	  
dislocation	  at	  9	  hours	  post	  treatment.	  Protein	  was	  extracted	  via	  bead	  homogenisation,	  quantified	  and	  western	  
blotting	  was	  performed	  for,	  A.	  p-­‐p38	  and	  p38,	  B.	  p-­‐HSP27,	  C.	  p-­‐p38	  and	  p38,	  D.	  p-­‐HSP27.	  Data	  are	  expressed	  
as	  mean	  +	  SEM.	  Normality	  was	  determined	  via	  a	  Kolmogorov-­‐Smirnov	  test.	  An	  unpaired	  t	  test	  was	  performed	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to	  analyse	  normally	  distributed	  data	  and	  a	  Mann-­‐Whitney	  test	  was	  used	  for	  non-­‐normally	  distributed	  data.	  *,	  
p<0.05;	  ***,	  p<0.001.	  n=3-­‐9.	  
	  
3.3	  Discussion	  
This	  aim	  was	  of	  this	  study	  was	  to	  initially	  define	  vehicle	  control	  murine	  labour.	  Thereafter,	  using	  this	  
as	   a	   baseline,	   the	   effect	   of	   pregnancy	  maintenance	   by	   prevention	   of	   the	   decline	   in	   progesterone	  
levels	  was	  investigated.	  Conversely,	  the	  effect	  of	  chemical	  withdrawal	  of	  progesterone	  preterm	  via	  
mifepristone	  administration	  was	  investigated.	  	  
The	  principal	  findings	  of	  the	  progesterone	  supplementation	  study	  are	  that	  murine	  labour	  is	  delayed	  
with	   a	   loss	   in	   upregulation	   of	   contraction-­‐associated	   proteins,	   but	  without	   a	   complete	   loss	   in	   the	  
inflammatory	   phenotype	   seen	   in	   association	   with	   vehicle	   labour.	   In	   the	   mifepristone	   model	   of	  
preterm	   labour,	   a	   bimodal	   distribution	   of	   cytokine	   and	   chemokine	   upregulation	   was	   noted.	   The	  
initial	  peak,	  at	  9	  hours	  post	  treatment,	  implicated,	  for	  the	  first	  time,	  p38	  in	  mifepristone	  signaling	  as	  
this	  corresponded	  to	  its	  maximal	  activation.	  	  
	  
3.3.1.	  Vehicle	  control	  labour	  
3.3.1.1.	  Inflammation	  
Much	  evidence	  exists	  from	  observations	  in	  humans	  and	  rodents,	  that	  parturition	  is	  associated	  with	  
inflammation,	   as	   evidenced	   by	   myometrial	   (as	   well	   as	   cervical	   and	   choriodecidual)	   infiltration	   by	  
leukocytes	   including	   neutrophils,	   macrophages	   and	   lymphocytes	   (10,	   251,	   356).	   In	   turn,	   these	  
leukocytes	   secrete	   pro-­‐inflammatory	   chemokines	   and	   cytokines	   (11)	   thus	   attracting	   more	  
inflammatory	  cells	  to	  the	  myometrium	  and	  setting	  up	  a	  positive	  feedback	  loop.	  Indeed,	  in	  a	  preterm	  
labour	  mouse	  model	  of	   severe	   inflammation	   (as	   seen	  after	   lipopolysaccharide	  administration),	   the	  
administration	   of	   a	   broad	   spectrum	   chemokine	   inhibitor	   delayed	   labour	   in	   association	   with	   a	  
decrease	  in	  inflammation	  (285).	  
In	  support	  of	  findings	  in	  the	  literature	  (283),	  the	  data	  presented	  here	  show	  that	  several	  chemokines	  
and	  cytokines	  start	  rising	  prior	  to	  vehicle	  control	  labour	  onset	  and	  reach	  their	  peak	  with	  labour	  itself.	  
Up-­‐regulation	  seen	  at	  the	  RNA	  level	  of	  predominantly	  Il6	  and	  Tnfa,	  but	  also	  Il1a,	  Il1b,	  Cxcl1	  and	  Ccl5	  
did	   not	   universally	   translate	   to	   increased	   protein	   levels	   and	   indeed	   certain	   upregulated	   proteins,	  
such	  as	  CXCL2,	  did	  not	  show	  a	  similar	  pattern	  at	  the	  RNA	  level.	  This	  may	  be	  a	  reflection	  of	  individual	  
chemokine/cytokine	  regulation.	  Regardless	  of	  the	  mechanism,	  vehicle	  control	  labour	  was	  associated	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with	   significantly	   raised	   protein	   levels	   of	   IL-­‐6,	   CXCL1	   and	   CXCL2.	   IL-­‐6	   is	   a	  major	   pro-­‐inflammatory	  
cytokine	   that	   is	   produced	   by	  multiple	   cell	   types	   including	  macrophages	   and	  myocytes	   (357,	   358).	  
CXCL1	  and	  CXCL2	  are	  pro-­‐inflammatory	  chemokines	  which	  mainly	  target	  neutrophils	  (359).	  They	  are	  
predominantly	   produced	   by	  macrophages	   (360),	   although	  myocytes	   have	   also	   been	   shown	   to	   be	  
capable	   of	   secreting	   chemokines	   (361).	   The	   chemokine	   CCL2,	  which	   in	   this	   study	   peaked	   prior	   to	  
labour	  on	  E18,	  has	  previously	  been	  shown	  to	  be	  produced	  by	  rodent	  myocytes	  at	  term	  labour	  (356).	  
Although	  not	  specifically	  studied	  in	  this	  set	  of	  experiments,	  based	  on	  the	  literature,	  it	  is	  possible	  that	  
a	  few	  days	  prior	  to	  labour	  onset	  the	  myometrium	  increases	  its	  chemokine	  and	  cytokine	  production	  
hence	  attracting	  inflammatory	  leukocytes	  to	  the	  uterus.	  	  	  
It	  was	  interesting	  to	  note	  that	  RNA	  levels	  of	  the	  anti-­‐inflammatory	  cytokine	  Il10,	  which	  inhibits	  IL-­‐1	  
synthesis	   (362),	   also	   peaked	   at	   the	   time	   of	   labour	   suggesting	   it	   plays	   a	   local	   regulatory	   role.	  
However,	  this	  pattern	  was	  not	  reflected	  at	  the	  protein	  level.	  	  
3.3.1.2.	  Contraction-­‐associated	  proteins	  
Simultaneously	   to	   the	   inflammation	   noted	  with	   term	   labour,	   an	   up-­‐regulation	   in	   the	   contraction-­‐
associated	  proteins	  Gja1,	  Ptgs2	  and	  Oxtr	  was	  observed	  at	  the	  RNA	  level	  at	  the	  time	  of	  labour.	  Similar	  
findings	   have	   previously	   been	   reported	   (283).	   Interestingly,	   at	   the	   protein	   level,	   only	   connexin-­‐43	  
reflected	  its	  RNA	  pattern	  with	  no	  peaks	  seen	  in	  COX-­‐2	  and	  OTR.	  These	  findings	  are	  consistent	  with	  
previous	   findings	   (271)	   where	   connexin-­‐43	   protein	   levels	   peak	   with	   labour	   but	   no	   changes	   are	  
observed	   in	   COX-­‐2.	   Indeed,	   the	   group’s	   previous	   work	   also	   incorporated	   earlier	   gestations	  
demonstrating	  that	  COX-­‐2	  levels	  at	  E11	  were	  significantly	  lower	  than	  E16	  onwards;	  this	  suggests	  that	  
COX-­‐2	   regulation	  may	  be	  more	   finely	   regulated	  on	   the	  post-­‐translational	   level.	  No	   reports	  of	  OTR	  
protein	  levels	  were	  identified	  in	  the	  literature	  and	  given	  the	  quality	  of	  the	  antibody,	  it	  is	  difficult	  to	  
reach	  any	  conclusions	  regarding	  how	  the	  levels	  may	  vary	  prior	  to	  and	  at	  labour	  onset.	  	  
3.3.1.3.	  Transcription	  factors	  
In	  this	  study,	  a	  trend	  towards	  increased	  JNK	  and	  c-­‐Jun	  activation	  was	  noted	  with	  no	  changes	  in	  p65	  
or	  any	  of	  the	  MAPKs.	  This	  is	  in	  contrast	  with	  previous	  findings	  of	  p65	  activation	  prior	  to	  labour	  onset	  
(271).	   In	  addition,	  the	  peak	   in	  JNK	  activation	  was	  previously	  seen	  at	  the	  time	  of	   labour	  whereas	   in	  
the	   data	   presented	   here,	   it	  was	   seen	   on	   E18	   but	   prior	   to	   labour	   onset.	   The	   discrepancy	   could	   be	  
accounted	  by	  two	  possible	  explanations:	  (i)	  previous	  work	  by	  the	  group	  was	  conducted	  on	  untreated	  
mice	  whereas	  the	  data	  presented	  here	  arises	  from	  animals	  receiving	  vehicle	  control	  treatment	  and	  
(ii)	  the	  data	  presented	  here	  comes	  from	  a	  greater	  number	  of	  biological	  replicates.	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3.3.1.4.	  Circadian	  rhythm	  genes	  
Clock,	  Bmal1	  Cry1,	  Npas2	  and	  Per1	  are	  examples	  of	  genes	  which	  are	  known	  regulators	  of	  circadian	  
function.	  Additionally,	  Nr1d2,	  Rorc	   and	  Ppargc1a	   act	   to	   regulate	   the	  previously	  mentioned	   genes.	  
Progesterone,	   acting	   via	   PR,	   has	   recently	   been	   shown	   to	   drive	   Clock,	   Cry1,	   Npas2	   and	   Per1	  
expression	   and	   decrease	   levels	   of	  Nr1d2,	  Rorc	   and	   Ppargc1a	   (152).	   Indeed	   there	   is	   an	   increasing	  
body	  of	  evidence	  demonstrating	  a	  link	  between	  fertility	  and	  circadian	  rhythm	  (363).	  Consistent	  with	  
the	  observations	  by	  Rubel	  et	  al.	   (152),	  the	  data	  presented	  here	  show	  a	  significant	  up-­‐regulation	  of	  
Nr1d2	   levels	  with	  vehicle	  control	  labour	  onset	  along	  with	  a	  similar	  trend	  for	  Ppargc1a.	  By	  contrast,	  
no	  change	  to	  Bmal1,	  Cry1,	  Npas2,	  Per1	  or	  Rorc	  RNA	  levels	  was	  seen.	  	  
Although	   not	   significant,	   a	   trend	   towards	   increased	   Clock	   RNA	   levels	   was	   noted	   with	   advancing	  
gestation.	  Even	  though	  this	  contradicts	  the	  theory	  of	  it	  being	  progesterone-­‐driven,	  it	   lends	  support	  
to	   the	   alternative	   report	   of	   Clock	   acting	   to	   enhance	   NF-­‐κB-­‐mediated	   transcription	   (162),	   as	  
evidenced	  by	  the	  increase	  in	  inflammation	  with	  advancing	  gestation.	  	  
	  
3.3.2.	  Progesterone-­‐supplemented	  murine	  pregnancy	  
If	   systemic	   progesterone	   levels	   are	   not	   allowed	   to	   drop	   at	   term,	   as	   with	   the	   progesterone	  
supplementation	  study	  performed	  here,	  mice	  do	  not	  go	  into	  labour	  at	  term	  and	  indeed	  demonstrate	  
no	  overt	  signs	  of	  labour	  48	  hours	  later.	  Although	  human	  and	  murine	  labour	  differ	  (functional	  versus	  
absolute	  progesterone	  withdrawal),	  this	  study	  serves	  to	  highlight	  the	  importance	  of	  progesterone	  in	  
pregnancy	   maintenance	   via	   reduction	   of	   inflammation	   and	   prevention	   of	   contraction-­‐associated	  
protein	  up-­‐regulation.	  	  
3.3.2.1.	  Inflammation	  
Progesterone	  supplementation	  significantly	  delayed	   the	  peak	  of	   several	   chemokines	  and	  cytokines	  
both	  at	   the	  RNA	  and	  protein	   levels,	  notably	   IL-­‐6,	  CXCL1	  and	  CXLX2.	  This	  provides	  evidence	   for	   the	  
anti-­‐inflammatory	  action	  of	  progesterone	  and	  provides	  support	  to	  the	  hypothesis	  that	  inflammation	  
plays	  a	  crucial	  role	   in	  the	  process	  of	  parturition.	   Interestingly	  however,	   it	  was	  noticed	  that	  by	  E20,	  
progesterone	   was	   no	   longer	   able	   to	   repress	   inflammation	   with	   chemokine	   and	   cytokine	   levels	  
broadly	   similar	   to	   those	   seen	   in	   vehicle	   control	   labour.	   This	   may	   suggest	   that	   a	   functional	  
progesterone	  withdrawal	  may	  be	  occurring	  despite	   the	  preservation	  of	  actual	   levels,	  although	   this	  
study	  does	  not	  allow	  for	  the	  provision	  of	  evidence	  for	  or	  against	  this	  hypothesis.	  	  Alternatively,	  the	  
decomposition	  of	  the	  dead	  pups	  may	  be	  the	  cause	  of	  inflammation	  overcoming	  the	  repressive	  effect	  
of	  progesterone.	  This	  hypothesis	  is	  supported	  by	  increasing	  inflammation	  from	  E19	  to	  E20	  which	  is	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coupled	  with	  a	  dramatic	   increase	   in	  the	  pup	  death	  rate	   from	  2.17%	  to	  89.7%	  respectively.	  Despite	  
this	   increased	   pup	   death	   rate,	   it	   cannot	   be	   definitively	   concluded	   that	   there	   is	   no	   concurrent	  
functional	   progesterone	   withdrawal.	   In	   order	   to	   dissect	   out	   the	   underlying	   cause	   of	   the	  
inflammation,	   in	   future,	   mice	   will	   be	   fitted	   with	   a	   telemetry	   device	   allowing	   remote	   real-­‐time	  
measurement	   of	   uterine	   activity,	   and	   hence	   labour	   which	   may	   be	   obstructed	   (thus	   clinically	   not	  
apparent)	  due	  to	  pup	  size.	  	  	  
3.3.2.2.	  Contraction-­‐associated	  proteins	  
The	   labour	   associated	   peak	   in	  Gja1,	  Ptgs2	   and	  Oxtr	   RNA	   levels	  was	   completely	   abolished	   in	  mice	  
receiving	  progesterone	  supplementation,	  as	  was	  the	  protein	  peak	  of	  connexin-­‐43.	  This	  is	  in	  contrast	  
to	  a	  study	   in	  which	  mice	  receiving	  vaginal	  progesterone	  or	  17alpha-­‐hydroxyprogesterone	  caproate	  
demonstrated	  no	  changes	  to	  RNA	  levels	  of	  Gja1,	  Ptgs2	  and	  Oxtr	  compared	  to	  vehicle	  control	  (364).	  
However,	  it	  must	  be	  recognised	  that	  in	  the	  study	  by	  Nold	  et	  al.	  (364)	  the	  comparison	  was	  made	  prior	  
to	  labour	  onset	  (at	  E17.5)	  and	  hence	  these	  data	  are	  not	  directly	  comparable	  to	  the	  data	  presented	  
here.	   A	   study	   of	   progesterone	   supplementation	   in	   rats	   demonstrated	   decreased	  Oxtr	   RNA	   in	   the	  
treated	  group	  on	  the	  day	  of	  labour	  onset	  (296).	  
It	   is	   interesting	   to	   note	   that	   by	   E20,	   unlike	   the	   pattern	   seen	   for	   chemokines	   and	   cytokines,	  
contraction-­‐associated	  protein	   levels	  do	  not	  return	  to	  vehicle	  control	   labour	   levels,	  suggesting	  that	  
the	  action	  of	  progesterone	  is	  preserved.	  This	  could	  support	  the	  hypothesis	  that	  the	  inflammation	  is	  
not	  arising	  due	  to	  a	  decline	  in	  progesterone	  levels	  but	  rather	  due	  to	  pup	  death	  and	  it	  is	  the	  decline	  
of	   progesterone	   levels,	   rather	   than	   the	   resulting	   inflammation,	   that	   is	   required	   for	   contraction-­‐
associated	  protein	  up-­‐regulation.	  	  
3.3.2.3.	  Transcription	  factors	  
With	   the	   exception	   of	   a	   trend	   towards	   delayed	   activation	   of	   c-­‐Jun,	   very	   little	   difference	   was	  
identified	   in	  transcription	  factor	   levels	  when	  animals	  received	  supplementary	  progesterone.	  This	   is	  
in	  contrast	  to	  in	  vitro	  studies	  (365,	  366)	  in	  which	  a	  reduction	  in	  activation	  of	  MAPK	  and	  p65	  has	  been	  
implicated	  in	  progesterone	  action;	  this	  may	  well	  represent	  a	  limitation	  of	  in	  vitro	  models	  in	  which	  for	  
example	  inflammation	  is	  stimulated	  by	  IL-­‐1β	  treatment.	  	  
3.3.2.4.	  Circadian	  rhythm	  genes	  
As	  would	   be	   expected	   from	   the	   literature	   (152),	   progesterone	   appeared	   to	   drive	  Clock,	  Cry1	   and	  
Per1	  when	  compared	  to	  gestationally	  matched	  controls.	  	  The	  Clock	  findings	  appear	  to	  be	  paradoxical	  
as	   levels	   tended	   to	   increase	   with	   advancing	   gestation	   in	   control	   pregnancy,	   i.e.	   with	   declining	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progesterone	   levels,	   but	   also	   after	   progesterone	   supplementation.	   This	   suggests	   that	   control	   of	  
Clock	  expression	  is	  not	  simply	  dependent	  on	  progesterone	  levels.	  	  
Further,	   progesterone	   supplementation	   raised	   levels	   of	   genes	   known	   to	   antagonise	   the	   circadian	  
rhythm	  genes	  positively	  regulated	  by	  progesterone.	  As	  all	  mice	  were	  euthanised	  at	  the	  same	  time	  of	  
day	   (with	   the	   exception	   of	   labouring	   mice)	   hence	   eliminating	   a	   time-­‐of-­‐day	   effect,	   these	   data	  
suggest	   that	   regulation	   of	   circadian	   rhythm	   genes	   may	   be	   multi-­‐factorial	   and	   not	   be	   simply	  
dependent	  on	  progesterone	  levels.	  	  
	  
3.3.3.	  Mifepristone-­‐induced	  murine	  preterm	  labour	  
The	  administration	  of	  mifepristone	  brought	  about	  a	  chemical	  withdrawal	  of	  progesterone	  action	  by	  
binding	  strongly	  to	  both	  PR	  and	  GR	  (367)	  and	  inhibiting	  their	  action.	  As	  a	  result,	  preterm	  labour	  was	  
precipitated	  in	  all	  animals.	  	  
3.3.3.1.	  Transcription	  factor	  activation	  
Indirect	   in	  vivo	  evidence	  is	  presented	  here	  to	  support	  the	  mutual	  inhibition	  of	  PR	  and	  p65	  that	  has	  
previously	   been	   reported	   in	   in	   vitro	   from	   studies	   in	   cell	   lines	   (211)	   and	   primary	  myometrial	   cells	  
(120,	  212).	  In	  addition,	  this	  is	  the	  first	  report	  of	  p38	  activation	  following	  mifepristone	  administration	  
with	   trends	   in	   increased	   phosphorylation	   of	   ERK1/2,	   JNK	   and	   c-­‐Jun	   consistent	   with	   the	   group’s	  
previous	   observations	   (271).	   Interestingly,	   mifepristone-­‐induced	   preterm	   labour	   appears	   to	   differ	  
from	  vehicle	  control	  labour	  at	  the	  transcription	  factor	  level	  as	  the	  latter	  does	  not	  show	  a	  similar	  rise	  
in	  p65	  and	  p38.	  	  
Unfortunately,	  attempts	  at	  p38	  inhibition	  failed	  with	  evidence	  of	  ML3403	  actually	  having	  agonist-­‐like	  
activity,	  with	  no	  effect	  observed	  in	  the	  case	  of	  SB203580.	  It	  is	  difficult	  to	  speculate	  why	  this	  may	  be	  
the	  case	  as	  both	  drugs	  have	  been	  successfully	  used	   in	  vivo	   (352-­‐355),	  albeit	  using	  different	  mouse	  
strains	   which	   could	   hence,	   at	   least	   partially,	   explain	   why	   p38	   inhibition	   was	   unsuccessful	   in	   our	  
hands.	  
3.3.3.2.	  Inflammation	  
Pro-­‐inflammatory	   chemokines	   and	   cytokines	   RNA	   levels	   peaked	   with	   labour	   whereas	   they	  
demonstrated	   a	   bi-­‐modal	   distribution	   at	   the	   protein	   level	   with	   an	   initial	   peak	   at	   9	   hours	   and	   a	  
second	  peak	  at	  labour.	  	  It	  is	  interesting	  to	  note	  that	  the	  initial	  protein	  peak	  coincides	  with	  maximal	  
p38	  activation.	  Studies	  in	  cardiomyocytes	  demonstrated	  that	  MK2,	  the	  kinase	  downsteam	  of	  p38,	  is	  
capable	   of	   promoting	   enhanced	   mRNA	   translation	   (368),	   which	   would	   account	   for	   the	   increased	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protein	   levels	  observed	  here	  without	  a	  change	   in	  RNA	  expression.	  Alternatively,	  the	  RNA	  peak	  and	  
secondary	  protein	  peak	  could	  be	  a	  reflection	  of	  the	   inflammatory	  cell	   influx	   into	  the	  myometrium.	  
Some	  authors	  have	  not	  observed	  a	  myometrial	   leukocytosis	   following	  mifepristone	  administration	  
(283),	  however	  data	  from	  this	  group	  have	  shown	  marked	  macrophage	  and	  neutrophil	  invasion	  with	  
mifepristone-­‐induced	  preterm	  labour	  (unpublished	  observation).	  	  
Upon	   comparison	   of	   vehicle	   control	   labour	   to	   mifepristone-­‐induced	   preterm	   labour,	   the	   same	  
chemokines	   and	   cytokines	   appeared	   to	   be	   most	   up-­‐regulated	   i.e.	   IL-­‐6,	   CXCL1	   and	   CXCL2.	  
Additionally,	  progesterone	  supplementation	  reduces	  the	  levels	  of	  these	  cytokines.	  This	  suggests	  that	  
these	  are	  key	  mediators	  of	   labour-­‐associated	  inflammation.	  However,	  mice	  deficient	   in	  IL-­‐6	  appear	  
to	   labour	   normally	   (369);	   this	   could	   be	   as	   a	   result	   of	   a	   degree	   of	   redundancy	   in	   the	   parturition	  
process,	  at	  least	  in	  terms	  of	  chemokines	  and	  cytokines.	  Alternatively,	  it	  could	  be	  hypothesised	  that	  
inflammation	  is	  merely	  associated	  with	  labour	  and	  is	  not	  causally	  linked	  to	  it.	  	  
It	   is	   important	   to	   consider	   that	   different	   models	   of	   murine	   preterm	   labour	   appear	   to	   activate	  
different	   signalling	   cascades	  with	  TLR-­‐4	   specific	  Salmonella	  abortus	   activating	  both	  NF-­‐κB	  and	   JNK	  
(370)	  whereas	  Escherischia	  coli-­‐derived	  LPS	  only	  leading	  to	  JNK	  (and	  AP-­‐1)	  activation	  with	  no	  NF-­‐κB	  
activation	  (271).	  Even	  different	  LPS	  serotypes	  were	  shown	  to	  have	  differential	  activation	  patterns	  of	  
pro-­‐inflammatory	   and	   contractile	   proteins	   (371).	   Hence,	   whereas	   an	   antagonist	   drug	   may	   delay	  
preterm	  labour	  in	  certain	  cases,	  for	  example	  JNK	  inhibition	  in	  Escherischia	  coli-­‐derived	  LPS	  preterm	  
labour	   (372),	   it	   may	   not	   in	   others.	   This	   serves	   to	   highlight	   that	   (i)	   although	   superior	   to	   in	   vitro	  
experiments,	  animal	  models	  do	  have	  limitations	  and	  (ii)	  preterm	  labour	  truly	  is	  a	  syndrome	  and	  even	  
not	  all	  infection-­‐induced	  preterm	  labour	  is	  likely	  to	  be	  the	  same	  at	  the	  molecular	  level.	  	  
3.3.3.3.	  Contraction	  associated	  proteins	  
Coinciding	   with	   maximal	   p38	   and	   p65	   activation,	   connexin-­‐43	   and	   OTR	   RNA	   and	   protein	   rose	  
significantly	  at	  9	  hours	  post-­‐mifepristone	  administration.	  A	  similar	  up-­‐regulation	  in	  connexin-­‐43	  and	  
OTR	   after	   chemical	   PR/GR	   blockade	   with	   mifepristone	   has	   been	   previously	   reported	   (144,	   283).	  
Unlike	   reports	   in	   the	   literature	   (283),	   no	   changes	   in	   COX-­‐2	   levels	   were	   observed	   in	   this	   set	   of	  
experiments.	  	  
The	   effect	   of	   mifepristone	   on	   contraction-­‐associated	   proteins	   was	   noted	   to	   be	   similar	   to	   vehicle	  
control	   labour	   with	   the	   exception	   of	   COX-­‐2.	   The	   crucial	   role	   of	   connexin-­‐43	   and	   OTR	   is	   also	  
highlighted	  by	  the	  reduction	  of	  their	   levels	  by	  progesterone	  supplementation.	  These	  data	  highlight	  
the	   importance	   of	   contraction-­‐associated	   proteins	   in	   the	   parturition	   process.	   Indeed,	   conditional	  
knockout	  of	  connexin-­‐43	  in	  smooth	  muscle	  cells	  brought	  about	  a	  delay	  in	  parturition	  in	  mice	  (329).	  
Interestingly,	   mice	   with	   global	   Oxtr	   knockout	   demonstrate	   normal	   parturition	   although	   this	   was	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purely	   based	   on	   clinical	   observation	   without	   any	   further	   detailed	  molecular	   studies	   (373).	   Global	  
Ptgs2	  knockout	  mice	  are	  infertile	  (374)	  and	  no	  studies	  using	  conditional	  knockouts	  were	  identified	  in	  
the	  literature.	  	  
3.3.3.4.	  Circadian	  rhythm	  genes	  
The	   administration	   of	  mifepristone	   led	   to	   a	  marked	   up-­‐regulation	   of	   both	   Clock,	   which	   has	   been	  
shown	   to	   enhance	   NF-­‐κB-­‐mediated	   transcription	   (162),	   as	   well	   as	  Bmal1	   which	   opposes	   the	   pro-­‐
inflammatory	  action	  of	  Clock	  and	  hence	  this	  may	  represent	  a	  method	  of	  regulation	  of	  the	  actions	  of	  
Clock.	  	  Although	  Per1	  levels	  did	  not	  follow	  the	  expected	  pattern,	  blockade	  of	  progesterone	  signalling	  
as	   expected	   led	   to	   a	   decline	   in	   Cry1	   and	   Npas2	   levels.	   Furthermore,	   levels	   of	   Nr1d2,	   Rorc	   and	  
Ppargc1a	   increased	   after	   mifepristone	   administration,	   which	   may	   also	   suggest	   a	   second	   tier	   of	  
regulation	  of	  the	  core	  circadian	  gene	  Bmal1.	  
	  
3.3.4.	  Summary	  
These	   data	   have	   demonstrated	   that	   vehicle	   control	   murine	   labour	   is	   a	   process	   associated	   with	  
inflammation,	   upregulation	   in	   contraction-­‐associated	   proteins	   and	   altered	   circadian	   rhythm	   gene	  
expression.	   Progesterone	   supplementation	   delayed	   labour	   in	   association	   with	   a	   decline	   in	  
inflammation	  and	   contraction-­‐associated	  protein	  expression.	  By	   E20	  however,	   inflammation	   levels	  
were	   greatly	   increased	  without	   a	   similar	   rise	   in	   contraction-­‐associated	   proteins	   raising	   interesting	  
questions	   regarding	   the	   role	   of	   inflammation.	   Further,	   mifepristone-­‐induced	   preterm	   labour	   has	  
demonstrated	   a	   novel	   bimodal	   nature	   to	   the	   labour-­‐associated	   inflammatory	   phenotype	   in	  
association	  with	  a	  potential	  role	  for	  p38.	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CHAPTER	   4:	   MYOMETRIAL	   EXPLANTS	   AS	   A	   MODEL	   FOR	   THE	   STUDY	   OF	  
PROGESTERONE	  SIGNALLING	  
	  
4.1	  Introduction	  	  
	  
4.1.1.	  In	  vitro	  models	  
Myometrial	   biopsies	   obtained	   at	   the	   time	   of	   Caesarean	   section	   are	   routinely	   used	   for	   primary	  
myometrial	   cell	   culture,	  where	   the	   tissue	   is	   finely	   dissected	   and	   the	   extracellular	  matrix	   digested	  
using	   a	   collagenase	  mixture	   to	   isolate	   the	  myometrial	   smooth	  muscle	   cells.	   This	  model	   has	   been	  
validated	  for	  the	  study	  of	  	  parturition	  (375)	  although	  crucially	  these	  validation	  experiments	  did	  not	  
incorporate	   a	   comparison	   to	   	   tissue	   snap	   frozen	   at	   the	   time	   of	   Caesarean	   section.	   Nevertheless,	  
primary	  myometrial	  cell	  culture	  has	  been	  widely	  used	  in	  the	  study	  of	  signalling	  in	  the	  myometrium	  
(120,	  145,	  376-­‐378).	  	  
Despite	  this,	  some	  authors	  have	  reported	  limitations	  with	  the	  primary	  cell	  culture	  model	  including	  a	  
decline	   in	   PR	   levels	   (379)	   and	   indeed	   more	   widespread	   changes	   of	   the	   cell	   transcriptome	   when	  
compared	  to	  tissue	  (380).	  Specifically,	  Zaitseva	  et	  al	  (380)	  obtained	  non-­‐pregnant	  myometrium	  from	  
women	  undergoing	  hysterectomy	  for	  fibroids	  and	  observed	  that,	  compared	  to	  their	  matched	  tissue	  
controls,	   primary	   cells	   at	   passage	   0	   and	   passage	   3	   expressed	   significantly	   higher	   levels	   of	   genes	  
associated	  with	  cell	  adhesion,	  cytoskeleton	  and	  fibre	  organisation	  and	  contractility.	  Conversely,	  they	  
observed	   significantly	   lower	   levels	   of	   genes	   associated	   with	   cell	   growth	   and	   maintenance,	   cell	  
communication	  and	  catalytic	  activity.	  	  
Various	  myometrial	  cell	  lines	  have	  been	  created	  including	  hTERT-­‐HM,	  which	  is	  frequently	  used	  in	  the	  
field	  of	  parturition	  research.	  It	  offers	  distinct	  advantages:	  cells	  divide	  rapidly	  in	  vitro,	  it	  removes	  the	  
reliance	   on	   patients	   to	   donate	   biopsies	   and	   yields	   readily	   reproducible	   data	   by	   removing	   patient	  
variability.	  The	  time	  required	  to	  culture	  enough	  primary	  cells	  for	  a	  typical	  experiment	  is	  in	  the	  region	  
of	   6-­‐8	   weeks,	   versus	   a	   week	   for	   hTERT-­‐HM.	   However,	   academics	   are	   concerned	   about	   how	  
representative	  hTERT-­‐HM	  cells	  are	  of	  the	  	  in	  vivo	  state	  (375).	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4.1.2.	  Progesterone	  anti-­‐inflammatory	  signalling	  in	  myometrial	  in	  vitro	  models	  	  
Inflammation	   in	   primary	   cell	   cultures	   is	   reproduced	   by	   treating	   cells	   with	   IL-­‐1β,	   which	   has	   been	  
shown	  to	  drive	  the	  expression	  of	  many	  pro-­‐inflammatory	  genes	  including	  PTGS2	  and	   IL8	  (120,	  366,	  
381).	  Furthermore,	  it	  drives	  the	  phosphorylation	  of	  ERK1/2,	  p38	  and	  JNK	  (366)	  as	  well	  as	  p65	  and	  c-­‐
Jun	  (120,	  145,	  381).	   In	  this	  model,	  progesterone	  has	  been	  shown	  to	  signal	  via	  GR	  to	  repress	   IL-­‐1β-­‐
driven	  COX-­‐2	  (120).	  Further,	  progesterone	  was	  shown	  to	  bring	  about	  a	  GR-­‐dependent	  up-­‐regulation	  
in	  MAPK	  phosphatase-­‐1	  (MKP-­‐1),	  which,	   in	  turn,	  reduced	  c-­‐Jun	  phosphorylation;	  at	  the	  same	  time,	  
total	  c-­‐Jun	  levels	  were	  reduced	  (145).	  
As	  with	  primary	   cells,	  progesterone	  has	  been	   shown	   to	   repress	   IL-­‐1β-­‐induced	  COX-­‐2	  expression	   in	  
hTERT-­‐HM	   (140).	   	   Using	   this	   paradigm,	   IL-­‐1β	   was	   shown	   to	   induce	   p65	   recruitment	   to	   NF-­‐κB	  
elements	  in	  the	  COX-­‐2	  promoter	  region	  and	  that	  this	  effect	  was	  abrogated	  by	  progesterone	  (140).	  A	  
rise	   in	   IκBα,	  an	   inhibitor	  of	  NF-­‐κB	  action,	  was	  proposed	  as	   the	  underlying	  mechanism	   (140).	  Work	  
carried	  out	  in	  non-­‐myometrial	  cell	  lines	  has	  also	  demonstrated	  a	  direct	  interaction	  between	  PR	  and	  
p65	   (211)	   thus	   providing	   another	   mechanism	   to	   explain	   progesterone	   action.	   Further,	   IL-­‐1β	   was	  
shown	  to	  stimulate	  increased	  NF-­‐κB	  binding	  to	  the	  PR	  promoter	  leading	  to	  increased	  levels	  of	  all	  PR	  
isoforms	  concluding	  that	  expression	  of	  inhibitory	  PR	  isoforms	  is	  enhanced	  by	  NF-­‐κB	  activation	  	  (189).	  
	  
4.1.3.	  Myometrial	  explant	  culture	  
Myometrial	   explant	   culture	   refers	   to	   an	   alternative	   model	   where	   rather	   than	   being	   digested,	  
myometrial	  biopsies	  are	  carefully	  dissected	  into	  3x3x3mm3	  segments	  (10-­‐20mg	  in	  weight)	  with	  any	  
vasculature	   that	   is	  obvious	   to	   the	  naked	  eye	  removed.	  Explants	  are	   then	  directly	  placed	   in	  culture	  
medium	   and	   treated	   as	   per	   the	   experimental	   protocol.	   Research	   using	   such	   explant	   models	   is	  
widespread	   both	   in	   non-­‐reproductive	   (382)	   and	   reproductive	   tissues	   (383-­‐385),	   including	   the	  
myometrium	  (386-­‐391).	  However,	   this	  model	  has	  undergone	  very	   little	  validation	  with	   two	  groups	  
reporting	  confirmation	  of	  viability	  (387,	  391)	  and	  only	  one	  reporting	  maintenance	  of	  phenotype,	  as	  
assessed	  by	  smooth	  muscle	  mark	  expression,	  and	  RNA	  integrity	  (387).	  Further,	  no	  direct	  comparison	  
to	  the	  more	  widely	  established	  cell	  culture	  systems	  has	  been	  performed.	  
The	   aim	   of	   this	   chapter	   was	   to	   (i)	   establish	  whether	  myometrial	   explants	   represented	   a	   superior	  
model	  compared	  for	  the	  study	  of	  progesterone	  action	  and	  (ii)	  study	  the	  anti-­‐inflammatory	  action	  of	  
progesterone	  before	  and	  after	  the	  onset	  of	  labour.	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4.2	  Results	  
	  
4.2.1.	  Primary	  cell	  culture	  data	  
In	   order	   to	   obtain	   enough	   primary	   myometrial	   cells	   to	   study	   progesterone	   signalling,	   they	   are	  
progressively	   passaged	   to	   passage	   3	   or	   4.	   	   At	   the	   outset	   of	   this	   project,	   I	   sought	   to	   determine	  
whether	  the	  previous	  reports	  of	  a	  decline	  in	  PR	  were	  reproducible	  in	  our	  population	  of	  myometrial	  
biopsies.	   	  Myometrial	  biopsies	  were	  obtained	  from	  women	  at	  term	  and	  not	   in	   labour.	  A	  portion	  of	  
tissue	  was	   immediately	  snap	  frozen	  (t=0)	  and	  the	  remaining	  portion	  was	  used	  for	  cell	  culture	  with	  
the	   first	   flask	   designated	   as	   passage	   0.	   Once	   confluent,	   cells	   were	   progressively	   passaged	   via	  
trypsinisation	  up	  to	  passage	  4.	  	  The	  levels	  of	  GR	  were	  shown	  not	  to	  alter	  with	  progressive	  passage,	  
however	  both	  PR	  isoforms	  were	  shown	  to	  drop	  dramatically	  reaching	  statistical	  significance	  for	  PR-­‐B	  
by	  passage	  3	  (Figure	  4.1).	  	  	  
	  
Figure	  4.1.	  Nuclear	  receptor	  receptors	  with	  primary	  myometrial	  cell	  passage.	  
A	  small	  portion	  of	  myometrial	  tissue	  was	  snap	  frozen	  in	  liquid	  nitrogen	  at	  the	  time	  of	  Caesarean	  section.	  The	  
remaining	  tissue	  was	  cultured	  as	  described	  in	  Methods	  with	  the	  first	  flask	  designated	  as	  passage	  0	  (P0).	  Cells	  
were	   subsequently	  passaged	  upon	   reaching	  80-­‐90%	  confluence	  up	   to	  passage	  4	   (P4).	   Protein	  was	  extracted	  
and	  western	  blotting	  was	  run	  for	  A.	  progesterone	  receptor	  (PR)	  and	  B.	  glucocorticoid	  receptor	  (GR).	  Data	  were	  
analysed	  using	  a	  Friedman	  test	  followed	  by	  Dunn’s	  multiple	  comparison	  test.	  	  *,	  p<0.05	  versus	  tissue.	  n=4.	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Subsequently,	   the	   response	   of	   primary	   cells	   to	   progesterone	   treatment	   was	   assessed	   using	   the	  
progesterone-­‐responsive	  genes	  hydroxysteroid	  11β	  dehydrogenase	  1	  (HSD11B1)	  and	  FK506	  binding	  
protein	   (FKBP)	   51	   as	   readouts.	   These	   genes	   were	   identified	   on	   the	   basis	   of	   microarray	   analysis	  
carried	  out	  previously	  by	  the	  group	  in	  primary	  cells	  treated	  with	  progesterone	  (NCBI	  GEO	  Accession	  
GSE68171).	  Primary	   cells	  were	   treated	  with	  various	  doses	  of	  progesterone	   ranging	   from	  0.1µM	  to	  
10µM	  for	  a	  period	  of	  24	  hours	  and	  RNA	  was	  extracted	  for	  cDNA	  synthesis	  and	  quantitative	  RT-­‐PCR.	  
The	   same	   protocol	   was	   repeated	   for	   protein	   extraction	   and	   western	   blotting.	   The	   data	  
demonstrated	   that	   high	   doses	   of	   progesterone	   (minimum	   5µM)	   were	   required	   to	   bring	   about	   a	  
modest	  (but	  significant)	  increase	  in	  progesterone	  responsive	  genes	  (Figs.	  4.2A	  &	  4.2B).	  No	  significant	  
increase	  with	  any	  dose	  of	  progesterone	  was	  observed	  at	  the	  protein	  level	  (Figs.	  4.2C	  &	  4.2D).	  	  
	  
Figure	  4.2.	  The	  effect	  of	  progesterone	  (P4)	  treatment	  on	  progesterone-­‐driven	  genes	  in	  primary	  myometrial	  
cells.	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Primary	  myometrial	  cells	  at	  passage	  4	  were	  treated	  with	  ethanol	  vehicle	  or	  increasing	  doses	  of	  progesterone	  
(0.1,	  0.5,	  1,	  5	  and	  10µM)	  for	  24	  hours.	  RNA	  was	  extracted	  and	  quantitative	  RT-­‐PCR	  was	  run	  for	  A.	  HSD11B1	  and	  
B.	   FKBP51.	   In	   a	   separate	   series	   of	   experiments,	   primary	   myometrial	   cells	   at	   passage	   4	   were	   treated	   with	  
ethanol	  vehicle	  or	  increasing	  doses	  of	  progesterone	  (0.1,	  1	  and	  10µM)	  for	  24	  hours.	  Protein	  was	  extracted	  and	  
Western	  blot	  was	  run	  for	  C.	  HSD11B1	  and	  D.	  FKBP51.	  Data	  are	  expressed	  as	  mean	  ±	  SEM.	  Normality	  was	  tested	  
using	  a	  Shapiro-­‐Wilk	  normality	  test.	  	  Normally	  distributed	  data	  were	  analysed	  by	  a	  repeated	  measures	  ANOVA	  
followed	   by	   Bonferroni’s	   multiple	   comparison	   test.	   Non	   normally	   distributed	   data	   were	   analysed	   by	   a	  
Friedman	   test	   followed	   by	   Dunn’s	  multiple	   comparison	   test.	   *,	   p<0.05	   versus	   vehicle	   control;	   ***,	   p<0.001	  
versus	  vehicle	  control.	  n=8.	  These	  experiments	  were	  performed	  in	  collaboration	  with	  Angela	  Yulia.	  	  
	  
4.2.2.	  Microarray	  analysis	  
As	  previously	  mentioned,	  myometrial	  explants	  are	  already	  in	  use	  in	  the	  field	  of	  parturition.	  However,	  
their	  superiority	  to	  primary	  cell	  cultures	  and/or	  hTERT-­‐HM	  has	  not	  been	  established.	  For	  this	  reason,	  
I	   next	   sought	   to	   determine	   whether	   myometrial	   explants	   did	   indeed	   represent	   a	   better	   model.	  
Myometrial	  biopsies	  were	  collected	   from	  pregnant	  women	  at	   term	  undergoing	  elective	  Caesarean	  
section.	  The	  biopsy	  was	  processed	  as	  follows:	  (i)	  a	  portion	  was	  immediately	  snap	  frozen	  (t=0),	  (ii)	  a	  
second	  portion	  was	  finely	  dissected	  into	  3x3x3mm3	  explants,	  and	  (iii)	  the	  remainder	  was	  digested	  in	  
order	   to	   isolate	   the	  cells	   for	  primary	  culture.	  Explants	  were	  cultured	   in	  DMEM	  supplemented	  with	  
penicillin/streptomycin	   alone	   for	   a	   total	   for	   30	   hours,	   at	  which	   point	   all	   pieces	  were	   snap	   frozen.	  
Primary	  cells	  were	  cultured	  in	  10%	  FCS	  and	  progressively	  passaged	  up	  to	  passage	  4.	  Once	  confluent,	  
they	  were	   incubated	  overnight	   in	  1%	  DCC-­‐FCS;	   the	  following	  morning,	   the	  media	  was	  refreshed	  to	  
DMEM	   supplemented	  with	   penicillin/streptomycin	   alone	   and	   cells	   were	   cultured	   for	   a	   further	   30	  
hours,	  at	  which	  point	   the	  media	  was	   removed	  and	  cells	  were	  placed	  directly	  at	   -­‐80°C.	  Similarly	   to	  
primary	  cells,	  hTERT-­‐HM	  was	  cultured	  in	  10%	  FCS	  until	  confluent.	  At	  this	  point	  they	  were	  incubated	  
overnight	   in	   1%	   FCS-­‐DCS	   and	   the	   media	   refreshed	   to	   DMEM	   supplemented	   with	  
penicillin/streptomycin	  alone	  for	  a	  total	  of	  30	  hours,	  at	  which	  point	  all	  the	  media	  was	  removed	  and	  
cells	  were	  placed	  directly	  at	  -­‐80°C.	  Total	  RNA	  was	  extracted	  from	  these	  samples	  and	  assessment	  of	  
the	  transcriptome	  was	  carried	  out	  by	  microarray	  analysis.	  	  
Primary	   component	   analysis	   (PCA)	   demonstrated	   that	   as	   expected	   none	   of	   the	   in	   vitro	   models	  
overlapped	   with	   t=0,	   however	   explants	   were	   most	   closely	   associated	   with	   it	   compared	   to	   both	  
primary	  cells	  and	  hTERT-­‐HM	  (Fig	  4.3).	  	  Ranked	  by	  p-­‐value,	  the	  top	  50	  genes	  in	  each	  of	  the	  3	  models	  
as	   compared	   to	   t=0	   are	   shown	   in	   appendices	   1-­‐3.	   Additionally,	   gene	   ontology	   analysis	   for	   each	  
model	  comparison	  to	  t=0	  is	  shown	  in	  appendices	  4-­‐6.	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Figure	  4.3.	  Principal	  component	  analysis	  (PCA)	  plot	  of	  snap	  frozen	  myometrial	  tissue,	  myometrial	  explants,	  
primary	  cells	  and	  HTERT-­‐HM.	  
Myometrial	   tissue	   obtained	   from	   term	   non-­‐labouring	   women	   was	   (i)	   snap	   frozen	   immediately	   (t=0),	   (ii)	  
dissected	   into	   3x3x3mm3	   explants	   or	   (iii)	   digested	   with	   a	   collagenase	   mixture	   to	   isolate	   cells	   for	   primary	  
culture.	  Explants	  were	  cultured	  in	  DMEM	  without	  treatment	  for	  30	  hours.	  After	   incubation	  with	  1%	  DCC-­‐FCS	  
overnight,	  the	  media	  of	  myometrial	  cells	  at	  passage	  4	  and	  hTERT-­‐HM	  cells	  was	  refreshed	  and	  cells	  incubated	  	  
for	  a	  further	  30	  hours	  without	  treatment.	  Total	  RNA	  was	  extracted	  and	  whole-­‐genome	  transcriptome	  analysis	  
was	   conducted	   by	   hybridisation	   to	   Affymetrix	   Human	   Gene	   2.1	   ST	   array	   strips	   and	   analysed	   using	   Partek	  
Genomics	  Suite	  6.6	  software.	  Differentially	  expressed	  genes	  (DEG)	  were	  identified	  by	  two-­‐way	  ANOVA,	  and	  p-­‐
values	  were	   adjusted	  using	   the	   FDR	   (false-­‐discovery	   rate)	  method	   to	   correct	   for	  multiple	   comparisons.	  DEG	  
were	  considered	  significant	  if	  p-­‐value	  was	  p≤0.05	  at	  a	  fold	  change	  of	  >2	  with	  FDR	  <0.05.	  n=6.	  
The	   differences	   between	   each	   group	   as	   compared	   to	   t=0	   can	   be	   visualised	   in	   the	   volcano	   plots	  
where	  each	  dot	  represents	  a	  gene	  (Fig	  4.4.).	  On	  the	  plots,	  increasingly	  significant	  p	  value	  is	  plotted	  
on	  the	  y-­‐axis	  and	  increasing/decreasing	  fold	  change	  from	  the	  midpoint	  of	  the	  x-­‐axis.	  It	  can	  be	  seen	  
that	   the	   angle	   of	   the	   V-­‐shape	   of	   the	   explant	   volcano	   plot	   is	   much	   more	   acute	   as	   compared	   to	  
primary	   cells	   and	   hTERT-­‐HM.	   Additionally,	   the	   spread	   of	   the	   data	   is	   much	   less	   pronounced	   for	  
explants	  when	  compared	  to	  the	  other	  two	  models.	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Figure	  4.4.	  Volcano	  plots	  of	  explant,	  primary	  cells	  and	  hTERT-­‐HM	  versus	  t=0.	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Myometrial	   tissue	   obtained	   from	   term	   non-­‐labouring	   women	   was	   (i)	   snap	   frozen	   immediately	   (t=0),	   (ii)	  
dissected	   into	   3x3x3mm3	   explants	   or	   (iii)	   digested	   with	   a	   collagenase	   mixture	   to	   isolate	   cells	   for	   primary	  
culture.	  Explants	  were	  cultured	  in	  DMEM	  without	  treatment	  for	  30	  hours.	  After	   incubation	  with	  1%	  DCC-­‐FCS	  
overnight,	  the	  media	  of	  myometrial	  cells	  at	  passage	  4	  and	  hTERT-­‐HM	  cells	  was	  refreshed	  and	  cells	  incubated	  	  
for	  a	  further	  30	  hours	  without	  treatment.	  Total	  RNA	  was	  extracted	  and	  whole-­‐genome	  transcriptome	  analysis	  
was	   conducted	   by	   hybridization	   to	   Affymetrix	   Human	   Gene	   2.1	   ST	   array	   strips	   and	   analysed	   using	   Partek	  
Genomics	  Suite	  6.6	  software.	  Differentially	  expressed	  genes	  (DEG)	  were	  identified	  by	  two-­‐way	  ANOVA,	  and	  p-­‐
values	  were	   adjusted	  using	   the	   FDR	   (false-­‐discovery	   rate)	  method	   to	   correct	   for	  multiple	   comparisons.	  DEG	  
were	  considered	  significant	  if	  p-­‐value	  was	  p≤0.05	  at	  a	  fold	  change	  of	  >2	  with	  FDR	  <0.05.	  n=6.	  
	  
The	  top	  differentially	  expressed	  genes	  (DEG)	  versus	  t=0	  were	  plotted	  in	  a	  Venn	  diagram	  (Fig.	  4.5.).	  As	  
expected	  from	  the	  PCA	  plot,	  explants	  had	  the	  least	  DEG	  versus	  t=0	  (1444),	  followed	  by	  primary	  cells	  
(3840)	  and	  hTERT-­‐HM	  (4603).	  Of	  these,	  555	  DEG	  were	  common	  to	  all	  3	  models,	  whereas	  119	  were	  
shared	  between	  explants	  and	  primary	  cells	  and	  137	  between	  explants	  and	  hTERT-­‐HM.	   In	  contrast,	  
primary	   cells	   and	   hTERT-­‐HM	   had	  many	  more	   DEG	   in	   common	   (2111)	   (Fig.	   4.5).	   Explants	   had	   633	  
unique	  DEG,	  primary	  cells	  had	  1055	  and	  hTERT-­‐HM	  1800	  (Fig.	  4.5.).	  The	  top	  50	  DEG	  for	  each	  section	  
of	   the	   Venn	   diagram	   along	   with	   their	   corresponding	   gene	   ontology	   analyses	   are	   shown	   in	  
appendices	  7-­‐20.	  	  
	  
Figure	  4.5.	  Venn	  diagram	  of	  top	  differentially	  expressed	  genes	   	  
Myometrial	   tissue	   obtained	   from	   term	   non-­‐labouring	   women	   was	   (i)	   snap	   frozen	   immediately	   (t=0),	   (ii)	  
dissected	   into	   3x3x3mm3	   explants	   or	   (iii)	   digested	   with	   a	   collagenase	   mixture	   to	   isolate	   cells	   for	   primary	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culture.	  Explants	  were	  cultured	  in	  DMEM	  without	  treatment	  for	  30	  hours.	  After	   incubation	  with	  1%	  DCC-­‐FCS	  
overnight,	  the	  media	  of	  myometrial	  cells	  at	  passage	  4	  and	  hTERT-­‐HM	  cells	  was	  refreshed	  and	  cells	  incubated	  	  
for	  a	  further	  30	  hours	  without	  treatment.	  Total	  RNA	  was	  extracted	  and	  whole-­‐genome	  transcriptome	  analysis	  
was	   conducted	   by	   hybridization	   to	   Affymetrix	   Human	   Gene	   2.1	   ST	   array	   strips	   and	   analysed	   using	   Partek	  
Genomics	  Suite	  6.6	  software.	  Differentially	  expressed	  genes	  (DEG)	  were	  identified	  by	  two-­‐way	  ANOVA,	  and	  p-­‐
values	  were	   adjusted	  using	   the	   FDR	   (false-­‐discovery	   rate)	  method	   to	   correct	   for	  multiple	   comparisons.	  DEG	  
were	  considered	  significant	  if	  p-­‐value	  was	  p≤0.05	  at	  a	  fold	  change	  of	  >2	  with	  FDR	  <0.05.	  n=6.	  
	  
The	   top	   gene	   ontology	   groups	   for	   the	   Venn	   diagram	   region	  where	   all	   3	  models	   overlap	   included	  
‘immune	  response’,	  ‘inflammatory	  response’	  and	  ‘leukocyte	  migration’	  with	  DEG	  such	  as	  MMP1	  and	  
IL6.	  In	  addition,	  in	  the	  region	  where	  explants	  and	  primary	  cells	  overlapped,	  gene	  ontology	  once	  again	  
had	   an	   inflammatory	   theme	   including	   ‘response	   to	   cytokine	   stimulus’	   and	   ‘response	   to	  
lipopolysaccharide’.	  Of	  note,	  ‘response	  to	  progesterone	  stimulus’	  also	  featured	  in	  the	  top	  10.	  In	  the	  
region	  where	  explants	  and	  hTERT-­‐HM	  overlapped,	   functions	  such	  as	   ‘cytokine	  activity’	  were	  highly	  
enriched	  with	  DEG	  such	  as	  IL1B	  and	  IL8.	  	  	  
In	   the	   region	   of	   genes	   uniquely	   up-­‐regulated	   in	   explants,	   gene	   ontology	   analysis	   included	  
‘gluconeogenesis’,	   ‘glucose	   transmembrane	   transporter	   activity’	   and	   ‘glucose	   metabolic	   process’.	  
The	   equivalent	   primary	   cell	   group	   gene	   ontology	   analysis	   included	   ‘signalling	   pathway’	   and	   ‘gap	  
junction’;	  for	  hTERT-­‐HM	  it	  included	  ‘cell	  adhesion’	  and	  ‘extracellular	  matrix	  organisation’.	  
4.2.2.1.	  Microarray	  Validation	  
In	  order	  to	  validate	  the	  microarray	  results,	  a	  second	  set	  of	  6	  biopsies	  was	  obtained	  from	  pregnant	  
women	  at	  term	  undergoing	  an	  elective	  Caesarean	  section.	  These	  were	  treated	   in	  exactly	  the	  same	  
way	   as	   the	   initial	   set.	   Furthermore,	   a	   second	   set	   of	   6	   individually-­‐grown	  well	   of	   hTERT-­‐HM	  were	  
cultured.	  Total	  RNA	  was	  extracted	  and	  cDNA	  synthesised	  for	  quantitative	  RT-­‐PCR.	  	  
A	  panel	  of	  15	  genes	  was	  chosen	  for	  validation	  using	  GAPDH	  as	  the	  housekeeping	  gene	  of	  choice	  for	  
consistency	  with	  western	   blot	   data	   (Table	   4.1).	   Three	   comparisons	  were	  made	   per	   gene:	   explant	  
versus	   t=0,	   primary	   cells	   versus	   t=0	   and	   hTERT-­‐HM	   versus	   t=0.	   	   Trends	  were	   preserved	   for	   genes	  
relevant	   to	   reproductive	   function	   (PTGS2,	   OXTR,	   PGR	   and	   GJA1)	   and	   genes	   relating	   to	   smooth	  
muscle	  phenotype	  (ACTA2,	  MYLK).	  Indeed,	  microarray	  and	  quantitative	  RT-­‐PCR	  data	  were	  consistent	  
in	  39	  of	  45	  cases	  (86.7%).	  Data	  differed	  for	  all	  3	  comparisons	  of	  NR3C1	  and	  for	  ESR1	  in	  primary	  cells.	  	  
The	   same	   panel	   of	   genes	   was	   also	   normalised	   to	   18S	   rRNA	   as	   the	   housekeeper	   demonstrating	  
concordance	  with	  GAPDH	  in	  43	  or	  45	  comparisons	  (95.6%).	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Gene 
symbol 
Model Quantitative 
RT-PCR fold 
change ± SEM 
Quantitative 
RT-PCR 
direction of 
change 
Microarray 
fold change 
Microarray 
direction of 
change ± SEM 
PTGS2 Explants 
Primary cells 
hTERT-HM 
7.02 ± 3.34 
2.43 ± 0.65 
1.73 ± 0.29 
↑ 
↑ 
↑ 
24.55 ± 0.45 
2.21 ± 0.41 
2.47 ± 0.02 
↑ 
↑ 
↑ 
IL8 Explants 
Primary cells 
hTERT-HM 
200.53 ± 43.89 
-4.51 ± 0.07 
14.26 ± 0.05 
↑ 
↓ 
↑ 
28.53 ± 0.45 
-1.22 ± 0.14 
9.92 ± 0.46 
↑ 
↓ 
↑ 
OXTR Explants 
Primary cells 
hTERT-HM 
-11.93 ± 0.05 
-34.74 ± 0.01 
-9.09 ± 0.02 
↓ 
↓ 
↓ 
-1.23 ± 0.21 
-7.74 ± 0.42 
-3.31 ± 0.20 
↓ 
↓ 
↓ 
PGR Explants 
Primary cells 
hTERT-HM 
-2.89 ± 0.04 
-4.43 ± 0.04 
-18.47 ± 0.00 
↓ 
↓ 
↓ 
-1.76 ± 0.08 
-3.35 ± 0.45 
-8.21 ± 0.08 
↓ 
↓ 
↓ 
IL1B Explants 
Primary cells 
hTERT-HM 
2.53 ± 0.09 
-35.06 ± 0.01 
18.90 ± 0.80 
↑ 
↓ 
↑ 
2.64 ± 0.40 
-1.31 ± 0.11 
18.44 ± 0.36 
↑ 
↓ 
↑ 
NR3C1 Explants 
Primary cells 
hTERT-HM 
-2.19 ± 0.04 
-1.64 ± 0.08 
-1.23 ± 0.04 
↓ 
↓ 
↓ 
1.39 ± 0.03 
1.28 ± 0.14 
1.81 ± 0.04 
↑ 
↑ 
↑ 
TPM1 Explants 
Primary cells 
hTERT-HM 
-1.37 ± 0.10 
-3.05 ± 0.04 
1.33 ± 0.06 
↓ 
↓ 
↑ 
-4.40 ± 0.05 
-2.77 ± 0.16 
-1.48 ± 0.08 
↓ 
↓ 
↓ 
TNFAIP3 Explants 
Primary cells 
hTERT-HM 
4.09 ± 1.30 
-13.44 ± 0.01 
-2.99 ± 0.04 
↑ 
↓ 
↓ 
6.44 ± 0.19 
-5.92 ± 0.12 
-1.08 ± 0.12 
↑ 
↓ 
↓ 
IL6 Explants 
Primary cells 
hTERT-HM 
20.12 ± 4.27 
1.66 ± 0.46 
8.32 ± 1.59 
↑ 
↑ 
↑ 
15.21 ± 0.21 
2.03 ± 0.31 
9.47 ± 0.11 
↑ 
↑ 
↑ 
ACTA2 Explants 
Primary cells 
hTERT-HM 
-10.48 ± 0.03 
-15.08 ± 0.02 
-44.47 ± 0.00 
↓ 
↓ 
↓ 
-1.79 ± 0.14 
-1.49 ± 0.24 
-2.83 ± 0.07 
↓ 
↓ 
↓ 
MYLK Explants 
Primary cells 
hTERT-HM 
-8.98 ± 0.02 
-13.14 ± 0.01 
-124.56 ± 0.00 
↓ 
↓ 
↓ 
-1.40 ± 0.03 
-1.14 ± 0.19 
-3.58 ± 0.06 
↓ 
↓ 
↓ 
PTGER3 Explants 
Primary cells 
hTERT-HM 
-3.59 ± 0.09 
-10.37 ± 0.03 
-653.11 ± 0.00 
↓ 
↓ 
↓ 
-1.10 ± 0.08 
-5.57 ± 0.21 
-24.47 ± 0.04 
↓ 
↓ 
↓ 
GJA1 Explants 
Primary cells 
hTERT-HM 
1.06 ± 0.18 
2.10 ± 0.19 
1.49 ± 0.11 
↑ 
↑ 
↑ 
1.58 ± 0.10 
2.56 ± 0.11 
1.39 ± 0.03 
↑ 
↑ 
↑ 
ESR1 Explants 
Primary cells 
hTERT-HM 
-1.58 ± 0.10 
1.41 ± 0.23 
-3.56 ± 0.02 
↓ 
↑ 
↓ 
1.30 ± 0.17 
-1.01 ± 0.13 
-1.32 ± 0.08 
↑ 
↓ 
↓ 
IL1A Explants 
Primary cells 
hTERT-HM 
3.36 ± 0.83 
-1.55 ± 0.04 
18.24 ± 3.60 
↑ 
↓ 
↑ 
2.71 ± 0.35 
-1.26 ± 0.10 
17.09 ± 0.19 
↑ 
↓ 
↑ 
Table	  4.1.	  Quantitative	  RT-­‐PCR	  validation	  of	  selected	  genes.	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4.2.3.	  Nuclear	  Receptors	  	  
The	  microarray	  data	   suggested	   that	  PR	   levels,	  at	   least	  at	   the	  RNA	   level,	  were	   least	   reduced	   in	   the	  
explant	  model;	  conflicting	  data	  arose	  for	  GR	  in	  all	  three	  models.	  In	  light	  of	  these	  observations,	  I	  next	  
sought	  to	  confirm	  the	  findings	  at	  the	  protein	  level.	  Given	  that	  the	  microarray	  showed	  hTERT-­‐HM	  to	  
be	  so	  dramatically	  different	  to	  t=0,	  further	  experiments	  focused	  solely	  on	  myometrial	  explants	  and	  
primary	   cells.	   Thus,	   a	   third	   set	   of	   biopsies	   obtained	   from	  pregnant	  non-­‐labouring	  women	  at	   term	  
were	  divided	  into	  (i)	  t=0,	  (ii)	  myometrial	  explants	  and	  (iii)	  primary	  cells	  used	  at	  passage	  4.	  	  
Western	   blotting	   demonstrated	   that	   levels	   of	   both	   PR	   isoforms	   in	   primary	   cells	  were	   significantly	  
reduced	  as	   compared	   to	  both	   t=0	  and	  explants	   (Fig.	  4.6).	  No	  difference	  was	  observed	   in	  PR	   levels	  
between	  t=0	  and	  explants.	  GR	   levels	  were	  also	  stably	  expressed	   in	  both	  explants	  and	  primary	  cells	  
upon	   comparing	   to	   t=0.	   Interestingly,	   the	   PR-­‐A:PR-­‐B	   ratio	   was	   increased	   in	   both	   explants	   and	  
primary	  cells	  when	  compared	  to	  	  t=0.	  	  
	  
Figure	  4.6.	  Comparison	  of	  nuclear	  receptor	  levels	  in	  myometrial	  explants	  and	  primary	  cells.	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Myometrial	   tissue	   obtained	   from	   term	   non-­‐labouring	   women	   was	   (i)	   snap	   frozen	   immediately	   (t=0),	   (ii)	  
dissected	   into	   3x3x3mm3	   explants	   or	   (iii)	   digested	   with	   a	   collagenase	   mixture	   to	   isolate	   cells	   for	   primary	  
culture.	  Explants	  were	  cultured	  in	  DMEM	  without	  treatment	  for	  30	  hours.	  After	   incubation	  with	  1%	  DCC-­‐FCS	  
overnight,	  the	  media	  of	  myometrial	  cells	  at	  passage	  4	  and	  hTERT-­‐HM	  cells	  was	  refreshed	  and	  cells	  incubated	  	  
for	   a	   further	   30	   hours	   without	   treatment.	   Protein	   was	   extracted	   and	   quantified.	   Western	   blotting	   was	  
performed	   for	  A.	   progesterone	   receptor	   (PR)	   and	  B.	   glucocorticoid	   receptor	   (GR).	   In	   addition	   the	  PR-­‐A:PR-­‐B	  
ratio	  was	  calculated	  (panel	  C).	  The	  data	  are	  expressed	  as	  mean	  +	  SEM.	  Normality	  was	  tested	  using	  a	  Shapiro-­‐
Wilk	   test	   followed	  Wilcoxon	   signed	   rank	   testing.	   #,	   p<0.05	   cells	   versus	   explants	   for	   PR-­‐B;	   ##,	   p<0.01	   cells	  
versus	  t=0	  for	  PR-­‐B;	  *,	  p<0.05	  cells	  versus	  explants	  for	  PR-­‐A;	  **,	  p<0.01	  cells	  versus	  t=0	  for	  PR-­‐A;	  $,	  p<0.05	  t=0	  
versus	  explants;	  $$,	  p<0.01	  t=0	  versus	  cells.	  n=8-­‐9.	  
4.2.4.	  Confirmation	  of	  smooth	  muscle	  phenotype	  
In	   order	   to	   confirm	   that	   myometrial	   explants	   were	   composed	   predominantly	   of	   smooth	   muscle,	  
immunohistochemical	   staining	   was	   undertaken	   using	   α-­‐smooth	   muscle	   actin	   as	   the	   marker	   of	  
choice.	  This	  demonstrated	   that	   the	  majority	  of	  biopsies	  were	   indeed	  composed	  of	   smooth	  muscle	  
(Fig.	  4.7.).	  	  
	  
Figure	  4.7.	  Immunohistochemical	  staining	  of	  myometrial	  explants.	  	  
Myometrial	   explants	   were	   fixed	   in	   formalin	   overnight,	   embedded	   in	   paraffin,	   cut	   into	   5µM	   sections	   and	  
mounted	   on	   poly-­‐D-­‐lysine	   slides.	   Following	   deparaffinisation,	   slides	  were	   stained	  with	  A.	   haematoxylin	   and	  
eosin,	  B.	  phosphate-­‐buffered	  saline	  (negative	  control)	  with	  haematoxylin	  nuclear	  counterstaining,	  C.	  α-­‐smooth	  
muscle	  actin	  (1:1000,	  Thermo	  Scientific)	  with	  haematoxylin	  nuclear	  counterstaining.	  
	  
4.2.5.	  Assessment	  of	  myometrial	  explant	  viability	  
Myometrial	  explants	  have	  been	  shown	  to	  respond	  to	  treatments	  such	  as	  progesterone	  throughout	  
the	  time	  period	  of	  being	  in	  culture,	  suggesting	  that	  the	  tissue	  remains	  viable.	  However,	   in	  order	  to	  
formally	   assess	   viability,	   a	   lactate	   dehydrogenase	   (LDH)	   assay	   was	   undertaken	   as	   described	   in	  
Methods	   with	   percentage	   necrosis	   expressed	   relative	   to	   paired	   tissue	   snap	   frozen	   at	   t=0	   and	  
homogenised	   to	   achieve	   100%	   lysis.	   The	   mean	   necrosis	   of	   myometrial	   explants	   at	   30	   hours	   was	  
107	  
	  
23.7%	   (SEM	   1.4%).	   Additionally,	   contractility	   data	   from	   a	   colleague	   in	   the	   group	   show	   that	  
myometrial	  tissue	  strips	  contract	  spontaneously	  and	  after	  stimulation	  with	  oxytocin	  throughout	  the	  
experimental	  period	  used	  for	  the	  work	  presented	  here.	  
	  
4.2.6.	  IL-­‐1β	  and	  progesterone	  dose	  response	  curves	  
In	   order	   to	   ensure	   that	   any	   changes	   in	   progesterone	   action	   were	   sensitively	   detected,	   the	   half	  
maximal	   effective	   concentration	   (EC50)	   of	   the	   inflammatory	   stimulus	   IL-­‐1β	   was	   identified	   to	   be	  
10ng/mL	   via	   a	   dose	   response	   experiment	   (Fig.	   4.8.).	   	   This	   dose	   was	   used	   to	   assess	   the	   anti-­‐
inflammatory	  effect	  of	  various	  doses	  of	  progesterone;	  1μM	  was	  thus	  identified	  as	  the	  half	  maximal	  
inhibitory	  concentration	  (IC50)	  (Fig.	  4.8.).	  	  
	  
Figure	  4.8.	  IL-­‐1β	  and	  progesterone	  dose	  response	  curves	  
Myometrial	   tissue	   obtained	   from	   term	   non-­‐labouring	   women	  was	   finely	   dissected	   into	   3x3x3mm3	   explants	  
after	  a	  portion	  was	  snap	  frozen	  (t=0).	  These	  were	  immediately	  pre-­‐treated	  for	  6	  hours	  with	  ethanol	  followed	  
by	   a	   24	   hour	   treatment	   with	   IL-­‐1β	   (1,	   10,	   20,	   50	   or	   100ng/mL)	   (Panel	   A).	   Alternatively,	   explants	   were	  
immediately	  pre-­‐treated	   for	  6	  hours	  with	  ethanol	  or	  progesterone	   (0.1,	  0.5,	  1,	  5	  or	  10µM)	   followed	  by	  a	  24	  
hour	   treatment	  with	   IL-­‐1β	   (10ng/mL)	   (Panel	  B).	   Protein	  was	   extracted	   and	   quantified.	  Western	   blotting	   for	  
cyclooxygenase-­‐2	  (COX-­‐2)	  was	  performed	  as	  described	  in	  Methods.	  A	  representative	  western	  blot	  is	  shown	  at	  
the	  top	  of	  each	  figure	  with	  densitometric	  analysis	  below.	  The	  data	  are	  expressed	  as	  mean	  +	  SEM.	  Normality	  
was	   tested	  a	  Shapiro-­‐Wilk	   test.	  Wilcoxon	   signed	   rank	   test	  was	  used	   for	  not	  normally	  distributed	  data	  and	  a	  
paired	  t	  test	  for	  normally	  distributed	  data;	  *,	  p<0.05	  versus	  control;;	  #,	  p<0.05	  versus	  IL-­‐1β;	  ##,	  p<0.01	  versus	  
IL-­‐1β.	  n=8.	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4.2.7.	  Myometrial	  explant	  culture	  media	  hormone	  supplementation	  
Although	  no	  significant	  reduction	  in	  PR	  isoforms	  was	  observed	  in	  explant	  culture	  versus	  t=0,	   it	  was	  
apparent	  that	  there	  was	  a	  degree	  of	  PR	  level	  reduction.	  For	  this	  reason,	  an	  experiment	  was	  designed	  
to	  determine	  whether	  PR	  levels	  could	  be	  better	  maintained	  in	  vitro	  by	  supplementation	  the	  culture	  
media	  with	  combinations	  of	  the	  following	  three	  agents:	  
i. Progesterone:	  1μM	  
ii. Foskolin	  (F):	  this	  is	  a	  cAMP	  agonist	  which	  our	  group	  has	  previously	  shown	  drives	  PR-­‐B	  (177).	  
A	   dose	   of	   10μM	   was	   chosen	   as	   unpublished	   data	   from	   a	   colleague	   in	   the	   group	  
demonstrated	  this	  to	  be	  a	  sufficient	  dose	  to	  maintain	  cAMP	  concentration	  at	  similar	  levels	  
to	  t=0.	  
iii. Estradiol	  (E2):	  this	  is	  known	  to	  stimulate	  PR	  expression	  (392);	  a	  dose	  of	  100nM	  was	  chosen	  
as	  this	  corresponds	  to	  levels	  at	  term	  (344).	  
	  
Fig.	   4.9.	   Myometrial	   explant	   progesterone	   receptor	   (PR)	   levels	   following	   culture	   media	   supplementation	  
with	  progesterone	  (P4),	  forskolin	  (F)	  and/or	  estradiol	  (E2).	  	  
Myometrial	   tissue	   obtained	   from	   term	   non-­‐labouring	   women	   was	   (i)	   snap	   frozen	   immediately	   (t=0)	   or	   (ii)	  
dissected	   into	   3x3x3mm3	   explants	   Explants	  were	   cultured	   in	  DMEM	   supplemented	  with	   ethanol	   and	  DMSO	  
vehicle,	  1μM	  progesterone	  (P4),	  10μM	  forkolin	  (F)	  –	  a	  cAMP	  agonist	  and/or	  100nM	  estradiol	  (E2)	  for	  30	  hours.	  
Protein	  was	  extracted	  and	  quantified.	  Western	  blotting	  was	  performed	  for	  A.	  progesterone	  receptor	  (PR).	   In	  
addition	  the	  PR-­‐A:PR-­‐B	  ratio	  was	  calculated	  (panel	  B).	  The	  data	  are	  expressed	  as	  mean	  +	  SEM.	  Normality	  was	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tested	  using	  a	  Shapiro-­‐Wilk	  test.	  	  Not	  normally	  distributed	  data	  were	  analysed	  by	  a	  Friedman	  test	  followed	  by	  
Dunn’s	  multiple	  comparison	  test.	  #,	  p<0.05	  versus	  t=0	  for	  PR-­‐B;	  ##=,	  p<0.001	  t=0	  for	  PR-­‐B;	  *,	  p<0.05	  versus	  t=0	  
for	  PR-­‐A;	  $,	  p<0.05	  versus	  t=0.	  n=8.	  
Compared	   to	   vehicle	   treatment	   alone,	   levels	   of	   both	   PR	   isoforms	  were	   not	   restored	   closer	   to	   t=0	  
when	   supplemented	   with	   various	   combinations	   of	   progesterone,	   forskolin	   or	   estradiol	   (Fig.	   4.9.).	  
Indeed,	  the	  PR-­‐A:PR-­‐B	  most	  closely	  resembled	  t=0	  after	  treatment	  with	  vehicle,	  progesterone	  alone	  
or	   estradiol	   alone.	   The	  decision	  not	   to	   supplement	   culture	  media	  with	   any	  hormones	   as	   standard	  
was	  taken	  on	  the	  basis	  of	   these	  results	  as	  well	  as	  the	  desire	  to	  remove	  any	  confounding	  agents	   in	  
our	  study	  of	  progesterone	  signalling	  in	  myometrial	  explants.	  	  	  
	  
4.2.8.	  Progesterone	  repression	  of	  IL-­‐1β-­‐driven	  COX-­‐2	  
Our	  group	  has	  previously	  demonstrated	  that	  a	  high	  dose	  of	  progesterone	  (10μM)	  is	  required	  to	  bring	  
about	   a	   significant	   reduction	   in	   IL-­‐1β-­‐driven	   COX-­‐2	   in	   primary	   cells.	   Having	   shown	   that	   the	   gene	  
expression	   profile	   of	   explants	   most	   closely	   resembles	   t=0,	   I	   proceeded	   to	   assess	   whether	  
functionally	  explants	  represented	  an	   in	  vitro	  model	  more	  closely	  resembling	  the	  in	  vivo	  state.	  Thus,	  
although	   the	   IC50	   of	   progesterone	   in	   myometrial	   explants	   was	   shown	   to	   10-­‐fold	   less	   at	   1μM,	   a	  
second	  experiment	  was	  carried	  out	  where,	  as	  previously,	  myometrial	  biopsies	  obtained	  at	  the	  time	  
of	  elective	  Caesarean	   section	  at	   term	  were	  divided	  as	   follows:	   (i)	   a	  portion	  was	   immediately	   snap	  
frozen	   (t=0),	   (ii)	   a	   second	   portion	   was	   finely	   dissected	   into	   myometrial	   explants,	   and	   (iii)	   the	  
remainder	  was	  digested	  in	  order	  to	  isolate	  the	  cells	  for	  primary	  culture.	  Explants	  and	  cells	  at	  passage	  
4	   were	   pre-­‐treated	   for	   6	   hours	   with	   ethanol	   vehicle,	   1μM	   progesterone	   or	   10μM	   progesterone	  
followed	  by	  24	  hours	  treatment	  with	  10ng/mL	  IL-­‐1β	  (Fig.	  4.10.).	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Figure	  4.10.	  Myometrial	  explants	  respond	  to	  1µM	  progesterone	  (P4)	  in	  paired	  biopsies	  whereas	  myometrial	  
cells	  do	  not.	  	  
Myometrial	  tissue	  obtained	  from	  term	  non-­‐labouring	  women	  was	  snap	  frozen,	  finely	  dissected	  into	  3x3x3mm3	  
explants	  or	  digested	  with	  a	  collagenase	  mixture	  to	  isolate	  cells	  for	  primary	  culture.	  Explants	  were	  immediately	  
pre-­‐treated	  for	  6	  hours	  with	  ethanol	  vehicle,	  1µM	  progesterone	  or	  10µM	  progesterone	  followed	  by	  a	  24	  hour	  
treatment	  with	  IL-­‐1β	  (10ng/mL).	  	  After	  incubation	  with	  1%	  DCC-­‐FCS	  overnight,	  primary	  cells	  at	  passage	  4	  were	  
pre-­‐treated	  for	  6	  hours	  with	  ethanol	  vehicle,	  1µM	  progesterone	  or	  10µM	  progesterone	  followed	  by	  a	  24	  hour	  
treatment	  with	  IL-­‐1β	  (10ng/mL).	  Protein	  was	  extracted	  and	  quantified.	  Western	  blotting	  for	  cyclooxygenase-­‐2	  
(COX-­‐2)	  was	   performed	   as	   described	   in	  Methods.	   A	   representative	  western	   blot	   is	   shown	   at	   the	   top	   of	   the	  
figure	  with	  densitometric	  analysis	  below.	  The	  data	  are	  expressed	  as	  mean	  +	  SEM.	  Normality	  was	  tested	  using	  a	  
Kolmogorov-­‐Smirnov	  test	   followed	  by	  comparison	  of	  control	  versus	   IL-­‐1β	  by	  Wilcoxon	  signed	  rank	  testing	  or	  
paired	   t	   testing	  depending	  on	   the	  data	  distribution;	  *,	  p<0.05	  versus	  control	   in	   that	  group;	  $,	  p<0.05	  versus	  
t=0.	   The	   IL-­‐1β,	   1µM	   P4	  &	   IL-­‐1β	   and	   10µM	   P4	  &	   IL-­‐1β	   conditions	   in	   each	   group	  were	   compared	   by	   ANOVA	  
followed	  by	  Bonferroni’s	  multiple	  comparison	  test;	  #,	  p<0.05	  versus	  IL-­‐1β	  in	  that	  group;	  ##,	  p<0.01	  versus	  IL-­‐1β	  
in	  that	  group.	  n=4-­‐8.	  
As	   expected	   from	   the	   microarray	   data,	   compared	   to	   t=0,	   basal	   COX-­‐2	   levels	   in	   explants	   were	  
significantly	   raised	   although	   this	   was	   not	   the	   case	   in	   cells.	   The	   addition	   of	   IL-­‐1β	   showed	   a	   trend	  
towards	   a	   greater	   increase	   in	   COX-­‐2	   in	   cells	   although	   this	   was	   not	   significant.	   Most	   importantly,	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these	  data	  serve	  to	  confirm	  previous	  data	  arising	  from	  non-­‐paired	  explant	  and	  cell	  experiments	  i.e.	  
that	  the	  IL-­‐1β-­‐induced	  increase	   in	  COX-­‐2	  was	  significantly	  down-­‐regulated	  by	  1μM	  progesterone	  in	  
explants	  whereas	  the	  minimum	  required	  dose	  to	  achieve	  a	  significant	  reduction	  in	  cells	  was	  10μM.	  	  
	  
4.2.9.	  Nuclear	  receptor	  antagonist	  studies	  
In	  order	  to	  establish	  which	  receptor	  progesterone	  signals	  via	  in	  myometrial	  explants,	  several	  nuclear	  
receptor	  antagonists	  were	  tested	  (Fig.	  4.11.).	  It	  was	  initially	  demonstrated	  that	  the	  mixed	  PR	  and	  GR	  
antagonist	  mifepristone	  (RU486)	  was	  able	  to	  reverse	  the	  anti-­‐inflammatory	  action	  of	  progesterone	  
on	   IL-­‐1β-­‐driven	   COX-­‐2	   (Fig.	   4.11A.).	   Other	   investigators	   have	   previously	   demonstrated	   that	  
onapristone	   (ZK299)	   at	   a	   concentration	   of	   1μM	   (393)	   specifically	   antagonises	   PR.	   These	   findings	  
were	  reproduced	  using	  the	  myometrial	  explant	  experimental	  model	  where	  1μM	  ZK299	  was	  able	  to	  
reverse	   the	   anti-­‐inflammatory	   action	   of	   progesterone,	   but	   not	   that	   of	   the	   GR-­‐agonist	  
dexamethasone	  (dex),	  suggesting	  that	  progesterone	  signals	  via	  PR	  in	  this	  system	  (Fig.	  4.11A.).	  
In	  an	  attempt	   to	  confirm	  these	   findings,	   several	  other	  antagonists	  were	  used.	  Firstly,	   the	  selective	  
progesterone	   receptor	   modulator	   ulipristal	   (UPA)	   was	   added.	   This	   drug	   has	   been	   shown	   to	   be	   a	  
potent	   antagonist	  of	   PR	  with,	   unlike	  RU486,	   little	   action	  on	  GR	  and	  other	   steroid	   receptors	   (394).	  
Following	  a	  literature	  review	  (395,	  396),	  three	  separate	  doses	  (0.1nM,	  10nM	  and	  1μM)	  were	  chosen	  
in	  order	  to	  cover	  a	  large	  concentration	  range.	  However,	  upon	  comparing	  the	  difference	  between	  IL-­‐
1β	   treatment	   and	   IL-­‐1β	   &	   steroid	   hormone	   treatment	   in	   the	   presence	   or	   absence	   of	   any	   UPA	  
concentration	  no	  reversal	  was	  observed	  in	  the	  action	  of	  either	  progesterone	  or	  dex	  (Fig.	  4.11B.).	  	  
Subsequently,	   SC51089	   was	   assessed	   as	   this	   has	   previously	   been	   shown	   to	   be	   a	   specific	   PR	  
antagonist	  at	  a	  concentration	  of	  10μM	  (397).	  Disappointingly,	  similar	  to	  UPA,	  the	  drug	  appeared	  to	  
have	  no	  effect	  on	  the	  anti-­‐inflammatory	  action	  of	  both	  progesterone	  and	  dex	  (Fig.	  4.11C.).	  	  
Finally,	  AL082D06	  (D06)	  was	  used	  as	  this	  has	  previously	  been	  shown	  to	  be	  a	  selective	  GR	  antagonist	  
in	  assays	  on	  cell	   lines	  (398,	  399).	  A	  dose	  of	  1μM	  of	  D06	  was	  chosen	  on	  the	  basis	  of	  reversal	  of	  the	  
dex	  effect	  	  in	  previously	  published	  work	  (398).	  D06	  was	  found	  to	  have	  no	  effect	  on	  progesterone	  or	  
dex	  signalling	  (Fig.	  4.11D).	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Figure	  4.11.	  Progesterone	  (P4)	  signals	  via	  the	  progesterone	  receptor	  (PR)	  in	  myometrial	  explants.	  	  
Myometrial	  tissue	  obtained	  from	  term	  non-­‐labouring	  women	  was	  finely	  dissected	  into	  3x3x3mm3	  explants	  and	  
immediately	  pre-­‐treated	   for	  6	  hours	  with	  ethanol	  ±	  DMSO	  vehicle,	  1µM	  progesterone,	  1µM	  dexamethasone	  
(dex),	  A.	  1µM	  RU486,	  1µM	  ZK299,	  B.	  0.1nM,	  10nM	  or	  1µM	  ulipristal,	  C.	  1µM	  SC51089	  or	  D.	  1µM	  AL082D06	  
(D06)	  	  followed	  by	  a	  24	  hour	  treatment	  with	  IL-­‐1β	  (10ng/mL).	  	  Protein	  was	  extracted	  and	  quantified.	  Western	  
blotting	  for	  cyclooxygenase-­‐2	  (COX-­‐2)	  was	  performed	  as	  described	  in	  Methods.	  A	  representative	  western	  blot	  
is	  shown	  at	  the	  top	  of	  the	  figure	  with	  densitometric	  analysis	  below.	  The	  data	  are	  expressed	  as	  mean	  +	  SEM.	  
The	   corresponding	  mean	  +	  SEM	  of	   the	  difference	   (Δ) between	   IL-­‐1β	   treatment	  and	   IL-­‐1β+steroid	  agonist	   is	  
also	  shown.	  Normality	  was	  tested	  using	  a	  Kolmogorov-­‐Smirnov	  for	  6	  replicates	  or	  a	  Shapiro-­‐Wilk	  test	  for	  more	  
than	   6	   replicates.	   The	   shaded	   groups	   were	   compared	   with	   a	   Friedman	   test	   followed	   by	   Dunn’s	   multiple	  
comparison	  test;	  $,	  p<0.05;	  $$,	  p<0.01.	  A	  Wilcoxon	  signed	  rank	  test	  was	  used	  for	  not	  normally	  distributed	  data	  
and	   a	   paired	   t	   test	   for	   normally	   distributed	   data.	   *,	   p<0.05	   versus	   control	   in	   that	   group;	   **,	   p<0.01	   versus	  
control	  in	  that	  group;	  #,	  p<0.05	  versus	  IL-­‐1β	  in	  that	  group;	  ##,	  p<0.01	  versus	  IL-­‐1β	  in	  that	  group;	  ###,	  p<0.001	  
versus	  IL-­‐1β	  in	  that	  group.	  n=3-­‐11.	  
	  
4.2.10.	  Progesterone	  action	  on	  transcription	  factors	  
The	   effect	   of	   IL-­‐1β	   on	   key	   intracellular	   mediators	   of	   inflammation	   was	   evaluated	   (Fig.	   4.12.)	  
demonstrating	   a	   significant	   increase	   in	   the	   phosphorylation	   of	   ERK	   and	   p38	   as	   well	   as	   the	  
downstream	   transcription	   targets	   c-­‐Jun	   and	   p65.	   Although	   a	   trend	   towards	   increased	  
phosphorylation	  levels	  of	  JNK	  and	  c-­‐Fos	  was	  seen,	  this	  was	  not	  significant.	  No	  significant	  change	  was	  
noted	  in	  total	  protein	  levels	  after	  IL-­‐1β	  treatment.	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Progesterone	   treatment	   alone	   did	   not	   drive	   phosphorylation	   of	   any	   of	   the	   MAPKs,	   nor	   the	  
transcription	  factors	  c-­‐Jun	  and	  p65.	  Interestingly,	  it	  did	  however	  increase	  the	  phosphorylation	  of	  c-­‐
Fos	  and	  reduced	  total	  p65	  levels	  (Fig.	  3.12.).	  
Pre-­‐treatment	  with	  progesterone	  followed	  by	  the	  addition	  of	   IL-­‐1β	   led	  to	  a	  significant	  reduction	   in	  
the	  IL-­‐1β-­‐driven	  phosphorylation	  of	  both	  p65	  and	  c-­‐Jun	  in	  association	  with	  a	  simultaneous	  reduction	  
in	  total	  levels	  of	  p65	  and	  c-­‐Jun.	  This	  was	  not	  associated	  with	  any	  alteration	  to	  the	  phosphorylation	  of	  
the	  MAPKs	  (Fig.	  4.12.).	  Furthermore	  MKP-­‐1	  and	  IκBα	  also	  did	  not	  appear	  to	  be	  implicated	  in	  the	  anti-­‐
inflammatory	  action	  of	  progesterone	  (Fig.	  4.12.).	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Figure	   4.12.	   Progesterone	   (P4)	   reduces	   the	   phosphorylation	   of	   pro-­‐inflammatory	   transcription	   factors	   in	  
myometrial	  explants.	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Myometrial	   tissue	   obtained	   from	   term	   non-­‐labouring	  women	  was	   finely	   dissected	   into	   3x3x3mm3	   explants.	  
These	  were	  immediately	  pre-­‐treated	  for	  6	  hours	  with	  ethanol	  vehicle	  or	  1µM	  progesterone	  followed	  by	  a	  30	  
minute	   treatment	   with	   IL-­‐1β	   (10ng/mL).	   	   Protein	   was	   extracted	   and	   quantified,	   and	   western	   blotting	   was	  
performed	   for	  A.	  ERK1/2,	  B.	  p38,	  C.	   JNK,	  D.	   c-­‐Jun,	  E.	   c-­‐Fos,	  F.	  MKP-­‐1,	  G.	  p65	  and	  H.	   IκBα	  was	  performed	  as	  
described	   in	  Methods.	  A	   representative	  Western	  blot	   is	   shown	  at	   the	   top	  of	  each	   figure	  with	  densitometric	  
analysis	  below.	  The	  data	  are	  normalised	  to	  control	  and	  expressed	  as	  mean	  +	  SEM.	  Normality	  was	  tested	  using	  
a	  Kolmogorov-­‐Smirnov	  for	  6	  replicates	  or	  a	  Shapiro-­‐Wilk	  test	  for	  more	  than	  6	  replicates.	  Wilcoxon	  signed	  rank	  
testing	  was	   used	   to	   compare	   between	   pairs;	   *,	   p<0.05	   versus	   control;	   **,	   p<0.01	   versus	   control;	   #,	   p<0.05	  
versus	  IL-­‐1β;	  ##,	  p<0.01	  versus	  IL-­‐1β.	  n=6-­‐8.	  Black	  bars:	  total	  (t)	  protein;	  clear	  bars:	  phosphorylated	  (p)	  protein.	  
	  
4.2.11.	  Progesterone	  action	  in	  the	  labouring	  myometrium	  
Myometrium	   was	   collected	   from	   women	   in	   term	   early	   (TEaL)	   and	   established	   (TesL)	   labour	  
undergoing	   an	   emergency	   Caesarean	   section	   in	   order	   to	   study	   the	   anti-­‐inflammatory	   action	   of	  
progesterone	  in	  labouring	  myometrial	  explants.	  Firstly,	  I	  sought	  to	  determine	  whether	  the	  action	  of	  
IL-­‐1β	  was	  altered	  by	   labour	   status	  by	  calculating	   the	  difference	   (delta,	  Δ)	   in	  COX-­‐2	   levels	  between	  
baseline	   (control)	   and	   IL-­‐1β	   treatment.	   No	   difference	   in	   IL-­‐1β-­‐driven	   COX-­‐2	   was	   identified	   (Fig.	  
4.13.).	  	  
	  
Figure	   4.13.	   The	   effect	   of	   IL-­‐1β	   on	   cyclooxygenase-­‐2	   (COX-­‐2)	   does	   not	   alter	   with	   labour	   status	   in	   the	  
myometrium.	  	  
Myometrial	  tissue	  obtained	  from	  women	  not	  in	  labour	  at	  term	  as	  well	  as	  in	  term	  early	  and	  established	  labour	  
was	  dissected	  into	  myometrial	  explants	  and	  treated	  for	  24	  hours	  with	  IL-­‐1β	  (10ng/mL).	  	  Protein	  was	  extracted,	  
quantified	  and	  western	  blotting	  for	  cyclooxygenase-­‐2	  (COX-­‐2)	  was	  performed.	  The	  data	  are	  expressed	  as	  mean	  
+	  SEM	  of	  the	  delta	  (Δ)	  between	  IL-­‐1β	  and	  control	  groups.	  Normality	  was	  tested	  using	  a	  Kolmogorov-­‐Smirnov	  
test	   followed	   by	   an	   ANOVA	   with	   Bonferroni’s	   multiple	   comparison	   test.	   n=6-­‐8.	   Labour	   status	   groups	   are	  
labelled	  as	  TNL	  (term	  no	  labour),	  TEaL	  (term	  early	  labour)	  and	  TEsL	  (term	  established	  labour).	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There	  was	  no	  evidence	  of	  progesterone	  treatment	  alone	  exerting	  pro-­‐inflammatory	  effects	  in	  terms	  
of	  COX-­‐2	  levels	  (Fig.	  4.14.).	  Furthermore,	  progesterone	  did	  not	  lose	  the	  ability	  to	  significantly	  reduce	  
the	  levels	  of	  IL-­‐1β-­‐driven	  COX-­‐2	  in	  both	  early	  and	  established	  labour	  at	  term	  (Fig.	  4.14.).	  	  
	  
Figure	  4.14.	  Progesterone	  (P4)	  maintains	  its	  anti-­‐inflammatory	  role	  throughout	  labour.	  	  
Myometrial	  tissue	  obtained	  from	  women	  in	  term	  A.	  early	  labour	  and	  B.	  established	  labour	  was	  finely	  dissected	  
into	   3x3x3mm3	   explants.	   These	   were	   immediately	   pre-­‐treated	   for	   6	   hours	   with	   ethanol	   vehicle	   or	   1µM	  
progesterone	   followed	  by	  a	  24	  hour	   treatment	  with	   IL-­‐1β	   (10ng/mL).	   	  Protein	  was	  extracted	  and	  quantified.	  
Western	   blotting	   for	   cyclooxygenase-­‐2	   (COX-­‐2)	   was	   performed	   as	   described	   in	  Methods.	   A	   representative	  
western	  blot	  is	  shown	  at	  the	  top	  of	  each	  figure	  with	  densitometric	  analysis	  below.	  The	  data	  are	  expressed	  as	  
mean	  +	  SEM.	  Normality	  was	   tested	  using	  a	  Shapiro-­‐Wilk	   test.	  A	  Wilcoxon	  signed	   rank	   test	  was	  used	   for	  not	  
normally	   distributed	   data	   and	   a	   paired	   t	   test	   for	   normally	   distributed	   data.	   **,	   p<0.01	   versus	   control;	   ***,	  
p<0.001	  versus	  control;	  #,	  p<0.05	  versus	  IL-­‐1β.	  n=8.	  
	  
On	  the	  basis	  of	  these	  findings,	  the	  action	  of	  progesterone	  in	  the	  setting	  of	  labour	  was	  further	  studied	  
by	   quantifying	   the	   levels	   of	   pro-­‐inflammatory	   chemokines	   and	   cytokines	   secreted	   in	   the	   tissue	  
culture	   media	   of	   explants.	   Term	   non-­‐labouring	   myometrium	   was	   used	   to	   identify	   cytokines	   and	  
chemokines	   fulfilling	   the	   following	   criteria:	   (i)	   IL-­‐1β-­‐driven	   and,	   (ii)	   significant	   reduction	   of	   IL-­‐1β	  
effect	  by	  progesterone.	   IL-­‐1α,	   IL-­‐1β,	  CCL2,	  CCL5,	  CCL20,	  CXCL1	  and	   ICAM	  were	  all	   IL-­‐1β-­‐driven	  but	  
this	   effect	   was	   not	   reduced	   by	   progesterone;	   CCL11	   was	   not	   detectable	   even	   when	   media	   was	  
assayed	  neat;	  LIF	  did	  fulfill	  both	  criteria	  but	   interestingly	  when	  media	  from	  labouring	  explants	  was	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assayed	   in	  a	   trial	  experiment,	   it	  was	  not	  detectable	  and	  hence	  was	  excluded	   from	  further	  analysis	  
(Fig.	  4.15.).	  	  
	  
Figure	  4.15.	  Chemokines/cytokines	  panel	  obtained	  from	  term	  non-­‐labouring	  myometrial	  explants.	  	  
The	  media	  from	  explant	  cultures	  obtained	  from	  patients	  at	  term	  non-­‐labouring	  women	  was	  used	  to	  run	  human	  
Bio-­‐Plex©	  ProTM	  chemokine/cytokine	  assays	  for	  A.	  IL-­‐1α,	  B.	  IL-­‐1β,	  C.	  CCL2,	  D.	  CCL5,	  E.	  CCL20,	  F.	  CXCL1,	  G.	  ICAM	  
and	  H.	  LIF	  as	  per	  the	  manufacturer’s	  protocol.	  Data	  were	  normalised	  to	  tissue	  weight.	  Normality	  was	  tested	  
using	  a	  Shapiro-­‐Wilk	  test.	  Wilcoxon	  matched	  pair	  testing	  was	  used	  for	  not	  normally	  distributed	  paired	  data	  and	  
paired	   t	   tests	   for	   normally	   distributed	   data.	   For	   comparisons	   to	   vehicle	   control,	   statistical	   significance	   is	  
indicated	  as	   follows:	  *,	  p<0.05;	  **,	  p<0.01;	  ***,	  p<0.001.	   For	   comparisons	   to	   IL-­‐1β,	   statistical	   significance	   is	  
indicated	  as	  follows:	  ###,	  p<0.001.	  n=10.	  	  
	  
CXCL2,	   IL-­‐6	  and	   IL-­‐8	   fulfilled	  both	   criteria	   and	  hence	  were	   chosen	   for	   further	  analysis	   in	   labouring	  
explants.	   	   No	   change	   to	   the	   delta	   between	   control	   and	   IL-­‐1β	   treated	   explants	   in	   the	   context	   of	  
labour	  was	  observed	  nor	  was	  there	  any	  difference	  after	  progesterone	  treatment	  alone.	  In	  addition,	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as	  with	   the	  COX-­‐2	   findings,	   progesterone	  maintained	   its	   ability	   to	   repress	   IL-­‐1β-­‐driven	  CXCL2,	   IL-­‐6	  
and	  IL-­‐8	  (Fig.	  4.16.).	  	  
	  
Figure	   4.16.	   Progesterone	   does	   not	   become	   pro-­‐inflammatory	   with	   labour	   onset	   and	   it	   reduces	   the	  
expression	  of	  proinflammatory	  cytokines/chemokines	  irrespective	  of	  labour	  status.	  	  
The	  media	  from	  explant	  cultures	  was	  used	  to	  run	  human	  Bio-­‐Plex©	  ProTM	  chemokine/cytokine	  assays	  for	  A,	  D,	  
G.	  CXCL2,	  B,	   E,	  H.	   IL-­‐6	   and	  C,	   F,	   I.	   IL-­‐8	   	   as	  per	   the	  manufacturer’s	  protocol.	  Data	  were	  normalised	   to	   tissue	  
weight.	  The	  data	  in	  panels	  A-­‐C	  are	  standardised	  to	  control	  and	  expressed	  as	  mean	  +	  SEM.	  The	  data	  in	  panels	  D-­‐
F	  are	  expressed	  as	  mean	  +	  SEM	  of	  the	  delta	  (Δ)	  between	  IL-­‐1β	  and	  control	  groups.	  The	  data	  in	  panels	  E-­‐I	  are	  
standardised	  to	  IL-­‐1β	  and	  expressed	  as	  mean	  +	  SEM.	  	  Normality	  was	  tested	  using	  a	  Kolmogorov-­‐Smirnov	  for	  6	  
replicates	   or	   a	   Shapiro-­‐Wilk	   test	   for	   more	   than	   6	   replicates.	   For	   groups	   of	   3,	   a	   Kruskal	   Wallis	   test	   was	  
performed	   followed	   by	   Dunn’s	   multiple	   comparison	   test	   for	   not	   normally	   distributed	   data	   and	   an	   ANOVA	  
followed	   by	   Bonferroni’s	   multiple	   comparison	   test	   was	   performed	   for	   normally	   distributed	   data.	   Wilcoxon	  
matched	   pair	   testing	   was	   used	   for	   not	   normally	   distributed	   paired	   data	   and	   paired	   t	   tests	   for	   normally	  
distributed	  data.	  For	  comparisons	  to	  vehicle	  control	  within	  matched	  labour	  status	  group,	  statistical	  significance	  
is	   indicated	  as	   follows:	  *,	  p<0.05;	  **,	  p<0.01;	  ***,	  p<0.001.	  For	  comparisons	  to	   IL-­‐1β	  within	  matched	   labour	  
status	   group,	   statistical	   significance	   is	   indicated	   as	   follows:	   #,	   p<	   0.05;	   	   ##,	   p<0.01;	   ###,	   p<0.001.	   n=6-­‐16.	  
Labour	  status	  groups	  are	  labelled	  as	  TNL	  (term	  no	  labour),	  TEaL	  (term	  early	  labour)	  and	  TEsL	  (term	  established	  
labour).	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4.2.12.	  Progesterone	  driven	  genes	  genes	  
As	  mentioned,	  a	  previous	  microarray	  on	  primary	  myometrial	  cells	   (NCBI	  GEO	  Accession	  GSE68171)	  
by	  the	  group	  identified	  HSD11B1	  and	  FKBP51	  as	  progesterone-­‐driven	  genes,	  although	  this	  could	  not	  
be	  replicated	  (Fig.	  4.2.).	  Treatment	  of	  explants	  with	  1μM	  led	  to	  a	  modest	  increase	  in	  both	  HSD11B1	  
and	  FKBP51	   RNA,	  which	  appeared	   to	  be	  more	  marked	   than	   cells	   from	  paired	  myometrial	  biopsies	  
(Fig	  4.17.).	  It	  was	  noted	  that	  RNA	  basal	  explant	  and	  primary	  cell	  levels	  of	  both	  HSD11B1	  and	  FKBP51	  
were	  significantly	  reduced	  compared	  to	  t=0.	  
However,	  this	  effect	  was	  even	  less	  marked	  at	  the	  protein	  level	  with	  the	  increase	  in	  the	  levels	  of	  both	  
HSD11B1	  and	  FKBP51	  not	  reaching	  statistical	  significance.	  Data	  from	  primary	  cells	  originating	  from	  
paired	  myometrial	  biopsies	  was	  not	  available	  at	  the	  protein	  level,	  but	  in	  light	  of	  the	  explant	  protein	  
findings,	  further	  experiments	  were	  not	  undertaken.	  	  
	  
Figure	  4.17.	  Explants	  show	  a	  moderate	  increase	  in	  progesterone-­‐driven	  genes.	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Myometrium	  obtained	  from	  term	  non-­‐labouring	  women	  was	  snap	  frozen	  (t=0),	  finely	  dissected	  into	  3x3x3mm3	  
explants	  or	  digested	  with	  a	   collagenase	  mixture	   to	   isolate	  myometrial	   cells.	   Explants	  were	   immediately	  pre-­‐
treated	   with	   ethanol	   vehicle	   or	   1µM	   progesterone	   for	   30	   hours.	   After	   incubation	   with	   1%	   DCC	   overnight,	  
myometrial	  cells	  at	  passage	  4	  were	  treated	  for	  30	  hours	  with	  ethanol	  vehicle	  or	  1µM	  progesterone.	  RNA	  was	  
extracted,	  cDNA	  synthesized	  and	  qPCR	  ran	  for	  A.	  HSD11B1	  and	  B.	  FKBP51.	  Protein	  from	  explants	  was	  extracted	  
and	   quantified,	   and	   western	   blotting	   for	   was	   performed	   for	   C.	  HSD11B1	   and	  D.	   FKBP51.	   A	   representative	  
western	  blot	   is	  shown	  at	   the	  top	  of	   the	   figure	  with	  densitometric	  analysis	  below.	  The	  data	  are	  expressed	  as	  
mean	  +	  SEM	   in	  panels	  A&B.	  For	  panels	  C&D,	  data	  are	  normalised	   to	  control	  and	  expressed	  as	  mean	  +	  SEM.	  
Normality	   was	   tested	   using	   a	   Shapiro-­‐Wilk	   test	   followed	   by	   comparison	   of	   pairs	   by	   Wilcoxon	   signed	   rank	  
testing	  or	  paired	  t	  testing	  depending	  on	  the	  data	  distribution;	  *,	  p<0.05	  versus	  control	  in	  that	  group;	  $,	  p<0.05	  
versus	  t=0;	  $$,	  p<0.01	  versus	  t=0.	  n=7-­‐9.	  
	  
Based	  on	  these	  findings,	  it	  was	  concluded	  that	  these	  may	  not	  in	  fact	  represent	  progesterone-­‐driven	  
genes	  as	  the	  data	  were	  established	  from	  cells	  which	  as	  has	  already	  been	  demonstrated	  express	  very	  
low	   PR	   levels.	   Having	   recognised	   this,	   it	   was	   decided	   to	   employ	   a	   novel	   approach	   in	   identifying	  
progesterone	  target	  genes	  by	  treating	  myometrial	  explants	  with	  the	  antiprogestin	  mifepristone.	  This	  
decision	  was	  taken	  with	  the	  aim	  of	  mitigating	  the	  repercussions	  of	  the	  non-­‐significant	  PR	  decrease	  in	  
this	  in	  vitro	  model.	  
	  
4.2.13.	  Mifepristone	  microarray	  and	  validation	  	  
On	   the	   basis	   of	   the	   murine	   mifepristone	   work,	   myometrial	   explants	   were	   treated	   with	   ethanol	  
vehicle	  or	  1μM	  RU486	  for	  9	  hours.	  Total	  RNA	  was	  extracted	  and	  microarray	  analysis	  was	  conducted.	  
Unexpectedly,	  as	  can	  be	  seen	  in	  the	  PCA	  plot,	  there	  was	  marked	  overlap	  between	  the	  two	  treatment	  
conditions	   (Fig.	  4.18.).	  A	  sources	  of	  variation	  graph	   further	  serves	   to	  highlight	   that	   treatment	  with	  
mifepristone	  did	  not	  contribute	  to	  significant	  variation	  compared	  to	  control	  (Fig.	  4.19.).	  Indeed,	  only	  
two	  genes	  matched	  the	  cut-­‐off	  criteria	  in	  terms	  of	  p-­‐value,	  FC	  and	  FDR:	  FXYD3	  and	  PPIAL4A.	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Figure	  4.18.	  PCA	  plot	  of	  vehicle	  and	  mifepristone	  (RU486)	  treated	  myometrial	  explants	  
Myometrial	   tissue	   obtained	   from	   term	   non-­‐labouring	   women	   was	   dissected	   into	   3x3x3mm3	   explants	   and	  
placed	   in	  DMEM.	  Explants	  were	   immediately	   treated	  with	  ethanol	   vehicle	  or	   1μM	  RU486	   for	   9	  hours.	   Total	  
RNA	  was	  extracted	  and	  whole-­‐genome	  transcriptome	  analysis	  was	  conducted	  by	  hybridisation	   to	  Affymetrix	  
Human	   Gene	   2.1	   ST	   array	   strips	   and	   analysed	   using	   Partek	   Genomics	   Suite	   6.6	   software.	   Differentially	  
expressed	  genes	  (DEG)	  were	  identified	  by	  two-­‐way	  ANOVA,	  and	  p-­‐values	  were	  adjusted	  using	  the	  FDR	  (false-­‐
discovery	   rate)	  method	   to	   correct	   for	  multiple	   comparisons.	  DEG	  were	   considered	   significant	   if	   p-­‐value	  was	  
p≤0.05	  at	  a	  fold	  change	  of	  >1.5	  with	  FDR	  <0.05.	  n=6.	  
	  
Figure	  4.19.	  Sources	  of	  variation	  for	  vehicle	  versus	  mifepristone	  treated	  myometrial	  explants	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The	  results	  were	  validated	  using	  quantitative	  RT-­‐PCR	  on	  a	  second	  set	  of	  myometrial	  explants	  treated	  
using	  the	  same	  protocol	  as	  the	  biopsies	  used	  in	  the	  microarray.	  The	  results	  demonstrated	  that	  only	  
PPIAL4A	   followed	  the	  same	  pattern	  for	  both	  quantitative	  RT-­‐PCR	  and	  microarray	  (Table	  4.2.).	  Data	  
was	  also	  normalised	  to	  18S	  rRNA	  with	  the	  same	  pattern	  observed	  for	  both	  genes	  as	  with	  GAPDH.	  
	  	  
Gene	  
symbol	  
Quantitative	  
RT-­‐PCR	   fold	  
change	  ± SEM	  
Quantitative	  
RT-­‐PCR	  
direction	   of	  
change	  
Microarray	  
fold	  change	  
Microarray	  
direction	   of	  
change	  ± SEM	  
FXYD3	   -­‐17.77	  ±	  0.04	   ↓ 1.56	  ±	  0.24	   ↑ 
PPIAL4A	   -­‐1.14	  ±	  0.05	   ↓ -­‐1.74	  ±	  0.23	   ↓ 
Table	  4.2.	  Quantitative	  RT-­‐PCR	  validation	  of	  mifepristone-­‐driven	  genes.	  	  	  
	  
4.3.	  Discussion	  
In	  this	  chapter,	  I	  set	  out	  to	  investigate	  whether	  myometrial	  explants	  constitute	  a	  superior	  model	  to	  
the	  existing	  in	  vitro	  models	  in	  the	  study	  of	  progesterone	  signalling.	  This	  was	  achieved	  both	  by	  direct	  
comparison	  of	  the	  available	  models	  but	  also	  additional	  profiling	  of	  other	  key	  characteristics	  including	  
cell	   type	   phenotyping	   and	   assessment	   of	   viability.	   I	   went	   on	   to	   investigate	   the	   anti-­‐inflammatory	  
action	  of	  progesterone	  both	  in	  non-­‐labouring	  and	  labouring	  myometrium.	  Finally,	  I	  investigated	  the	  
feasibility	  of	  using	  mifepristone	  as	  a	  means	  of	  further	  understanding	  progesterone	  action.	  	  
In	  summary,	  this	  study	  serves	  to	  establish	  myometrial	  explants	  as	  a	  superior	  model	  compared	  to	  cell	  
cultures	  for	  the	  study	  of	  progesterone	  signalling	  as	  demonstrated	  by	  the	  microarray	  study.	  Using	  this	  
model,	  progesterone	  has	  been	  shown	  to	  signal	  via	  PR	  to	  reduce	  the	  activation	  of	  p65	  and	  c-­‐Jun,	  via	  a	  
reduction	  in	  total	  protein	  levels.	  Further,	  the	  ability	  of	  progesterone	  to	  exert	  pro-­‐quiescent	  and	  anti-­‐
inflammatory	   effects	   was	   shown	   to	   be	   maintained	   with	   labour	   onset,	   hence	   raising	   interesting	  
questions	  regarding	  its	  mechanism	  of	  action.	  	  	  	  
	  
4.3.1.	  The	  myometrial	  explant	  model	  
The	   need	   for	   the	   identification	   of	   a	   superior	   model	   for	   the	   study	   of	   progesterone	   signalling	   was	  
identified	  based	  on	  observations	  in	  the	  literature	  (379,	  380)	  and	  supported	  by	  our	  preliminary	  data	  
demonstrating	   a	   significant	   reduction	   of	   PR	   isoforms	   in	   vitro	   and	   a	   moderate	   response	   of	  
progesterone-­‐driven	  genes	  to	  high	  progesterone	  doses.	  The	  data	  presented	  in	  this	  thesis	  show	  that,	  
of	  the	  three	  in	  vitro	  models,	  the	  myometrial	  explant	  gene	  expression	  profile	  most	  closely	  resembles	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the	   in	  vivo	   state	  of	   the	  myometrium.	  This	  can	  visually	  be	  seen	  by	  the	  proximity	  of	   the	  myometrial	  
explant	   group	   to	   t=0	   in	   the	   PCA	   plot.	   Additionally,	   it	   can	   be	   seen	   in	   the	   volcano	   plots	  where	   the	  
degree	  of	  spread,	  and	  hence	  deviation	  from	  t=0,	  is	  least	  for	  explants	  and	  most	  for	  hTERT-­‐HM.	  
For	   the	   microarray	   validation	   process	   via	   quantitative	   RT-­‐PCR,	   genes	   related	   to	   smooth	   muscle	  
phenotype	   and	   reproductive	   function	   were	   chosen.	   The	   expression	   of	   genes	   relating	   to	   smooth	  
muscle	  phenotype	  such	  as	  alpha	  smooth	  muscle	  actin	  (ACTA2)	  and	  myosin	  light	  chain	  kinase	  (MYLK)	  
were	  noted	  to	  most	  closely	  resemble	  t=0	  in	  explants.	  This	  was	  also	  the	  case	  for	  genes	  important	  in	  
reproductive	   function	   including	   progesterone	   receptor	   (PGR),	   connexin-­‐43	   (GJA1)	   and	   oxytocin	  
receptor	  (OXTR).	  	  Due	  to	  its	  importance,	  the	  PR	  findings	  were	  also	  confirmed	  at	  the	  protein	  level	  for	  
t=0,	   explants	   and	   primary	   cells.	   Additionally,	   due	   to	   its	   implication	   in	   progesterone	   signalling	   in	  
primary	  cells	  and	  the	  discrepancy	  in	  validation,	  GR	  was	  also	  studied	  in	  the	  protein	  level	  showing	  no	  
changes	  in	  levels	  across	  the	  groups.	  
PTGS2	   (COX-­‐2)	  was	   noted	   to	   be	  most	   up-­‐regulated	   in	   explants	  when	   compared	   to	   the	   other	   two	  
models	  and	  these	  findings	  were	  also	  confirmed	  at	  the	  protein	  level.	  However,	  for	  our	  experimental	  
model,	  once	   IL-­‐1β	  was	  added	  the	  basal	  COX-­‐2	   levels	  were	  negligible	  as	   the	   ratio	  of	   signal-­‐to-­‐noise	  
was	   calculated	   at	   17.7	   (400).	   Indeed,	   a	   degree	   of	   inflammation	  was	   noted	   in	   all	   three	  models	   as	  
exemplified	   by	   gene	   ontology	   analysis	   for	   the	   Venn	   diagram	   region	   with	   all	   models	   overlapping	  
(Appendix	  8),	  but	  also	  in	  the	  region	  of	  overlap	  between	  explants	  and	  primary	  cells	  (Appendix	  10)	  and	  
between	  explants	  and	  hTERT-­‐HM	  (Appendix	  12).	  This	  could	  be	  a	  reflection	  of	  the	  fact	  that	  because	  
explants	   and	   cells	   are	   cultured	   in	   nutrient	   rich	   media,	   the	   in	   vivo	   status	   cannot	   faithfully	   be	  
reproduced.	  	  
Given	  that	  DMEM	  is	  rich	   in	  glucose,	   it	  was	   interesting	  to	  note	  that	  glucose	  metabolism	  featured	  in	  
the	  region	  of	  genes	  uniquely	  up-­‐regulated	  in	  explants	  versus	  t=0.	  The	  presence	  of	  elevated	  levels	  of	  
lactate	  have	  previously	  been	  linked	  to	  dystocia	  (401)	  and	  hence	  this	  represents	  an	  area	  of	  possible	  
further	  study,	  where	  culture	  media	  is	  supplemented	  with	  more	  nutrients.	   	  The	  equivalent	  uniquely	  
upregulated	   regions	   for	   primary	   cells	   versus	   t=0	   included	   gene	   ontology	   categories	   such	   as	  
‘extracellular	  matrix’,	  ‘cell	  adhesion’	  and	  ‘gap	  junction’.	  Similarly,	  the	  same	  region	  for	  hTERT-­‐HM	  also	  
contained	  categories	  relating	  to	  tissue	  architecture	  and	  signalling	  such	  as	  ‘extracellular	  matrix’,	  ‘cell	  
adhesion’	   and	   ‘signal	   transduction’.	   These	   gene	   ontology	   categories	   serve	   to	   highlight	   the	  
fundamental	  differences	  between	  the	  in	  vivo	  status	  and	  cell	  culture	  models	  and	  how	  this	  is	  likely	  to	  
have	  a	  major	  impact	  on	  intracellular	  signalling.	  	  
A	  decline	  in	  PR	  levels	  in	  non-­‐pregnant	  myometrial	  explant	  culture	  models	  of	  approximately	  70%	  in	  8	  
hours	  has	  previously	  been	  reported	  (390).	  Similar	  findings	  were	  reported	  by	  other	  authors	  regarding	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PR	  levels	  in	  non-­‐pregnant	  myometrial	  explants,	  however	  interestingly	  they	  reported	  stable	  PR	  levels	  
over	  48	  hours	  in	  pregnant	  myometrial	  explants	  (386).	  Although	  the	  data	  presented	  here	  do	  show	  a	  
decline,	  this	  was	  not	  of	  the	  same	  magnitude.	  Similarly	  to	  previously	  published	  data	  (390),	  estradiol	  
and/or	   progesterone	   supplementation	   failed	   to	   rescue	   PR	   levels	   independently	   nor	   did	   the	  
introduction	  of	  forskolin.	  A	  microarray	  study	  also	  using	  non-­‐pregnant	  myometrium,	  in	  which	  tissue	  
was	  compared	  to	  passage	  0	  and	  passage	  3	  primary	  cells,	  (380)	  reported	  no	  significant	  changes	  in	  PR	  
levels	  although	  with	  the	  major	  caveat	  of	  levels	  being	  universally	  very	  low.	  Furthermore,	  quantitative	  
RT-­‐PCR	   validation	   reported	   contradictory	   findings	   of	   a	   significant	   reduction	   in	   PR	   levels	   between	  
tissue	  and	  both	  passage	  0	  and	  3	  of	  primary	  cells.	  	  
Indeed,	  this	  is	  the	  first	  gene	  expression	  analysis	  comparing	  pregnant	  myometrium	  at	  t=0	  to	  matched	  
explants	  and	  primary	  cell	  cultures	  as	  well	  as	  the	  hTERT-­‐HM	  cell	  line.	  One	  microarray	  study	  which	  did	  
use	  pregnant	  myometrium	  divided	  into	  explants	  compared	  gene	  expression	  profiles	  between	  control	  
and	  progestin	   treatment	   (388)	  and	  hence	  cannot	  be	  meaningfully	   compared	   to	  our	   study.	   	   Similar	  
microarray	   studies	  have	  been	  carried	  out	  using	  primary	  cells	  where	  comparisons	  have	  been	  made	  
between	   untreated	   cells	   and	   progestin	   treatment	   (402,	   403).	   It	   is	   not	   possible	   to	   make	   any	  
meaningful	   comparisons	   between	   such	   studies	   and	   our	   own.	   Other	   authors	   (6,	   264,	   265)	   have	  
sought	   to	   identify	   changes	   in	   gene	   expression	   in	   the	  myometrium	   before	   and	   after	   the	   onset	   of	  
labour.	   They	   have	   reported	   significant	   changes	   in	   gene	   expression	   profiles	   and	   this	   raises	   the	  
question	   as	   to	  whether	   these	   changes	   are	  maintained	   in	   vitro	   during	   explant	   culture.	   	   As	   part	   of	  
future	   studies,	   it	  would	   be	   interesting	   to	   carry	   out	   a	   gene	   expression	   study	   comparing	   t=0	   tissue	  
from	  non-­‐labouring	  and	  labouring	  patients	  to	  that	  of	  matched	  explants	  in	  order	  to	  demonstrate	  that	  
there’s	  no	  loss	  of	  phenotype	  in	  vitro.	  	  
Explants	   are	   comprised	   of	   myometrial	   smooth	   muscle	   cells,	   vascular	   smooth	   muscle	   cells,	  
fibroblasts,	   stromal	   fibroblasts,	   endothelial	   cells	   and	   blood	   cells.	   Immunohistochemical	   staining	  
confirmed	   smooth	   muscle	   cells	   made	   up	   the	   majority	   of	   the	   explant.	   However	   in	   the	   study	   of	  
parturition,	  one	  should	  perhaps	  not	  aim	  to	  study	  a	  particular	  cell	  type,	  as	  with	  cell	  culture	  systems,	  
but	  the	  entire	  milieu	  as	  this	  represents	  the	  in	  vivo	  status	  more	  closely.	  	  
There	  are	  few	  reports	  myometrial	  explant	  viability	   in	  the	   literature	  and	  these	  data	  are	  not	  directly	  
comparable	  to	  those	  presented	  here	  (387,	  391).	  The	  data	  reported	  here	  are	  however	  comparable	  to	  
lung	  explants	  cultured	  for	  50	  hours	  (382).	  In	  addition,	  data	  by	  a	  colleague	  in	  the	  group	  demonstrate	  
that	   myometrial	   strips,	   which	   are	   tissue	   pieces	   slightly	   larger	   than	   explants,	   contract	   both	  
spontaneously	   and	   after	   oxytocin	   stimulation	   throughout	   the	   experimental	   period	   used	   for	   this	  
work.	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4.3.2.	  Progesterone	  signalling	  in	  myometrial	  explants	  	  
In	  order	  to	  ensure	  changes	   in	  progesterone	  signalling	  were	  sensitively	   identified,	  the	  EC50	  of	   IL-­‐1β	  
(10ng/mL)	  and	   IC50	  of	  progesterone	  (1μM)	  were	  defined	   in	  myometrial	  explants.	   It	   is	  perhaps	  not	  
surprising	   to	   note	   that	   the	   EC50	   of	   IL-­‐1β	   is	   higher	   compared	   to	   previously	   published	   data	   from	  
primary	  myometrial	   cell	   cultures	   (404).	   Indeed,	   the	  action	  of	   IL-­‐1β	  was	  more	  marked	   in	   cells	   than	  
explants.	  It	  could	  be	  speculated	  that	  the	  difference	  in	  EC50	  and	  primary	  cell	  sensitivity	  to	  IL-­‐1β	  is	  due	  
to	  the	  difference	  in	  cellular	  organisation	  of	  a	  complex	  tissue	  comprised	  of	  multiple	  cell	  types	  versus	  
a	   simple	   monolayer	   of	   smooth	   muscle	   cells.	   However,	   no	   evidence	   of	   increased	   progesterone	  
sensitivity	   was	   shown	   in	   primary	   cells	   suggesting	   that	   the	   sensitivity	   of	   each	   model	   to	   various	  
treatments	  is	  not	  simply	  reliant	  upon	  architecture.	  	  
I	   then	   went	   on	   to	   confirm	   that	   in	   experiments	   arising	   from	   the	   same	   myometrial	   biopsy,	   the	  
minimum	   dose	   progesterone	   to	   significantly	   reduce	   IL-­‐1β-­‐driven	   COX-­‐2	   was	   1μM	   in	   explants	   and	  
10μM	  in	  primary	  cells.	   Interestingly,	   the	  anti-­‐inflammatory	  action	  of	  progesterone	  was	  maintained	  
even	  though	  there	  was	  a	  shift	  towards	  PR-­‐A	  dominance,	  which	  other	  groups	  have	  associated	  with	  an	  
inflammatory	  phenotype	   (141).	   Indeed,	  an	   in	  vivo	  study	  showed	  that	  raised	  PR-­‐A	  expression	   levels	  
do	  not	  affect	  reproductive	  function	  in	  mice	  (405).	  
The	   nuclear	   receptor	   antagonist	   studies	   were	   hampered	   by	   a	   lack	   of	   specific	   nuclear	   receptor	  
antagonists.	  ZK299	  has	  previously	  been	  shown	  to	  have	  reduced	  antiglucocorticoid	  activity	  (367)	  and	  
unlike	  RU486,	  it	  does	  not	  promote	  PR	  dimerisation	  (406,	  407).	  Even	  though	  the	  effect	  was	  marginal,	  
similarly	   to	   previous	   studies	   (393),	   1μM	   ZK299	   reversed	   the	   progesterone	   action	   but	   not	   that	   of	  
dexamethasone	  suggesting	  that	  progesterone	  signals	  via	  PR	  in	  myometrial	  explants.	  However	  these	  
effects	   were	   not	   confirmed	   by	   the	   use	   the	   PR	   antagonists	   UPA	   and	   SC51089	   as	   neither	   had	   any	  
impact	   on	   progesterone	   or	   dexamethasone	   signalling.	   Similarly	   the	   GR	   antagonist	   D06	   failed	   to	  
reverse	   dexamethasone	   and	   progesterone	   signalling.	   An	   alternative	   way	   to	   confirm	   the	   findings	  
presented	  here	  would	  be	  the	  use	  of	  siRNA	  technology	  to	  silence	  gene	  expression	  in	  explants.	  In	  vivo	  
delivery	   of	   siRNA	   to	   muscle	   tissue	   has	   been	   previously	   been	   demonstrated	   via	   hydrodynamic	  
injection	  (408),	  electroporation	  (409,	  410)	  or	  lentiviral	  vector	  (411).	  	  
Regarding	   progesterone	   signalling	   after	   binding	   to	   PR,	   the	   data	   presented	   here	   is	   consistent	  with	  
previous	  reports	  in	  the	  literature	  in	  terms	  of	  activation	  of	  MAPKs	  (ERK1/2,	  p38	  but	  not	  JNK),	  NF-­‐κB	  
and	  AP-­‐1	  (120,	  140,	  145,	  366).	   In	  support	  of	  group	  findings	  in	  primary	  cells	  (145),	  no	  evidence	  was	  
found	   to	   support	   a	   role	   for	   IκBα	   in	   the	   anti-­‐inflammatory	   action	   of	   progesterone	   in	   myometrial	  
explants,	  which	  has	  previously	  been	  reported	  by	  other	  researchers	  using	  hTERT-­‐HM	  (140).	  However,	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in	   contrast	   to	   group	   findings,	   MKP-­‐1	   did	   not	   appear	   to	   be	   involved	   in	   the	   reduction	   of	   c-­‐Jun	  
phosphorylation	   as	   previously	   reported	   by	   the	   group	   in	   primary	   cells	   (145).	   The	   presence	   of	  
progesterone	   reduced	   total	   p65	   levels	   independent	   of	   the	   presence	   of	   IL-­‐1β.	   In	   contrast,	   pre-­‐
treatment	   with	   progesterone	   significantly	   reduced	   total	   IL-­‐1β-­‐driven	   c-­‐Jun	   levels	   even	   though	   (i)	  
progesterone	  did	  not	  reduce	  basal	  c-­‐Jun	  levels	  and	  (ii)	  IL-­‐1β	  did	  not	  drive	  c-­‐Jun	  levels.	  It	  is	  difficult	  to	  
account	   for	   this	  observation	  however	   it	  may	  be	   the	   trend	  of	   IL-­‐1β-­‐driven	   c-­‐Jun	  up-­‐regulation	   is	   in	  
fact	  significant	  if	  the	  n	  number	  were	  further	  increased.	  	  
In	   contrast	   to	   our	   data,	   a	   study	   on	   the	   tissue	   level	   reported	   a	   rise	   in	   total	   c-­‐Fos	   levels	  with	   term	  
labour	  onset	  with	  no	  changes	  in	  c-­‐Jun	  levels	  (270).	  Indeed,	  we	  found	  that	  progesterone	  drove	  c-­‐Fos	  
phosphorylation.	  This	  finding	  may	  reflect	  the	  fact	  that	  the	  in	  vitro	   inflammatory	  stimulus,	  i.e.	  IL-­‐1β,	  
does	  not	  faithfully	  reproduce	  the	  labouring	  phenotype.	  	  
The	  data	  presented	  here	  demonstrate	  that	  progesterone,	  at	  least	  in	  myometrial	  explants,	  does	  not	  
lose	  its	  ability	  to	  repress	  inflammation	  even	  in	  the	  context	  of	  labour	  in	  terms	  of	  COX-­‐2,	  CXCL2,	  IL-­‐6	  
and	   IL-­‐8.	   Although	   these	   data	   should	   not	   hastily	   be	   extrapolated	   to	   the	   in	   vivo	   situation,	   as	   a	  
confirmation	  of	  maintenance	  of	  the	  labouring	  phenotype	  in	  explants	  has	  not	  been	  proven,	  they	  raise	  
an	   interesting	   question	   regarding	   the	   significance	   of	   the	   anti-­‐inflammatory	   properties	   of	  
progesterone.	   The	   possibility	   of	   a	   loss	   of	   the	   anti-­‐inflammatory	   action	   of	   progesterone	   on	   other	  
inflammatory	  markers	  not	  identified	  here	  or	  indeed	  other	  non-­‐inflammation	  progesterone-­‐mediated	  
functions	   remains.	   Another	   study	   showed	   no	   effect	   of	   progesterone	   treatment	   on	   baseline	   pro-­‐
inflammatory	  cytokine	  release	   in	  myometrial	  explants	  originating	  from	  term	  non-­‐labouring	  women	  
(391).	   However,	   this	   work	   was	   performed	   on	   myometrium	   originating	   from	   twin	   pregnancies	   in	  
which	  progesterone	  is	  known	  to	  be	  ineffective	  (412).	  
It	   was	   noted	   with	   interest	   that	   even	   though	   CCL11	   was	   readily	   detectable	   in	   non-­‐labouring	  
myometrium,	   levels	   were	   below	   the	   limit	   of	   detection	   in	   labouring	   myometrium.	   CCL11	   is	   an	  
eosinophil	   chemoattractant,	   which	   has	   been	   shown	   to	   be	   up-­‐regulated,	   at	   the	   RNA	   level,	   in	   the	  
cervix	  of	   labouring	  mice	   (413).	  This	  may	   represent	  an	  area	   for	   further	   study	  although,	   if	   anything,	  
they	  appear	  to	  contradict	  the	  inflammatory	  phenotype	  associated	  with	  labour.	  	  
The	   mifepristone	   microarray	   was	   performed	   in	   order	   to	   identify	   mifepristone-­‐driven	   genes	   and	  
hence	  progesterone-­‐antagonised	  genes,	  with	  the	  ultimate	  aim	  of	  better	  understanding	  progesterone	  
signalling.	  However,	  mifepristone	  appeared	  to	  have	  a	  virtually	  no	  effect	  in	  terms	  of	  gene	  expression	  
on	   myometrial	   explants	   derived	   from	   non-­‐labouring	   patients.	   Only	   two	   genes	   fulfilled	   the	   DEG	  
criteria	   of	  which	   only	   one,	  PPIAL4A	   –	   a	   gene	   encoding	   a	   protein	   implicated	   in	   the	   acceleration	  of	  
protein	   folding,	   was	   validated	   by	   quantitative	   RT-­‐PCR.	   Data	   from	   animals	   with	   no	   absolute	   pre-­‐
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labour	   drop	   in	   progesterone	   levels	   suggest	   that	   the	   target	   organ	   of	   mifepristone	   is	   in	   fact	   the	  
myometrium,	   as	   it	   increases	   its	   sensitivity	   to	   uterotonics	   (414).	   However,	   based	   on	   the	   data	  
presented	   here,	   the	   possibility	   is	   raised	   that	   the	   myometrium	   is	   in	   fact	   not	   a	   direct	   target	   of	  
mifepristone.	   Instead	   it	   may	   be	   that	   its	   sensitivity	   to	   oxytocin	   and	   prostaglandins	   is	   indirectly	  
increased	  after	  mifepristone	  treatment.	  	  
In	  the	  only	  other	  study	  reported	  in	  the	  literature	  in	  which	  myometrial	  explants	  were	  used	  to	  identify	  
progesterone-­‐regulated	   genes,	   100nM	   medroxyprogesterone	   acetate	   (MPA)	   was	   used	   as	   the	  
progestin	  of	   choice	   (388).	   Frustratingly,	   at	   that	  dose,	  MPA	  has	  agonist	   activity	  not	  only	  on	  PR	  but	  
also	   GR	   as	  well	   as	   the	   androgen	   receptor	   hence	  making	   it	   difficult	   to	   reach	   accurate	   conclusions	  
relating	   to	   progesterone	   action	   (415).	   Nevertheless,	   the	   authors	   of	   the	   myometrial	   explant	  
microarray	  reported	  that	  MPA	  treatment	  led	  to	  down-­‐regulation	  of	  genes	  relating	  to	  inflammatory	  
response,	  growth	  factor	  activity	  and	  cytokine	  activity	  (388).	  The	  labouring	  explant	  data	  presented	  in	  
this	   chapter	   raise	   questions	   regarding	   the	   importance	   of	   the	   anti-­‐inflammatory	   action	   of	  
progesterone,	  but	  the	  earlier	  paper	  identified	  cytokines	  not	  studied	  closely	  in	  this	  chapter	  such	  as	  IL-­‐
11	  and	  IL-­‐24.	  	  
	  
4.3.3.	  Summary	  
The	   data	   presented	   in	   this	   chapter	   offer	   some	   insight	   into	   progesterone	   signalling	   in	  myometrial	  
explants,	   an	   in	   vitro	   model	   which	   most	   closely	   resembles	   the	   in	   vivo	   state.	   However,	   important	  
questions	   are	   raised	   regarding	   how	   progesterone	   action	  may	   be	  withdrawn	  with	   labour	   onset	   as	  
there	   is	   no	   loss	   of	   the	   anti-­‐inflammatory	   and	   pro-­‐quiescent	   action	   of	   progesterone	   with	   labour	  
onset.	  In	  addition,	  the	  data	  raise	  an	  important	  question	  regarding	  the	  target	  organ(s)	  of	  mifepristone	  
action	  and	  highlight	  the	  need	  for	  further	  studies	  in	  this	  area.	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CHAPTER	  5:	  FUNCTIONAL	  PROGESTERONE	  WITHDRAWAL	  IN	  HUMAN	  LABOUR	  
	  
5.1	  Introduction	  	  
Unlike	   in	   animals,	   progesterone	   (P4)	   levels	   do	  not	   fall	   prior	   to	   labour	   onset	   in	   humans	   (179-­‐181).	  
Nevertheless,	   if	   progesterone	  action	   is	   blocked	  by	  mifepristone	   (RU486)	   labour	   ensues	   (123).	   This	  
has	  led	  to	  the	  hypothesis	  that	  a	  functional	  progesterone	  withdrawal	  must	  be	  taking	  place	  with	  the	  
onset	  of	  labour	  and	  many	  theories	  have	  been	  put	  forward	  to	  account	  for	  this	  phenomenon.	  	  
	  
5.1.1.	  Myometrial	  hormone	  levels	  
Although	  systemic	  progesterone	  levels	  do	  not	  decline	  in	  humans	  prior	  to	  parturition,	  it	  is	  proposed	  
that	  local	  myometrial	  levels	  may	  do	  so.	  	  Indeed	  a	  down-­‐regulation	  in	  the	  progesterone-­‐synthesising	  
enzyme	  17β-­‐hydroxysteroid	  dehydrogenase	  has	  been	  identified	  in	  the	  context	  of	  human	  parturition	  
(210),	   in	   association	   with	   a	   concurrent	   accumulation	   of	   progesterone	   metabolites	   (207-­‐209).	  
Further,	   it	  has	  been	  reported	  that	  oestrogen,	   including	  estradiol	   (E2)	  and	  estriol,	   levels	   increase	  at	  
the	  time	  of	   labour	  onset	  (416,	  417)	  along	  with	  increased	  oestrogen	  receptor	  activity	  (90,	  196,	  387,	  
418).	  It	  has	  been	  proposed	  that	  the	  net	  effect	  of	  the	  changes	  in	  these	  hormones	  is	  to	  cause	  uterine	  
activation	  and	  increased	  contractility.	  	  
	  
5.1.2.	  Progesterone	  receptor	  isoforms	  
The	  action	  of	  progesterone	  is	  understood	  to	  be	  mediated	  by	  its	  cognate	  receptor,	  PR,	  which	  acts	  as	  a	  
transcription	   factor	   upon	   ligand	   binding.	   PR	   is	   comprised	   of	   two	   principal	   isoforms:	   PR-­‐B	   which	  
mediates	  progesterone	  action	  and	  PR-­‐A	  which	  antagonises	  it.	  Indeed,	  a	  switch	  from	  PR-­‐B	  dominance	  
to	   PR-­‐A	   dominance	   is	   one	   of	   the	   proposed	   mechanisms	   underlying	   functional	   progesterone	  
withdrawal	  in	  human	  labour	  (117,	  141).	  	  
	  
5.1.3.	  Progesterone	  receptor	  chaperones,	  co-­‐chaperones	  and	  co-­‐regulators	  
PR,	  both	  in	  its	  liganded	  and	  unliganded	  state,	  does	  not	  exist	  in	  isolation,	  but	  rather	  is	  associated	  with	  
a	   complex	   network	   of	   proteins,	   including	   co-­‐regulators	   and	   chaperones,	   which	   are	   capable	   of	  
influencing	  its	  function.	  Reduced	  PR	  binding	  to	  its	  response	  element	  has	  been	  documented	  at	  labour	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onset	   hence	   potentially	   implicating	   co-­‐regulator	   and	   chaperone	   molecules	   in	   functional	  
progesterone	  withdrawal	  (200).	  
5.1.3.1.	  Chaperones	  and	  Co-­‐chaperones	  
Chaperone	   proteins,	   including	   heat	   shock	   protein	   70	   (HSP70)	   and	   heat	   shock	   protein	   90	   (HSP90),	  
play	  a	  crucial	  role	  in	  nuclear	  receptor	  protein	  folding	  in	  order	  to	  ensure	  it	  is	  capable	  of	  binding	  to	  its	  
ligand	  (94,	  97,	  419).	  Co-­‐chaperone	  is	  the	  term	  used	  to	  describe	  a	  protein	  that	  can	  become	  associated	  
with	   chaperones	   and	   it	   is	   interesting	   to	   note	   that	   their	   presence	   is	   not	   essential	   for	   chaperone	  
interaction	  with	  nuclear	  receptors	  (94).	  FK506-­‐binding	  protein	  51	  (FKBP51)	  is	  one	  such	  co-­‐chaperone	  
which	   is	  known	  to	   interact	  with	  HSP90	   (420).	  FKBP51,	  which	  has	  been	  shown	  by	   this	  group	   	   (402)	  
and	  others	  (421)	  to	  be	  progesterone-­‐driven,	  reduces	  nuclear	  receptor	  activity	  and	  it	  has	  thus	  been	  
proposed	  that	  its	  function	  relates	  to	  negative	  feedback	  of	  receptor	  signalling	  (99).	  
5.1.3.2.	  Co-­‐regulators	  
Over	  350	   co-­‐regulators	  have	  been	   identified	   to	  date	  and	   it	   has	  been	   recognised	   that	   they	   show	  a	  
degree	  of	   redundancy,	  which	  may	  be	   a	   reflection	  of	   their	   tissue-­‐specific	   and	   gene-­‐specific	   actions	  
(106,	   422).	   Disruption	   in	   co-­‐regulator	   expression	   has	   been	   associated	   with	   pathology	   including	  
breast	   and	   prostate	   cancers	   (423).	   In	   the	   field	   of	   human	   parturition,	   it	   has	   been	   proposed	   that	  
changes	   in	  co-­‐regulator	   levels	  may	  represent	  a	  mechanism	  for	   functional	  progesterone	  withdrawal	  
(12,	  90).	  	  
Co-­‐regulators	   are	   non-­‐DNA-­‐binding	   proteins	   which	   are	   divided	   into	   two	   categories:	   co-­‐activators,	  
which	   interact	   with	   liganded	   nuclear	   receptors	   to	   enhance	   gene	   transcription;	   and	   co-­‐repressors,	  
which	   usually	   interact	   with	   unliganded	   nuclear	   receptors	   to	   reduce	   transcription	   (101).	   It	   should	  
however	   be	   noted	   that	   cases	   have	   been	   reported	   where	   co-­‐activators	   act	   to	   reduce	   gene	  
transcription	  (113)	  and	  conversely,	  co-­‐repressors	  enhance	  gene	  transcription	  (116).	  
Steroid	  receptor	  co-­‐activators	  (SRC)	  1,	  2	  and	  3	  make	  up	  the	  p160	  co-­‐activator	  family	  (423).	  They	  play	  
a	  role	  in	  recruiting	  other	  co-­‐regulators	  to	  the	  PR	  complex,	  thence	  facilitating	  chromatin	  remodeling	  
and	  recruitment	  of	  the	  transcription	  apparatus	  (423,	  424).	  In	  vitro	  studies	  have	  shown	  that	  PR-­‐B	  has	  
a	  higher	  binding	  affinity	  for	  SRC1	  and	  SRC2	  compared	  to	  PR-­‐A	  (112).	  
Nuclear	   receptor	   co-­‐repressor	   (NCoR)	   and	   silencing	   mediator	   for	   retinoid	   or	   thyroid	   hormone	  
(SMRT)	  represent	  the	  principal	  co-­‐repressors	  and	  it	  has	  been	  proposed	  that	  they	  have	  no	  role	  in	  PR	  
physiology	   (106).	   Nevertheless,	   they	   are	   both	   detectable	   at	   least	   on	   the	   messenger	   level	   in	   the	  
myometrium	  (425)	  and	  SMRT	  has	  been	  shown	  to	  preferentially	  associate	  with	  PR-­‐A	  and	  not	  PR-­‐B	  in	  
cell	  lines	  (112).	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5.1.4.	  Myometrial	  tissue	  bank	  
The	   research	   group	   has	   collected	   a	   large	   bank	   of	   myometrial	   tissue	   from	   women	   at	   different	  
gestations	   as	  well	   as	  different	   stages	  of	   labour	   (both	  at	   term	  and	  preterm).	   The	  aim	  of	   this	   study	  
was,	   using	   the	   tissue	   bank,	   to	   identify	   whether	   levels	   of	   local	   hormones,	   nuclear	   receptors	   and	  
various	  co-­‐regulators,	  chaperones	  or	  co-­‐chaperones	  varied	  at	  different	  stages	  of	  labour.	  	  
	  
5.2	  Results	  
	  
5.2.1.	  Demographic	  Data	  
In	   order	   to	   define	   the	   expression	   patterns	   of	   co-­‐regulators,	   chaperones	   and	   co-­‐chaperones,	   the	  
tissue	  bank	  was	  divided	  broadly	  into	  two	  groups:	  
1. Term	  labour:	  the	  aim	  was	  to	  define	  changes	  in	  expression	  patterns	  with	  advancing	  gestation	  
and	   the	   onset	   of	   term	   labour.	   This	   study	   was	   comprised	   of	   the	   following	   four	   groups:	  
preterm	   no	   labour,	   term	   no	   labour,	   term	   early	   labour	   and	   term	   established	   labour.	   The	  
demographic	  data	  for	  these	  groups	  are	  shown	  in	  Table	  5.1.	  
2. Preterm	   labour:	   the	   aim	   was	   to	   define	   changes	   in	   expression	   patterns	   in	   the	   context	   of	  
preterm	  labour	  arising	  due	  to	  specific	  pathology.	  This	  study	  was	  comprised	  of	  the	  following	  
groups:	   preterm	   no	   labour,	   idiopathic	   preterm	   labour,	   preterm	   labour	   secondary	   to	  
chorioamnionitis,	   preterm	   twin	   gestations	   not	   in	   labour	   and	   preterm	   twin	   gestations	   in	  
labour.	  The	  demographic	  data	  for	  these	  groups	  are	  shown	  in	  Table	  5.2.	  
	  
 PTNL TNL TEaL TEsL 
Number of biopsies 18 17 18 18 
Maternal age 35.06 ± 1.73 32.94 ± 1.16 34.61 ± 0.73 34.50 ± 0.93  
Gestational age 30.84 ± 0.68 38.96 ± 0.17 38.65 ± 0.29 39.33 ± 0.26 
BMI 27.39 ± 1.10 23.59 ± 0.27 24.61 ± 0.48 22.89 ± 0.88 
Table	  5.1.	  Demographic	  data	  for	  comparison	  of	  preterm	  no	  labour	  (PTNL),	  term	  no	  labour	  (TNL),	  term	  early	  
labour	  (TEaL)	  and	  term	  established	  labour	  (TEsL)	  patients.	  Data	  are	  expressed	  as	  mean	  +	  SEM.	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 PTNL IPTL PTLC PTTWNL PTTWL 
Number of biopsies 17 17 12 10 12 
Maternal age 34.50 ± 1.87 33.77 ± 1.46 33.42 ± 1.74 34.90 ± 1.25   35.17 ± 2.45 
Gestational age 30.35 ± 0.75 35.04 ± 0.59 29.58 ± 0.83 35.60 ± 0.42 34.13 ± 0.42 
BMI 26.86 ± 1.31 24.93 ± 1.39 24.93 ± 1.14 22.00 ± 1.00  22.75 ± 1.59 
Table	  5.2.	  Demographic	  data	  for	  comparison	  of	  preterm	  no	  labour	  (PTNL),	  idiopathic	  preterm	  labour	  (IPTL),	  
preterm	   labour	  secondary	   to	  chorioamnionitis	   (PTLC),	  preterm	  twins	  not	   in	   labour	   (PTTWNL)	  and	  preterm	  
twins	  in	  labour	  (PTTWL).	  Data	  are	  expressed	  as	  mean	  +	  SEM.	  
	  
5.2.2.	  Myometrial	  hormone	  levels	  
No	   change	   in	  myometrial	   P4,	   E2	   or	   cortisol	   levels	   were	   noted	  with	   the	   onset	   of	   labour	   although	  
interestingly	   a	   trend	   towards	   a	   reduction	   in	   both	   P4	   and	   E2	   levels	   was	   observed	   with	   advancing	  
gestation	   (Fig.	   5.1.).	   A	   significant	   increase	   in	   E2	   levels	   was	   observed	  with	   the	   onset	   of	   idiopathic	  
preterm	  labour	  although	  this	  was	  not	  replicated	  in	  other	  causes	  leading	  to	  preterm	  labour	  (Fig.	  5.2.).	  
Further,	  no	  changes	  were	  observed	  in	  P4	  or	  cortisol	  levels	  in	  preterm	  labour	  (Fig.	  5.2.).	  	  
	  
Figure	  5.1.	  Progesterone	  (P4),	  estradiol	  (E2)	  and	  cortisol	  levels	  in	  term	  labour.	  
A	  whole	  cell	   lysate	  was	  prepared	  by	  bead	  homogenisation,	  protein	  levels	  were	  quantified	  and	  2μg	  of	  protein	  
lysate	   was	   used	   to	   quantify	   A.	   progesterone,	   B.	   estradiol	   and	   C.	   cortisol	   levels	   as	   per	   the	   manufacturer’s	  
protocol.	  Assays	  were	  read	  using	  a	  Bio-­‐Plex©	  MAGPIX©	  reader.	  Data	  are	  expressed	  as	  mean	  +	  SEM.	  Normality	  
was	  determined	  via	  a	  Shapiro-­‐Wilk	  test	  followed	  by	  a	  one-­‐way	  ANOVA	  and	  Bonferroni’s	  multiple	  comparison	  
testing	  for	  normally	  distributed	  data	  or	  a	  Kruskal-­‐Wallis	  test	  and	  Dunn’s	  multiple	  comparison	  testing	  for	  non-­‐
normally	  distributed	  data.	  n=	  15-­‐19.	  PTNL:	  preterm	  no	   labour;	  TNL:	  term	  no	   labour;	  TEaL:	  term	  early	   labour;	  
TEsL:	  term	  established	  labour.	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Figure	  5.2.	  Progesterone	  (P4),	  estradiol	  (E2)	  and	  cortisol	  levels	  in	  preterm	  labour	  
A	  whole	  cell	   lysate	  was	  prepared	  by	  bead	  homogenisation,	  protein	  levels	  were	  quantified	  and	  2μg	  of	  protein	  
lysate	   was	   used	   to	   quantify	   A&D.	   progesterone,	   B&E.	   estradiol	   and	   C&F.	   cortisol	   levels	   as	   per	   the	  
manufacturer’s	  protocol.	  Assays	  were	  read	  using	  a	  Bio-­‐Plex©	  MAGPIX©	  reader.	  Data	  are	  expressed	  as	  mean	  +	  
SEM.	   Normality	   was	   determined	   via	   a	   Shapiro-­‐Wilk	   test	   followed	   by	   a	   one-­‐way	   ANOVA	   and	   Bonferroni’s	  
multiple	   comparison	   testing	   for	   normally	   distributed	   data	   or	   a	   Kruskal-­‐Wallis	   test	   and	   Dunn’s	   multiple	  
comparison	   testing	   for	   non-­‐normally	   distributed	   data.	   n=	   8-­‐15.	   PTNL:	   preterm	   no	   labour;	   IPTL:	   idiopathic	  
preterm	   labour;	   PTLC:	   preterm	   labour	   secondary	   to	   chorioamnionitis;	   PTTWNL:	   preterm	   twins	   no	   labour;	  
PTTWL:	  preterm	  twins	  in	  labour.	  	  
	  
5.2.3.	  Nuclear	  receptors	  
5.2.3.1.	  Progesterone	  receptor	  
At	   term,	   PR-­‐B	   protein	   levels	   were	   found	   to	   decrease	   significantly	   upon	   comparing	   non-­‐labouring	  
women	   to	   women	   in	   early	   labour,	   with	   no	   changes	   to	   PR-­‐A	   (Fig.	   5.3.).	   This	   observation	   was	  
associated	  with	  a	  significant	  increase	  in	  the	  PR-­‐A:PR-­‐B	  ratio	  (Fig.	  5.4.).	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Figure	  5.3.	  Progesterone	  receptor	  (PR)	  isoform	  levels	  in	  term	  labour.	  	  
Protein	   was	   extracted	   by	   bead	   homogenisation,	   quantified	   and	   western	   blotting	   was	   performed	   for	   PR	   to	  
compare	  A.	  preterm	  no	  labour	  (PTNL)	  to	  term	  no	  labour	  (TNL),	  B.	  term	  no	  labour	  to	  term	  early	  labour	  (TEaL),	  
C.	   term	  no	   labour	   to	   term	  established	   labour	   (TEsL),	  and	  D.	   term	  early	   labour	   to	   term	  established	   labour.	  A	  
representative	  western	   blot	   is	   shown	   at	   the	   top	  of	   each	   figure	  with	   densitometric	   analysis	   below.	  Data	   are	  
expressed	  as	  mean	  +	  SEM.	  Normality	  was	  determined	  via	  a	  Shapiro-­‐Wilk	  test	  followed	  by	  unpaired	  t	  testing	  for	  
normally	  distributed	  data	  and	  Mann	  Whitney	  testing	  for	  non-­‐normally	  distributed	  data.	  *,	  p<0.05.	  n=	  17-­‐18.	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Figure	  5.4.	  Progesterone	  receptor-­‐A	  and	  –B	  (PR-­‐A:PR-­‐B)	  ratio	  in	  term	  labour.	  	  
Protein	   was	   extracted	   by	   bead	   homogenisation,	   quantified	   and	   western	   blotting	   was	   performed	   for	   PR	   to	  
compare	  A.	  preterm	  no	  labour	  (PTNL)	  to	  term	  no	  labour	  (TNL),	  B.	  term	  no	  labour	  to	  term	  early	  labour	  (TEaL),	  
C.	  term	  no	  labour	  to	  term	  established	  labour	  (TEsL),	  and	  D.	  term	  early	  labour	  to	  term	  established	  labour.	  Data	  
are	   expressed	   as	  mean	   +	   SEM	  of	   the	   ratio	   of	   PR-­‐A:PR-­‐B.	  Normality	  was	   determined	   via	   a	   Shapiro-­‐Wilk	   test	  
followed	   by	   unpaired	   t	   testing	   for	   normally	   distributed	   data	   and	   Mann	   Whitney	   testing	   for	   non-­‐normally	  
distributed	  data.	  *,	  p<0.05.	  n=	  17-­‐18.	  	  
	  
In	   the	  context	  of	   idiopathic	  preterm	   labour,	  an	   increase	   in	  PR-­‐A	   levels	  was	  observed	  compared	   to	  
preterm	  non-­‐labouring	  women	   (Fig.	   5.5.),	   although	   this	   effect	   did	   not	   change	   the	   PR-­‐A:PR-­‐B	   ratio	  
sufficiently	   to	   reach	   statistical	   significance	   (Fig.	   5.6.).	   Preterm	   labour	   due	   to	   chorioamnionitis	   and	  
multiple	  gestation	  was	  not	  associated	  with	  any	  change	  in	  PR	  isoform	  levels	  (Fig.	  5.5.)	  or	  the	  PR-­‐A:PR-­‐
B	  ratio	  (Fig.	  5.6.).	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Figure	  5.5.	  Progesterone	  receptor	  (PR)	  isoform	  levels	  in	  preterm	  labour.	  	  
Protein	   was	   extracted	   by	   bead	   homogenisation,	   quantified	   and	   western	   blotting	   was	   performed	   for	   PR	   to	  
compare	  A.	   preterm	  no	   labour	   (PTNL)	   to	   idiopathic	  preterm	   labour	   (IPTL),	  B.	   preterm	  no	   labour	   to	  preterm	  
labour	  due	  to	  chorioamnionitis	   (PTLC),	  and	  C.	  preterm	  twins	  no	   labour	  (PTTWNL)	  to	  preterm	  twins	   in	   labour	  
(PTTWL).	  A	  representative	  western	  blot	  is	  shown	  at	  the	  top	  of	  each	  figure	  with	  densitometric	  analysis	  below.	  
Data	  are	  expressed	  as	  mean	  +	  SEM.	  Normality	  was	  determined	  via	  a	  Shapiro-­‐Wilk	  test	  followed	  by	  unpaired	  t	  
testing	  for	  normally	  distributed	  data	  and	  Mann	  Whitney	  testing	  for	  non-­‐normally	  distributed	  data.	  *,	  p<0.05.	  
n=	  10-­‐17.	  	  
	  
Figure	  5.6.	  Progesterone	  receptor-­‐A	  and	  –B	  (PR-­‐A:PR-­‐B)	  ratio	  in	  preterm	  labour.	  
Protein	   was	   extracted	   by	   bead	   homogenisation,	   quantified	   and	   western	   blotting	   was	   performed	   for	   PR	   to	  
compare	  A.	   preterm	  no	   labour	   (PTNL)	   to	   idiopathic	  preterm	   labour	   (IPTL),	  B.	   preterm	  no	   labour	   to	  preterm	  
labour	  due	  to	  chorioamnionitis	   (PTLC),	  and	  C.	  preterm	  twins	  no	   labour	  (PTTWNL)	  to	  preterm	  twins	   in	   labour	  
(PTTWL).	  Data	  are	  expressed	  as	  mean	  +	  SEM.	  Normality	  was	  determined	  via	  a	  Shapiro-­‐Wilk	  test	   followed	  by	  
unpaired	  t	  testing	  for	  normally	  distributed	  data	  and	  Mann	  Whitney	  testing	  for	  non-­‐normally	  distributed	  data.	  
n=	  10-­‐17.	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5.2.3.2.	  Glucocorticoid	  receptor	  
In	   light	   of	   the	   group’s	   primary	   cell	   data	   (120)	   identifying	   a	   potential	   role	   for	   GR	   in	   progesterone	  
signalling,	   GR	   expression	  was	   quantified	   at	   different	   stages	   of	   pregnancy	   and	   labour.	   No	   changes	  
were	  observed	   in	  GR	   levels	  during	   the	   transition	   from	  term	  no	   labour	   to	   labour	  at	   term	   (Fig.	  5.7).	  
Additionally,	  no	  changes	   in	  GR	   levels	  were	  noted	   in	  preterm	   labour	  as	  compared	  to	  non-­‐labouring	  
preterm	  deliveries	  (Fig.	  5.8.)	  
	  
Figure	  5.7.	  Glucocorticoid	  receptor	  (GR)	  levels	  in	  term	  labour.	  	  
Protein	   was	   extracted	   by	   bead	   homogenisation,	   quantified	   and	   western	   blotting	   was	   performed	   for	   GR	   to	  
compare	  A.	  preterm	  no	  labour	  (PTNL)	  to	  term	  no	  labour	  (TNL),	  B.	  term	  no	  labour	  to	  term	  early	  labour	  (TEaL),	  
C.	   term	  no	   labour	   to	   term	  established	   labour	   (TEsL),	  and	  D.	   term	  early	   labour	   to	   term	  established	   labour.	  A	  
representative	  western	   blot	   is	   shown	   at	   the	   top	  of	   each	   figure	  with	   densitometric	   analysis	   below.	  Data	   are	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expressed	  as	  mean	  +	  SEM.	  Normality	  was	  determined	  via	  a	  Shapiro-­‐Wilk	  test	  followed	  by	  unpaired	  t	  testing	  for	  
normally	  distributed	  data	  and	  Mann	  Whitney	  testing	  for	  non-­‐normally	  distributed	  data.	  n=	  17-­‐18.	  	  
	  
Figure	  5.8.	  Glucocorticoid	  receptor	  (GR)	  levels	  in	  preterm	  labour.	  	  
Protein	   was	   extracted	   by	   bead	   homogenisation,	   quantified	   and	   western	   blotting	   was	   performed	   for	   GR	   to	  
compare	  A.	   preterm	  no	   labour	   (PTNL)	   to	   idiopathic	  preterm	   labour	   (IPTL),	  B.	   preterm	  no	   labour	   to	  preterm	  
labour	  due	  to	  chorioamnionitis	   (PTLC),	  and	  C.	  preterm	  twins	  no	   labour	  (PTTWNL)	  to	  preterm	  twins	   in	   labour	  
(PTTWL).	  A	  representative	  western	  blot	  is	  shown	  at	  the	  top	  of	  each	  figure	  with	  densitometric	  analysis	  below.	  
Data	  are	  expressed	  as	  mean	  +	  SEM.	  Normality	  was	  determined	  via	  a	  Shapiro-­‐Wilk	  test	  followed	  by	  unpaired	  t	  
testing	  for	  normally	  distributed	  data	  and	  Mann	  Whitney	  testing	  for	  non-­‐normally	  distributed	  data.	  n=	  10-­‐17.	  	  
	  
5.2.4.	  Chaperone	  and	  co-­‐chaperone	  molecules	  
5.2.4.1.	  Heat	  shock	  protein	  70	  
HSP70	  was	   found	   to	  decrease	   significantly	   from	  early	   to	   established	   labour	   at	   term	   (Fig.	   5.9.).	  No	  
changes	  were	  seen	  in	  the	  context	  of	  preterm	  labour	  (Fig.	  5.10.).	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Figure	  5.9.	  Heat	  shock	  protein	  70	  (HSP70)	  levels	  in	  term	  labour.	  	  
Protein	  was	  extracted	  by	  bead	  homogenisation,	  quantified	  and	  western	  blotting	  was	  performed	  for	  HSP70	  to	  
compare	  A.	  preterm	  no	  labour	  (PTNL)	  to	  term	  no	  labour	  (TNL),	  B.	  term	  no	  labour	  to	  term	  early	  labour	  (TEaL),	  
C.	   term	  no	   labour	   to	   term	  established	   labour	   (TEsL),	  and	  D.	   term	  early	   labour	   to	   term	  established	   labour.	  A	  
representative	  western	   blot	   is	   shown	   at	   the	   top	  of	   each	   figure	  with	   densitometric	   analysis	   below.	  Data	   are	  
expressed	  as	  mean	  +	  SEM.	  Normality	  was	  determined	  via	  a	  Shapiro-­‐Wilk	  test	  followed	  by	  unpaired	  t	  testing	  for	  
normally	  distributed	  data	  and	  Mann	  Whitney	  testing	  for	  non-­‐normally	  distributed	  data.	  *,	  p<0.05.	  n=	  17-­‐18.	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Figure	  5.10.	  Heat	  shock	  protein	  70	  (HSP70)	  levels	  in	  preterm	  labour.	  	  
Protein	  was	  extracted	  by	  bead	  homogenisation,	  quantified	  and	  western	  blotting	  was	  performed	  for	  HSP70	  to	  
compare	  A.	   preterm	  no	   labour	   (PTNL)	   to	   idiopathic	  preterm	   labour	   (IPTL),	  B.	   preterm	  no	   labour	   to	  preterm	  
labour	  due	  to	  chorioamnionitis	   (PTLC),	  and	  C.	  preterm	  twins	  no	   labour	  (PTTWNL)	  to	  preterm	  twins	   in	   labour	  
(PTTWL).	  A	  representative	  western	  blot	  is	  shown	  at	  the	  top	  of	  each	  figure	  with	  densitometric	  analysis	  below.	  
Data	  are	  expressed	  as	  mean	  +	  SEM.	  Normality	  was	  determined	  via	  a	  Shapiro-­‐Wilk	  test	  followed	  by	  unpaired	  t	  
testing	  for	  normally	  distributed	  data	  and	  Mann	  Whitney	  testing	  for	  non-­‐normally	  distributed	  data.	  n=	  10-­‐17.	  	  
	  
5.2.4.2.	  Heat	  shock	  protein	  90	  
HSP90	  levels	  did	  not	  alter	  through	  the	  different	  stages	  of	   labour	  at	  term	  (Fig.	  5.11.),	  however	  they	  
increased	  significantly	  in	  the	  context	  of	  chorioamnionitis	  (Fig.	  5.	  12.).	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Figure	  5.11.	  Heat	  shock	  protein	  90	  (HSP90)	  levels	  in	  term	  labour.	  	  
Protein	  was	  extracted	  by	  bead	  homogenisation,	  quantified	  and	  western	  blotting	  was	  performed	  for	  HSP90	  to	  
compare	  A.	  preterm	  no	  labour	  (PTNL)	  to	  term	  no	  labour	  (TNL),	  B.	  term	  no	  labour	  to	  term	  early	  labour	  (TEaL),	  
C.	   term	  no	   labour	   to	   term	  established	   labour	   (TEsL),	  and	  D.	   term	  early	   labour	   to	   term	  established	   labour.	  A	  
representative	  western	   blot	   is	   shown	  at	   the	   top	  of	   each	   figure	  with	   densitometric	   analysis	   below.	  Data	   are	  
expressed	  as	  mean	  +	  SEM.	  Normality	  was	  determined	  via	  a	  Shapiro-­‐Wilk	  test	  followed	  by	  unpaired	  t	  testing	  for	  
normally	  distributed	  data	  and	  Mann	  Whitney	  testing	  for	  non-­‐normally	  distributed	  data.	  n=	  17-­‐18.	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Figure	  5.12.	  Heat	  shock	  protein	  90	  (HSP90)	  levels	  in	  preterm	  labour.	  	  
Protein	  was	  extracted	  by	  bead	  homogenisation,	  quantified	  and	  western	  blotting	  was	  performed	  for	  HSP90	  to	  
compare	  A.	   preterm	  no	   labour	   (PTNL)	   to	   idiopathic	  preterm	   labour	   (IPTL),	  B.	   preterm	  no	   labour	   to	  preterm	  
labour	  due	  to	  chorioamnionitis	   (PTLC),	  and	  C.	  preterm	  twins	  no	   labour	  (PTTWNL)	  to	  preterm	  twins	   in	   labour	  
(PTTWL).	  A	  representative	  western	  blot	  is	  shown	  at	  the	  top	  of	  each	  figure	  with	  densitometric	  analysis	  below.	  
Data	  are	  expressed	  as	  mean	  +	  SEM.	  Normality	  was	  determined	  via	  a	  Shapiro-­‐Wilk	  test	  followed	  by	  unpaired	  t	  
testing	  for	  normally	  distributed	  data	  and	  Mann	  Whitney	  testing	  for	  non-­‐normally	  distributed	  data.	  **,	  p<0.01.	  
n=	  10-­‐17.	  	  
	  
5.2.4.3.	  FK506-­‐Binding	  Protein	  1	  
FKBP51	   levels	  did	  not	   alter	  with	   the	  onset	  of	   term	   labour	   (Fig.	   5.13.).	   Compared	   to	  non-­‐labouring	  
preterm	   women,	   the	   myometrial	   levels	   of	   FKBP51	   in	   the	   context	   of	   chorioamnionitis	   were	  
significantly	   increased	  (Fig.	  5.14.).	  FKBP51	  levels	  were	  not	  altered	  in	  other	  types	  of	  preterm	  labour	  
(Fig.	  5.14.).	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Figure	  5.13.	  FK506-­‐binding	  protein	  1	  (FKBP51)	  levels	  in	  term	  labour.	  	  
Protein	  was	  extracted	  by	  bead	  homogenisation,	  quantified	  and	  western	  blotting	  was	  performed	  for	  FKBP51	  to	  
compare	  A.	  preterm	  no	  labour	  (PTNL)	  to	  term	  no	  labour	  (TNL),	  B.	  term	  no	  labour	  to	  term	  early	  labour	  (TEaL),	  
C.	   term	  no	   labour	   to	   term	  established	   labour	   (TEsL),	  and	  D.	   term	  early	   labour	   to	   term	  established	   labour.	  A	  
representative	  western	   blot	   is	   shown	   at	   the	   top	  of	   each	   figure	  with	   densitometric	   analysis	   below.	  Data	   are	  
expressed	  as	  mean	  +	  SEM.	  Normality	  was	  determined	  via	  a	  Shapiro-­‐Wilk	  test	  followed	  by	  unpaired	  t	  testing	  for	  
normally	  distributed	  data	  and	  Mann	  Whitney	  testing	  for	  non-­‐normally	  distributed	  data.	  n=	  17-­‐18.	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Figure	  5.14.	  FK506-­‐binding	  protein	  1	  (FKBP51)	  levels	  in	  preterm	  labour.	  	  
Protein	  was	  extracted	  by	  bead	  homogenisation,	  quantified	  and	  western	  blotting	  was	  performed	  for	  FKBP51	  to	  
compare	  A.	   preterm	  no	   labour	   (PTNL)	   to	   idiopathic	  preterm	   labour	   (IPTL),	  B.	   preterm	  no	   labour	   to	  preterm	  
labour	  due	  to	  chorioamnionitis	   (PTLC),	  and	  C.	  preterm	  twins	  no	   labour	  (PTTWNL)	  to	  preterm	  twins	   in	   labour	  
(PTTWL).	  A	  representative	  western	  blot	  is	  shown	  at	  the	  top	  of	  each	  figure	  with	  densitometric	  analysis	  below.	  
Data	  are	  expressed	  as	  mean	  +	  SEM.	  Normality	  was	  determined	  via	  a	  Shapiro-­‐Wilk	  test	  followed	  by	  unpaired	  t	  
testing	  for	  normally	  distributed	  data	  and	  Mann	  Whitney	  testing	  for	  non-­‐normally	  distributed	  data.	  **,	  p<0.01.	  
n=	  10-­‐17.	  	  
	  
5.2.5.	  Co-­‐activators	  
5.2.5.1.	  Steroid	  receptor	  co-­‐activator	  1	  
No	  change	  was	  observed	  in	  SRC1	  levels	  with	  the	  onset	  of	  labour	  at	  term	  (Fig.	  5.15.).	  SRC1	  levels	  were	  
significantly	  reduced	  in	  the	  context	  of	  chorioamnionitis	  and	  were	  not	  altered	  in	   idiopathic	  preterm	  
labour	  or	  in	  twin	  labour	  (Fig.	  5.16.).	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Figure	  5.15.	  Steroid	  receptor	  co-­‐activator	  1	  (SRC1)	  levels	  in	  term	  labour.	  	  
Protein	  was	  extracted	  by	  bead	  homogenisation,	  quantified	  and	  western	  blotting	  was	  performed	   for	  SRC1	   to	  
compare	  A.	  preterm	  no	  labour	  (PTNL)	  to	  term	  no	  labour	  (TNL),	  B.	  term	  no	  labour	  to	  term	  early	  labour	  (TEaL),	  
C.	   term	  no	   labour	   to	   term	  established	   labour	   (TEsL),	  and	  D.	   term	  early	   labour	   to	   term	  established	   labour.	  A	  
representative	  western	   blot	   is	   shown	   at	   the	   top	  of	   each	   figure	  with	   densitometric	   analysis	   below.	  Data	   are	  
expressed	  as	  mean	  +	  SEM.	  Normality	  was	  determined	  via	  a	  Shapiro-­‐Wilk	  test	  followed	  by	  unpaired	  t	  testing	  for	  
normally	  distributed	  data	  and	  Mann	  Whitney	  testing	  for	  non-­‐normally	  distributed	  data.	  n=	  17-­‐18.	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Figure	  5.16.	  Steroid	  receptor	  co-­‐activator	  1	  (SRC1)	  levels	  in	  preterm	  labour.	  	  
Protein	  was	  extracted	  by	  bead	  homogenisation,	  quantified	  and	  western	  blotting	  was	  performed	   for	  SRC1	   to	  
compare	  A.	   preterm	  no	   labour	   (PTNL)	   to	   idiopathic	  preterm	   labour	   (IPTL),	  B.	   preterm	  no	   labour	   to	  preterm	  
labour	  due	  to	  chorioamnionitis	   (PTLC),	  and	  C.	  preterm	  twins	  no	   labour	  (PTTWNL)	  to	  preterm	  twins	   in	   labour	  
(PTTWL).	  A	  representative	  western	  blot	  is	  shown	  at	  the	  top	  of	  each	  figure	  with	  densitometric	  analysis	  below.	  
Data	  are	  expressed	  as	  mean	  +	  SEM.	  Normality	  was	  determined	  via	  a	  Shapiro-­‐Wilk	  test	  followed	  by	  unpaired	  t	  
testing	   for	  normally	  distributed	  data	  and	  Mann	  Whitney	  testing	   for	  non-­‐normally	  distributed	  data.*,	  p<0.05.	  
n=	  10-­‐17.	  	  
	  
5.2.5.2.	  Steroid	  receptor	  co-­‐activator	  2	  
Levels	   of	   SRC2	  were	   not	   altered	   in	   term	   labour	   (Fig.	   5.17.),	   idiopathic	   preterm	   labour	   or	   preterm	  
labour	  secondary	  to	  chorioamnionitis	  or	  twin	  gestation	  (Fig.	  5.18.).	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Figure	  5.17.	  Steroid	  receptor	  co-­‐activator	  2	  (SRC2)	  levels	  in	  term	  labour.	  	  
Protein	  was	  extracted	  by	  bead	  homogenisation,	  quantified	  and	  western	  blotting	  was	  performed	   for	  SRC2	   to	  
compare	  A.	  preterm	  no	  labour	  (PTNL)	  to	  term	  no	  labour	  (TNL),	  B.	  term	  no	  labour	  to	  term	  early	  labour	  (TEaL),	  
C.	   term	  no	   labour	   to	   term	  established	   labour	   (TEsL),	  and	  D.	   term	  early	   labour	   to	   term	  established	   labour.	  A	  
representative	  western	   blot	   is	   shown	   at	   the	   top	  of	   each	   figure	  with	   densitometric	   analysis	   below.	  Data	   are	  
expressed	  as	  mean	  +	  SEM.	  Normality	  was	  determined	  via	  a	  Shapiro-­‐Wilk	  test	  followed	  by	  unpaired	  t	  testing	  for	  
normally	  distributed	  data	  and	  Mann	  Whitney	  testing	  for	  non-­‐normally	  distributed	  data.	  n=	  17-­‐18.	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Figure	  5.18.	  Steroid	  receptor	  co-­‐activator	  2	  (SRC2)	  levels	  in	  preterm	  labour.	  	  
Protein	  was	  extracted	  by	  bead	  homogenisation,	  quantified	  and	  western	  blotting	  was	  performed	   for	  SRC2	   to	  
compare	  A.	   preterm	  no	   labour	   (PTNL)	   to	   idiopathic	  preterm	   labour	   (IPTL),	  B.	   preterm	  no	   labour	   to	  preterm	  
labour	  due	  to	  chorioamnionitis	   (PTLC),	  and	  C.	  preterm	  twins	  no	   labour	  (PTTWNL)	  to	  preterm	  twins	   in	   labour	  
(PTTWL).	  A	  representative	  western	  blot	  is	  shown	  at	  the	  top	  of	  each	  figure	  with	  densitometric	  analysis	  below.	  
Data	  are	  expressed	  as	  mean	  +	  SEM.	  Normality	  was	  determined	  via	  a	  Shapiro-­‐Wilk	  test	  followed	  by	  unpaired	  t	  
testing	  for	  normally	  distributed	  data	  and	  Mann	  Whitney	  testing	  for	  non-­‐normally	  distributed	  data.	  n=	  10-­‐17.	  	  
	  
5.2.5.3.	  Steroid	  receptor	  co-­‐activator	  3	  
SRC3	   levels	   remained	   unaltered	   throughout	   all	   stages	   of	   labour	   at	   term	   (Fig.	   5.19.).	   Similarly,	   no	  
change	  to	  levels	  was	  observed	  in	  the	  different	  types	  of	  preterm	  labour	  studied	  (Fig.	  5.20.).	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Figure	  5.19.	  Steroid	  receptor	  co-­‐activator	  3	  (SRC3)	  levels	  in	  term	  labour.	  	  
Protein	  was	  extracted	  by	  bead	  homogenisation,	  quantified	  and	  western	  blotting	  was	  performed	   for	  SRC3	   to	  
compare	  A.	  preterm	  no	  labour	  (PTNL)	  to	  term	  no	  labour	  (TNL),	  B.	  term	  no	  labour	  to	  term	  early	  labour	  (TEaL),	  
C.	   term	  no	   labour	   to	   term	  established	   labour	   (TEsL),	  and	  D.	   term	  early	   labour	   to	   term	  established	   labour.	  A	  
representative	  western	   blot	   is	   shown	   at	   the	   top	  of	   each	   figure	  with	   densitometric	   analysis	   below.	  Data	   are	  
expressed	  as	  mean	  +	  SEM.	  Normality	  was	  determined	  via	  a	  Shapiro-­‐Wilk	  test	  followed	  by	  unpaired	  t	  testing	  for	  
normally	  distributed	  data	  and	  Mann	  Whitney	  testing	  for	  non-­‐normally	  distributed	  data.	  n=	  17-­‐18.	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Figure	  5.20.	  Steroid	  receptor	  co-­‐activator	  3	  (SRC3)	  levels	  in	  preterm	  labour.	  	  
Protein	  was	  extracted	  by	  bead	  homogenisation,	  quantified	  and	  western	  blotting	  was	  performed	   for	  SRC2	   to	  
compare	  A.	   preterm	  no	   labour	   (PTNL)	   to	   idiopathic	  preterm	   labour	   (IPTL),	  B.	   preterm	  no	   labour	   to	  preterm	  
labour	  due	  to	  chorioamnionitis	   (PTLC),	  and	  C.	  preterm	  twins	  no	   labour	  (PTTWNL)	  to	  preterm	  twins	   in	   labour	  
(PTTWL).	  A	  representative	  western	  blot	  is	  shown	  at	  the	  top	  of	  each	  figure	  with	  densitometric	  analysis	  below.	  
Data	  are	  expressed	  as	  mean	  +	  SEM.	  Normality	  was	  determined	  via	  a	  Shapiro-­‐Wilk	  test	  followed	  by	  unpaired	  t	  
testing	  for	  normally	  distributed	  data	  and	  Mann	  Whitney	  testing	  for	  non-­‐normally	  distributed	  data.	  n=	  10-­‐17.	  	  
	  
5.2.6.	  Co-­‐repressors	  
5.2.6.1.	  Nuclear	  receptor	  co-­‐repressor	  
NCoR	   levels	   remained	   unaltered	   at	   term	   although	   a	   trend	   towards	   a	   decline	   was	   observed	   upon	  
comparing	  non	  labouring	  women	  to	  women	  in	  established	  labour	  (Fig.	  5.21.).	  A	  significant	  decline	  in	  
levels	  was	  observed	  in	  the	  context	  of	  chorioamnionitis	  (Fig.	  5.22.).	  In	  the	  context	  of	  preterm	  labour	  
in	  twins,	  levels	  were	  significantly	  higher	  when	  compared	  to	  non-­‐labouring	  twins	  (Fig.	  5.22.).	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Figure	  5.21.	  Nuclear	  receptor	  co-­‐repressor	  (NCoR)	  levels	  in	  term	  labour.	  	  
Protein	  was	  extracted	  by	  bead	  homogenisation,	  quantified	  and	  western	  blotting	  was	  performed	  for	  NCoR	  to	  
compare	  A.	  preterm	  no	  labour	  (PTNL)	  to	  term	  no	  labour	  (TNL),	  B.	  term	  no	  labour	  to	  term	  early	  labour	  (TEaL),	  
C.	   term	  no	   labour	   to	   term	  established	   labour	   (TEsL),	  and	  D.	   term	  early	   labour	   to	   term	  established	   labour.	  A	  
representative	  western	   blot	   is	   shown	   at	   the	   top	  of	   each	   figure	  with	   densitometric	   analysis	   below.	  Data	   are	  
expressed	  as	  mean	  +	  SEM.	  Normality	  was	  determined	  via	  a	  Shapiro-­‐Wilk	  test	  followed	  by	  unpaired	  t	  testing	  for	  
normally	  distributed	  data	  and	  Mann	  Whitney	  testing	  for	  non-­‐normally	  distributed	  data.	  n=	  17-­‐18.	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Figure	  5.22.	  Nuclear	  receptor	  c-­‐orepressor	  (NCoR)	  levels	  in	  preterm	  labour.	  	  
Protein	  was	  extracted	  by	  bead	  homogenisation,	  quantified	  and	  western	  blotting	  was	  performed	  for	  NCoR	  to	  
compare	  A.	   preterm	  no	   labour	   (PTNL)	   to	   idiopathic	  preterm	   labour	   (IPTL),	  B.	   preterm	  no	   labour	   to	  preterm	  
labour	  due	  to	  chorioamnionitis	   (PTLC),	  and	  C.	  preterm	  twins	  no	   labour	  (PTTWNL)	  to	  preterm	  twins	   in	   labour	  
(PTTWL).	  A	  representative	  western	  blot	  is	  shown	  at	  the	  top	  of	  each	  figure	  with	  densitometric	  analysis	  below.	  
Data	  are	  expressed	  as	  mean	  +	  SEM.	  Normality	  was	  determined	  via	  a	  Shapiro-­‐Wilk	  test	  followed	  by	  unpaired	  t	  
testing	  for	  normally	  distributed	  data	  and	  Mann	  Whitney	  testing	  for	  non-­‐normally	  distributed	  data.	  *,	  p<0.05;	  
***,	  p<0.001.	  n=	  10-­‐17.	  	  
	  
5.2.6.2.	  Silencing	  mediator	  for	  retinoid	  or	  thyroid	  hormone	  
SMRT	  was	   not	   detectable	   in	  myometrium	   originating	   in	   all	   groups	   studied	   (Fig.	   5.23.).	   A	   positive	  
control	  was	  used	  in	  order	  to	  ensure	  there	  was	  no	  underlying	  methodological	  error.	  	  
	  
	  
	  
Figure	  5.23.	  Silencing	  mediator	  for	  retinoid	  or	  thyroid	  hormone	  (SMRT)	  levels	  in	  preterm	  labour.	  	  
Protein	  was	  extracted	  by	  bead	  homogenisation,	  quantified	  and	  western	  blotting	  was	  performed	  for	  SMRT	  to	  
compare	  for	  preterm	  twins	  no	  labour	  (PTTWNL)	  to	  preterm	  twins	  in	  labour	  (PTTWL);	  20μg	  HeLa	  nuclear	  extract	  
(C)	  was	  used	  as	  a	  positive	  control.	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5.2.7.	  Co-­‐regulator,	  chaperone	  and	  co-­‐chaperone	  levels	  in	  myometrial	  explants	  
In	  summary,	  the	  data	  above	  demonstrated	  that	  in	  the	  context	  of	  choriamnionitis,	  HSP90	  and	  FKBP51	  
levels	   increased	   whereas	   SRC1	   and	   NCoR	   levels	   decreased.	   In	   order	   to	   confirm	   these	   findings,	  
inflammation	  was	   simulated	   in	   vitro	   by	   treating	  myometrial	   explants	   with	   IL-­‐1β.	   	   No	   change	  was	  
observed	  in	  the	  levels	  of	  any	  of	  these	  proteins	  which	  corresponded	  to	  the	  in	  vivo	  findings	  (Fig.	  5.24.).	  
The	  levels	  of	  HSP90,	  SRC1	  and	  NCoR	  did	  not	  significantly	  vary	  between	  snap	  frozen	  tissues	  collected	  
at	   the	   time	   of	   Caesarean	   section	   (t=0)	   and	   vehicle	   treatment,	   whereas	   FKBP51	   levels	   were	  
significantly	  decreased.	  	  
No	  increase	  was	  observed	  in	  NCoR	  levels	  with	  the	  onset	  of	  singleton	  labour	  whereas	  an	  increase	  was	  
seen	  with	  the	  onset	  of	  twin	  preterm	  labour.	  For	  this	  reason,	  the	  effect	  of	  tension	  of	  NCoR	  levels	  was	  
studied.	   However,	   no	   change	   was	   observed	   when	   myometrial	   strips	   were	   kept	   under	   different	  
degrees	  of	  tension	  in	  vitro	  (Fig.	  5.25.).	  
	  
Figure	  5.24.	  Coregulator	  molecule	  levels	  in	  myometrial	  explants.	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Myometrial	   tissue	   obtained	   from	   term	   non-­‐labouring	   women	  was	   finely	   dissected	   into	   3x3x3mm3	   explants	  
after	  a	  portion	  was	  snap	  frozen	  (t=0).	  These	  were	  immediately	  treated	  with	  water	  vehicle	  of	  10ng/mL	  IL-­‐1β	  for	  
24	  hours.	  Protein	  was	  extracted	  by	  bead	  homogenisation,	  quantified	  and	  western	  blotting	  was	  performed	  for	  
A.	   heat	   shock	   protein	   90	   (HSP90),	   B.	   FK506-­‐binding	   protein	   1	   (FKBP51),	   C.	   steroid	   receptor	   co-­‐activator	   1	  
(SRC1)	  and	  D.	  nuclear	  receptor	  co-­‐repressor	  (NCoR).	  	  A	  representative	  western	  blot	  is	  shown	  at	  the	  top	  of	  each	  
figure	  with	  densitometric	  analysis	  below.	  Data	  are	  expressed	  as	  mean	  +	  SEM.	  Normality	  was	  determined	  via	  a	  
Shapiro-­‐Wilk	  test	   followed	  by	  unpaired	  t	  testing	  for	  normally	  distributed	  data	  and	  Mann	  Whitney	  testing	  for	  
non-­‐normally	  distributed	  data.**,	  p<0.01.	  n=8-­‐10.	  
	  
	  
Figure	   5.25.	  Nuclear	   receptor	   co-­‐repressor	   (NCoR)	   levels	   in	  myometrial	   strips	   under	   differenti	   degrees	   of	  
tension.	  	  	  
After	   a	   portion	   was	   snap	   frozen	   (t=0),	   myometrial	   tissue	   obtained	   from	   term	   non-­‐labouring	   women	   was	  
dissected	   into	  strips	  by	  cutting	   lengthways	  along	  fasciculata	  bundles.	  Some	  strips	  were	  cultured	  without	  any	  
tension	  whereas	  	  a	  glass	  weight	  of	  either	  0.6-­‐0.7g	  (low	  tension)	  or	  2.2.-­‐2.4g	  (high	  tension)	  mass	  was	  attached	  
to	  others	  to	  maintain	  them	  under	  isotonic	  tension.	  Strips	  were	  immediately	  treated	  with	  ethanol	  vehicle	  for	  24	  
hours.	   Protein	   was	   extracted	   by	   bead	   homogenisation,	   quantified	   and	   western	   blotting	   was	   run	   NCoR.	   A	  
representative	   western	   blot	   is	   shown	   at	   the	   top	   the	   figure	   with	   densitometric	   analysis	   below.	   Data	   are	  
expressed	  as	  mean	  +	  SEM.	  Normality	  was	  determined	  via	  a	  Kolmogorov-­‐Smirnov	  test	  followed	  by	  unpaired	  t	  
testing	  for	  normally	  distributed	  data	  and	  Mann	  Whitney	  testing	  for	  non-­‐normally	  distributed	  data.	  n=6.8.	  This	  
experiment	  was	  conducted	  in	  collaboration	  with	  Dr	  Pei	  Lai.	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5.3.	  Discussion	  
This	  study	  confirms	  previous	  data	  demonstrating	  a	  shift	  towards	  PR-­‐A	  dominance	  with	  labour	  onset	  
at	  term.	  Further,	  for	  the	  first	  time,	  this	  study	  has	  identified	  myometrial	  changes	  in	  the	  expression	  of	  
PR	   chaperones,	   co-­‐chaperones	   and	   co-­‐regulators	   with	   the	   onset	   of	   term	   and	   preterm	   labour.	  
Specifically,	  HSP70	  was	  shown	  to	  decrease	  in	  term	  established	  labour	  as	  compared	  to	  early	  labour.	  
Furthermore,	   in	   the	   context	   of	   preterm	   labour	   arising	   secondary	   to	   chorioamnionitis,	   HSP90	   and	  
FKBP51	  levers	  were	  increased,	  whereas	  NCoR	  and	  SRC1	  levels	  were	  decreased.	  Finally,	  in	  the	  context	  
of	  preterm	  labour	  arising	  in	  twin	  pregnancies,	  NCoR	  levels	  were	  increased.	  	  
5.3.1.	  Local	  hormone	  levels	  
Data	   originating	   from	   murine	   studies	   has	   lent	   support	   to	   the	   hypothesis	   that	   altered	   local	  
progesterone	   metabolism	   can	   impact	   on	   parturition	   onset.	   Specifically,	   mice	   lacking	   enzymes	  
responsible	   for	  progesterone	  degradation	   including	  5α-­‐reductase	  (203,	  204)	  or	  20α-­‐hydroxysteroid	  
dehydrogenase	  (205,	  206)	  have	  a	  prolonged	  gestation.	  More	  recently,	  evidence	  of	   increased	   levels	  
of	   the	   progesterone-­‐catabolising	   enzyme	   20α-­‐hydroxysteroid	   dehydrogenase	   have	   been	  
documented	   in	   human	   myometrium	   (195),	   however	   these	   were	   not	   formally	   quantified.	   Unlike	  
these	  observations,	  no	  evidence	  of	   lower	  myometrial	  progesterone	   levels	  was	   found	   in	   this	   study,	  
suggesting	   that	   this	   may	   not	   be	   a	   mechanism	   underlying	   functional	   progesterone	   withdrawal	   in	  
humans.	  	  
Further,	  no	  change	   in	  estradiol	   levels	  was	  observed	  with	  term	  labour	  although	  a	  trend	  towards	  an	  
increase	   was	   noted.	   Previous	   publications	   suggest	   that	   in	   humans,	   oestrogen	   levels	   begin	   to	   rise	  
mid-­‐gestation	  until	   labour	  (179,	  180),	  although	  this	   is	  not	  reflected	   in	  the	  findings	  presented	  here.	  
Nevertheless,	   significantly	   increased	  estradiol	   levels	  were	  observed	  with	   idiopathic	  preterm	   labour	  
lending	  support	  to	  the	  importance	  of	  estradiol	  in	  labour	  onset.	  	  
Although	  the	  systemic	  administration	  of	  corticosteroids	  to	  aid	  fetal	  lung	  maturity	  has	  no	  impact	  on	  
gestational	   length	   (426),	   glucocorticoids	   have	   been	   implicated	   in	   parturition	   at	   least	   in	   certain	  
animal	  species	  (427).	  Further,	  some	  researchers	  have	  proposed	  that	  glucocorticoids	  may	  indeed	  play	  
a	  role	  in	  the	  parturition	  process	  (426).	  For	  this	  reason,	  cortisol	  levels	  were	  also	  quantified	  as	  part	  of	  
this	  study,	  however	  no	  change	  in	  levels	  was	  observed.	  	  
	  
5.3.2.	  Nuclear	  receptor	  levels	  
The	   data	   presented	   here	   demonstrate	   a	   switch	   from	   PR-­‐B	   dominance	   to	   PR-­‐A	   dominance	   with	  
labour	   onset	   at	   term.	   A	   shift	   in	   the	   PR-­‐A:PR-­‐B	   ratio	   favouring	   PR-­‐A	   in	   the	   context	   of	   labour	   has	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previously	   been	   shown	   at	   the	   RNA	   and	   protein	   levels	   (117,	   134,	   196).	   This	   precipitated	   a	  
considerable	  body	  of	   in	   vitro	  work	  by	   the	  Mesiano	  group	   in	  which	  PR-­‐B	  was	   shown	   to	  upregulate	  
anti-­‐inflammatory	   genes	   and	   conversely	   PR-­‐A	  was	   shown	   to	   exert	   pro-­‐inflammatory	   effects	   (141).	  
The	  inhibitory	  action	  of	  PR-­‐A	  on	  PR-­‐B	  has	  been	  independently	  verified	  in	  vitro	  (135).	  Further,	  another	  
group	  has	  implicated	  the	  PR-­‐C	  isoform	  in	  functional	  P4	  withdrawal	  (189),	  although	  the	  existence	  of	  
this	  isoform	  has	  since	  been	  questioned	  (218).	  The	  findings	  presented	  here	  support	  a	  shift	  in	  the	  PR-­‐
A:PR-­‐B	   ratio	   with	   the	   onset	   of	   labour.	   It	   is	   important	   to	   note	   however,	   that	   other	   investigators	  
observed	   no	   reproductive	   sequelae	   in	   transgenic	   mice	   with	   PR-­‐A	   overexpression	   (405)	   or	   PR-­‐B	  
knocked-­‐out	   (188)	   and	   that	   PR-­‐A	   dominance	   observed	   in	   myometrial	   explants	   in	   Chapter	   4	  
demonstrated	   no	   loss	   of	   the	   anti-­‐inflammatory	   action	   of	   progesterone.	   These	   observations	   raise	  
important	   questions	   regarding	   the	   significance	   of	   the	   PR-­‐A:PR-­‐B	   ratio	   in	   functional	   progesterone	  
withdrawal.	  	  
Interestingly,	   even	   though	   there	   was	   a	   significant	   up-­‐regulation	   in	   PR-­‐A	   levels	   in	   the	   context	   of	  
idiopathic	  preterm	  labour,	  this	  did	  not	  alter	  the	  PR-­‐A:PR-­‐B	  ratio.	  Indeed,	  there	  was	  no	  change	  to	  this	  
ratio	   in	  any	  of	   the	  underlying	  aetiologies	   for	  preterm	   labour	  studied	  here.	  This	   suggests	   that	  even	  
though	   the	   relative	   dominance	   of	   specific	   PR	   isoforms	   may	   have	   a	   role	   to	   play	   in	   myometrial	  
pathophysiology,	  it	  is	  likely	  not	  to	  represent	  the	  sole	  regulatory	  step	  for	  the	  transition	  from	  a	  state	  
of	  quiescence	  to	  a	  state	  of	  contractility/activation.	  	  
As	   with	   a	   study	   carried	   out	   on	   placental	   tissue	   (428),	   no	   evidence	   of	   a	   change	   in	   GR	   levels	   was	  
identified	  in	  term	  or	  preterm	  labour.	  The	  potential	  role	  for	  GR	  in	  mediating	  progesterone	  signalling	  
which	   has	   been	   previously	   identified	   in	   primary	   cells	   (120)	   may	   have	   been	   a	   reflection	   of	   the	  
limitations	  of	  in	  vitro	  cell	  culture	  rather	  than	  an	  indication	  of	  in	  vivo	  	  events.	  	  	  
	  
5.3.3.	  Chaperone	  and	  co-­‐chaperone	  proteins	  
HSP70	   levels	   have	   previously	   been	   shown	   to	   increase	   both	   in	   serum	   and	   placental	   tissue	   in	   the	  
context	   of	   both	   term	   and	   preterm	   labour	   especially	   in	   the	   presence	   of	   infection	   (429).	   Similar	  
findings	  have	  been	  reported	   in	  amnionic	   fluid	   (430).	  The	  data	  presented	  here	   indicate	  a	  decline	   in	  
HSP70	  in	  the	  advanced	  stages	  of	  term	  labour,	  with	  no	  changes	  identified	  in	  preterm	  labour.	  HSP70	  is	  
increasingly	   being	   recognised	   as	   existing	   in	   two	   forms:	   extracellular	   HSP70,	   which	   activates	   the	  
immune	   system,	   and	   intracellular	   HSP70,	   which	   has	   anti-­‐inflammatory	   action	   (431,	   432).	   As	  
myometrial	   tissue	  was	   used	   to	   obtain	   the	   data	   presented	   in	   this	   chapter,	  most	   of	   the	  whole	   cell	  
lysate	  consisted	  of	  intracellular	  protein,	  which	  could	  account	  for	  the	  decrease	  seen.	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By	  contrast,	  levels	  of	  HSP90	  and	  its	  co-­‐chaperone	  FKBP51	  were	  significantly	  increased	  in	  the	  context	  
of	  preterm	  labour	  secondary	  to	  chorioamnionitis.	  An	  increase	  in	  HSP90	  has	  previously	  been	  reported	  
in	   animal	   models	   of	   preterm	   labour	   (433).	   Apart	   from	   its	   association	   with	   PR,	   HSP90	   is	   also	  
associated	  with	  several	  mediators	  of	  inflammation	  including	  NF-­‐κB	  (434),	  hence	  its	  up-­‐regulation	  in	  
chorioamnionitis	  may	  be	  a	  consequence	  of	   the	   infection-­‐associated	   inflammation.	  Further,	  FKBP51	  
has	  been	  shown	   in	  multiple	  cancer	  models	   to	  enhance	  NF-­‐κB	  action	   (435-­‐437)	  suggesting	   that	   the	  
up-­‐regulation	  seen	  in	  chorioamnionitis	  may	  again	  be	  a	  result	  of	  the	  infective	  process.	  The	  resulting	  
increase	  then	  acts	  to	  reduce	  the	  pro-­‐quiescent	  effects	  of	  progesterone	  hence	  precipitating	  preterm	  
labour	  (99).	  
The	  findings	  of	   increased	  HSP90	  and	  FKBP51	  levels	  as	  well	  as	   lower	  SRC1	  in	  chorioamnionitis	  were	  
not	  reproducible	  in	  vitro	  using	  IL-­‐1β	  treatment	  of	  myometrial	  explants.	  This	  could	  be	  because	  IL-­‐1β	  
does	  not	  reproduce	  the	  same	  inflammatory	  milieu	  as	  that	  of	  chorioamnionitis.	  Alternatively	  it	  could	  
be	   that	   the	  changes	   the	   tissue	  undergoes	  by	  virtue	  of	  being	  cultured	  ex	  vivo,	   as	  evidenced	  by	   the	  
significant	  down-­‐regulation	  of	   FKBP51	  as	   compared	   to	   t=0,	   affect	   its	   response	   to	  an	   inflammatory	  
stimulus.	  	  
These	   data	   indicate	   that	   both	   PR	   isoform	   expression	   as	   well	   as	   co-­‐regulator,	   chaperone	   and	   co-­‐
chaperone	  expression	  alter	  with	  the	  onset	  of	  labour.	  However,	  the	  changes	  seen	  differ	  depending	  on	  
the	  underlying	  cause	  of	  labour.	  Although	  a	  causal	  association	  between	  the	  changes	  seen	  and	  labour	  
onset	   cannot	   be	   established	   based	   on	   the	   data	   here,	   it	   can	   be	   hypothesised	   that	   functional	  
progesterone	  withdrawal	  is	  a	  multifactorial	  process	  with	  a	  degree	  of	  redundancy.	  	  
	  
5.3.4.	  Co-­‐regulators	  
This	   is	   the	   first	   report	  of	  a	  decline	   in	  SRC1	   levels	   in	   the	  context	  of	  chorioamnionitis.	  Similar	   to	   the	  
data	   presented	   here,	   other	   investigators	   found	   no	   change	   to	   myometrial	   SRC1	   levels	   with	   term	  
labour	  (201).	   Interestingly,	  a	  decline	   in	  SRC1	  protein	   levels	  with	   labour	  onset	  has	  been	  reported	   in	  
choriodecidua	  with	  no	  change	  observed	  in	  amnion	  levels	  (202).	  
No	  change	   in	  SRC2	  and	  SRC3	   levels	  was	  observed	  either	  at	   term	  on	  preterm	   in	   this	  data	   set,	  with	  
similar	   trends	   previously	   observed	   in	   amnion	   and	   choriodecidua	   (202).	   However,	   decreased	   SRC2	  
and	  SRC3	  nuclear	  localisation	  has	  been	  reported	  in	  the	  myometrium	  with	  labour	  onset	  (201).	  	  
A	  significant	  delay	  in	  parturition	  was	  observed	  in	  SRC1	  and	  SRC2	  double-­‐deficient	  mice	  in	  association	  
with	   decreased	   NF-­‐κB	   activation	   and	   decreased	   levels	   of	   contraction-­‐associated	   proteins	   (110).	  
Based	  on	  the	  observation	  that	  double	  deficiency	  was	  required	  for	  the	  delayed	  parturition	  phenotype	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to	  be	  apparent,	  the	  authors	  suggest	  that	  one	  co-­‐activator	  may	  compensate	  for	  deficiency	  in	  another.	  
The	  authors	  reported	  a	  role	  for	  SRC1	  and	  SRC2	  in	  fetal	  lung	  surfactant	  protein-­‐A,	  which	  may	  explain	  
why	  labour	   is	  delayed	  in	  co-­‐activator	  deficient	  mice,	  whereas	   levels	  are	  seen	  to	  decline	   in	  preterm	  
labour	  arising	  due	  to	  chorioamnionitis.	  	  
The	  NCoR	  data	  presented	  here	  are	  contrasting	   in	  that	   levels	  vary	   in	  opposite	  directions	  depending	  
on	   the	   underlying	   cause	   of	   preterm	   labour.	   In	   chorioamnionitis,	   NCoR	   is	   at	   the	   limit	   of	   detection	  
whereas	   in	   the	   context	  of	   twin	  preterm	   labour,	   levels	   are	   significantly	   increased.	   It	  has	  previously	  
been	  shown	  that	  inflammation,	  as	  modelled	  by	  IL-­‐1β	  treatment,	  promotes	  the	  translocation	  of	  NCoR	  
out	   of	   the	   nucleus	   (438),	   where	   it	   may	   degraded	   hence	   providing	   a	   possible	   explanation	   for	   the	  
observation	   made	   in	   the	   context	   of	   severe	   inflammation	   as	   seen	   in	   chorioamnionitis.	   Indeed	  
although	  NCoR	  was	  initially	  shown	  to	  interact	  with	  nuclear	  receptors,	  it	  has	  also	  been	  shown	  to	  exert	  
its	  repressive	  effect	  directly	  on	  pro-­‐inflammatory	  transcription	  factors	  including	  NF-­‐κB	  (439)	  and	  AP-­‐
1	  (440).	  In	  the	  context	  of	  infection,	  Toll-­‐like	  receptors	  are	  stimulated	  by	  bacterial	  components	  with	  
downstream	   signalling	   leading	   to	   transcription	   factor	   phosphorylation	   and	   subsequent	   NCoR	  
dissociation	  and	  destruction	  (440).	  
In	   contrast,	   the	   increase	   seen	   in	   twin	  preterm	   labour,	   as	   compared	   to	  gestationally-­‐matched	  non-­‐
labouring	  twins	  could	  represent	  a	  mechanism	  of	  functional	  progesterone	  withdrawal	  hence	  allowing	  
labour	   to	   proceed.	   Indeed,	   as	   a	   proof	   of	   principle,	   NCoR	   levels	   have	   previously	   been	   shown	   to	  
decline	  after	   treatment	  of	  myometrial	  cells	  with	   foskolin	   (an	  adenylyl	  cyclase	  activator),	  which	  has	  
been	  shown	  to	  enhance	  progesterone	  action	  (177,	  441).	  As	  a	  potential	  alternative	  explanation	  in	  the	  
pattern	  seen,	  Zhu	  et	  al.	  have	  shown	  that	   inflammation	  can	  bring	  about	  a	  switch	   in	  the	  function	  of	  
NCoR	   from	   steroid	   receptor	   (as	   opposed	   to	   inflammatory	   transcription	   factor)	   co-­‐repressor	   to	   co-­‐
activator	  (442),	  hence	  the	  increase	  in	  levels	  could	  represent	  an	  attempted	  compensatory	  mechanism	  
to	  maintain	  uterine	  quiescence.	  	  	  
Taken	   together,	   the	  NCoR	   findings	   firstly	   contradict	   the	  hypothesis	   that	   this	   co-­‐repressor	  plays	  no	  
role	  in	  PR	  physiology	  (106)	  and	  secondly	  serve	  to	  highlight	  that	  preterm	  labour	  is	  not	  a	  diagnosis	  but	  
a	  syndrome	  of	  disease	  with	  different	  underlying	  aetiologies.	  No	  increase	  in	  NCoR	  levels	  was	  seen	  in	  
vitro	   when	   myometrial	   strips	   were	   kept	   under	   differential	   degrees	   of	   tension	   which	   could	   be	   a	  
reflection	  of	  the	  fact	  that	   it	   is	  not	  the	  tension	  that	  alters	  expression	  but	  rather	   labour	  onset	   itself;	  
alternatively,	  this	  could	  be	  a	  reflection	  of	  a	  limitation	  of	  the	  in	  vitro	  model.	  	  
SMRT	  was	   readily	  detectable	  at	   the	  RNA	   level	   in	  myometrial	   samples	  of	   the	   tissue	  bank	  where	  no	  
difference	   was	   detected	   in	   term	   or	   preterm	   labouring	   levels	   as	   compared	   to	   their	   equivalent	  
controls	  (data	  in	  thesis	  by	  Natasha	  Singh).	  SMRT	  may	  not	  have	  been	  detectable	  at	  the	  protein	  level	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due	   to	   a	   multitude	   of	   reasons	   including	   rapid	   protein	   turnover	   or	   degradation	   during	   tissue	  
processing	  in	  the	  laboratory.	  
	  
5.3.5.	  Summary	  
The	   data	   presented	   here	   demonstrate	   that,	   in	   association	   with	   both	   term	   and	   preterm	   labour,	  
changes	   occur	   in	   the	   expression	   pattern	   of	   PR	   and	   some	   of	   its	   associated	   chaperones,	   co-­‐
cochaperones	  and	  co-­‐regulators.	  This	  suggests	  that	  these	  molecules	  may	  be	  implicated	  in	  functional	  
progesterone	  withdrawal.	   Further,	   these	   changes	  do	  not	  universally	   follow	   the	   same	  pattern	  with	  
the	   onset	   of	   each	   labour	   subtype	   suggesting	   that	   labour	   does	   not	   represent	   a	   single	   terminal	  
pathway	   and	   that	   multiple	   mechanisms	   may	   serve	   to	   achieve	   the	   same	   result.	   This	   degree	   of	  
redundancy	  could	   reflect	  an	  evolutionary	  method	  of	  ensuring	   timely	  parturition,	  albeit	  one	   that	   is	  
dysregulated	  in	  preterm	  labour.	  Further	  study	  is	  required	  to	  prove	  causation	  between	  the	  changes	  
reported	  here	  and	   the	  onset	  of	   labour.	   If	   this	   is	   shown	   to	  be	   the	  case,	   then	  novel	  pharmaceutical	  
agents	  could	  be	  developed	  to	  prevent	  the	  onset	  of	  preterm	  labour	  in	  cases	  where	  it	  would	  be	  safe	  to	  
do	  so.	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CHAPTER	  6:	  FINAL	  SUMMARY	  AND	  DISCUSSION	  
Preterm	  birth	  has	  a	  significant	  worldwide	   impact	  and	  there	  has	  been	  minimal	  progress	   in	  reducing	  
its	   rate.	   Progesterone	   is	   currently	   the	   only	   pharmacological	   agent	   in	   widespread	   use	   aiming	   to	  
reduce	   the	   incidence	   of	   preterm	   labour	   in	   high-­‐risk	   women.	   However,	   its	   efficacy	   is	   increasingly	  
questioned.	   Nevertheless,	   there	   is	   a	   substantial	   body	   of	   evidence	   both	   from	   animal	   and	   human	  
studies	   to	   show	   that	   progesterone	   acts	   to	  maintain	   uterine	   quiescence	   and	   suppress	   the	   labour-­‐
associated	  pro-­‐inflammatory	  phenotype	  and	   increases	   in	   contraction-­‐associated	  proteins.	   	   For	   this	  
reason,	  understanding	  the	  mechanism	  of	  progesterone	  action	  is	  more	  important	  than	  ever	  in	  order	  
to	  facilitate	  the	  development	  of	  novel	  therapeutic	  agents	  to	  combat	  preterm	  labour.	  	  
	  
6.1.	  Principal	  findings	  
The	  data	  presented	  in	  this	  thesis	  serve	  to	  confirm	  the	  anti-­‐inflammatory	  action	  of	  progesterone	  both	  
in	   vivo	   and	   in	   vitro.	   Further,	   they	   raise	   questions	   as	   to	   the	   importance	   of	   this	   anti-­‐inflammatory	  
action	   in	   the	   context	   of	   labour	   onset	   as	   (i)	   labour	   does	   not	   occur	   in	   progesterone-­‐supplemented	  
mice	  despite	   increasing	   inflammation,	  and	   (ii)	  progesterone	  maintains	   its	  anti-­‐inflammatory	  action	  
after	   labour	  onset	   in	  myometrial	   explants.	  As	  potential	   alternative	  mechanisms	  underlying	  human	  
labour	   onset,	   this	   thesis	   has	   identified	   changes	   in	   PR	   isoform	   as	   well	   certain	   co-­‐regulator	   and	  
chaperone	  levels,	  which	  could	  alter	  progesterone	  action	  and	  enhance	  myometrial	  contractility.	  
Murine	   labour	   has	   been	   shown	   to	   be	   associated	   with	   an	   inflammatory	   phenotype	   and	   increased	  
levels	   of	   contraction-­‐associated	   proteins.	   Upon	   progesterone	   supplementation,	   labour	   was	  
abolished	   in	  association	  with	  a	  delay,	  but	  not	   complete	   loss,	  of	   inflammation.	   In	   contrast,	   the	  up-­‐
regulation	  of	   contraction-­‐associated	  proteins	  was	   completely	   lost.	  No	   significant	   change	   in	   second	  
messenger	   action	   was	   seen	   either	   in	   control	   labour	   or	   after	   progesterone	   supplementation.	   	   In	  
contrast,	  RU486-­‐induced	  preterm	  labour	  was	  characterised	  by	  inflammation,	  increased	  contraction-­‐
associated	  protein	  expression	  and	  elevated	  levels	  of	  p65	  and	  p38	  phosphorylation.	  Taken	  together,	  
the	  main	  conclusion	  of	  these	  animal	  studies	  was	  that	  inflammation	  is	  a	  feature	  of	  mouse	  labour	  but,	  
on	   its	  own,	   it	  does	  not	  appear	  to	  be	  sufficient	  to	  bring	  about	  parturition	  as	   it	  remains	  a	  feature	  of	  
progesterone-­‐supplemented	  mice	  which	  fail	  to	  go	  into	  labour.	  	  
A	   link	   between	   circadian	   rhythm	   and	   the	   inflammatory	   response	   has	   previously	   been	   reported,	  
possibly	  mediated	   through	   the	   Rev-­‐Erb	   family	   of	   nuclear	   receptors	   (443)	   or	   via	   an	   interaction	   of	  
Clock	  with	  NF-­‐κB	  (162).	  This	  suggests	  that	  the	  circadian	  clock	  may	  directly	  contribute	  to	  the	  labour-­‐
associated	  inflammatory	  phenotype.	  However,	  the	  findings	  presented	  here	  are	  inconsistent	  with	  the	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levels	  of	  certain	  ‘pro-­‐inflammatory’	  circadian	  genes,	  such	  as	  Clock,	  being	  unaffected	  by	  progesterone	  
levels.	  Nevertheless,	  it	  would	  be	  interesting	  to	  study	  these	  genes	  further,	  for	  example	  at	  the	  protein	  
level,	   in	   order	   to	   further	   define	   their	   expression	   pattern	   and	   hence	   their	   possible	   role	   in	   labour	  
onset.	  	  
Much	   of	   the	   in	   vitro	   work	   conducted	   previously	   used	   the	   hTERT-­‐HM	   cell	   line	   and/or	   primary	  
myometrial	   cell	   culture.	   This	   thesis	   demonstrates	   for	   the	   first	   time	   that,	   even	   though	   these	   cell	  
models	  may	   allow	   for	   easy	   study	   of	   intracellular	   cell	   pathways,	   their	   gene	   expression	   profiles	   are	  
markedly	  different	   to	   the	   in	  vivo	   state.	   In	  order	   to	  mitigate	   this	  observation,	  a	  human	  myometrial	  
explant	  model	  was	   developed	   and	   validated	   to	   a	   far	   greater	   degree	   than	   previously.	   The	   explant	  
model	   was	   used	   to	   study	   the	   anti-­‐inflammatory	   action	   of	   progesterone,	   firstly	   in	   the	   absence	   of	  
labour,	  demonstrating	  that	  progesterone	  acts	  most	   likely	  via	   the	  nuclear	  progesterone	  receptor	  to	  
repress	   both	   contraction-­‐associated	   protein	   levels,	   as	   shown	   by	   COX-­‐2,	   and	   pro-­‐inflammatory	  
cytokine	   levels,	   as	   evidenced	   by	   CXCL2,	   IL-­‐6	   and	   IL-­‐8.	   These	   observations	  were	   associated	  with	   a	  
decline	  in	  both	  NF-­‐κB	  and	  AP-­‐1	  activation,	  but	  without	  any	  change	  to	  their	  respective	  inhibitors,	  IκBα	  
and	  MKP-­‐1.	  Most	  controversially,	  progesterone	  treatment	  of	  myometrium	  obtained	  from	  women	  in	  
early	  or	  established	  labour	  showed	  that	  progesterone	  retained	  the	  ability	  to	  repress	  inflammation.	  	  
With	   the	   exception	   of	   two	   genes,	   treatment	   of	   non-­‐labouring	  myometrium	  with	   RU486	   failed	   to	  
identify	  any	  genes	  which	  were	  upregulated	  or	  downregulated.	  This	  suggests	   that	   the	  myometrium	  
may	  not	  be	  the	  target	  organ	  of	  RU486	  in	  humans	  or,	  alternatively,	  that	  the	  drug	  actually	  acts	  at	  the	  
post-­‐translation	   level.	   This	   contradicts	   the	   findings	   observed	   in	   murine	   RU486-­‐induced	   preterm	  
labour,	  which	  is	  characterised	  by	  an	  inflammatory	  and	  pro-­‐contractile	  phenotype.	  It	  is	  possible	  that	  
in	   the	  murine	  model,	   choriodecidual	   tissue	   is	   initially	   targeted	   by	   RU486,	   as	   has	   been	   previously	  
suggested	   (444),	  which	   sets	  off	  an	   inflammatory	  cascade	   subsequently	   involving	   the	  myometrium.	  
This	  would	  also	  explain	  why,	  in	  the	  presence	  of	  IL-­‐1β-­‐driven	  inflammation	  in	  vitro,	  RU486	  appears	  to	  
antagonise	  the	  action	  of	  progesterone.	  	  
With	  the	  onset	  of	  both	  preterm	  and	  term	  human	  labour,	  there	  is	  no	  evidence	  of	  a	  local	  withdrawal	  
of	   progesterone	   levels	   suggesting	   this	   is	   unlikely	   to	   be	   a	   mechanism	   underlying	   functional	  
progesterone	   withdrawal.	   An	   increase	   in	   the	   PR-­‐A:PR-­‐B	   ratio	   was	   noted	   with	   the	   onset	   of	   term	  
labour	   but	   this	   was	   not	   the	   case	   for	   the	   underlying	   aetiologies	   of	   preterm	   labour	   studied.	   This	  
highlights	   that	   the	  mechanism	   underlying	   labour	   onset	  may	   be	  multifactorial,	   but	   even	   if	   so,	   it	   is	  
unclear	  what	  stimulates	  the	  change	  in	  the	  balance	  of	  PR	  isoforms	  with	  term	  labour.	  Further,	  changes	  
in	   the	   expression	   of	   chaperones,	   co-­‐chaperones	   as	  well	   as	   co-­‐regulators	  were	   observed	   in	   labour	  
due	  to	  multiple	  aetiologies;	  however,	  the	  most	  marked	  changes	  were	  noted	  to	  be	  in	  the	  context	  of	  
chorioamnionitis.	   Here,	   NCoR	   levels	   were	   markedly	   reduced	   suggesting	   a	   loss	   of	   its	   possible	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repressive	   effect	   on	   inflammation	   (439,	   440).	   Indeed,	   NCoR	   has	   been	   shown	   to	   work	   with	   the	  
circadian	  rhythm	  Rev-­‐Erb	  nuclear	  receptor	  family	  to	  repress	  inflammation,	  hence	  providing	  another	  
possible	  mechanism	  for	  the	  inflammatory	  phenotype	  seen	  in	  this	  context	  (443).	  
In	  conclusion,	  although	  the	  underlying	  mechanism	  has	  not	  been	  confirmed,	  these	  data	  suggest	  that	  
different	  pathways	  could	  precipitate	  labour	  both	  at	  term	  and	  preterm.	  Further	  it	  seems	  possible	  that	  
it	   is	   not	   a	   single	  mechanism	   that	   brings	   about	   the	   onset	   of	   labour	   but	   rather	  multiple	   ones.	   This	  
degree	  of	  redundancy	  could	  offer	  an	  evolutionary	  advantage	  by	  ensuring	  parturition	  can	  go	  proceed	  
even	  if	  one	  pathway	  is	  blocked.	  	  
	  
6.2.	  Future	  work	  
In	  order	  to	  further	  study	  the	  role	  of	  p65	  and	  p38	  in	  murine	  RU486-­‐induced	  preterm	  labour,	  the	  cre-­‐
loxP	  technique	  could	  be	  utilised	  to	  selectively	  abolish	  the	  expression	  of	  these	  transcription	  factors	  in	  
the	  myometrium.	  This	  would	  allow	  determination	  of	  their	  relative	  importance	  in	  mediating	  the	  pro-­‐
contractile	  and	  pro-­‐inflammatory	  phenotype	  observed	  in	  the	  myometrium	  of	  these	  animals.	  
The	   data	   from	   the	   progesterone	   supplementation	   murine	   study	   presented	   in	   this	   thesis	  
demonstrated	  an	  inflammatory	  phenotype	  by	  E20	  in	  the	  absence	  of	  a	  contraction-­‐associated	  protein	  
up-­‐regulation.	  It	  is	  unclear	  whether	  this	  phenotype	  arose	  due	  to	  pup	  death-­‐induced	  inflammation	  or	  
a	  human-­‐type	   functional	  progesterone	  withdrawal.	  For	   this	   reason,	  progesterone	  supplementation	  
will	   be	   undertaken	   in	   pregnant	   mice	   fitted	   with	   telemetry	   probes	   capable	   of	   measuring	   uterine	  
activity.	   Delivery	   of	   the	   pups	   will	   be	   performed	   by	   Caesarean	   section	   upon	   detection	   of	   uterine	  
activity,	   in	   order	   to	   assess	   pup	   viability	   and	   subsequently	   quantify	   cytokines	   and	   contraction-­‐
associated	  protein	  levels.	  	  
The	   role	   of	   circadian	   rhythm	   genes	   should	   be	   further	   studied	   at	   the	   protein	   level	   in	   control,	  
progesterone-­‐supplemented	   and	   RU486-­‐treated	  mice.	   Further,	   a	   ChIP-­‐Seq	   study	   of	   PR	   binding	   in	  
pregnant	  women	   before	   and	   after	   the	   onset	   of	   labour	  would	   serve	   to	   identify	  whether	   circadian	  
rhythm	   genes	   are	   modulated	   with	   parturition.	   Additionally,	   such	   a	   study	   would	   allow	   for	   broad	  
identification	  of	  potential	  changes	  to	  PR	  targets.	  	  
Progesterone	  signalling	  in	  the	  explant	  model	  can	  be	  further	  studied	  by	  using	  adenoviral	  technology	  
to	   knockdown	   PR	   or	   GR	   and	   definitively	   determine	   the	   nuclear	   receptor(s)	   through	   which	   this	  
hormone	  signals.	  Further,	  it	  would	  be	  important	  to	  carry	  out	  a	  gene	  expression	  analysis	  study	  using	  
myometrium	   in	   explant	   culture	   and	   primary	   cell	   culture	   obtained	   from	   women	   in	   early	   and	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established	  labour.	  This	  would	  confirm,	  as	  with	  term	  no	  labour,	  whether	  the	  labouring	  phenotype	  is	  
preserved	  in	  explants	  to	  a	  greater	  degree	  than	  in	  primary	  cells.	  	  
Given	  that	  NCoR	  knockout	  is	  lethal	  in	  the	  embryonic	  period	  (445),	  the	  role	  of	  NCoR	  could	  be	  further	  
investigated	   by	   undertaking	   a	   ChIP-­‐Seq	   study	   to	   identify	   NCoR-­‐DNA	   interactions	   in	   preterm	   non-­‐
labouring	  women	  and	  those	  in	  preterm	  labour	  secondary	  to	  chorioamnionitis.	  This	  will	  facilitate	  the	  
identification	  of	  NCoR	  target	  genes	  in	  the	  quiescent	  and	  active	  myometrium,	  hence	  allowing	  further	  
elucidation	  of	  its	  mechanism	  of	  action.	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Appendix	  1.	  Top	  50	  genes	  in	  explants	  versus	  t=0.	  
Gene	  Assignment	   Gene	  Symbol	   RefSeq	  
perilipin	  2	  	   PLIN2	   NR_038064	  
homocysteine-­‐inducible,	  endoplasmic	  reticulum	  stress-­‐
inducible,	  ubiquitin-­‐Like	  domain	  member	  1	   HERPUD1	   ENST00000439977	  
solute	  carrier	  family	  38,	  member	  5	  	   SLC38A5	   NM_033518	  
bradykinin	  receptor	  B1	   BDKRB1	   ENST00000216629	  
6-­‐phosphofructo-­‐2-­‐kinase/fructose-­‐2,6-­‐biphosphatase	  3	  	   PFKFB3	   NM_004566	  
high	  mobility	  group	  AT-­‐hook	  1	  	   HMGA1	   BT006774	  
uncharacterized	  LOC100134229	  	  
LOC10013422
9	   NR_024451	  
dual-­‐specificity	  tyrosine-­‐(Y)-­‐phosphorylation	  regulated	  
kinase	   DYRK3	   NM_001004023	  
neuromedin	  B	  	   NMB	   NM_021077	  
bone	  morphogenetic	  protein	  2	  	   BMP2	   NM_001200	  
HIF1A-­‐AS2	  	   HIF1A-­‐AS2	  
OTTHUMT0000041186
4	  
breast	  cancer	  anti-­‐oestrogen	  resistance	  1	   BCAR1	   NM_001170714	  
lung	  cancer	  associated	  transcript	  1	  (non-­‐protein	  coding)	  	   LUCAT1	   AK091866	  
ectodysplasin	  A2	  receptor	  	   EDA2R	   ENST00000374719	  
membrane-­‐spanning	  4-­‐domains,	  subfamily	  A,	  member	  
4A	  //	  11q	   MS4A4A	   ENST00000355131	  
sestrin	  2	  	   SESN2	   NM_031459	  
ring	  finger	  protein	  24	  	   RNF24	   NM_007219	  
angiopoietin-­‐like	  4	  	   ANGPTL4	   NM_139314	  
stearoyl-­‐CoA	  desaturase	  (delta-­‐9-­‐desaturase)	  	   SCD	   NM_005063	  
chromosome	  3	  open	  reading	  frame	  35	   C3orf35	   ENST00000328376	  
integrin,	  alpha	  2	  (CD49B,	  alpha	  2	  subunit	  of	  VLA-­‐2	  
receptor)	  	   ITGA2	   NR_073105	  
phosphoglycerate	  kinase	  1	  	   PGK1	   ENST00000373316	  
family	  with	  sequence	  similarity	  171,	  member	  B	  	   FAM171B	   ENST00000304698	  
cytochrome	  P450,	  family	  1,	  subfamily	  A,	  polypeptide	  1	  	   CYP1A1	   NM_000499	  
protein	  phosphatase	  1,	  regulatory	  subunit	  15A	  	   PPP1R15A	   NM_014330	  
B-­‐cell	  translocation	  gene	  1,	  anti-­‐proliferative	  	   BTG1	   NM_001731	  
microRNA	  126	   MIR126	   NR_029695	  
ADAM	  metallopeptidase	  with	  thrombospondin	  type	  1	  
motif,	  4	   ADAMTS4	   NM_005099	  
PAP	  associated	  domain	  containing	  7	  	   PAPD7	   NM_006999	  
uncharacterized	  LOC401281	   FLJ27255	   AK130765	  
high	  mobility	  group	  AT-­‐hook	  1	  	   HMGA1	   NM_145901	  
quinone	  oxidoreductase-­‐like	  protein	  2	  pseudogene	  	   LOC730102	   NR_037167	  
stanniocalcin	  1	  	   STC1	   NM_003155	  
BCL2/adenovirus	  E1B	  19kDa	  interacting	  protein	  3	  	   BNIP3	   NM_004052	  
gamma-­‐aminobutyric	  acid	  (GABA)	  A	  receptor,	  rho	  2	  	   GABRR2	   NM_002043	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decapping	  mRNA	  1A	  	   DCP1A	   NM_018403	  
C-­‐type	  lectin	  domain	  family	  2,	  member	  B	  	   CLEC2B	   ENST00000228438	  
fibrillin	  1	  	   FBN1	   NM_000138	  
Sec61	  gamma	  subunit	  	   SEC61G	   NM_014302	  
HIF1A	  antisense	  RNA	  2	  	   HIF1A-­‐AS2	   NR_045406	  
death	  effector	  domain	  containing	  2	  	   DEDD2	   NM_133328	  
small	  integral	  membrane	  protein	  3	  	   SMIM3	   NM_032947	  
ribosomal	  protein	  S27	  	   RPS27	   ENST00000493224	  
Rho	  family	  GTPase	  3	  	   RND3	   NM_001254738	  
Solute	  Carrier	  Family	  9,	  Subfamily	  B	  (NHA2,	  Cation	  
Proton	  Antiporter	  2),	  Member	  2	   SLC9B2	   NM_178833	  
activating	  transcription	  factor	  3	   ATF3	   NM_001040619	  
tropomyosin	  1	  (alpha)	  	   TPM1	   NM_000366	  
tumor	  necrosis	  factor	  receptor	  superfamily,	  member	  
10d,	  decoy	   TNFRSF10D	   NM_003840	  
DnaJ	  (Hsp40)	  homolog,	  subfamily	  B,	  member	  9	  	   DNAJB9	   ENST00000249356	  
DnaJ	  (Hsp40)	  homolog,	  subfamily	  B,	  member	  1	  	   DNAJB1	   NM_006145	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Appendix	  2.	  Top	  50	  genes	  in	  primary	  cells	  versus	  t=0.	  
Gene	  Assignment	   Gene	  Symbol	   RefSeq	  
myosin,	  heavy	  chain	  11,	  smooth	  muscle	  	   MYH11	   NM_002474	  
SPARC-­‐like	  1	  (hevin)	  	   SPARCL1	   NM_001128310	  
major	  histocompatibility	  complex,	  class	  II,	  DR	  alpha	  	   HLA-­‐DRA	   ENST00000416883	  
major	  histocompatibility	  complex,	  class	  II,	  DR	  alpha	  	   HLA-­‐DRA	   BC071659	  
sulfatase	  2	  	   SULF2	   NM_198596	  
desmin	  	   DES	   NM_001927	  
frizzled	  family	  receptor	  2	  	   FZD2	   NM_001466	  
major	  histocompatibility	  complex,	  class	  II,	  DR	  alpha	   HLA-­‐DRA	   AK301134	  
kinesin	  family	  member	  26B	  	   KIF26B	   NM_018012	  
growth	  regulation	  by	  oestrogen	  in	  breast	  cancer	  1	  	   GREB1	   NM_014668	  
glutathione	  peroxidase	  8	  (putative)	  	   GPX8	   NM_001008397	  
synaptic	  vesicle	  glycoprotein	  2A	   SV2A	   NM_014849	  
von	  Willebrand	  factor	  	   VWF	   NM_000552	  
mannose	  receptor,	  C	  type	  1	  	   MRC1	   ENST00000239761	  
TYRO	  protein	  tyrosine	  kinase	  binding	  protein	  	   TYROBP	   NM_003332	  
mannose	  receptor,	  C	  type	  1	  	   MRC1	   ENST00000239761	  
amine	  oxidase,	  copper	  containing	  3	  	   AOC3	   NM_003734	  
membrane-­‐spanning	  4-­‐domains,	  subfamily	  A,	  member	  7	  	   MS4A7	   NM_021201	  
serpin	  peptidase	  inhibitor,	  clade	  B	  (ovalbumin),	  member	  7	   SERPINB7	   NM_003784	  
RAB3B,	  member	  RAS	  oncogene	  family	  	   RAB3B	   NM_002867	  
calponin	  2	  	   CNN2	   NM_004368	  
delta-­‐like	  4	  (Drosophila)	  	   DLL4	   NM_019074	  
CD14	  molecule	  	   CD14	   ENST00000302014	  
protocadherin	  10	  	   PCDH10	   NM_032961	  
lysosomal	  protein	  transmembrane	  5	  	   LAPTM5	   NM_006762	  
reversion-­‐inducing-­‐cysteine-­‐rich	  protein	  with	  kazal	  motifs	  	   RECK	   ENST00000377966	  
chordin-­‐like	  1	  	   CHRDL1	   NM_001143981	  
methylsterol	  monooxygenase	  1	  	   MSMO1	   ENST00000261507	  
fms-­‐related	  tyrosine	  kinase	  1	  	   FLT1	   NM_002019	  
teneurin	  transmembrane	  protein	  4	  	   TENM4	   ENST00000278550	  
tandem	  C2	  domains,	  nuclear	  	   TC2N	   NM_152332	  
hemicentin	  1	  	   HMCN1	   NM_031935	  
engulfment	  and	  cell	  motility	  1	  	   ELMO1	   NM_001206480	  
fibroblast	  growth	  factor	  5	  	   FGF5	   NM_004464	  
MIR31	  host	  gene	  (non-­‐protein	  coding)	  	   MIR31HG	   NR_027054	  
cadherin	  5,	  type	  2	  (vascular	  endothelium)	  	   CDH5	   NM_001795	  
palmdelphin	  	   PALMD	   NM_017734	  
solute	  carrier	  family	  9,	  subfamily	  A	  (NHE7,	  cation	  proton	  ant	   SLC9A7	   NM_001257291	  
solute	  carrier	  family	  16,	  member	  2	  (thyroid	  hormone	  
transporter)	   SLC16A2	   NM_006517	  
potassium	  channel,	  subfamily	  K,	  member	  2	  	   KCNK2	   NM_001017424	  
chromodomain	  helicase	  DNA	  binding	  protein	  7	   CHD7	   NM_017780	  
//	  7-­‐dehydrocholesterol	  reductase	  	   DHCR7	   ENST00000355527	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neuritin	  1	  	   NRN1	   NM_016588	  
cytochrome	  b-­‐245,	  beta	  polypeptide	   CYBB	   NM_000397	  
kinase	  insert	  domain	  receptor	  (a	  type	  III	  receptor	  tyrosine	  
kinase)	   KDR	   NM_002253	  
alpha-­‐2-­‐macroglobulin	  	   A2M	   ENST00000318602	  
phosphoserine	  phosphatase	  	   PSPH	   NM_004577	  
lymphocyte	  cytosolic	  protein	  2	  (SH2	  domain	  containing	  
leukocyte	  protein	  of	  76kDa) 	   LCP2	   ENST00000046794	  
serpin	  peptidase	  inhibitor,	  clade	  F	  (alpha-­‐2	  antiplasmin,	  
pigment	  epithelium	  derived	  factor),	  member	  1 	   SERPINF1	   NM_002615	  
regulator	  of	  cell	  cycle	  	   RGCC	   NM_014059	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Appendix	  3.	  Top	  50	  genes	  in	  hTERT-­‐HM	  versus	  t=0.	  
Gene	  Assignment	   Gene	  Symbol	   RefSeq	  
telomerase	  reverse	  transcriptase	  	   TERT	   NM_198253	  
uncharacterized	  LOC643401	   LOC643401	   NR_038848	  
insulin-­‐like	  growth	  factor	  2	  mRNA	  binding	  protein	  1	   IGF2BP1	   NM_006546	  
SPANX	  family,	  member	  B1	  	   SPANXB1	   NM_032461	  
cadherin	  12,	  type	  2	  (N-­‐cadherin	  2)	  	   CDH12	   NM_004061	  
keratoconus	  gene	  6	  	   KC6	   NR_002838	  
synovial	  sarcoma,	  X	  breakpoint	  1	   SSX1	   NM_005635	  
myosin,	  heavy	  chain	  11,	  smooth	  muscle	  	   MYH11	   NM_002474	  
sulfatase	  2	  	   SULF2	   NM_198596	  
major	  histocompatibility	  complex,	  class	  II,	  DR	  alpha	   HLA-­‐DRA	   ENST00000416883	  
SPARC-­‐like	  1	  (hevin)	  	   SPARCL1	   NM_001128310	  
major	  histocompatibility	  complex,	  class	  II,	  DR	  alpha	   HLA-­‐DRA	   BC071659	  
cadherin	  9,	  type	  2	  (T1-­‐cadherin)	   CDH9	   NM_016279	  
thymocyte	  expressed,	  positive	  selection	  associated	  1	   TESPA1	   NM_001136030	  
frizzled	  family	  receptor	  2	  	   FZD2	   NM_001466	  
ZNF667	  antisense	  RNA	  1	  (head	  to	  head)	   ZNF667-­‐AS1	   NR_036521	  
desmin	  	   DES	   NM_001927	  
CSAG	  family,	  member	  2	  	   CSAG2	   NM_001080848	  
chloride	  channel	  accessory	  2	   CLCA2	   NM_006536	  
major	  histocompatibility	  complex,	  class	  II,	  DR	  alpha	   HLA-­‐DRA	   AK301134	  
uncharacterized	  LOC100506465	   LOC100506465	   BC007399	  
synaptic	  vesicle	  glycoprotein	  2A	   SV2A	   NM_014849	  
growth	  regulation	  by	  oestrogen	  in	  breast	  cancer	  1	  	   GREB1	   NM_014668	  
transcription	  factor	  AP-­‐2	  alpha	  (activating	  enhancer	  
binding	  protein	  2	  alpha) 	   TFAP2A	   NM_003220	  
mannose	  receptor,	  C	  type	  1	   MRC1	   ENST00000239761	  
membrane-­‐spanning	  4-­‐domains,	  subfamily	  A,	  member	  7	  	   MS4A7	   NM_021201	  
mannose	  receptor,	  C	  type	  1	  	   MRC1	   ENST00000239761	  
neurofibromin	  1	  	   NF1	   NM_001042492	  
chromosome	  7	  open	  reading	  frame	  69	   C7orf69	   ENST00000258776	  
von	  Willebrand	  factor	  	   VWF	   NM_000552	  
TYRO	  protein	  tyrosine	  kinase	  binding	  protein	  	   TYROBP	   NM_003332	  
chemokine	  (C-­‐X-­‐C	  motif)	  ligand	  6	  	   CXCL6	   NM_002993	  
melanoma	  antigen	  family	  C,	  2	  	   MAGEC2	   NM_016249	  
serpin	  peptidase	  inhibitor,	  clade	  B	  (ovalbumin),	  member	  7	  	   SERPINB7	   NM_003784	  
kinesin	  family	  member	  26B	  	   KIF26B	   NM_018012	  
amine	  oxidase,	  copper	  containing	  3	  	   AOC3	   NM_003734	  
regulator	  of	  cell	  cycle	   RGCC	   NM_014059	  
glucosidase,	  beta,	  acid	  3	   GBA3	   NM_020973	  
alpha-­‐2-­‐macroglobulin	  	   A2M	   ENST00000318602	  
gamma-­‐aminobutyric	  acid	  (GABA)	  A	  receptor,	  alpha	  3	   GABRA3	   ENST00000370314	  
tandem	  C2	  domains,	  nuclear	  	   TC2N	   NM_152332	  
fibroblast	  growth	  factor	  5	  	   FGF5	   NM_004464	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insulin-­‐like	  growth	  factor	  2	  mRNA	  binding	  protein	  3	  	   IGF2BP3	   NM_006547	  
palmdelphin	  	   PALMD	   NM_017734	  
teneurin	  transmembrane	  protein	  4	  	   TENM4	   ENST00000278550	  
protocadherin	  10	  	   PCDH10	   NM_032961	  
Serpin	  Peptidase	  Inhibitor,	  Clade	  F	  (Alpha-­‐2	  Antiplasmin,	  
Pigment	  Epithelium	  Derived	  Factor),	  Member	  1	   SERPINF1	   NM_002615	  
maltase-­‐glucoamylase	  (alpha-­‐glucosidase)	  	   MGAM	   ENST00000549489	  
transmembrane	  and	  tetratricopeptide	  repeat	  containing	  1	  	   TMTC1	   NM_001193451	  
heat	  shock	  70kDa	  protein	  2	  	   HSPA2	   NM_021979	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Appendix	  4.	  Gene	  ontology	  analysis	  for	  explants	  versus	  t=0.	  	  
Function	   Enrichment	  
Score	  
Enrichment	  p-­‐
value	  
%	  genes	  in	  
group	  that	  
are	  present	  
immune	  response	   29.0041	   2.53E-­‐13	   14.9123	  
cytokine-­‐mediated	  signalling	  pathway	   28.4038	   4.62E-­‐13	   20.7547	  
inflammatory	  response	   22.3597	   1.95E-­‐10	   15.7205	  
response	  to	  hypoxia	   22.1686	   2.36E-­‐10	   17.9641	  
extracellular	  space	   20.5483	   1.19E-­‐09	   9.82962	  
response	  to	  lipopolysaccharide	   20.3534	   1.45E-­‐09	   19.3798	  
extracellular	  region	   19.8179	   2.47E-­‐09	   7.65115	  
cellular	  response	  to	  hypoxia	   17.9436	   1.61E-­‐08	   36.3636	  
positive	  regulation	  of	  anti-­‐apoptosis	   15.8059	   1.37E-­‐07	   30.7692	  
type	  I	  interferon-­‐mediated	  signalling	  pathway	   15.1649	   2.59E-­‐07	   23.0769	  
cell-­‐cell	  signalling	   14.9215	   3.31E-­‐07	   12.9707	  
leukocyte	  migration	   14.5442	   4.83E-­‐07	   17.9245	  
growth	  factor	  activity	   14.1574	   7.10E-­‐07	   14.7239	  
response	  to	  drug	   14.0709	   7.75E-­‐07	   11.6667	  
response	  to	  organic	  cyclic	  compound	   13.6675	   1.16E-­‐06	   16.9643	  
interferon-­‐gamma-­‐mediated	  signalling	  pathway	   13.1599	   1.93E-­‐06	   21.2121	  
cellular	  response	  to	  interleukin-­‐1	   12.4244	   4.02E-­‐06	   43.75	  
endoplasmic	  reticulum	  unfolded	  protein	  
response	   12.3719	   4.24E-­‐06	   36.3636	  
positive	  regulation	  of	  T	  cell	  proliferation	   12.349	   4.33E-­‐06	   27.7778	  
positive	  regulation	  of	  angiogenesis	   12.1932	   5.06E-­‐06	   22.6415	  
positive	  regulation	  of	  apoptosis	   12.1606	   5.23E-­‐06	   13.9241	  
blood	  coagulation	   12.1252	   5.42E-­‐06	   9.67033	  
proteinaceous	  extracellular	  matrix	   12.0617	   5.78E-­‐06	   12.5	  
signal	  transduction	   12.0422	   5.89E-­‐06	   7.59275	  
anti-­‐apoptosis	   12.0125	   6.07E-­‐06	   12.7551	  
positive	  regulation	  vascular	  endothelial	  growth	  
factor	  production	   11.7508	   7.88E-­‐06	   50	  
cell	  surface	  receptor	  linked	  signalling	  pathway	   11.649	   8.73E-­‐06	   13.4969	  
chemokine	  activity	   11.6282	   8.91E-­‐06	   23.4043	  
organ	  regeneration	   11.2001	   1.37E-­‐05	   22.449	  
response	  to	  radiation	   10.9541	   1.75E-­‐05	   30.7692	  
positive	  regulation	  of	  neutrophil	  chemotaxis	   10.6537	   2.36E-­‐05	   42.8571	  
plasma	  membrane	   10.58	   2.54E-­‐05	   6.08797	  
negative	  regulation	  of	  cell	  proliferation	   10.2622	   3.49E-­‐05	   10.2236	  
cellular	  response	  to	  lipopolysaccharide	   10.0738	   4.22E-­‐05	   24.3243	  
negative	  regulation	  of	  smooth	  muscle	  cell	  
proliferation	   9.97171	   4.67E-­‐05	   31.8182	  
apoptosis	   9.93622	   4.84E-­‐05	   8.46024	  
extracellular	  matrix	  structural	  constituent	   9.68814	   6.20E-­‐05	   17.9104	  
complement	  activation	   9.54493	   7.16E-­‐05	   25.8065	  
negative	  regulation	  of	  hormone	  secretion	   9.37849	   8.45E-­‐05	   45.4545	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response	  to	  nicotine	   9.34679	   8.72E-­‐05	   29.1667	  
skeletal	  system	  development	   9.31651	   8.99E-­‐05	   13.4921	  
response	  to	  progesterone	  stimulus	   9.05965	   0.000116264	   28	  
chemotaxis	   8.90817	   0.000135279	   13.5593	  
response	  to	  unfolded	  protein	   8.90323	   0.000135949	   19.2308	  
integrin-­‐mediated	  signalling	  pathway	   8.75216	   0.00015812	   17.4603	  
response	  to	  hyperoxia	   8.65598	   0.000174083	   31.5789	  
glycolysis	   8.63022	   0.000178626	   20.4545	  
blood	  circulation	   8.63022	   0.000178626	   20.4545	  
cytokine	  activity	   8.59552	   0.000184932	   11.9497	  
positive	  regulation	  of	  smooth	  muscle	  cell	  
proliferation	   8.40999	   0.000222633	   22.2222	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Appendix	  5.	  Gene	  ontology	  analysis	  for	  primary	  cells	  versus	  t=0.	  	  
Function	   Enrichment	  
Score	  
Enrichment	  p-­‐
value	  
%	  genes	  in	  
group	  that	  are	  
present	  
plasma	  membrane	   60.1451	   7.57E-­‐27	   16.487	  
integral	  to	  plasma	  membrane	   45.7151	   1.40E-­‐20	   20.9419	  
cell	  adhesion	   45.1446	   2.48E-­‐20	   24.7756	  
extracellular	  matrix	   36.6345	   1.23E-­‐16	   36.9128	  
blood	  coagulation	   36.2732	   1.77E-­‐16	   24.6154	  
extracellular	  region	   36.1841	   1.93E-­‐16	   17.068	  
inflammatory	  response	   32.0628	   1.19E-­‐14	   29.6943	  
proteinaceous	  extracellular	  matrix	   29.5559	   1.46E-­‐13	   29.8077	  
platelet	  activation	   28.4874	   4.25E-­‐13	   28.2051	  
cholesterol	  biosynthetic	  process	   27.8939	   7.69E-­‐13	   66.6667	  
signal	  transduction	   27.546	   1.09E-­‐12	   17.8602	  
immune	  response	   26.3937	   3.45E-­‐12	   24.269	  
leukocyte	  migration	   24.7654	   1.76E-­‐11	   35.8491	  
membrane	   23.8611	   4.34E-­‐11	   14.0741	  
cell	  surface	   23.5704	   5.80E-­‐11	   24.8227	  
receptor	  activity	   23.0416	   9.84E-­‐11	   16.2581	  
aging	   21.1714	   6.39E-­‐10	   32.7434	  
integral	  to	  membrane	   21.0608	   7.14E-­‐10	   13.7343	  
extracellular	  space	   20.6671	   1.06E-­‐09	   18.3486	  
angiogenesis	   20.5654	   1.17E-­‐09	   29.4521	  
biological	  regulation	   20.0316	   2.00E-­‐09	   24.5902	  
cell-­‐cell	  signalling	   19.8818	   2.32E-­‐09	   24.6862	  
biological_process	   19.5308	   3.30E-­‐09	   24.2915	  
defense	  response	  to	  virus	   19.4729	   3.49E-­‐09	   47.619	  
positive	  regulation	  of	  cell	  proliferation	   19.3092	   4.11E-­‐09	   22.1557	  
integrin-­‐mediated	  signalling	  pathway	   19.2325	   4.44E-­‐09	   39.6825	  
regulation	  of	  biological	  process	   18.4562	   9.65E-­‐09	   24.7706	  
integrin	  complex	   16.9651	   4.29E-­‐08	   53.5714	  
calcium	  ion	  binding	   16.5537	   6.47E-­‐08	   18.0153	  
regulation	  of	  cellular	  process	   16.4815	   6.95E-­‐08	   28.0303	  
response	  to	  drug	   16.2557	   8.71E-­‐08	   21.6667	  
cell	  surface	  receptor	  linked	  signalling	  pathway	   15.8696	   1.28E-­‐07	   25.7669	  
response	  to	  organic	  cyclic	  compound	   14.9382	   3.25E-­‐07	   28.5714	  
guanyl-­‐nucleotide	  exchange	  factor	  activity	   14.8463	   3.57E-­‐07	   26.4286	  
membrane	  fraction	   14.7792	   3.81E-­‐07	   18.6	  
response	  to	  wounding	   14.775	   3.83E-­‐07	   35.4839	  
response	  to	  progesterone	  stimulus	   14.4133	   5.50E-­‐07	   52	  
interstitial	  matrix	   13.6259	   1.21E-­‐06	   69.2308	  
organ	  morphogenesis	   13.5697	   1.28E-­‐06	   28.4314	  
basement	  membrane	   13.5268	   1.33E-­‐06	   32.3944	  
response	  to	  cAMP	   13.4685	   1.41E-­‐06	   36.5385	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B	  cell	  receptor	  signalling	  pathway	   13.1075	   2.03E-­‐06	   55	  
T	  cell	  costimulation	   12.7042	   3.04E-­‐06	   31.8841	  
apoptosis	   12.477	   3.81E-­‐06	   17.2589	  
cellular	  response	  to	  hypoxia	   12.3191	   4.47E-­‐06	   42.4242	  
scavenger	  receptor	  activity	   12.1889	   5.09E-­‐06	   38.0952	  
defense	  response	   11.8892	   6.86E-­‐06	   31.3433	  
MHC	  class	  II	  protein	  complex	   11.889	   6.87E-­‐06	   60	  
cytokine-­‐mediated	  signalling	  pathway	   11.5773	   9.38E-­‐06	   23.2704	  
integrin	  binding	   11.4299	   1.09E-­‐05	   29.7297	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Appendix	  6.	  Gene	  ontology	  analysis	  for	  hTERT-­‐HM	  versus	  t=0.	  	  
Function	   Enrichment	  
Score	  
Enrichment	  p-­‐
value	  
%	  genes	  in	  
group	  that	  are	  
present	  
plasma	  membrane	   62.3075	   8.71E-­‐28	   20.4486	  
cell	  adhesion	   52.8045	   1.17E-­‐23	   30.7002	  
integral	  to	  plasma	  membrane	   48.5873	   7.92E-­‐22	   25.5511	  
extracellular	  region	   48.2328	   1.13E-­‐21	   22.0974	  
extracellular	  matrix	   38.3636	   2.18E-­‐17	   42.953	  
inflammatory	  response	   38.0332	   3.04E-­‐17	   36.6812	  
immune	  response	   34.8282	   7.49E-­‐16	   31.2865	  
blood	  coagulation	   33.9356	   1.83E-­‐15	   28.5714	  
extracellular	  space	   31.9584	   1.32E-­‐14	   24.6396	  
platelet	  activation	   30.5818	   5.23E-­‐14	   33.7607	  
signal	  transduction	   30.4585	   5.92E-­‐14	   22.2606	  
proteinaceous	  extracellular	  matrix	   27.1024	   1.70E-­‐12	   33.6538	  
angiogenesis	   22.8788	   1.16E-­‐10	   35.6164	  
cell	  surface	   22.868	   1.17E-­‐10	   29.078	  
leukocyte	  migration	   22.5996	   1.53E-­‐10	   39.6226	  
biological	  regulation	   20.0421	   1.98E-­‐09	   29.0984	  
biological_process	   19.4682	   3.51E-­‐09	   28.7449	  
external	  side	  of	  plasma	  membrane	   19.1188	   4.98E-­‐09	   35.5372	  
cholesterol	  biosynthetic	  process	   18.4087	   1.01E-­‐08	   60	  
positive	  regulation	  of	  cell	  proliferation	   17.423	   2.71E-­‐08	   25.7485	  
wound	  healing	   16.728	   5.43E-­‐08	   43.3333	  
cell	  surface	  receptor	  linked	  signalling	  pathway	   16.3926	   7.60E-­‐08	   30.6748	  
integrin	  binding	   15.8034	   1.37E-­‐07	   39.1892	  
regulation	  of	  small	  GTPase	  mediated	  signal	  
transduction	   15.6921	   1.53E-­‐07	   29.8246	  
membrane	  fraction	   15.3101	   2.24E-­‐07	   22.8	  
scavenger	  receptor	  activity	   15.0726	   2.84E-­‐07	   47.619	  
defense	  response	  to	  virus	   15.0726	   2.84E-­‐07	   47.619	  
membrane	   15.0414	   2.93E-­‐07	   16.9093	  
regulation	  of	  biological	  process	   15.0249	   2.98E-­‐07	   27.5229	  
multicellular	  organismal	  development	   14.9413	   3.24E-­‐07	   20.304	  
actin	  cytoskeleton	  organization	   14.8866	   3.43E-­‐07	   32.2581	  
receptor	  activity	   14.4268	   5.43E-­‐07	   18.7097	  
guanyl-­‐nucleotide	  exchange	  factor	  activity	   14.3573	   5.82E-­‐07	   30.7143	  
aging	   14.3001	   6.16E-­‐07	   32.7434	  
chemotaxis	   14.1723	   7.00E-­‐07	   32.2034	  
integrin-­‐mediated	  signalling	  pathway	   14.1065	   7.48E-­‐07	   39.6825	  
organ	  morphogenesis	   13.7271	   1.09E-­‐06	   33.3333	  
intracellular	  signal	  transduction	   13.703	   1.12E-­‐06	   24.8322	  
integral	  to	  membrane	   13.6052	   1.23E-­‐06	   16.6469	  
response	  to	  organic	  cyclic	  compound	   13.4573	   1.43E-­‐06	   32.1429	  
calcium	  ion	  binding	   13.3815	   1.54E-­‐06	   21.0687	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positive	  regulation	  of	  ERK1	  and	  ERK2	  cascade	   13.1093	   2.03E-­‐06	   40.7407	  
positive	  regulation	  of	  peptidyl-­‐tyrosine	  
phosphorylation	   12.7314	   2.96E-­‐06	   38.9831	  
axon	  guidance	   12.6917	   3.08E-­‐06	   24.1158	  
protein	  homodimerization	  activity	   12.5627	   3.50E-­‐06	   21.9917	  
cell-­‐cell	  signalling	   12.5005	   3.72E-­‐06	   25.523	  
negative	  regulation	  of	  cell	  proliferation	   12.4409	   3.95E-­‐06	   23.9617	  
regulation	  of	  Rho	  protein	  signal	  transduction	   11.8545	   7.11E-­‐06	   35.7143	  
integrin	  complex	   11.659	   8.64E-­‐06	   50	  
homophilic	  cell	  adhesion	   11.4914	   1.02E-­‐05	   28.5714	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Appendix	  7.	  Top	  50	  genes	  shared	  between	  explants,	  primary	  cells	  and	  hTERT-­‐HM.	  
Gene	  Assignment	   Gene	  Symbol	   RefSeq	  
phosphoserine	  aminotransferase	  1	  	   PSAT1	   NM_058179	  
four	  jointed	  box	  1	  (Drosophila)	   FJX1	   NM_014344	  
ADAM	  metallopeptidase	  domain	  12	   ADAM12	   NM_003474	  
high	  mobility	  group	  AT-­‐hook	  1	   HMGA1	   BT006774	  
solute	  carrier	  family	  7	  (anionic	  amino	  acid	  transporter	  light	  c	   SLC7A11	   NM_014331	  
neuropilin	  (NRP)	  and	  tolloid	  (TLL)-­‐like	  2	  	   NETO2	   NM_018092	  
alanyl	  (membrane)	  aminopeptidase	   ANPEP	   NM_001150	  
StAR-­‐related	  lipid	  transfer	  (START)	  domain	  containing	  4	  	   STARD4	  
ENST00000296
632	  
transmembrane	  protein	  171	  	   TMEM171	   NM_173490	  
integrin,	  alpha	  2	  (CD49B,	  alpha	  2	  subunit	  of	  VLA-­‐2	  receptor)	  	   ITGA2	   NR_073105	  
bradykinin	  receptor	  B1	  	   BDKRB1	  
ENST00000216
629	  
stearoyl-­‐CoA	  desaturase	  (delta-­‐9-­‐desaturase)	  	   SCD	   NM_005063	  
matrix	  metallopeptidase	  1	  (interstitial	  collagenase)	  	   MMP1	   NM_002421	  
tumor	  necrosis	  factor	  receptor	  superfamily,	  member	  11b	   TNFRSF11B	   NM_002546	  
family	  with	  sequence	  similarity	  180,	  member	  A	  	   FAM180A	   NM_205855	  
interleukin	  6	  (interferon,	  beta	  2)	   IL6	   NM_000600	  
protocadherin	  17	  	   PCDH17	  
NM_00104042
9	  
insulin	  induced	  gene	  1	  	   INSIG1	   NM_005542	  
SH3-­‐domain	  GRB2-­‐like	  (endophilin)	  interacting	  protein	  1	   SGIP1	   NM_032291	  
tumor	  necrosis	  factor	  receptor	  superfamily,	  member	  10d,	  
decoy	   TNFRSF10D	   NM_003840	  
solute	  carrier	  family	  7	  (amino	  acid	  transporter	  kight	  chain,	  L	  
system),	  member	  5	   SLC7A5	   NM_003486	  
thrombospondin	  2	  	   THBS2	   NM_003247	  
FOS-­‐like	  antigen	  1	  	   FOSL1	   NM_005438	  
high	  mobility	  group	  AT-­‐hook	  1	  	   HMGA1	   NM_145901	  
pleckstrin	  homology-­‐like	  domain,	  family	  A,	  member	  2	  	   PHLDA2	   NM_003311	  
ST6	  (alpha-­‐N-­‐acetyl-­‐neuraminyl-­‐2,3-­‐beta-­‐galactosyl-­‐1,3)-­‐N-­‐
acetylgalactosaminide	  alpha-­‐2,6-­‐sialyltransferase	  5	   ST6GALNAC5	  
ENST00000477
717	  
microRNA	  181b-­‐1	  	   MIR181B1	   NR_029612	  
solute	  carrier	  family	  20	  (phosphate	  transporter),	  member	  1	  	   SLC20A1	   NM_005415	  
adrenomedullin	  	   ADM	  
ENST00000530
439	  
laminin,	  alpha	  1	  	   LAMA1	   NM_005559	  
family	  with	  sequence	  similarity	  171,	  member	  B	  	   FAM171B	  
ENST00000304
698	  
fibrillin	  2	  	   FBN2	   NM_001999	  
programmed	  cell	  death	  1	  ligand	  2	  	   PDCD1LG2	   NM_025239	  
endothelial	  cell-­‐specific	  molecule	  1	  	   ESM1	  
ENST00000381
405	  
NIMA-­‐related	  kinase	  10	  	   NEK10	   NM_199347	  
177	  
	  
sodium	  channel,	  voltage-­‐gated,	  type	  IX,	  alpha	  subunit	  	   SCN9A	   NM_002977	  
T-­‐box	  3	  	   TBX3	   NM_016569	  
basic	  helix-­‐loop-­‐helix	  family,	  member	  e41	   BHLHE41	   NM_030762	  
ectodysplasin	  A2	  receptor	   EDA2R	  
ENST00000374
719	  
musculin	  	   MSC	   NM_005098	  
inhibin,	  beta	  A	  	   INHBA	  
ENST00000242
208	  
transmembrane	  protein	  132A	  	   TMEM132A	   NM_017870	  
monooxygenase,	  DBH-­‐like	  1	  	   MOXD1	   NM_015529	  
interleukin	  11	  	   IL11	   NM_000641	  
heat	  shock	  70kDa	  protein	  4-­‐like	   HSPA4L	   NM_014278	  
docking	  protein	  5	  	   DOK5	   NM_018431	  
SRY	  (sex	  determining	  region	  Y)-­‐box	  4	  	   SOX4	   NM_003107	  
glycosyltransferase	  8	  domain	  containing	  2	  	   GLT8D2	   NM_031302	  
aldo-­‐keto	  reductase	  family	  1,	  member	  B1	  (aldose	  reductase)	  	   AKR1B1	   NM_001628	  
pleckstrin	  2	  	   PLEK2	  
ENST00000216
446	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Appendix	  8.	  Gene	  ontology	  analysis	  for	  genes	  shared	  between	  explants,	  primary	  cells	  and	  hTERT-­‐
HM.	  
Function	   Enrichment	  
Score	  
Enrichment	  
p-­‐value	  
%	  genes	  in	  
group	  that	  
are	  present	  
immune	  response	   25.7546	   6.53E-­‐12	   8.47953	  
inflammatory	  response	   22.1749	   2.34E-­‐10	   9.60699	  
receptor	  activity	   18.8268	   6.66E-­‐09	   3.93548	  
extracellular	  region	   17.8333	   1.80E-­‐08	   3.63831	  
cytokine-­‐mediated	  signalling	  pathway	   17.1294	   3.64E-­‐08	   10.0629	  
leukocyte	  migration	   16.5007	   6.82E-­‐08	   12.2642	  
blood	  coagulation	   15.0114	   3.02E-­‐07	   5.71429	  
plasma	  membrane	   14.8515	   3.55E-­‐07	   2.9129	  
integral	  to	  plasma	  membrane	   14.8057	   3.71E-­‐07	   4.20842	  
T	  cell	  costimulation	   14.5721	   4.69E-­‐07	   14.4928	  
cell	  surface	  receptor	  linked	  signalling	  pathway	   13.2248	   1.81E-­‐06	   8.58896	  
positive	  regulation	  of	  T	  cell	  proliferation	   12.6038	   3.36E-­‐06	   19.4444	  
proteinaceous	  extracellular	  matrix	   11.8984	   6.80E-­‐06	   7.21154	  
cell-­‐cell	  signalling	   11.6549	   8.68E-­‐06	   6.69456	  
extracellular	  space	   11.4245	   1.09E-­‐05	   4.19397	  
cell	  adhesion	   11.2982	   1.24E-­‐05	   4.66786	  
hemopoietic	  progenitor	  cell	  differentiation	   11.2664	   1.28E-­‐05	   44.4444	  
signal	  transduction	   11.0317	   1.62E-­‐05	   3.62381	  
negative	  regulation	  of	  follicle-­‐stimulating	  hormone	  
secretion	   10.6452	   2.38E-­‐05	   75	  
cellular	  response	  to	  hypoxia	   10.5628	   2.59E-­‐05	   18.1818	  
interferon-­‐gamma-­‐mediated	  signalling	  pathway	   10.5605	   2.59E-­‐05	   12.1212	  
platelet	  activation	   10.4985	   2.76E-­‐05	   6.41026	  
biological	  regulation	   10.0151	   4.47E-­‐05	   6.14754	  
regulation	  of	  biological	  process	   9.90457	   4.99E-­‐05	   6.42202	  
humoral	  immune	  response	   9.88271	   5.10E-­‐05	   16.2162	  
biological_process	   9.87542	   5.14E-­‐05	   6.07287	  
guanyl-­‐nucleotide	  exchange	  factor	  activity	   9.84455	   5.30E-­‐05	   7.85714	  
positive	  regulation	  of	  anti-­‐apoptosis	   9.57449	   6.95E-­‐05	   15.3846	  
antigen	  processing	  and	  presentation	   9.2844	   9.29E-­‐05	   14.6341	  
positive	  regulation	  of	  neutrophil	  chemotaxis	   9.26627	   9.46E-­‐05	   28.5714	  
MHC	  class	  II	  protein	  complex	   8.97056	   0.0001271	   26.6667	  
response	  to	  lipopolysaccharide	   8.95266	   0.00012939	   7.75194	  
blood	  circulation	   8.87931	   0.00013924	   13.6364	  
integrin-­‐mediated	  signalling	  pathway	   8.83144	   0.00014607	   11.1111	  
AT	  DNA	  binding	   8.51705	   0.00020003	   42.8571	  
positive	  regulation	  of	  dendritic	  cell	  antigen	  processing	  
and	  presentation	   8.51705	   0.00020003	   42.8571	  
defense	  response	   8.4414	   0.00021575	   10.4478	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complement	  activation	   8.39295	   0.00022646	   16.129	  
chemotaxis	   8.06032	   0.00031583	   7.62712	  
female	  pregnancy	   7.99202	   0.00033815	   9.72222	  
negative	  regulation	  of	  T	  cell	  proliferation	   7.98463	   0.00034066	   21.0526	  
integrin	  binding	   7.82289	   0.00040046	   9.45946	  
B	  cell	  receptor	  signalling	  pathway	   7.77589	   0.00041973	   20	  
complement	  activation,	  classical	  pathway	   7.67061	   0.00046633	   13.8889	  
defense	  response	  to	  protozoan	   7.6688	   0.00046718	   33.3333	  
organ	  morphogenesis	   7.48506	   0.00056141	   7.84314	  
T	  cell	  receptor	  signalling	  pathway	   7.42369	   0.00059695	   8.86076	  
negative	  regulation	  of	  blood	  vessel	  endothelial	  cell	  
migration	   7.32572	   0.00065839	   30	  
positive	  regulation	  of	  interleukin-­‐17	  production	   7.32572	   0.00065839	   30	  
receptor	  signalling	  protein	  activity	   7.29185	   0.00068107	   12.8205	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Appendix	  9.	  Top	  50	  genes	  for	  genes	  shared	  between	  explants	  and	  primary	  cells.	  
Gene	  Assignment	   Gene	  Symbol	   RefSeq	  
interleukin	  13	  receptor,	  alpha	  2	  	   IL13RA2	   NM_000640	  
hexokinase	  2	  	   HK2	   NM_000189	  
tissue	  factor	  pathway	  inhibitor	  2	   TFPI2	   NM_006528	  
chitinase	  3-­‐like	  1	  (cartilage	  glycoprotein-­‐39)	   CHI3L1	   NM_001276	  
KIAA1199	   KIAA1199	   NM_018689	  
tumor	  necrosis	  factor,	  alpha-­‐induced	  protein	  3	   TNFAIP3	   NM_001270508	  
sestrin	  2	  	   SESN2	   NM_031459	  
very	  low	  density	  lipoprotein	  receptor	   VLDLR	   NM_003383	  
transmembrane	  protein	  38B	   TMEM38B	   NM_018112	  
suppressor	  of	  cytokine	  signalling	  3	   SOCS3	   NM_003955	  
unc-­‐5	  homolog	  B	  (C.	  elegans)	   UNC5B	   NM_170744	  
baculoviral	  IAP	  repeat	  containing	  3	   BIRC3	   NM_001165	  
solute	   carrier	   family	   3	   (amino	   acid	   transporter	   heavy	   chain),	  
member	  2 	   SLC3A2	   NM_001012662	  
growth	  arrest	  and	  DNA-­‐damage-­‐inducible,	  alpha	   GADD45A	  
ENST000003709
86	  
jun	  B	  proto-­‐oncogene	   JUNB	   NM_002229	  
homocysteine-­‐inducible,	   endoplasmic	   reticulum	   stress-­‐
inducible,	  ubiquitin-­‐like	  domain	  member	  1	   HERPUD1	  
ENST000004399
77	  
uncharacterized	  LOC284561	   LOC284561	   AK023809	  
nuclear	  factor	  of	  kappa	  light	  polypeptide	  gene	  enhancer	  in	  B-­‐
cel	   NFKBIA	   NM_020529	  
family	  with	  sequence	  similarity	  57,	  member	  A	   FAM57A	   NM_024792	  
cytoglobin	   CYGB	   NM_134268	  
ADAM	  metallopeptidase	  domain	  28	  	   ADAM28	  
ENST000002657
69	  
solute	   carrier	   family	   9,	   subfamily	   A	   (NHE1,	   cation	   proton	  
antiporter	  1),	  member	  1 	   SLC9A1	   NM_003047	  
ADP-­‐ribosylation	  factor-­‐like	  4C	  	   ARL4C	   NM_005737	  
RAB33A,	  member	  RAS	  oncogene	  family	  	   RAB33A	  
ENST000002570
17	  
neuronatin	   NNAT	   NM_005386	  
cyclin	  E1	   CCNE1	   NM_001238	  
zinc	  finger,	  CCHC	  domain	  containing	  14	   ZCCHC14	  
ENST000002686
16	  
EGF,	  latrophilin	  and	  seven	  transmembrane	  domain	  containing	  
1	  	   ELTD1	   NM_022159	  
histone	  cluster	  1,	  H2bn	   HIST1H2BN	   BC009783	  
parathyroid	  hormone-­‐like	  hormone	   PTHLH	   NM_002820	  
methylenetetrahydrofolate	   dehydrogenase	   (NADP+	  
dependent)	  	   MTHFD2	  
ENST000003940
53	  
solute	   carrier	   family	   25	   (pyrimidine	   nucleotide	   carrier),	  
member	  33	   SLC25A33	   NM_032315	  
internexin	  neuronal	  intermediate	  filament	  protein,	  alpha	  	   INA	   NM_032727	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ZNFX1	  antisense	  RNA	  1	   ZFAS1	   NR_003604	  
brain	  abundant,	  membrane	  attached	  signal	  protein	  1	  	   BASP1	   NM_006317	  
jun	  proto-­‐oncogene	  	   JUN	  
ENST000003712
22	  
mex-­‐3	  homolog	  B	  (C.	  elegans)	  	   MEX3B	   NM_032246	  
superoxide	  dismutase	  2,	  mitochondrial	   SOD2	   NM_001024465	  
v-­‐rel	  reticuloendotheliosis	  viral	  oncogene	  homolog	  (avian)	   REL	  
ENST000002950
25	  
lon	  peptidase	  1,	  mitochondrial	  	   LONP1	   NM_004793	  
mitogen-­‐activated	  protein	  kinase	  6	   MAPK6	   NM_002748	  
dedicator	  of	  cytokinesis	  4	   DOCK4	   NM_014705	  
adenosine	  monophosphate	  deaminase	  2	   AMPD2	   NM_004037	  
glutamic	  pyruvate	  transaminase	  (alanine	  aminotransferase)	  2	  	   GPT2	  
ENST000004407
83	  
enhancer	  of	  zeste	  homolog	  2	  (Drosophila)	   EZH2	   NM_004456	  
Rho/Rac	  guanine	  nucleotide	  exchange	  factor	  (GEF)	  2	   ARHGEF2	   NM_001162383	  
solute	  carrier	  family	  1	  (glial	  high	  affinity	  glutamate	  transport	   SLC1A3	   NM_004172	  
FAT	  atypical	  cadherin	  4	   FAT4	   NM_024582	  
uncharacterized	  LOC100128979	  	   LOC100128979	  
ENST000005612
41	  
MSH5-­‐SAPCD1	  readthrough	  (NMD	  candidate)	   MSH5-­‐SAPCD1	  
ENST000003757
55	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Appendix	  10.	  Gene	  ontology	  analysis	  for	  genes	  shared	  between	  explants	  and	  primary	  cells.	  
function	   Enrichment	  
Score	  
Enrichment	  p-­‐
value	  
%	   genes	   in	  
group	   that	  
are	  present	  
response	  to	  cytokine	  stimulus	   12.6929	   3.07E-­‐06	   8.33333	  
response	  to	  lipopolysaccharide	   11.6041	   9.13E-­‐06	   4.65116	  
response	  to	  drug	   11.0016	   1.67E-­‐05	   2.66667	  
stereocilium	  bundle	   10.0749	   4.21E-­‐05	   66.6667	  
release	  of	  cytochrome	  c	  from	  mitochondria	   9.94705	   4.79E-­‐05	   15.7895	  
positive	  regulation	  of	  cell	  differentiation	   9.78724	   5.62E-­‐05	   15	  
anti-­‐apoptosis	   9.25059	   9.61E-­‐05	   3.06122	  
type	  I	  interferon-­‐mediated	  signalling	  pathway	   9.15249	   0.00010596	   6.15385	  
response	  to	  progesterone	  stimulus	   9.09886	   0.00011179	   12	  
oxygen	  binding	   8.25665	   0.00025953	   9.09091	  
cytokine-­‐mediated	  signalling	  pathway	   7.99986	   0.00033551	   3.14465	  
negative	  regulation	  of	  chondrocyte	  differentiation	   7.85353	   0.00038838	   25	  
negative	  regulation	  of	  caspase	  activity	   7.26843	   0.0006972	   6.52174	  
response	  to	  organic	  cyclic	  compound	   7.06896	   0.00085112	   3.57143	  
Rac	  GTPase	  binding	   6.84124	   0.00106878	   15.3846	  
cellular	  response	  to	  calcium	  ion	   6.41777	   0.0016323	   12.5	  
cellular	  response	  to	  interleukin-­‐1	   6.41777	   0.0016323	   12.5	  
response	  to	  light	  stimulus	   6.29504	   0.00184543	   11.7647	  
liver	  development	   6.21879	   0.00199166	   4.54545	  
interferon-­‐gamma-­‐mediated	  signalling	  pathway	   6.21879	   0.00199166	   4.54545	  
extracellular	  matrix	  structural	  constituent	   6.17566	   0.00207943	   4.47761	  
negative	  regulation	  of	  DNA	  binding	   5.87033	   0.00282194	   9.52381	  
response	  to	  corticosterone	  stimulus	   5.68892	   0.00338326	   8.69565	  
cellular	  process	   5.68892	   0.00338326	   8.69565	  
cytosol	   5.36648	   0.00467055	   0.75543	  
mitochondrion	  organization	   5.29957	   0.00499375	   7.14286	  
mitochondrial	  nucleoid	   4.91931	   0.00730418	   5.88235	  
cellular	  response	  to	  lipopolysaccharide	   4.75501	   0.00860842	   5.40541	  
aging	   4.71207	   0.00898618	   2.65487	  
cation	  binding	   4.70337	   0.00906467	   5.26316	  
protein	  homotetramerization	   4.60428	   0.0100089	   5	  
response	  to	  hydrogen	  peroxide	   4.60428	   0.0100089	   5	  
response	  to	  mechanical	  stimulus	   4.51032	   0.0109949	   4.7619	  
response	  to	  acidity	   4.48293	   0.0113003	   33.3333	  
homologous	  chromosome	  segregation	   4.48293	   0.0113003	   33.3333	  
AMP	  deaminase	  activity	   4.48293	   0.0113003	   33.3333	  
purine	  nucleotide	  metabolic	  process	   4.48293	   0.0113003	   33.3333	  
I-­‐kappaB/NF-­‐kappaB	  complex	   4.48293	   0.0113003	   33.3333	  
cellular	   chaperone-­‐mediated	   protein	   complex	  
assembly	  
4.48293	   0.0113003	   33.3333	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G-­‐quadruplex	  DNA	  binding	   4.48293	   0.0113003	   33.3333	  
positive	   regulation	   of	   transcription	   from	   RNA	  
polymerase	  II	  promoter	  during	  mitosis	  
4.48293	   0.0113003	   33.3333	  
very-­‐low-­‐density	  lipoprotein	  particle	  clearance	   4.48293	   0.0113003	   33.3333	  
malate-­‐aspartate	  shuttle	   4.48293	   0.0113003	   33.3333	  
L-­‐glutamate	  import	   4.48293	   0.0113003	   33.3333	  
D-­‐aspartate	  import	   4.48293	   0.0113003	   33.3333	  
methenyltetrahydrofolate	  cyclohydrolase	  activity	   4.48293	   0.0113003	   33.3333	  
glomerular	  visceral	  epithelial	  cell	  differentiation	   4.48293	   0.0113003	   33.3333	  
retinal	  dehydrogenase	  activity	   4.48293	   0.0113003	   33.3333	  
detection	  of	  oxygen	   4.48293	   0.0113003	   33.3333	  
smooth	  muscle	  contractile	  fiber	   4.48293	   0.0113003	   33.3333	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Appendix	  11.	  Top	  50	  genes	  shared	  between	  explants	  and	  hTERT-­‐HM.	  
Gene	  Assignment	   Gene	  Symbol	   RefSeq	  
interleukin	  1,	  beta	  	   IL1B	  
ENST00000263
341	  
interleukin	  1,	  alpha	  	   IL1A	   NM_000575	  
interleukin	  8	  	   IL8	   NM_000584	  
neural	   precursor	   cell	   expressed,	   developmentally	   down-­‐
regulated	  4-­‐like,	  E3	  ubiquitin	  protein	  ligase	  	   NEDD4L	  
NM_00114496
7	  
chemokine	  (C-­‐X-­‐C	  motif)	  ligand	  12	   CXCL12	   NM_199168	  
DnaJ	  (Hsp40)	  homolog,	  subfamily	  C,	  member	  6	  	   DNAJC6	  
NM_00125686
5	  
serpin	  peptidase	  inhibitor,	  clade	  B	  (ovalbumin),	  member	  2	   SERPINB2	  
NM_00114381
8	  
janus	  kinase	  and	  microtubule	  interacting	  protein	  2	  	   JAKMIP2	  
NM_00127094
1	  
interleukin	  24	   IL24	   NM_006850	  
uncharacterized	  LOC541472	  	   LOC541472	  
ENST00000325
042	  
RFX	  family	  member	  8,	  lacking	  RFX	  DNA	  binding	  domain	   RFX8	  
ENST00000428
343	  
solute	   carrier	   family	   22	   (organic	   cation/ergothioneine	  
transporter),	  member	  4	  
	   SLC22A4	   NM_003059	  
transmembrane	  protein	  2	  	   TMEM2	   NM_013390	  
STEAP	  family	  member	  2,	  metalloreductase	   STEAP2	  
NM_00124494
4	  
SATB	  homeobox	  2	   SATB2	   NM_015265	  
bradykinin	  receptor	  B2	   BDKRB2	   NM_000623	  
UDP-­‐glucose	  ceramide	  glucosyltransferase	  	   UGCG	  
ENST00000374
279	  
uncharacterized	  LOC401164	   LOC401164	   NR_033869	  
pleckstrin	  homology-­‐like	  domain,	  family	  A,	  member	  1	  	   PHLDA1	   NM_007350	  
ephrin-­‐B2	   EFNB2	   NM_004093	  
microRNA	  222	   MIR222	   NR_029636	  
PR	  domain	  containing	  1,	  with	  ZNF	  domain	   PRDM1	   NM_001198	  
colony	  stimulating	  factor	  3	  (granulocyte)	   CSF3	   NR_033662	  
chemokine	  (C-­‐X-­‐C	  motif)	  ligand	  5	   CXCL5	   NM_002994	  
glycerol-­‐3-­‐phosphate	  acyltransferase,	  mitochondrial	  	   GPAM	   NM_020918	  
phosphoglucomutase	  5	  pseudogene	  2	   PGM5P2	  
ENST00000591
207	  
sprouty	  homolog	  4	  (Drosophila)	   SPRY4	   NM_030964	  
solute	  carrier	  family	  16,	  member	  3	  (monocarboxylic	  acid	  tran	   SLC16A3	  
NM_00104242
3	  
interleukin-­‐1	  receptor-­‐associated	  kinase	  2	  	   IRAK2	   NM_001570	  
embigin	  	   EMB	   NM_198449	  
angiopoietin	  1	  	   ANGPT1	   NM_001146	  
serine	  palmitoyltransferase,	  long	  chain	  base	  subunit	  3	   SPTLC3	   NM_018327	  
185	  
	  
intercellular	  adhesion	  molecule	  1	  	   ICAM1	   NM_000201	  
leukemia	  inhibitory	  factor	  	   LIF	   NM_002309	  
C-­‐type	  lectin	  domain	  family	  2,	  member	  B	  	   CLEC2B	  
ENST00000228
438	  
ras	  homolog	  family	  member	  J	   RHOJ	   NM_020663	  
solute	  carrier	  family	  6	  (neurotransmitter	  transporter,	  taurine),	   SLC6A6	   NM_003043	  
sprouty	  homolog	  2	  (Drosophila)	  	   SPRY2	   NM_005842	  
microRNA	  29a	  	   MIR29A	   NR_029503	  
tropomodulin	  1	  	   TMOD1	  
NM_00116611
6	  
prostaglandin-­‐endoperoxide	   synthase	   2	   (prostaglandin	   G/H	  
synthase	  and	  cyclooxygenase)	   PTGS2	   NM_000963	  
DLGAP1	  antisense	  RNA	  2	  	   DLGAP1-­‐AS2	   BC094703	  
collagen,	  type	  V,	  alpha	  2	   COL5A2	   NM_000393	  
phosphoribosyl	  pyrophosphate	  amidotransferase	  	   PPAT	   NM_002703	  
CXADR-­‐like	  membrane	  protein	  	   CLMP	  
ENST00000448
775	  
zinc	  finger	  CCCH-­‐type	  containing	  12A	   ZC3H12A	   NM_025079	  
pannexin	  1	  	   PANX1	   NM_015368	  
metallothionein	  1X	   MT1X	  
ENST00000394
485	  
Src	  homology	  2	  domain	  containing	  adaptor	  protein	  B	   SHB	   NM_003028	  
adenosine	  kinase	   ADK	   NM_001123	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Appendix	  12.	  Gene	  ontology	  analysis	  for	  genes	  shared	  between	  explants	  and	  hTERT-­‐HM.	  
Function	   Enrichment	  
Score	  
Enrichment	   p-­‐
value	  
%	   genes	   in	  
group	  that	  are	  
present	  
positive	   regulation	   vascular	   endothelial	   growth	  
factor	  production	   10.5329	   2.66E-­‐05	   25	  
negative	  regulation	  of	  calcium	  ion	  transport	   9.48877	   7.57E-­‐05	   66.6667	  
extracellular	  space	   9.07116	   0.00011493	   1.7038	  
extracellular	  region	   9.06365	   0.0001158	   1.1771	  
response	  to	  ozone	   8.79893	   0.0001509	   50	  
cytokine	  activity	   8.77187	   0.00015503	   3.77358	  
positive	  regulation	  of	  ERK1	  and	  ERK2	  cascade	   8.74342	   0.00015951	   7.40741	  
positive	   regulation	   of	   nitric	   oxide	   biosynthetic	  
process	   8.23346	   0.00026562	   12	  
positive	  regulation	  of	  interleukin-­‐6	  production	   8.00039	   0.00033533	   11.1111	  
negative	  regulation	  of	  MAP	  kinase	  activity	   8.00039	   0.00033533	   11.1111	  
immune	  response	   7.99555	   0.00033696	   2.33918	  
regulation	  of	  vascular	  permeability	   7.88924	   0.00037476	   33.3333	  
embryo	  implantation	   7.68346	   0.00046038	   10	  
positive	  regulation	  of	  fever	  generation	   7.55606	   0.00052293	   28.5714	  
phospholipid	  homeostasis	   7.55606	   0.00052293	   28.5714	  
response	  to	  organic	  nitrogen	   7.39888	   0.00061194	   9.09091	  
response	  to	  metal	  ion	   7.27167	   0.00069495	   25	  
lung	  vasculature	  development	   7.27167	   0.00069495	   25	  
response	  to	  fructose	  stimulus	   7.27167	   0.00069495	   25	  
response	  to	  L-­‐ascorbic	  acid	   7.02365	   0.00089057	   22.2222	  
ovulation	   7.02365	   0.00089057	   22.2222	  
negative	  regulation	  of	  cell	  proliferation	   6.86498	   0.0010437	   2.23642	  
cytokine-­‐mediated	  signalling	  pathway	   6.66452	   0.00127537	   3.14465	  
positive	  regulation	  of	  cell	  division	   6.61913	   0.00133459	   6.97674	  
interleukin-­‐1	  receptor	  binding	   6.60642	   0.00135166	   18.1818	  
growth	  factor	  activity	   6.55447	   0.00142374	   3.06748	  
blood	  circulation	   6.55215	   0.00142704	   6.81818	  
body	  fluid	  secretion	   6.42739	   0.00161666	   16.6667	  
response	  to	  ATP	   6.42739	   0.00161666	   16.6667	  
chemokine	  activity	   6.36068	   0.00172819	   6.38298	  
positive	   regulation	   of	   interleukin-­‐2	   biosynthetic	  
process	   6.26363	   0.00190432	   15.3846	  
organ	  regeneration	   6.24024	   0.00194938	   6.12245	  
leukocyte	  migration	   6.18869	   0.00205251	   3.77358	  
positive	   regulation	   of	   stress-­‐activated	   MAPK	  
cascade	   6.11277	   0.00221441	   14.2857	  
embryonic	  digestive	  tract	  development	   6.11277	   0.00221441	   14.2857	  
response	  to	  organic	  cyclic	  compound	   5.98828	   0.00250798	   3.57143	  
maternal	  process	  involved	  in	  female	  pregnancy	   5.97295	   0.00254671	   13.3333	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negative	  regulation	  of	  ERK1	  and	  ERK2	  cascade	   5.72083	   0.00327699	   11.7647	  
regulation	  of	  cell	  differentiation	   5.72083	   0.00327699	   11.7647	  
decidualization	   5.72083	   0.00327699	   11.7647	  
wound	  healing	   5.66105	   0.00347885	   5	  
response	  to	  copper	  ion	   5.60633	   0.00367453	   11.1111	  
response	  to	  vitamin	  D	   5.60633	   0.00367453	   11.1111	  
regulation	  of	  cell	  death	   5.60633	   0.00367453	   11.1111	  
regulation	  of	  apoptosis	   5.60633	   0.00367453	   11.1111	  
regulation	  of	  programmed	  cell	  death	   5.60633	   0.00367453	   11.1111	  
positive	  regulation	  of	  cytokine	  secretion	   5.49839	   0.00409337	   10.5263	  
neutrophil	  chemotaxis	   5.49839	   0.00409337	   10.5263	  
response	  to	  gamma	  radiation	   5.2995	   0.00499407	   9.52381	  
positive	  regulation	  of	  vasoconstriction	   5.11978	   0.00597735	   8.69565	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Appendix	  13.	  Top	  50	  genes	  shared	  between	  primary	  cells	  and	  hTERT-­‐HM.	  
Gene	  Assignment	   Gene	  Symbol	   RefSeq	  
serpin	  peptidase	  inhibitor,	  clade	  B	  (ovalbumin),	  member	  7	   SERPINB7	   NM_003784	  
protocadherin	  10	  	   PCDH10	   NM_032961	  
protease,	  serine,	  12	  (neurotrypsin,	  motopsin)	   PRSS12	  
ENST00000296
498	  
potassium	  channel,	  subfamily	  K,	  member	  2	   KCNK2	   NM_001017424	  
RAB3B,	  member	  RAS	  oncogene	  family	   RAB3B	   NM_002867	  
solute	  carrier	  family	  14	  (urea	  transporter),	  member	  1	  (Kidd	  	   SLC14A1	   NM_001146037	  
MIR31	  host	  gene	  (non-­‐protein	  coding)	  	   MIR31HG	   NR_027054	  
FERM	  and	  PDZ	  domain	  containing	  4	   FRMPD4	   NM_014728	  
family	  with	  sequence	  similarity	  196,	  member	  B	   FAM196B	   NM_001129891	  
cadherin	  10,	  type	  2	  (T2-­‐cadherin)	  	   CDH10	   NM_006727	  
hemicentin	  1	   HMCN1	   NM_031935	  
adenylate	  kinase	  5	   AK5	   NM_174858	  
solute	  carrier	  organic	  anion	  transporter	  family,	  member	  4C1	  	   SLCO4C1	   NM_180991	  
pentraxin	  3,	  long	   PTX3	   NM_002852	  
leucine	  rich	  repeat	  containing	  17	   LRRC17	   NM_005824	  
zinc	  finger	  protein	  804A	   ZNF804A	   NM_194250	  
sodium	  channel,	  voltage-­‐gated,	  type	  II,	  alpha	  subunit	   SCN2A	   NM_021007	  
UDP-­‐N-­‐acetyl-­‐alpha-­‐D-­‐galactosamine:polypeptide	  N-­‐
acetylgalactosaminyltransferase	  5	  (GalNAc-­‐T5) 	   GALNT5	  
ENST00000259
056	  
solute	   carrier	   family	   6	   (neutral	   amino	   acid	   transporter),	  
member	  15	   SLC6A15	   NM_182767	  
solute	  carrier	  family	  9,	  subfamily	  A	  (NHE7,	  cation	  proton	  
antiproter	  7),	  Member	  7	   SLC9A7	   NM_001257291	  
calmegin	   CLGN	  
ENST00000325
617	  
frizzled	  family	  receptor	  2	   FZD2	   NM_001466	  
collagen,	  type	  VIII,	  alpha	  1	   COL8A1	  
ENST00000261
037	  
solute	   carrier	   family	   9,	   subfamily	   A	   (NHE7,	   cation	   proton	  
antiporter	  7),	  member	  7	   SLC9A7	   NM_001257291	  
eyes	  absent	  homolog	  1	  (Drosophila)	   EYA1	   NM_172058	  
coagulation	  factor	  II	  (thrombin)	  receptor-­‐like	  2	  	   F2RL2	   NM_004101	  
signal	  peptide,	  CUB	  domain,	  EGF-­‐like	  3	  	   SCUBE3	  
ENST00000274
938	  
mitochondria-­‐localized	  glutamic	  acid-­‐rich	  protein	  	   MGARP	   NM_032623	  
synaptic	  vesicle	  glycoprotein	  2A	   SV2A	   NM_014849	  
gremlin	  1,	  DAN	  family	  BMP	  antagonist	  	   GREM1	  
ENST00000300
177	  
dystrophin	  related	  protein	  2	  	   DRP2	  
ENST00000395
209	  
EH-­‐domain	  containing	  3	   EHD3	   NM_014600	  
teneurin	  transmembrane	  protein	  4	   TENM4	  
ENST00000278
550	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kinesin	  family	  member	  26B	   KIF26B	   NM_018012	  
24-­‐dehydrocholesterol	  reductase	   DHCR24	   NM_014762	  
ventricular	  zone	  expressed	  PH	  domain-­‐containing	  1	  	   VEPH1	   NM_024621	  
fibroblast	  growth	  factor	  5	   FGF5	   NM_004464	  
sodium	  channel,	  voltage-­‐gated,	  type	  III,	  alpha	  subunit	   SCN3A	   NM_006922	  
SERTA	  domain	  containing	  4	  	   SERTAD4	  
ENST00000367
012	  
cadherin	  2,	  type	  1,	  N-­‐cadherin	  (neuronal)	   CDH2	  
ENST00000269
141	  
UL16	  binding	  protein	  1	   ULBP1	   NM_025218	  
microfibrillar-­‐associated	  protein	  2	  	   MFAP2	   NM_017459	  
mucolipin	  3	   MCOLN3	   NM_018298	  
high	  mobility	  group	  AT-­‐hook	  2	  	   HMGA2	  
ENST00000403
681	  
small	  nucleolar	  RNA,	  C/D	  box	  114-­‐20	   SNORD114-­‐20	   NR_003213	  
solute	   carrier	   family	   16,	   member	   4	   (monocarboxylic	   acid	  
transporter	  5)	  	   SLC16A4	   NM_004696	  
forkhead	  box	  D1	  	   FOXD1	   NM_004472	  
paternally	  expressed	  10	  	   PEG10	   NM_015068	  
popeye	  domain	  containing	  3	  	   POPDC3	   NM_022361	  
KIAA1549-­‐like	   KIAA1549L	   NM_012194	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Appendix	  14.	  Gene	  ontology	  analysis	  for	  genes	  shared	  between	  primary	  cells	  and	  hTERT-­‐HM.	  
Function	   Enrichment	  
Score	  
Enrichment	  
p-­‐value	  
%	   genes	   in	  
group	   that	  
are	  present	  
plasma	  membrane	   46.7817	   4.82E-­‐21	   10.4282	  
integral	  to	  plasma	  membrane	   33.0052	   4.63E-­‐15	   13.3267	  
cell	  adhesion	   29.4782	   1.58E-­‐13	   15.4399	  
blood	  coagulation	   27.0669	   1.76E-­‐12	   16.044	  
cholesterol	  biosynthetic	  process	   25.5275	   8.19E-­‐12	   53.3333	  
platelet	  activation	   24.395	   2.54E-­‐11	   19.6581	  
extracellular	  region	   21.9364	   2.97E-­‐10	   10.2729	  
extracellular	  matrix	   21.0995	   6.86E-­‐10	   22.1477	  
aging	   16.3312	   8.08E-­‐08	   22.1239	  
membrane	   15.5028	   1.85E-­‐07	   8.50575	  
angiogenesis	   14.9028	   3.37E-­‐07	   19.1781	  
signal	  transduction	   14.7676	   3.86E-­‐07	   10.44	  
immune	  response	   14.0934	   7.57E-­‐07	   14.0351	  
cell	  surface	   14.0821	   7.66E-­‐07	   14.8936	  
inflammatory	  response	   12.5718	   3.47E-­‐06	   15.2838	  
integrin-­‐mediated	  signalling	  pathway	   11.3132	   1.22E-­‐05	   23.8095	  
scavenger	  receptor	  activity	   11.3012	   1.24E-­‐05	   28.5714	  
antigen	   processing	   and	   presentation	   of	   peptide	   or	  
polysaccharide	  antigen	  via	  MHC	  class	  II	   11.2504	   1.30E-­‐05	   50	  
calcium	  ion	  binding	   10.9185	   1.81E-­‐05	   10.9924	  
extracellular	  space	   10.84	   1.96E-­‐05	   10.616	  
leukocyte	  migration	   10.8148	   2.01E-­‐05	   18.8679	  
proteinaceous	  extracellular	  matrix	   10.7934	   2.05E-­‐05	   14.9038	  
MHC	  class	  II	  protein	  complex	   10.6811	   2.30E-­‐05	   46.6667	  
isoprenoid	  biosynthetic	  process	   10.6811	   2.30E-­‐05	   46.6667	  
integral	  to	  membrane	   10.5503	   2.62E-­‐05	   8.05115	  
cell	  surface	  receptor	  linked	  signalling	  pathway	   10.462	   2.86E-­‐05	   15.9509	  
regulation	  of	  cell	  migration	   10.1924	   3.75E-­‐05	   30.303	  
organ	  morphogenesis	   10.1593	   3.87E-­‐05	   18.6275	  
muscle	  contraction	   9.93277	   4.86E-­‐05	   18.9474	  
platelet	  alpha	  granule	  lumen	   9.83288	   5.37E-­‐05	   25	  
integrin	  complex	   9.81472	   5.46E-­‐05	   32.1429	  
basement	  membrane	   9.80246	   5.53E-­‐05	   21.1268	  
actin	  binding	   9.6836	   6.23E-­‐05	   12.9693	  
regulation	   of	   G-­‐protein	   coupled	   receptor	   protein	  
signalling	  pathway	   9.62999	   6.57E-­‐05	   28.5714	  
defense	  response	  to	  virus	   9.58079	   6.90E-­‐05	   26.1905	  
membrane	  fraction	   9.28645	   9.27E-­‐05	   11.2	  
oxidoreductase	   activity,	   acting	   on	   the	   CH-­‐NH2	  
group	  of	  donors,	  oxygen	  as	  acceptor	   9.28274	   9.30E-­‐05	   80	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long-­‐chain	  fatty-­‐acyl-­‐CoA	  biosynthetic	  process	   9.26026	   9.51E-­‐05	   38.8889	  
receptor	  activity	   9.17435	   0.00010367	   9.03226	  
positive	  regulation	  of	  cell	  proliferation	   9.08626	   0.00011321	   12.2754	  
calmodulin	  binding	   9.01363	   0.00012174	   15.5405	  
cell-­‐cell	  signalling	   8.97185	   0.00012693	   13.3891	  
wound	  healing	   8.94408	   0.00013051	   21.6667	  
MHC	  class	  II	  receptor	  activity	   8.93978	   0.00013107	   55.5556	  
cell	  junction	   8.89937	   0.00013648	   11.2798	  
external	  side	  of	  plasma	  membrane	   8.86973	   0.00014058	   16.5289	  
guanyl-­‐nucleotide	  exchange	  factor	  activity	   8.84811	   0.00014365	   15.7143	  
lamellipodium	  membrane	   8.72009	   0.00016327	   42.8571	  
regulation	  of	  heart	  contraction	   8.65551	   0.00017416	   28.125	  
positive	  regulation	  of	  ERK1	  and	  ERK2	  cascade	   8.61008	   0.00018226	   22.2222	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Appendix	  15.	  Top	  50	  genes	  uniquely	  upregulated	  in	  explants.	  
Gene	  Assignment	   Gene	  Symbol	   RefSeq	  
matrix	  metallopeptidase	  10	  (stromelysin	  2)	   MMP10	   NM_002425	  
angiopoietin-­‐like	  4	  	   ANGPTL4	   NM_139314	  
bone	  morphogenetic	  protein	  2	  	   BMP2	   NM_001200	  
lung	  cancer	  associated	  transcript	  1	  (non-­‐protein	  coding)	  	   LUCAT1	   AK091866	  
HIF1A	  antisense	  RNA	  2	  	   HIF1A-­‐AS2	   NR_045406	  
activating	  transcription	  factor	  3	  	   ATF3	   NM_001040619	  
neuromedin	  B	  	   NMB	   NM_021077	  
hypoxia	  inducible	  lipid	  droplet-­‐associated	   HILPDA	   NM_013332	  
ADAM	  metallopeptidase	  with	  thrombospondin	  type	  1	  motif,	  4	   ADAMTS4	   NM_005099	  
uncharacterized	  LOC401281	  	   FLJ27255	   AK130765	  
6-­‐phosphofructo-­‐2-­‐kinase/fructose-­‐2,6-­‐biphosphatase	  3	  	   PFKFB3	   NM_004566	  
uncharacterized	  LOC100134229	  	   LOC100134229	   NR_024451	  
solute	   carrier	   family	   2	   (facilitated	   glucose	   transporter),	  
member	  1	   SLC2A1	   NM_006516	  
TBC1	  domain	  family,	  member	  3	  pseudogene	  5	   TBC1D3P5	   NR_033892	  
DNA-­‐damage-­‐inducible	  transcript	  4	  	   DDIT4	   NM_019058	  
cysteine-­‐serine-­‐rich	  nuclear	  protein	  1	  	   CSRNP1	   NM_033027	  
nuclear	  receptor	  subfamily	  4,	  group	  A,	  member	  2	   NR4A2	   NM_006186	  
neuron-­‐derived	  neurotrophic	  factor	   NDNF	   NM_024574	  
ankyrin	  repeat	  and	  ubiquitin	  domain	  containing	  1	   ANKUB1	  
ENST000004815
85	  
cytochrome	  P450,	  family	  1,	  subfamily	  A,	  polypeptide	  1	   CYP1A1	   NM_000499	  
prostaglandin	  E	  synthase	   PTGES	   NM_004878	  
chromosome	  3	  open	  reading	  frame	  35	  	   C3orf35	  
ENST000003283
76	  
microRNA	  126	  	   MIR126	   NR_029695	  
perilipin	  2	  	   PLIN2	   NR_038064	  
pro-­‐platelet	  basic	  protein	  (chemokine	  (C-­‐X-­‐C	  motif)	  ligand	  7)	  	   PPBP	   NM_002704	  
coagulation	  factor	  II	  (thrombin)	  receptor-­‐like	  3	  	   F2RL3	  
ENST000002480
76	  
solute	  carrier	  family	  46,	  member	  2	  	   SLC46A2	   NM_033051	  
solute	   carrier	   family	   16,	   member	   6	   (monocarboxylic	   acid	  
transporter	  7)	   SLC16A6	   NM_001174166	  
arginase	  2	  	   ARG2	   NM_001172	  
G	  protein-­‐coupled	  receptor,	  family	  C,	  group	  5,	  member	  A	  	   GPRC5A	  
ENST000000149
14	  
snail	  family	  zinc	  finger	  1	  	   SNAI1	   NM_005985	  
leucine-­‐rich	  single-­‐pass	  membrane	  protein	  1	  	   LSMEM1	   NM_182597	  
protein	  phosphatase	  1,	  regulatory	  subunit	  15A	  	   PPP1R15A	   NM_014330	  
family	  with	  sequence	  similarity	  117,	  member	  B	  	   FAM117B	   NM_173511	  
nicotinamide	  phosphoribosyltransferase	   NAMPT	   U02020	  
v-­‐myc	  myelocytomatosis	  viral	  oncogene	  homolog	  (avian)	  	   MYC	   NM_002467	  
early	  growth	  response	  1	  	   EGR1	   NM_001964	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human	   immunodeficiency	   virus	   type	   I	   enhancer	   binding	  
protein	  2	  	   HIVEP2	   NM_006734	  
uncharacterized	  LOC100126784	   LOC100126784	   NR_015384	  
zinc	  finger	  and	  BTB	  domain	  containing	  2	   ZBTB2	   NM_020861	  
heme	  oxygenase	  (decycling)	  1	   HMOX1	  
ENST000002161
17	  
lysine	  (K)-­‐specific	  demethylase	  6B	  	   KDM6B	   NM_001080424	  
caspase	  12	  (gene/pseudogene)	  	   CASP12	   NM_001191016	  
solute	   carrier	   family	   5	   (sodium/myo-­‐inositol	   cotransporter),	  
member	  3	   SLC5A3	   NM_006933	  
renin	  	   REN	   NM_000537	  
dual	  specificity	  phosphatase	  5	  	   DUSP5	  
ENST000003695
83	  
serine	  peptidase	  inhibitor,	  Kazal	  type	  1	   SPINK1	   NM_003122	  
small	  integral	  membrane	  protein	  3	  	   SMIM3	   NM_032947	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Appendix	  16.	  Gene	  ontology	  analysis	  for	  genes	  uniquely	  upregulated	  in	  explants.	  
Function	   Enrichment	  
Score	  
Enrichment	  p-­‐
value	  
%	   genes	   in	  
group	   that	  
are	  present	  
endoplasmic	  reticulum	  unfolded	  protein	  response	   15.5946	   1.69E-­‐07	   31.8182	  
glycolysis	   12.9445	   2.39E-­‐06	   18.1818	  
response	  to	  hypoxia	   11.7856	   7.61E-­‐06	   8.38323	  
gluconeogenesis	   10.878	   1.89E-­‐05	   16.6667	  
glucose	  transmembrane	  transporter	  activity	   10.8726	   1.90E-­‐05	   44.4444	  
response	  to	  unfolded	  protein	   9.44969	   7.87E-­‐05	   13.4615	  
positive	  regulation	  of	  angiogenesis	   9.32531	   8.91E-­‐05	   13.2075	  
response	  to	  nicotine	   9.20182	   0.00010086	   20.8333	  
glucose	  metabolic	  process	   8.64569	   0.00017588	   9.09091	  
substrate-­‐specific	   transmembrane	   transporter	  
activity	   8.58605	   0.00018669	   26.6667	  
ER-­‐associated	  protein	  catabolic	  process	   8.25716	   0.0002594	   17.2414	  
ER	  overload	  response	   8.22217	   0.00026863	   42.8571	  
misfolded	  protein	  binding	   7.76723	   0.00042338	   37.5	  
positive	  regulation	  of	  protein	  ubiquitination	   7.08889	   0.00083432	   13.5135	  
brown	  fat	  cell	  differentiation	   7.01891	   0.0008948	   18.1818	  
transcription	  corepressor	  activity	   6.80806	   0.00110483	   6.53595	  
oxidoreductase	   activity,	   acting	   on	   single	   donors	  
with	   incorporation	   of	   molecular	   oxygen,	  
incorporation	  of	  two	  atoms	  of	  oxygen	   6.73761	   0.00118548	   10.1695	  
response	  to	  iron(III)	  ion	   6.72344	   0.0012024	   66.6667	  
oxidoreductase	  activity,	  acting	  on	  a	  sulfur	  group	  of	  
donors,	  disulfide	  as	  acceptor	   6.72344	   0.0012024	   66.6667	  
negative	  regulation	  of	  helicase	  activity	   6.72344	   0.0012024	   66.6667	  
positive	  regulation	  of	  apoptosis	   6.56499	   0.00140884	   6.32911	  
negative	  regulation	  of	  cell	  growth	   6.52718	   0.00146312	   7.47664	  
negative	   regulation	   of	   transcription	   from	   RNA	  
polymerase	  II	  promoter	   6.49176	   0.00151588	   4.71976	  
growth	  factor	  activity	   6.33246	   0.00177765	   6.13497	  
positive	   regulation	   of	   cellular	   component	  
movement	   6.21169	   0.00200585	   23.0769	  
response	  to	  osmotic	  stress	   6.21169	   0.00200585	   23.0769	  
positive	  regulation	  of	  cell	  migration	   6.14354	   0.00214731	   7.86517	  
anti-­‐apoptosis	   6.13354	   0.0021689	   5.61224	  
6-­‐phosphofructo-­‐2-­‐kinase	  activity	   6.04374	   0.00237268	   50	  
fructose	  2,6-­‐bisphosphate	  metabolic	  process	   6.04374	   0.00237268	   50	  
antigen	  receptor-­‐mediated	  signalling	  pathway	   6.04374	   0.00237268	   50	  
maternal	  process	  involved	  in	  parturition	   6.04374	   0.00237268	   50	  
positive	   regulation	   of	   transcription	   elongation	  
from	  RNA	  polymerase	  II	  promoter	   6.04374	   0.00237268	   50	  
phosphopyruvate	  hydratase	  complex	   6.04374	   0.00237268	   50	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phosphopyruvate	  hydratase	  activity	   6.04374	   0.00237268	   50	  
endoplasmic	  reticulum	   5.72682	   0.00325741	   3.36488	  
response	  to	  stress	   5.66979	   0.00344859	   6	  
induction	  of	  apoptosis	   5.65191	   0.00351082	   5.58659	  
cellular	  response	  to	  interleukin-­‐1	   5.58461	   0.0037552	   18.75	  
positive	  regulation	  of	  keratinocyte	  migration	   5.54634	   0.00390173	   40	  
skeletal	  system	  development	   5.50665	   0.00405967	   6.34921	  
integral	  to	  endoplasmic	  reticulum	  membrane	   5.4669	   0.00422429	   9.43396	  
reactive	  oxygen	  species	  metabolic	  process	   5.40539	   0.00449232	   17.6471	  
protein	  folding	   5.38134	   0.00460164	   5.37634	  
kinase	  binding	   5.25658	   0.00521312	   11.4286	  
cysteine-­‐type	  endopeptidase	  activity	   5.22989	   0.00535412	   8.92857	  
carbohydrate	  metabolic	  process	   5.1622	   0.00572906	   4.52962	  
carbohydrate	  transport	   5.15455	   0.00577306	   11.1111	  
positive	   regulation	   of	   smooth	   muscle	   cell	  
proliferation	   5.15455	   0.00577306	   11.1111	  
fructose-­‐2,6-­‐bisphosphate	  2-­‐phosphatase	  activity	   5.15427	   0.00577468	   33.3333	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Appendix	  17.	  Top	  50	  genes	  uniquely	  upregulated	  in	  primary	  cells.	  
Gene	  Assignment	   Gene	  Symbol	   RefSeq	  
5-­‐hydroxytryptamine	  (serotonin)	  receptor	  2B,	  G	  protein-­‐coupled	   HTR2B	   NM_000867	  
stathmin-­‐like	  2	  	   STMN2	  
NM_00119921
4	  
mesoderm	  specific	  transcript	  	   MEST	   NM_002402	  
lipase,	  endothelial	  	   LIPG	   NM_006033	  
sarcoglycan,	  gamma	  (35kDa	  dystrophin-­‐associated	  glycoprotein)	  	   SGCG	   NM_000231	  
poly(A)	  binding	  protein,	  cytoplasmic	  4-­‐like	  	   PABPC4L	  
NM_00111473
4	  
secreted	  frizzled-­‐related	  protein	  4	  	   SFRP4	   NM_003014	  
synaptophysin-­‐like	  2	  	   SYPL2	  
NM_00104070
9	  
melanoma	  antigen	  family	  D,	  4	  	   MAGED4	  
NM_00127206
1	  
furry	  homolog	  (Drosophila)	  	   FRY	   NM_023037	  
ubiquitin	  specific	  peptidase	  53	  	   USP53	   NM_019050	  
melanoma	  antigen	  family	  D,	  4	  	   MAGED4	  
NM_00127206
1	  
adrenomedullin	  2	  	   ADM2	   NM_024866	  
secreted	  frizzled-­‐related	  protein	  1	  	   SFRP1	   NM_003012	  
collagen,	  type	  XI,	  alpha	  1	   COL11A1	   NM_001854	  
ectonucleotide	  pyrophosphatase/phosphodiesterase	  5	  (putative)	  	   ENPP5	   NM_021572	  
carboxypeptidase	  A4	   CPA4	   NM_016352	  
fibroblast	  growth	  factor	  9	  (glia-­‐activating	  factor)	   FGF9	   NM_002010	  
solute	  carrier	  family	  7	  (orphan	  transporter),	  member	  14	   SLC7A14	   NM_020949	  
Dab,	  reelin	  signal	  transducer,	  homolog	  1	  (Drosophila)	  	   DAB1	   NM_021080	  
Xg	  blood	  group	  	   XG	  
NM_00114191
9	  
myosin,	  heavy	  chain	  10,	  non-­‐muscle	  	   MYH10	  
NM_00125601
2	  
Xg	  pseudogene,	  Y-­‐linked	  2	  	   XGPY2	   NR_003254	  
chloride	  intracellular	  channel	  3	   CLIC3	  
ENST0000049
4426	  
fibroblast	  growth	  factor	  7	  	   FGF7	  
ENST0000026
7843	  
tumor	  necrosis	  factor	  receptor	  superfamily,	  member	  19	   TNFRSF19	   NM_018647	  
KIAA1211	   KIAA1211	   NM_020722	  
BMP	   and	   activin	   membrane-­‐bound	   inhibitor	   homolog	   (Xenopus	  
laevis)	   BAMBI	   NM_012342	  
methyltransferase	  like	  21C	  	   METTL21C	  
NM_00101097
7	  
heparan	  sulfate	  (glucosamine)	  3-­‐O-­‐sulfotransferase	  3B1	  	   HS3ST3B1	  
ENST0000036
0954	  
TLR4	  interactor	  with	  leucine-­‐rich	  repeats	  	   TRIL	   NM_014817	  
NR2F1	  antisense	  RNA	  1	  	   NR2F1-­‐AS1	   NR_021491	  
Fraser	  syndrome	  1	  	   FRAS1	   NM_025074	  
197	  
	  
microRNA	  503	   MIR503	   NR_030228	  
wingless-­‐type	  MMTV	  integration	  site	  family	  member	  2	  	   WNT2	   NM_003391	  
activin	  A	  receptor,	  type	  IIA	  	   ACVR2A	  
ENST0000024
1416	  
chromosome	  1	  open	  reading	  frame	  198	  	   C1orf198	  
ENST0000036
6663	  
NADPH	  oxidase	  4	  	   NOX4	   NM_016931	  
ALG1,	  chitobiosyldiphosphodolichol	  beta-­‐mannosyltransferase	  	   ALG1	   NM_019109	  
growth	  differentiation	  factor	  6	   GDF6	  
NM_00100155
7	  
solute	   carrier	   family	   16,	   member	   13	   (monocarboxylic	   acid	  
transporters),	  member	  13	   SLC16A13	   NM_201566	  
asparaginyl-­‐tRNA	  synthetase	  2,	  mitochondrial	  (putative)	  	   NARS2	   NM_024678	  
CUB	  and	  Sushi	  multiple	  domains	  2	   CSMD2	  
ENST0000037
3381	  
FOXF1	  adjacent	  non-­‐coding	  developmental	  regulatory	  RNA	   FENDRR	   NR_033925	  
NUAK	  family,	  SNF1-­‐like	  kinase,	  1	  	   NUAK1	   NM_014840	  
nuclear	  receptor	  subfamily	  2,	  group	  F,	  member	  1	  	   NR2F1	  
ENST0000032
7111	  
transmembrane	  protein	  119	  	   TMEM119	   NM_181724	  
retinoic	  acid	  receptor	  responder	  (tazarotene	  induced)	  2	   RARRES2	   NM_002889	  
MDM2	  oncogene,	  E3	  ubiquitin	  protein	  ligase	  	   MDM2	   NM_002392	  
activating	  transcription	  factor	  5	  	   ATF5	  
NM_00119364
6	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Appendix	  18.	  Gene	  ontology	  analysis	  for	  genes	  uniquely	  upregulated	  in	  primary	  cells.	  
Function	   Enrichment	  
Score	  
Enrichment	  
p-­‐value	  
%	   genes	   in	  
group	   that	  
are	  present	  
extracellular	  matrix	   11.6056	   9.11E-­‐06	   9.39597	  
thiosulfate	  sulfurtransferase	  activity	   11.3198	   1.21E-­‐05	   100	  
hydrolase	  activity,	  acting	  on	  glycosyl	  bonds	   9.57319	   6.96E-­‐05	   15.5556	  
integral	  to	  membrane	   8.26908	   0.00025632	   3.03102	  
regulation	  of	  cellular	  metabolic	  process	   8.16495	   0.00028445	   15	  
positive	   regulation	   of	   canonical	   Wnt	   receptor	  
signalling	  pathway	   8.16495	   0.00028445	   15	  
gap	  junction	   8.08088	   0.0003094	   26.6667	  
cerebellar	  Purkinje	  cell	  layer	  development	   7.38071	   0.00062316	   37.5	  
regulation	   of	   reactive	   oxygen	   species	   metabolic	  
process	   7.17901	   0.00076242	   15.625	  
proteinaceous	  extracellular	  matrix	   6.81041	   0.00110224	   6.25	  
cell	  adhesion	   6.71894	   0.00120782	   4.48833	  
cell-­‐cell	  adhesion	   6.70754	   0.00122166	   9.85915	  
membrane	   6.58417	   0.00138208	   2.96296	  
positive	  regulation	  of	  DNA	  biosynthetic	  process	   6.46083	   0.0015635	   66.6667	  
metanephric	  glomerular	  capillary	  formation	   6.46083	   0.0015635	   66.6667	  
Clara	  cell	  differentiation	   6.46083	   0.0015635	   66.6667	  
regulation	  of	  biological	  process	   6.38743	   0.00168258	   5.9633	  
vasculature	  development	   6.35675	   0.001735	   17.3913	  
positive	  regulation	  of	  cell	  proliferation	   6.21718	   0.00199486	   5.08982	  
chloride	  channel	  activity	   6.15683	   0.00211895	   10.3448	  
positive	   regulation	   of	   transcription	   from	   RNA	  
polymerase	  II	  promoter	   6.06369	   0.00232581	   4.4898	  
chloride	  transport	   5.98267	   0.00252209	   10	  
tRNA	  aminoacylation	  for	  protein	  translation	   5.92628	   0.00266838	   11.9048	  
endoplasmic	  reticulum	  lumen	   5.88567	   0.00277898	   7.69231	  
interstitial	  matrix	   5.83586	   0.00292092	   23.0769	  
collagen	  binding	   5.82142	   0.00296339	   11.6279	  
induction	  of	  apoptosis	   5.82126	   0.00296386	   6.14525	  
substrate-­‐dependent	  cell	  migration,	  cell	  extension	   5.78305	   0.00307931	   50	  
methylenetetrahydrofolate	   dehydrogenase	  
(NADP+)	  activity	   5.78305	   0.00307931	   50	  
menstrual	  cycle	  phase	   5.78305	   0.00307931	   50	  
positive	  regulation	  of	  cell-­‐substrate	  adhesion	   5.74517	   0.00319818	   14.8148	  
regulation	  of	  cellular	  process	   5.65163	   0.00351179	   6.81818	  
protein	  oligomerization	   5.60911	   0.00366432	   14.2857	  
biological	  regulation	   5.41565	   0.00444643	   5.32787	  
positive	   regulation	   of	   Wnt	   receptor	   signalling	  
pathway	   5.40573	   0.00449079	   20	  
biological_process	   5.31408	   0.00492179	   5.26316	  
199	  
	  
sphingomyelin	  catabolic	  process	   5.28756	   0.00505407	   40	  
inner	  ear	  receptor	  cell	  development	   5.28756	   0.00505407	   40	  
Type	  II	  pneumocyte	  differentiation	   5.28756	   0.00505407	   40	  
voltage-­‐gated	  chloride	  channel	  activity	   5.21514	   0.00543365	   18.75	  
positive	   regulation	   of	   mesenchymal	   cell	  
proliferation	   5.11811	   0.00598732	   12.5	  
ion	  transport	   5.10809	   0.00604762	   4.07801	  
ion	  channel	  activity	   5.10231	   0.0060827	   5.58376	  
positive	  regulation	  of	  Ras	  GTPase	  activity	   5.03803	   0.00648654	   17.6471	  
phospholipid	  biosynthetic	  process	   4.99643	   0.00676206	   9.61538	  
biosynthetic	  process	   4.99643	   0.00676206	   9.61538	  
extracellular	  matrix	  organization	   4.94229	   0.00713824	   8.10811	  
heparin	  binding	   4.92208	   0.00728394	   6.55738	  
endoplasmic	  reticulum	   4.90051	   0.0074428	   3.57518	  
oxidoreductase	  activity,	  acting	  on	  the	  CH-­‐CH	  group	  
of	  donors,	  NAD	  or	  NADP	  as	  acceptor	   4.89741	   0.00746592	   33.3333	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Appendix	  19.	  Top	  50	  genes	  uniquely	  upregulated	  in	  hTERT-­‐HM.	  
Gene	  Assignment	   Gene	  Symbol	   RefSeq	  
telomerase	  reverse	  transcriptase	   TERT	   NM_198253	  
uncharacterized	  LOC643401	  	   LOC643401	   NR_038848	  
insulin-­‐like	  growth	  factor	  2	  mRNA	  binding	  protein	  1	   IGF2BP1	   NM_006546	  
SPANX	  family,	  member	  B1	   SPANXB1	   NM_032461	  
SPANX	  family,	  member	  B1	  	   SPANXB1	   NM_032461	  
cadherin	  12,	  type	  2	  (N-­‐cadherin	  2)	   CDH12	   NM_004061	  
keratoconus	  gene	  6	   KC6	   NR_002838	  
synovial	  sarcoma,	  X	  breakpoint	  1	  	   SSX1	   NM_005635	  
cadherin	  9,	  type	  2	  (T1-­‐cadherin)	   CDH9	   NM_016279	  
thymocyte	  expressed,	  positive	  selection	  associated	  1	   TESPA1	   NM_001136030	  
ZNF667	  antisense	  RNA	  1	  (head	  to	  head)	   ZNF667-­‐AS1	   NR_036521	  
CSAG	  family,	  member	  2	  	   CSAG2	   NM_001080848	  
CSAG	  family,	  member	  2	  	   CSAG2	   NM_001080848	  
chloride	  channel	  accessory	  2	  	   CLCA2	   NM_006536	  
uncharacterized	  LOC100506465	  	  
LOC10050646
5	   BC007399	  
transcription	   factor	   AP-­‐2	   alpha	   (activating	   enhancer	   binding	  
protein	  2	  alpha	   TFAP2A	   NM_003220	  
neurofibromin	  1	  	   NF1	   NM_001042492	  
uncharacterized	  LOC100506827	  	  
LOC10050682
7	  
ENST000005126
78	  
chromosome	  7	  open	  reading	  frame	  69	  	   C7orf69	  
ENST000002587
76	  
chemokine	  (C-­‐X-­‐C	  motif)	  ligand	  6	  	   CXCL6	   NM_002993	  
melanoma	  antigen	  family	  C,	  2	  	   MAGEC2	   NM_016249	  
glucosidase,	  beta,	  acid	  3	  	   GBA3	   NM_020973	  
gamma-­‐aminobutyric	  acid	  (GABA)	  A	  receptor,	  alpha	  3	   GABRA3	  
ENST000003703
14	  
insulin-­‐like	  growth	  factor	  2	  mRNA	  binding	  protein	  3	  	   IGF2BP3	   NM_006547	  
maltase-­‐glucoamylase	  (alpha-­‐glucosidase)	  	   MGAM	  
ENST000005494
89	  
transmembrane	  and	  tetratricopeptide	  repeat	  containing	  1	  	   TMTC1	   NM_001193451	  
CD200	  molecule	  	   CD200	   NM_001004196	  
caspase	  recruitment	  domain	  family,	  member	  17	  	   CARD17	   AK128199	  
single-­‐minded	  homolog	  2	  (Drosophila)	   SIM2	   NM_009586	  
serpin	  peptidase	  inhibitor,	  clade	  G	  (C1	  inhibitor),	  member	  1	  	   SERPING1	   NM_000062	  
late	  cornified	  envelope	  2A	  	   LCE2A	   NM_178428	  
papillary	   thyroid	   carcinoma	   susceptibility	   candidate	   3	   (non-­‐
protein	  coding)	   PTCSC3	   NR_049735	  
uncharacterized	  LOC285501	  	   LOC285501	   NR_028342	  
Down	  syndrome	  critical	  region	  gene	  8	   DSCR8	   NR_026839	  
P	  antigen	  family,	  member	  2B	  	   PAGE2B	   NM_001015038	  
syndecan	  2	   SDC2	   ENST000003021
201	  
	  
90	  
runt-­‐related	  transcription	  factor	  2	  	   RUNX2	  
ENST000003714
38	  
melanocortin	  2	  receptor	  accessory	  protein	  2	   MRAP2	   NM_138409	  
empty	  spiracles	  homeobox	  2	   EMX2	  
ENST000003692
01	  
fibromodulin	   FMOD	  
ENST000003549
55	  
fibrinogen	  C	  domain	  containing	  1	  	   FIBCD1	   NM_001145106	  
EPH	  receptor	  B4	  	   EPHB4	   NM_004444	  
transcription	   factor	   AP-­‐2	   beta	   (activating	   enhancer	   binding	  
protein	  2	  beta)	   TFAP2B	   NM_003221	  
SMEK	   homolog	   3,	   suppressor	   of	   mek1	   (Dictyostelium)	  
pseudogene	  	   SMEK3P	   NR_002784	  
ring	  finger	  protein	  17	  	   RNF17	   NM_031277	  
glycine-­‐N-­‐acyltransferase-­‐like	  2	  	   GLYATL2	  
ENST000002872
75	  
chromosome	  14	  open	  reading	  frame	  23	   C14orf23	   BX248251	  
carbohydrate	  (N-­‐acetylgalactosamine	  4-­‐sulfate	  6-­‐O)	  sulfotransfer	   CHST15	   NM_015892	  
melanoma	  antigen	  family	  A,	  6	  	   MAGEA6	  
ENST000003293
42	  
tripartite	  motif	  containing	  62	  	   TRIM62	   NM_018207	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Appendix	  20.	  Gene	  ontology	  analysis	  for	  uniquely	  upregulated	  genes	  in	  hTERT-­‐HM.	  
Function	   Enrichment	  
Score	  
Enrichment	   p-­‐
value	  
%	   genes	   in	  
group	   that	   are	  
present	  
extracellular	  matrix	   12.0215	   6.01E-­‐06	   15.4362	  
cell	  adhesion	   10.4047	   3.03E-­‐05	   9.69479	  
kidney	  development	   9.9294	   4.87E-­‐05	   19.697	  
positive	   regulation	  of	   transcription	   from	  RNA	  
polymerase	  II	  promoter	   9.65277	   6.42E-­‐05	   9.79592	  
embryonic	  forelimb	  morphogenesis	   9.05136	   0.00011723	   31.8182	  
embryonic	  skeletal	  system	  development	   9.05136	   0.00011723	   31.8182	  
extracellular	  matrix	  organization	   8.70098	   0.00016642	   17.5676	  
apicolateral	  plasma	  membrane	   8.21347	   0.00027098	   57.1429	  
artery	  morphogenesis	   8.19905	   0.00027492	   33.3333	  
positive	  regulation	  of	  axonogenesis	   8.19905	   0.00027492	   33.3333	  
regulation	   of	   small	   GTPase	   mediated	   signal	  
transduction	   7.75808	   0.00042728	   12.2807	  
proteinaceous	  extracellular	  matrix	   7.73158	   0.00043875	   11.5385	  
axon	  guidance	   7.72698	   0.00044077	   10.2894	  
lymphangiogenesis	   7.56456	   0.00051851	   50	  
head	  development	   7.38058	   0.00062324	   75	  
hepatocyte	   growth	   factor	   receptor	   signalling	  
pathway	   7.38058	   0.00062324	   75	  
ureteric	  bud	  development	   7.04877	   0.00086847	   21.0526	  
proximal/distal	  pattern	  formation	   7.00021	   0.00091169	   33.3333	  
negative	  regulation	  of	  transcription	  from	  RNA	  
polymerase	  II	  promoter	   6.95495	   0.0009539	   9.73451	  
extracellular	  space	   6.80177	   0.00111181	   8.12582	  
multicellular	  organismal	  development	   6.63944	   0.00130776	   7.81759	  
regulation	  of	  ossification	   6.55417	   0.00142417	   40	  
signal	  transduction	   6.53336	   0.00145411	   7.50647	  
extracellular	  region	   6.51254	   0.00148471	   7.0091	  
mRNA	  5'-­‐UTR	  binding	   6.50586	   0.00149465	   60	  
negative	   regulation	   of	   actin	   filament	  
polymerization	   6.50586	   0.00149465	   60	  
protein	  homooligomerization	   6.33776	   0.00176825	   14.4578	  
nervous	  system	  development	   6.12106	   0.00219613	   9.02256	  
glycogen	  catabolic	  process	   6.08867	   0.00226842	   27.7778	  
sequence-­‐specific	  DNA	  binding	   6.08344	   0.00228033	   8.39286	  
blastocyst	  formation	   5.85418	   0.00286789	   50	  
metallopeptidase	  activity	   5.83488	   0.00292377	   13.6364	  
plasma	  membrane	   5.73782	   0.00322178	   6.43752	  
anterior/posterior	  pattern	  specification	   5.71354	   0.00330097	   14.1026	  
Golgi	  apparatus	   5.69938	   0.00334804	   7.61478	  
positive	  regulation	  of	  bone	  mineralization	   5.65681	   0.00349364	   21.4286	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negative	  regulation	  of	  cell	  migration	   5.64892	   0.00352132	   15.7895	  
heart	  development	   5.64004	   0.00355272	   11.5942	  
embryonic	  cranial	  skeleton	  morphogenesis	   5.58652	   0.00374806	   25	  
homophilic	  cell	  adhesion	   5.49739	   0.00409746	   11.4286	  
central	  nervous	  system	  neuron	  development	   5.46065	   0.00425079	   30.7692	  
retinoic	  acid	  metabolic	  process	   5.46065	   0.00425079	   30.7692	  
adrenal	  gland	  development	   5.35993	   0.00470123	   23.8095	  
ephrin	  receptor	  signalling	  pathway	   5.35993	   0.00470123	   23.8095	  
cartilage	   development	   involved	   in	  
endochondral	  bone	  morphogenesis	   5.3359	   0.00481558	   42.8571	  
negative	  regulation	  of	  cell-­‐matrix	  adhesion	   5.3359	   0.00481558	   42.8571	  
positive	  regulation	  of	  protein	  sumoylation	   5.3359	   0.00481558	   42.8571	  
collagen	  fibril	  organization	   5.29481	   0.00501756	   20	  
response	  to	  interleukin-­‐1	   5.29481	   0.00501756	   20	  
protein	  homodimerization	  activity	   5.18008	   0.00562753	   8.29876	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